annual report contents scienceled strategic report global healthcare company business model chairmans statement ceos statement financial performance longterm priorities purpose culture improve quality human life helping people feel better key performance indicators live longer industry trends stakeholder engagement goal pharmaceuticals become one worlds innovative bestperforming trusted vaccines healthcare companies consumer healthcare trust strategy risk management bring differentiated highquality needed healthcare products group financial review many people possible three global businesses scientific corporate governance technical knowhow talented people chairmans governance statement longterm priorities board priorities underpinned ambition build performance corporate executive team focused culture aligned values expectations responsible leadership division responsibilities innovation composition succession invest scientific technical excellence develop launch evaluation pipeline new products meet needs patients payers nominations committee report consumers audit risk internal control audit risk committee report performance science committee report deliver growthbased performance investing effectively corporate responsibility business developing people executing competitively committee report trust section statement responsible company commit use science directors ' report technology address health needs make products affordable remuneration report available modern employer chairmans annual statement values expectations annual report remuneration values patient focus transparency respect integrity remuneration policy summary expectations courage accountability development teamwork remuneration policy report financial statements directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap investor information cautionary statement quarterly trend see inside back cover document cautionary statement regarding fiveyear record forwardlooking statements product development pipeline products competition nonifrs measures intellectual property use number adjusted nonifrs measures report performance business principal risks uncertainties total reported results represent group 's overall performance ifrs adjusted results proforma growth rates nonifrs measures may considered addition share capital share price substitute superior information presented accordance ifrs adjusted results dividends nonifrs measures defined pages reconciliations nearest financial calendar ifrs measures pages annual general meeting believe adjusted results considered together total results provide investors tax information shareholders analysts stakeholders helpful complementary information understand better shareholder services contacts financial performance position group period period allow group 's us law regulation performance easily compared majority peer companies group companies measures also used management planning reporting purposes may glossary terms directly comparable similarly described measures used companiesstrategic report governance remuneration financial statements investor information business model three global businesses discover develop manufacture innovative medicines vaccines consumer healthcare products every day help improve health millions people around world operations span value chain identifying ability launch new products successfully researching developing testing groundbreaking grow sales existing portfolio key discoveries regulatory approval manufacturing commercial success patients consumers commercialisation deliver transformational medicines vaccines consumer healthcare products included employees across countries billion packs medicines million vaccine outstanding scientific technical knowhow doses billion consumer healthcare products deep expertise regulation intellectual property commercialisation also work worldleading part capital allocation framework invest experts form strategic partnerships complement three businesses provide returns existing capabilities shareholders form dividends share value growth paid dividend p per share innovation critical improve health create delivered billion free cash flow financial value researchbased healthcare company rely intellectual property protection help ensure make positive contribution communities reasonable return investments operate creating employment working continue research develop new innovative suppliers paying tax offer broad range medicines invested billion rd employee benefits including preventative healthcare pharmaceuticals vaccines focus science services able attract retain related immune system human genetics best people delivering purpose greatest advanced technology consumer healthcare contribution make improve health people leverage scientific expertise deep consumer around world medicines vaccines insights create healthcare products meet consumer healthcare products consumer demands pharmaceuticals vaccines consumer healthcare pharmaceuticals business worlds largest vaccines worldleading consumer healthcare broad portfolio innovative company revenue delivering vaccines business combines science established medicines respiratory protect people stages life consumer insights create innovative hiv immunoinflammation oncology rd focuses developing everyday healthcare brands strengthening rd pipeline vaccines infectious diseases consumers trust experts recommend focus immunology human combine high medical need finalised agreement genetics advanced technologies strong market potential pfizer combine two consumer help us identify transformational healthcare businesses new medicines patients read read read turnover turnover turnover respiratory hiv meningitis wellness immunoinflammation shingles oral health oncology influenza nutrition established pharmaceuticals established vaccines skin health total total total gsk annual report business model continued preparing future investing rd new products new programme use unique catalyst separation order successful increasing investment rd reset capabilities cost base companies new products deliver future growth since announcing help support delivery significant value creation new approach rd made significant opportunities see new gsk new consumer progress strengthen pipeline particularly oncology healthcare medicines vaccines pipeline new gsk see clear opportunity drive common three major approvals eight regulatory approach rd science related immune system submissions six positive readouts pivotal studies converges across pharmaceuticals vaccines progressed four new assets pivotal studies enable us even effective allocate also completed transactions tesaro budget share technical scientific expertise deliver merck kgaa strengthening position pipeline regardless modality oncology initiated alliances build platform programme also seek improve technologies genomics university california capabilities create efficiencies global support cell therapy lyell immunopharma functions continue simplify focus manufacturing positive clinical data generating progress network ensuring supply chain ready launch made strengthen pipeline underpins decision new speciality medicines rationalise portfolio increase investment rd next two years divestments creating two new companies new consumer healthcare company programme early consistent strategic priorities support building key technology infrastructure previous announcements started twoyear programme expertise necessary operate standalone company prepare gsk separation two new leading companies believe increased investment pipeline new new gsk biopharma company rd approach products together effective implementation new focused science related immune system use twoyear programme set new company genetics new technologies new consumer strong foundations future performance financial healthcare company categoryleading power brands benefits costs reporting associated programme innovation based science consumer insights set pages intention remains separate around three years close transaction resulted formation new consumer healthcare joint venture july capital allocation capital allocation framework key priorities capital invest business rd pipeline including business development vaccines capacity innovation new products improved shareholder returns dividends performance cash target x x cover generation returning dividend growth trust strict discipline returns gsk annual report strategic report governance remuneration financial statements investor information chairmans statement delighted introduce first gsk annual report chairman passionate life sciences worked industry many years sector know make meaningful difference patients people around world gsk proud history innovation environment social governance esg exciting future ahead made joining gsk irresistible first year required compliance opportunity create worlds revised uk corporate governance code leading consumer health business also create increased emphasis value esg factors overall biopharma business founded todays leading scientific performance pleased find gsks purpose platforms board outstanding management team strategy priorities well placed deliver longterm value led emma determined achieve society shareholders need give greater prominence clear gsk delivered good operating performance start good place growth sales earnings good cash generation emma team sucessfully focused strengthening gsk strong foundation global health innovation pipeline delivering strong commercial execution continues play important role promising data evident contribution growth new candidate tb vaccine recognition gsks leadership products results antimicrobial resistance major global health threat good demonstration access affordability medicines innovation critical issue industry society company saw good progress groups priority strengthen continues focused making products affordable pharmaceuticals pipeline particularly oncology eight available responsible pricing strategic access filings four assets moved pivotal trials board programmes partnerships particularly pleased see positive data came assets acquired tesaro transaction tackling climate change require action everyone gsk committed playing part company delivering distinctive new approach rd focus well reducing carbon footprint line paris immune system use genetics advanced analytical agreement assessing opportunities risks technologies also advancing formation transition low carbon economy presents partnerships including university california andme lyell attraction new talent board changes organisation longer term new approach made progress searching judy lewents promises deliver productive rd organisation successor chair audit risk committee delivering higher number differentiated medicines delighted judy agreed stay year area board science committee working facilitate transition stepping board closely management agm whilst mindful uk corporate governance code indicates nonexecutive directors first months many conversations serve nine years firmly believe smooth shareholders pleased report strong support transition best interests company shareholders strategic direction company intention separate two new companies successfully deliver set detail section board governance group initiated new programme help prepare reevaluated priorities board committee separation consequently established new architecture able support oversee creation board committee work closely management two outstanding new organisations provide support oversight next two years year sir philip hampton stood board capital allocation anticipated last years annual report iain mackay board supports managements clear framework capital became chief financial officer replacing simon dingemans allocation prioritises investment pharmaceuticals id like take opportunity thank philip simon pipeline building vaccine supply capacity disciplined service gsk support business development opportunities also part finally thanks go gsks employees partners framework course board also mindful shareholders customers support warm welcome returns shareholders returned p per share expected total shareholder return sir jonathan symonds chairman gsk annual report ceos statement pleased progress made three longterm priorities innovation performance trust strengthened pipeline improved operational execution reshaped group growth sales earnings continue build capabilities new platform group sales grew actual exchange rates technologies notably pioneering new partnership constant exchange rates billion good university california establish stateoftheart performance particularly considering laboratory crispr geneediting technologies first year generic version advair us biotech company lyell development new cell therapies also pleased partnership andme new products drove increase sales reflecting progressing well identified eight new targets innovation focus commercial execution shingrix work together immunology oncology neurology shingles vaccine remarkable year sales cardiovascular disease billion successful biopharma launch last years product also received prestigious preparing future prix galien award innovation respiratory saw strong delivering innovation first priority recent growth trelegy nucala hiv new twodrug data readouts together progress made regimens dovato juluca contributed sales million strengthen pipeline underpin decision increase investment rd new products total group operating margin increased percentage longterm growth points adjusted operating margin decreased percentage points cer reflecting decision invest time continue focus operational new products priority pipeline programmes execution including delivering successful integration total earnings per share p actual consumer healthcare following completion exchange rates cer adjusted earnings per share transaction pfizer july grew actual exchange rates cer p also preparing separation group achieved strong cash generation free cash flow previously stated intention separate around billion expected announced dividend three years closing transaction therefore p expect initiated twoyear programme prepare two new companies new gsk biopharma company rd approach landmark year rd focused science related immune system use became ceo made strengthening rd pipeline genetics advanced technologies new consumer first priority made significant progress healthcare company worldleading portfolio brands leadership dr hal barron chief scientific officer scale delivered three major approvals eight regulatory filings new medicines six positive readouts assets pivotal new programme aims use unique catalyst studies progressed four new assets pivotal studies separation set competitive capabilities cost base three biologics companies help deliver significant value creation patients consumers shareholders progress reflects successful prioritisation development pipeline core areas hiv respiratory building trust fast emerging areas oncology gsk consistently continue take action particularly pleased see pivotal data zejula ovarian make broader contribution society addition delivery cancer belantamab mafodotin multiple myeloma financial returns made good progress across believe assets potential transform trust commitments well placed respond patients treated underserved cancer types increasing investor interest environmental social governance esg performance pleased ranked medicines vaccines currently top pharma company dow jones sustainability index clinical development expect least six sector potential product approvals also expect substantial amount proofofconcept data including combination studies various immunooncology agents innovative vaccines respiratory syncytial virus rsv chronic obstructive pulmonary disease copd gsk annual report strategic report governance remuneration financial statements investor information ceo 's statement continued notable several recent initiatives related people culture global health health security following publication continue work develop performancefocused excellent data candidate tb vaccine early culture strong emphasis ethics values building secured groundbreaking agreement new trust internally remains key priority regular employee gates medical research institute develop vaccine survey helps us review levels employee engagement use lowincome countries new alliance reflects pleased achieve excellent engagement scores aim take sustainable approach global health levels organisation course last year focusing efforts expertise science research also pursuing broad agenda promote inclusion partnering others ensure development diversity female representation across organisation delivery also filed regulatory submissions new increased particularly senior management level gsk formulation latest hiv medicine expand recognised stonewall lgbt rights group top access use children resource poor settings global employer also pleased see science research significant progress made due effort recognised gsks leadership access talent dedication gsk people work medicine foundations antimicrobial resistance want thank enormous contribution benchmark count february support global response outbreak caused coronavirus sarscov formed collaborations cepi coalition epidemic preparedness innovations institutions companies make vaccine adjuvant technology available development emma walmsley effective vaccine virus chief executive officer another area trust agenda working hard reduce environmental impact underpinned five public targets goal reduce impact one quarter report also set approach climate change risk including first voluntary disclosure using recommendations taskforce climaterelated financial disclosure tcfd gsk annual report financial performance total results growth turnover turnover cer turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs profit disposal interest associates share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p performed operating profit total operating profit million compared cost sales million reduced remeasurement charges total cost sales percentage turnover contingent consideration liabilities consumer percentage points higher aer percentage points healthcare put option charge increased profits disposals higher cer terms primarily reflected increase increase value shares hindustan unilever costs major restructuring programmes unwind limited received disposal horlicks fair value uplift inventory arising completion consumer healthcare brands partly offset increased consumer healthcare joint venture pfizer continued charges major restructuring significant legal matters adverse pricing pressure pharmaceuticals partly offset favourable product mix vaccines tax charge million represented effective tax rate selling general administration total results reflected total sga costs percentage turnover different tax effects various adjusting items percentage points higher aer percentage points higher cer included increased significant legal charges noncontrolling interests arising settlement existing matters provisions allocation total earnings noncontrolling interests ongoing litigation increased investment resulting amounted million million increase acquisition tesaro greater promotional product support primarily due increased allocation viiv healthcare particularly new launches profits research development earnings per share total rd expenditure million turnover total earnings per share p compared p aer cer reflected significant increase increase earnings per share primarily reflected study clinical trial material investment oncology reduced remeasurement charges contingent increased spending progression key nononcology consideration liabilities put options increase assets partly offset savings early phase portfolio value shares hindustan unilever limited received reprioritisation late disposal horlicks consumer healthcare brands reduced effective tax rate increased share operating incomeexpense aftertax profits associates result nonrecurring net operating income primarily reflected profit income tax benefit innoviva disposal rabies tickborne encephalitis vaccines number asset disposals together increase value shares hindustan unilever limited received disposal horlicks consumer healthcare brands gsk annual report strategic report governance remuneration financial statements investor information financial performance continued total adjusted results total reported results represent groups overall performance gsk undertaking number boardapproved major restructuring programmes response significant changes gsk uses number adjusted nonifrs measures groups trading environment overall strategy report performance business adjusted results following material acquisitions costs cash noncash nonifrs measures may considered addition programmes provided individual elements substitute superior information presented approved meet accounting recognition criteria accordance ifrs see fuller definition result charges may incurred number years gsk believes adjusted results considered together following initiation major restructuring programme total results provide investors analysts group also initiated twoyear separation preparation stakeholders helpful complementary information programme prepare gsk separation two new leading understand better financial performance position companies biopharma consumer healthcare group period period allow groups performance easily compared majority gsk committed continuously improving financial peer companies measures also used reporting line evolving regulatory requirements management planning reporting purposes may best practice directly comparable similarly described measures gsk 's reported results include five months results used companies former pfizer consumer healthcare business august gsk encourages investors analysts rely proforma growth rates cer calculated single financial measure review gsks annual reports including equivalent five months results including financial statements notes entirety former pfizer consumer healthcare business comparative period fully described divestments intangible intangible significant total asset asset major transaction legal adjusted adjusting items results amortisation impairment restructuring related items results turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p intangible asset amortisation impairment transactionrelated amortisation impairment intangible assets goodwill transactionrelated accounting adjustments related excludes computer software significant acquisitions major restructuring divestments significant legal items major restructuring costs include impairments tangible proceeds costs disposals associates products assets computer software specific boardapproved businesses significant legal charges net insurance programmes structural significant scale recoveries expenses settlement litigation costs individual related projects exceed million government investigations operating income including integration costs following material acquisitions royalty income items gsk annual report financial performance continued adjusted results growth turnover turnover cer turnover cost sales gross profit selling general administration research development royalty income operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p performed operating profit cost sales adjusted operating profit million higher adjusted cost sales percentage turnover aer flat cer turnover increase cer percentage points higher aer percentage points adjusted operating margin percentage higher cer proforma basis adjusted cost sales points lower aer percentage points lower percentage turnover percentage points cer basis proforma basis adjusted higher cer primarily reflected continued adverse operating profit lower cer turnover increase pricing pressure pharmaceuticals partly offset cer adjusted proforma operating margin favourable product mix vaccines largely due growth percentage points lower cer basis shingrix us reduction proforma adjusted operating profit primarily reflected continuing price pressure investments rd selling general administration promotional product support partly offset benefit adjusted sga costs percentage turnover sales growth particularly vaccines favourable mix percentage point higher aer percentage point vaccines consumer healthcare continued benefit higher cer basis proforma basis adjusted sga restructuring costs percentage turnover percentage points higher cer compared primarily tax reflected increased investment resulting acquisition tax adjusted profit amounted million tesaro promotional product support particularly represented effective adjusted tax rate new launches vaccines respiratory hiv partly offset reflecting impact settlement continuing benefit restructuring pharmaceuticals number open issues tax authorities tight control ongoing costs noncontrolling interests research development allocation adjusted earnings noncontrolling interests adjusted rd expenditure million amounted million million increase turnover higher aer higher cer primarily reflected increased allocation consumer proforma basis adjusted rd expenditure grew healthcare profits reflected significant increase study clinical trial earnings per share material investment oncology increased spending adjusted eps p compared p progression key nononcology assets partly offset aer cer adjusted operating profit flat savings early phase portfolio reprioritisation cer improvement primarily resulted reduced late effective tax rate increased share aftertax profits associates partly offset increased net finance costs higher noncontrolling interest allocation consumer healthcare profits gsk annual report strategic report governance remuneration financial statements investor information longterm priorities longterm priorities designed create lasting value patients consumers shareholders important year execution made good progress delivering objectives innovation performance trust invest scientific deliver growth investing responsible company technical excellence develop effectively business commit use science launch pipeline new developing people technology address health products meet needs executing competitively needs make products patients payers consumers affordable available modern employer objectives objectives objectives deliver continued strong sales trelegy continue drive sales growth focus supply service levels execute ellipta nucala hiv twodrug regimen operational performance portfolio network simplification shingrix successful integration tesaro deliver progress trust commitments continue strengthen pipeline deliver restructuring benefits progress global health research tb execution new rd approach develop plan integration pfizers hiv accelerating priority assets optimising consumer healthcare business deliver modern employer programmes recent strategic business development accelerate capability building priority empower employees transactions areas including digital data analytics feel good keep growing gsk progress progress progress delivered strong sales key launches group sales billion aer filed fda eu regulatory submissions notably shingrix sales billion cer proforma paediatric dolutegravir strengthened pipeline eight filings free cash flow billion released positive final phase ii results six positive pivotal trial results four total earnings per share p candidate tb vaccine built priority assets accelerating phase iiiii aer cer adjusted earnings per collaboration bill melinda gates accelerated oncology pipeline share p aer cer medical research institute regulatory submissions zejula firstline successful integration tesaro built continued development asset maintenance ovarian cancer belantamab capability priority areas notably specialty developing countries finalised mafodotin relapsedrefractory multiple therapies including oncology announced january myeloma dostarlimab endometrial continued delivery restructuring benefits continued embed modern employer cancer support investment innovation new programmes progress engagement developed advanced technology capability launches diversity inclusion employee health significant hires partnerships completed consumer healthcare jv wellbeing development worldleading scientists pfizer track deliver synergies ranked top dow jones sustainability index pharmaceuticals industry invested new talent build capability priority objectives priority objectives priority objectives deliver innovation sales excellent prioritise spending deliver growth continue deliver ontime infull supply commercial rd supply chain return investment products execution successful consumer healthcare jv build reputation focus innovation accelerate strengthen pipeline integration including driving growth deliver progress trust commitments six potential approvals expected delivering synergies deliver capability building specialty pharmaceuticals deliver twoyear programme prepare gsk separation two new companies culture committed developing right culture drive maximise performance empowering enabling everyone gsk live values expectations changing way work accelerate delivery longterm priorities principal risks principal risks patient safety product quality financial controls reporting antibribery corruption commercial practices privacy research practices third party oversight environment health safety sustainability information security supply continuity risk management framework designed support longterm priorities see pages gsk annual report culture building performancefocused culture aligned values expectations help us achieve purpose power longterm priorities gsk wellestablished purpose help people enabling culture change feel better live longer together strong culture change longterm commitment requires values patient focus respect transparency integrity focus every level company extremely proud purpose values lead made companywide changes incentive us company however operating environment schemes governance ways working including changing rapidly stakeholders increasing implementing key performance indicators standardised expectations us performance reviews recognise culture must greater focus continue strengthen values expectations performance growth remaining firmly purposeled embedded recruitment processes leadership valuesbased necessary shift culture key development employee training performance evaluation delivering goal becoming one worlds across whole company two broad themes innovative best performing trusted healthcare companies focusing clearer accountability better expectations courage accountability development decisionmaking drive pace performance teamwork sit alongside values help us develop open honest straighttalking culture people behaviours need desired culture trust leaders feel confident share views courage high ambitions setting accelerated pace businesses set clear objectives drive smart risk taking appropriate making right decisions culture shift needed area assertively even difficult speaking leaders managers role models see opportunities improve concern desired culture starts right people made significant changes top leaders accountability taking ownership single point new appointments internal movement external accountability decision making prioritising work hires last year invested significantly supports strategy delivering promise building high performing teams hpt including development prioritising people 's development corporate executive team taking part ongoing hpt encouraging ask give open honest development programmes feedback continually grow individuals teams tracking progress organisation track cultural change range indicators teamwork ensuring people work better together board receives regular updates addition specific lead aligned objectives understand contribute indicators business area measure employee feedback longterm priorities encouraging diversity thought across company global employee survey inspiring holding account focuses progress embedding culture prioritises innovation b discipline competitive edge speed agility deliver growth orientated performance c employee trust including pride purpose progress modern employer priorities well values expectations embedded ways working also measure progress key drivers culture strength talent succession plans key roles effectiveness global people manager population global one survey see use employee engagement scores additional indicator progress embedding culture employees inspired purpose working together best way meet longterm priorities bring competitive returns shareholders help patients consumers gsk annual report strategic report governance remuneration financial statements investor information key performance indicators track progress longterm priorities ten operating key performance indicators measure performance group level across three businesses operating key performance indicators kpis reviewed track operating kpis internally regularly corporate executive team board provide performance data report externally employees updated progress every due commercial sensitivities publish data quarter performance system aligns employees bonuses operating kpis indicated nr use number adjusted relevant subset ten indicators remuneration noninternational financial reporting standards ifrs policy used reward performance executives also measures report business performance described includes measures linked kpis see pages pages include adjusted results free cash flow cer growth rates nonifrs measures may considered addition substitute superior information presented line ifrs innovation innovation sales r pharmaceuticals vaccines sales products launched last five years bn bna bna consumer healthcare sales products new market last three years total sales pipeline value progress value products pipeline rd milestones achieved nr nr nr performance group turnover r aer cer bn bn bn profit r total operating profit aer cer bn bn bn adjusted operating profit aer flat cer bn bn bn total operating margin adjusted operating margin free cash flow r bn bn bnb market share market share relation competitors nr nr nr top talent succession plans key roles talented employees key roles succession plans place nr nr nr trust employee feedback employee engagement scores global employee survey supply service level percentage orders delivered ontime infull nr nr nr corporate reputation reputation index among stakeholders informed public measured globally top markets nr nr nr r linked executive lti awards bonus see pages comparative information reflects sales products meet definition b revised include proceeds sale intangible assets nr reported externally gsk annual report industry trends healthcare industry operates rapidly changing environment strong growth potential strategy designed respond context maximising opportunities mitigating risks operating dynamic environment shaped fast intellectual property ip protection important continue changing interdependent global trends continue incentivise innovation helps researchbased healthcare responsive changing environment monitoring companies ensure reasonable return investments industry trends engaging key stakeholder groups allows continue conduct research develop see pages new innovative medicines ip protection expires challenges patent upheld generic competitors global healthcare industry rapidly capture large share market vaccines biologics face exposure generic global growth projected rise estimated competition patent cliffs require high downward revision capital investment due highly technical manufacturing previous world economic outlook rising geopolitical tensions processes complex regulatory quality requirements increased uncertainty future global trading system international cooperation taking toll business global trends opportunities challenges confidence investment decisions changing demographics global healthcare market continues grow demographic change increasing demand preventive worldwide pharmaceutical sales totalling billion therapeutic healthcare products september north america remains largest pharmaceutical market share global worlds population continues grow estimated sales europe representing china second billion people worldwide global population largest individual country pharmaceutical sales representing predicted grow billion virtually countries global sales global vaccine sales rose experiencing population ageing proportion approximately billion around worlds population projected nearly double global consumer healthcare market estimated people living cities affluence approximately billion growing size global middle class projected approximately billion people billion healthcare sector remains intensely competitive companies increasingly pursuing mergers acquisitions partnerships strengthen pipelines portfolios response saw significant activity oncology speciality care factors contributing rising demand healthcare together several company mergers notably including areas focused oncology bristolmyers squibb acquiring celgene abbvie respiratory well pressuring healthcare systems acquiring allergan restrain spending growth part innovation priority investing developing launching pipeline new products meet changing needs patients payers consumers see pages ensure products serve broad demographic global health pricing strategies see pages imf world economic outlook update iqvia data internal data httpspopulationunorgwpppublicationsfileswpp highlightspdf httpswwwwhointnewsroomfactsheetsdetailageingandhealth httpoecdobserverorgnewsfullstoryphpaidanemerging middleclasshtml gsk annual report strategic report governance remuneration financial statements investor information industry trends continued advances science technology europe majority markets established price rapid advances innovative science technology control processes place national healthcare authorities transforming sector cell therapy technologies continually looking sharpen tools response cells become living medicines changing definition changing market dynamics disparity access supply profile medicine new advances functional genomics availability across eu markets topic recurrent crispr changing possible drug debate recent years member states repeatedly raised discovery enable researchers pinpoint novel targets serious concerns problem medicines shortages higher probability success scale data call transparency prices rd costs public genetic libraries genomics requires artificial intelligence ai subsidies pushing roll back existing flexibilities eu interpret machine learning helps predict possible new legislation andor create additional hurdles market access pathways medicine growth data also improving europe many emerging markets international reference healthcare ecosystem helping build virtuous pricing irp continues gain traction markets cycle data technology rd regulators purchasers using primary lever pricing control use technologies track product effectiveness increasingly countries also cooperating health consumers relying digital tools manage technology assessments htas new eu hta regulation health understand genetic profiles helping proposal would centralise clinical assessments new research efforts building better understanding medicines medical devices genetics disease beyond europe many countries implementing various response forms hta china several policies proposed application advanced technologies central rd boost quality efficiency value healthcare delivery approach part innovation priority developing hta implementation among key initiatives proposed core capabilities ai machine learning functional genomics products high clinical value particularly seeking cell therapy accelerate pace identify premium price likely prioritised hta review develop novel targets medicines including creating especially oncology critical disease areas laboratory genomics research stateoftheart lab accelerating access innovation china also apply crispr gene editing technologies drug discovery implementing cost containment measures balance made significant investments help us realise healthcare budget saudi arabia establishing new potential cuttingedge technologies ultimately independent evidencebased hta entity help strengthen pipeline also attracting best maximise health gains efficient use resources scientific minds work us us entering finally japan pharmaceutical industry remains ambitious creative collaborations partnership concerned proposed use hta pricing lyell immunopharma enhance cell gene therapy control rather value assessment programme andme eight ongoing joint programmes see response aim improve health millions people year pricing access making products available responsible prices pricing healthcare products increasing pressure sustainable business getting right fundamental fund highcost innovative therapies continues attract performance trust priorities setting significant attention governments public price medicines developed markets apply calls better transparency prices set valuebased approach balance reward innovation greater emphasis value health outcomebased pricing access affordability see aim bring truly government payer budgets remain subject increasing differentiated innovative products bring highly effective review demand healthcare grows healthcare health outcomes patients payers even policy environment remains fluid payers introducing products high cost bring value patients increasingly restrictive costcontrol mechanisms healthcare systems investing genetics genomics us government proposed several drug pricing big data ai accelerating pace initiatives including new international pricing index order develop transformational medicines prioritising molecules reduce healthcare costs patients government higher probability success know genetically still significant potential obstacles validated drug candidates twice likely become implementation national drug pricing proposals multiple registered medicines improving productivity states also passed legislation regulation increases rd investment oversight transparency andor control pharmaceutical prices organisations assess value pharmaceutical products relative price health outcomes institute clinical economic review also rising prominence us gsk annual report industry trends continued regulatory environment societal expectations healthcare highly regulated industry reflecting public expectations business changing well delivering expectations products comply stringent levels quality financial returns companies expected create value safety efficacy range stakeholders taking action social environmental issues calling purpose governments continue introduce develop regulatory business redefined groups like business approaches support accelerated development roundtable leading business group us saying introduction new medicines encourage pharmaceutical corporation exists benefit stakeholders moving away innovation regulatory authorities exploring progress longstanding endorsement shareholder primacy adapt regulatory science address new potentially disruptive technologies digital healthcare cell order attract retain best talent companies need gene therapies big data realworld evidence work rise expectations workforce motivated crossborder harmonisation pharmaceutical regulation delivering greater purpose employees work increasing supranational bodies company strong sense purpose feel international council harmonisation geographic scope connected three times likely thrive continues expand including emerging markets work supporting introduction development time investors increasingly asking companies initiatives regulators different jurisdictions share articulate managing range environmental cooperate assessment regulatory submissions social governance esg risks opportunities major example us food drug administration fda institutional investors publicly stating believe providing framework concurrent submission review esg factors impact companys longterm success oncology products international partners important investment decisions response companies expected contribute un sustainable gsk closely monitors relevant appropriate development goals sdgs especially move engages improve regulation particularly final decade delivery growing public uk europe us example scientific innovation demand companies play role managing climate moves beyond scope current regulation standards change mitigating climate risk well address working sector engage governments environmental issues plastics air pollution water explore new policies processes incentives would management companies also increasing pressure support discovery delivery medicines developed address social issues human rights inclusion emerging technologies techniques see diversity fair pay direct operations throughout supply chain pharmaceutical sector particular trust deficit remains sustained scrutiny around sales marketing practices ethics compliance also facing additional reputational challenges related issues like opioid crisis us well growing momentum antivaccine movement regions response trust priority designed respond multistakeholder expectations prioritise areas positioned significant sustainable impact set public commitments support trust priority making good progress see pages recognise expectations moving quickly need respond accordingly see pages mercer global talent trends study input executives hr leaders employees industries countries gsk annual report strategic report governance remuneration financial statements investor information stakeholder engagement engaging building trust broad range stakeholders interact impacted business key delivering strategy ensuring success long term section statement various mechanisms enable management board understand consider stakeholder views part oversight decision making explained section statement set full incorporated reference strategic report summarise key stakeholder groups engage issues matter response patients insights patients consumers enable us matters consumers develop products better meet needs pricing healthcare products particularly outofpocket engage expenses advisory boards diseasespecific patient panels differentiated product innovation based patient patient advocacy leaders summits provide consumer needs patient insights access reliable supply highquality safe products engagement support patient groups disclosed gskcom initiatives empower patients take valuesbased approach pricing balance get involved medicine development reward innovation access affordability market research consumer sensory labs help strengthening pipeline bring innovative products uncover consumer insights patients ensure maintain high standards product quality safety investors maintain regular constructive dialogue matters investors communicate strategy performance financial performance commercial success order promote investor confidence ensure understanding rd strategy successfully continued access capital developing pipeline engage management key environment social governance ongoing communications including agm quarterly esg issues mitigate risk create opportunity results calls detailed company information online onetoone meetings board members senior continuing report line best practice disclosure executives institutional investors including introduction progress towards financial targets strategic goals roadshows new chairman cfo specific business rd updates events eg viiv meet biannual investors analysts perception study management vaccines investor day oncology roundtables first time conducted specific esg study increasing engagement esg matters healthcare work healthcare professionals hcps matters professionals medical experts understand patient needs access product scientific information ensure products administered medical responsible sales marketing practices right way experts safety efficacy differentiated innovation engage scientific dialogue increase understanding increasing use digital channels deliver disease management patient experience personalised effective sharing information hcps providing highquality balanced information updating salesforce incentive policy attract medicines vaccines retain best talent upholding ethical standards collaboration clinical trials research using hcp insights disease management patient experience inform development medicines rd partners partner scientific institutions national health matters academia systems business partners academia help finding right partner accelerate potential medicine ensure develop differentiated healthcare products vaccine approval reach patients engage pushing science far go advance human collaboration outstanding scientists organisations health across globe dissemination advancement scientific knowledge establishing joint ventures strengthen innovation efficiency working world leading experts biotechs universities working academic institutions accelerate scientific institutions improve drug discovery discovery development new medicines increase productivity rd pipeline collaborating partners open targets finngen uk biobank focused identifying diseaserelevant genes validate highpotential targets gsk annual report stakeholder engagement continued governments work governments regulators advocate matters regulators policies encourage innovation promote environments value innovation drive investment efficient management healthcare spending life sciences give patients support need scientific funding collaboration engage medicines pricing reimbursement meeting regulatory bodies throughout public health threats development process ensure high quality safe new products working policymakers support operating environment engaging government health agencies remains competitive rd investment enables mobility demonstrate value products scientific talent accelerates uptake innovative working governments build strong medicines including uk life sciences industrial strategy operating environment life sciences actively engaging government proposals healthcare reform including us successfully ensured patient access full treatment regimes hiv cancer maintained partnering authorities china ensure support global innovation including swift regulatory approval shingrix benlysta ngos work partners improve access healthcare matters multilateral services products advocate access medicines vaccines policy environment successful organisations achieving un sdgs targets specific engage disease areas working nongovernmental organisations ngos universal health coverage uhc future partners research develop products health systems address global health challenges sustainable financing global health collaborating ngos generic manufacturers sustainably supply products developing countries focusing unique valueadd global health partner partnerships strengthen health systems developing develop products scientific expertise countries drive progress global health priorities partnering organisations complementary capabilities reach create sustainable models share risk including working partners pilot implementation malaria vaccine leveraging community investment programmes support scientific expertise deliver impact patients suppliers work thousands suppliers large matters small provide goods services support prompt payment smaller suppliers us delivering reliable supply highquality understanding gsk standards policies ensure safe products patients consumers compliance engage opportunities innovate grow relationship regular direct engagement business owner supplier ensure support gsk 's strategies updating payment practices ensure smaller targets uk suppliers benefit preferential payment terms engage suppliers third party oversight conducting business suppliers share values programme conducting indepth audits high quality ethical standards ensure security supply participate crossindustry forums engaging suppliers develop improvement plans pharmaceutical supply chain initiative track progress identify areas improvement consumer goods forum improve supply expanding thirdparty environment health safety chain sustainability team countries priority suppliers located provide proactive support employees involve listen employees help us maintain matters strong employee engagement retain talented opportunities career personal development people flexible working support balancing wider responsibilities engage working inclusive diverse environment regular interactive lets talk events working purposeful company great line manager corporate executive team senior leaders facilitating dialogue collaboration providing employees access new development internal communications platform portal resources relevant roles global diversity councils employee resource development needs interests groups covering different strands diversity largest markets formal flexible working carer global allemployee survey one survey policies markets reviewing competitiveness employees provide feedback line managers monitoring employee engagement employee survey acting feedback improve engagement gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals pharmaceuticals business broad portfolio innovative established medicines respiratory hiv immunoinflammation oncology strengthening rd pipeline focus immunology human genetics advanced technologies help us deliver transformational medicines patients progress longterm priorities innovation performance trust strengthened rd pipeline total turnover billion filed us eu regulatory eight filings four assets aer flat cer submissions simplify optimise advancing pivotal phase iiiii strengthened capabilities extend use dolutegravir studies specialty care medicine children living hiv accelerated oncology portfolio changed sales incentive progressed gepotidacin positive pivotal data readouts programme recruit retain first new chemical class regulatory submissions representatives best antibiotics treat drug resistant zejula firstline maintenance expertise experience bacteria phase iii clinical ovarian cancer belantamab research supply chain productivity mafodotin relapsedrefractory since donated million albendazole multiple myeloma dostarlimab tablets support efforts end endometrial cancer lymphatic filariasis control received approvals expanded intestinal worms schoolage indications key medicines children across portfolio pharmaceutical regulatory invested significantly advanced inspections satisfactory technologies including establishing results laboratory genomics research collaborating lyell immunopharma read read read pages innovation new rd approach focuses science related rd pipeline contains potential new medicines immune system use human genetics application including clinical oncology assets doubled advanced technologies functional genomics number assets clinical oncology portfolio machine learning artificial intelligence cell therapy since early approach powered multiplier effect science x advanced four assets pivotal phase iiiii technology x culture helping strengthen pipeline studies achieved positive regulatory decisions data accelerate pace discover develop deliver readouts across portfolio medicines improve patients lives received approvals three medicines dovato hiv prepare create new gsk drive common treatment dectova treatment influenza b new approach rd across pharmaceuticals vaccines selfadministration options respiratory biologic nucala enable us effectively allocate capital also received expanded indications medicines including share technical scientific expertise deliver pipeline zejula oral poly adpribose polymerase parp inhibitor regardless modality new biopharma company ovarian cancer benlysta worlds first biologic evolving rd culture embrace singlepoint treatment systemic lupus erythematosus sle lupus accountable decision making smart risk taking submitted eight filings regulatory approval rewarding good decisions even outcome may expected help us deliver scientific technological excellence gsk annual report pharmaceuticals continued hiv oncology around million people living hiv worldwide cancer remains major global cause death work longstanding commitment combatting oncology aspires maximise patient survival preventing ultimately curing hiv helping make transformational medicines increasingly large smaller part peoples lives broad portfolio assets development alone novel combination studies pipeline focused hiv business managed viiv healthcare four areas immunooncology uses human majority owned gsk pfizer shionogi immune system treat cancer cell therapy human shareholders viiv healthcare sole global specialist tcells engineered target disease cancer epigenetics hiv pharmaceutical company forefront generegulatory system epigenome modulated innovation worlds hivdedicated discovery curb cancer synthetic lethality two mechanisms early development facility portfolio approved work together synergistically destroy cancerous cells antiretroviral medicines offers range therapeutic options people living hiv include established making good progress since early therapies tivicay triumeq contain dolutegravir doubled number assets clinical oncology pipeline considered potent available antiretroviral achieved three positive pivotal data readouts track three oncology launches pivotal year viiv healthcare growing achieved accelerating clinical momentum portfolio twodrug regimen dr programmes fasttracking assets acquired therapies powered dolutegravir launched oncologyfocused biopharmaceutical company tesaro dovato new oncedaily singlepill dr first approved successful business development collaborations treatmentnave patients us eu followed including strategic alliance merck kgaa positive results gemini tango studies showed dovato effective dolutegravirbased strengthen oncology pipeline enhance threedrug regimens containing fewer antiretrovirals cell gene therapy programme announced fiveyear traditional hiv treatments dovato first dr juluca collaboration lyell immunopharma lyell exploring ways aim reduce number hiv drugs people living improving function fitness tcells enhance virus take lifetime following launch response rates solid tumour cancers prevent relapses us japan nine european markets juluca achieved due tcell exhaustion combining cell gene therapy reimbursement additional markets programmes lyells technologies potential year sword studies demonstrated julucas enhance activity specificity cell therapies solid longterm safety efficacy tolerability tumour cancers submitted cabotegravir rilpivirine first oncemonthly current oncology assets complete longacting hiv regimen regulatory review zejula oral parp inhibitor approved us us eu followed global atlas flair pivotal europe women recurrent ovarian cancer phase iii studies demonstrated therapy believe zejula could transform treatment options effective daily oral threedrug regimen maintaining patients additional ovarian cancer stages viral suppression december received complete men women cancers response letter fda regarding us submission following priority review october fda work closely regulatory authority determine approved expanded indication zejula lateline appropriate next steps regulatory review eu ongoing treatment women whose advanced ovarian cancer july launched yearlong customize study associated homologous recombination deficiency identify evaluate ways implementing oncemonthly approval supported positive results hiv regimen clinical practice programme involves phase ii quadra study approval allows us address viiv healthcare employees working clinical staff healthcare unmet clinical need demonstrates zejula active providers people living hiv across us late line therapy women beyond brca mutations december also filed us approval december filed us regulatory approval zejula firstline maintenance therapy women fostemsavir firstinclass attachment inhibitor heavily platinum responsive ovarian cancer submission treatmentexperienced adults hiv infection including accepted fda based positive results failing current antiretroviral regimens phase iii prima study showed significant exhausted treatment options submission followed reduction disease progression women irrespective positive results week phase iii brighte study biomarker status line commitment delivering optimal hiv treatment reflecting broad development plan number formulations children made two regulatory submissions clinical studies zejula alone combination december aim simplify optimise extend therapies progress additional ovarian cancer stages use dolutegravir paediatric hiv patients well nonsmall cell lung cancer breast cancer information see gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals continued belantamab mafodotin firstinclass humanised respiratory immunoconjugate bcell maturation antigen gsk world leader respiratory five decades antibcma studied treatment multiple pioneering development modern innovative medicines myeloma second common blood cancer asthma chronic obstructive pulmonary disease copd currently cure extensive development launched six new treatments since establishing programme asset enable us move quickly broadest portfolio oncedaily inhaled respiratory earlier lines treatment december filed medicines industry regulatory approval following positive results pivotal continued successful roll trelegy ellipta dreamm study explored belantamab mafodotin single inhaler triple therapy copd available patients relapsedrefractory multiple myeloma markets key launches included subsequently granted priority review fda japan china following positive results phase iii secondline setting phase iii dreamm study captain study showed effect trelegy treating assessing belantamab mafodotin combination patients asthma filed new indication us standard care results inform pivotal secondline japan studies due start second half nucala firstinclass biologic patients severe also started two studies dreamm fourthline eosinophilic asthma sea continued strengthen phase iii study exploring use combination novel agents clinical profile approval us eu two new dreamm phase iii firstline study combination selfadministration options early data realitia standard care study showing nucala significantly reduces exacerbations dostarlimab pd inhibitor targeting endometrial cancer realworld setting approval us use children sixth common cancer women evaluated sea aged six provided new option difficult use monotherapy combination treat patient population immunooncology agents filed regulatory approval despite advances respiratory medicines still secondline endometrial cancer setting late areas significant unmet need continue innovate following positive results garnet study exploring nucalas potential across spectrum largest ever trial antipd monotherapy patients eosinophildriven diseases reported positive results advanced recurrent endometrial cancer september hypereosinophilic syndrome programme enrolled first patients ruby firstline study support regulatory submissions initiated new dostarlimab combination chemotherapy phase iii study copd data nasal polyps february announced global alliance merck programme anticipated achieved proof kgaa jointly develop bintrafusp alfa investigational concept two investigational medicines bifunctional fusion protein immunotherapy currently biologics pipeline longacting antiinterleukin il development multiple difficulttotreat cancers antagonist sea antiil receptor severe asthma advanced potential registration study secondline biliary hope provide new options patients extend tract cancer group rare aggressive gastrointestinal cancers respiratory leadership future associated limited treatment options poor outcomes immunoinflammation antiicos agonist antibody gsk designed committed research development selectively enhance function tcells studying medicines immunemediated diseases lupus antibody alone combination therapies rheumatoid arthritis ra significant health burden due considerable potential across range tumour patients society research focuses biology types following positive results induce study immune system reflecting aim develop immunological initiated phase iiiii study registration potential based medicines alter course inflammatory disease combination pembrolizumab firstline recurrent company biologic treatment benlysta metastatic head neck squamous cell carcinoma specifically developed approved adult paediatric lead tcell immunotherapy gsk targets lupus medicine approved adults china nyeso antigen expressed across multiple one million people lupus cancer types therapy accelerated development year intravenous benlysta became first biologic treatment path received european prime us fda approved us eu japan children breakthrough status ongoing phase ii studies synovial limited treatment options challenging disease also sarcoma lung cancer multiple myeloma asset along announced positive results pivotal blissln study cell therapies could enhanced leveraging showing effect benlysta active lupus nephritis technologies available us via new collaboration inflammation kidneys caused sle lyell immunopharma announced start phase iii study otilimab anti gmcsf antibody patients ra following results phase ii baroque study million people globally affected ra chronic systemic inflammatory condition gsk annual report pharmaceuticals continued pharmaceuticals pipeline overview assets development focused oncology expect number pivotal readouts phase compound indication pivotalregistration benlysta rituxan systemic lupus erythematosus cabotegravir la rilpivirine longacting hiv dovato hiv daprodustat hifphi anaemia fostemsavir attachment inhibitor hiv nucala copdhypereosinophilic syndromenasal polyps trelegy asthma dectova iv iv influenza nucala prefilled syringe severe asthma belantamab mafodotin bcma adc multiple myeloma zejula parp inhibitor firstline maintenance ovarian cancer dostarlimab pd antagonist endometrial cancer bintrafusp alfa tgf trapantipdl biliary tract cancer otilimab rheumatoid arthritis gepotidacin uncomplicated urinary tract infection gonorrhoea icos receptor agonist head neck squamous cell carcinoma phase expansionphase ii maturation inhibitor hiv hbv aso hepatitis b ilr antagonist severe asthma nyeso tcr cancer osm antagonist systemic sclerosis sarm copd muscle weakness molibresib bet inhibitor cancer linerixibat ibat inhibitor cholestatic pruritus primary biliary cholangitis prmt inhibitor cancer gr oxytocin postpartum haemorrhage tsr tim antagonist cancer leucyl trna inhibitor tuberculosis lag ulcerative colitis tsr lag antagonist cancer phase ccl antagonist osteoarthritis pain il la antagonist asthma tlr agonist cancer broadly neutralising antibody hiv nyeso immtac cancer hpgds inhibitor duchenne muscular dystrophy prmt inhibitor cancer nemiralisib pikd inhibitor activated phosphoinositide kinase delta syndrome sting agonist cancer ox agonist cancer crk inhibitor visceral leishmaniasis combinectin entry inhibitor hiv approved progressednew inlicence alliance relationship note oncology phase studies third party conducted patients progression includes programmes pivotal phases development pivotal data additional indications also investigation phase phase ii defined expansion reported regulatory submissions icos hnscc phase iiiii study cohorts started consideration review registrational potential gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals continued infectious diseases fiveyear collaboration university california started two phase iii studies gepotidacin first establish laboratory genomics research lgr new chemical class antibiotics treat drug resistant designed create stateoftheart lab apply crispr bacteria urogenital gonorrhoea uncomplicated urinary gene editing technologies drug discovery new laboratory tract infection marks first time infections explore gene mutations cause disease aim addressed new oral antibiotics years develop new crisprbased technologies understand first results expected end gene function geneticallyvalidated targets twice likely become successful medicines applications crispr brazil became first malariaendemic country drug discovery important approach improve approve kozenis radical cure p vivax malaria rd productivity singledose kozenis known krintafel us first new treatment p vivax malaria years lgr programme builds collaboration milestone follows publication positive results andme worlds leading consumer research genetics detective gather phase iii studies company enhancing ability identify function diseaserelevant genes validate highpotential disease using new technology develop novel medicines targets aim begin first clinical programme hepatitis b viral infection liver lead andme eight ongoing joint programmes significant health conditions including cirrhosis liver failure across oncology immunology neurology cardiovascular liver cancer exercised option license ionis lgr also extends relevance genetics genomics pharmaceuticals antisense medicines people collaborations open targets collaboration chronic hepatitis b following positive phase ii results led discovery new synthetic lethal target received eu approval dectova intravenous treating cancers genomic instability wrn reqq helicase treatment influenza b cause epidemic gsk scientists collaboration sanger institute seasonal infections innovation intended hospitalised uk additional important collaborations include finngen patients complements oral version neuraminidase uk biobank dutch human functional genomics inhibitor market relenza project viiv healthcare announced fiveyear additional programmes collaboration japan filed regulatory approval daprodustat delivering next generation medicines oral hypoxiainducible factor prolyl hydroxylase inhibitor evolving culture rd better patients anaemia associated chronic kidney equipped discover deliver next generation disease approved daprodustat provide new transformational medicines incentivising scientists convenient oral treatment option patients mindset singlepoint accountability smart risk leveraging advanced technologies taking courageous decisions made owned advanced technologies central rd approach individuals rather consensusdriven made significant investments artificial intelligence significant steps taken across rd ensure machine learning functional genomics cell therapy prioritising best assets ending exiting accelerate identification novel targets medicines underperforming programmes moving away therapy realise potential cuttingedge technologies area based approach research helping teams made numerous internal appointments lead focus molecules likely become medicines build inhouse capabilities also announced embracing fresh thinking new talent external partnerships ambitious goals key rd roles around half joining outside company moved integrated governance model involving scientific peer review commercial input data driven decisions gsk annual report pharmaceuticals continued performance pharmaceuticals turnover million creating specialtyready competitive supply chain aer flat cer hiv sales aer cer reliable supply core growth key therapy areas million respiratory sales aer creating modern agile supply chain underpinned cer million sales established pharmaceuticals new technology launch specialty medicines speed million aer cer see group accelerating delivery across portfolio financial review full details opened nextgeneration biopharmaceutical accelerating growth transitioning towards manufacturing facility upper merion pennsylvania site specialty care technologicallyadvanced million manufacturing hub continued align resources behind flexibility speed necessary making complex markets therapy areas brands greatest specialty medicines new analytical lab also part opportunity growth improve performance facility brings together rd manufacturing teams excellent execution launches hiv respiratory upper merion help us develop highlyskilled major focus concentrating key markets assets workforce improved technological scientific capabilities ongoing investment clinical evidence deliver right infrastructure research potential new genetic targets compelling competitive medicine profiles achieved manufacture new medicines also completed strong performances new recent launches million expansion rockville maryland site including trelegy ellipta nucala juluca dovato increase manufacturing capacity benlysta line growing shift portfolio innovative singapore opened new stateoftheart pharmaceutical specialty care products including oncology reinforced manufacturing facility jurong site million capabilities areas anticipation three oncology development included creation two continuous launches leveraging acquisition tesaro manufacturing facilities expansion modernisation made rapid material progress developing oncology existing production unit transformation expected commercial expertise recruiting outstanding people significantly improve efficiency expand capacity track record success oncology key markets including manufacturing assets including daprodustat rebalancing us salesforce also increased broader dolutegravir reduce medicine production times investment specialty care example benlysta completed exits guarulhos brazil cork additional resource new team drove strong performance ireland suzhou china sites network initiated part twoyear programme prepare separation exit verona italy site expect complete support longterm priorities rationalise portfolio divestments plan review several improving supply performance assets including prescription dermatology business ontime infull supply performance levels customers engaging healthcare professionals improved putting gsk top quartile support transition towards specialty care benchmarked peers measure productivity focused portfolio revised incentive programme sales levels risen past three representatives certain countries allow us attract years new products introduced time including retain best salespeople enhancing quality successful delivery firstmarket launches dovato dialogue healthcare professionals hcps help new nucala selfadministration options better serve patients changes uphold ethical continued perform well safety quality valuesled approach hcp engagement full compliance compliance measures pharmaceutical laws policies supporting delivery strong regulatory inspections satisfactory performance applied initially us uk canada comprehensive training controls monitoring digital transformation ensure appropriate implementation progressing towards goal becoming digital datadriven organisation continued also evolved way engage hcps certain improve way harness technology developing new countries improve understanding new data clinical ways working drive performance increase ability experience innovative products deliver better deliver medicines patients leveraging data outcomes patients included introduction unlock smarter faster interactions customers scientific workshops enable interactive debate understand impact commercial activities among hcps increased use digital channels prescribing includes piloting artificial intelligencedriven support scientific engagement virtual advisory boards recommendations help optimise hcp engagement educational activities webinars initiatives also applying advanced analytics drive efficiencies wellreceived positive feedback hcps across business supply chain management early indications suggest changes enhancing manufacturing commercial operations identifying understanding science behind key medicines opportunities free resources including nucala dr hiv treatments gsk annual report strategic report governance remuneration financial statements investor information vaccines worlds largest vaccines company revenue delivering vaccines protect people stages life rd focuses developing vaccines infectious diseases combine high medical need strong market potential innovation performance trust progressed four new candidate total turnover billion released positive final phase ii vaccines human trials aer cer results tb candidate vaccine including one using novel primarily driven growth announced licensing vaccine technology sam shingrix gates mri continued received fda fast track optimised supply chain development low income designation three increase shingrix production countries high tb burden rsv candidate vaccines capabilities january increased pipeline focus received authorisation shingrix launched rtss malaria therapeutic antimicrobial china prevention vaccine selected regions resistance vaccines shingles adults aged malawi ghana kenya agreed three partnerships part whocoordinated pilot programme accelerate development new assets technology made adjuvant technology available partners including cepi early support rapid development candidate vaccines coronavirus sarscov read read read pages innovation rd approach powered multiplier effect category lifecycle management focused science x technology x culture focus expected development new presentations indications enable us develop deliver groundbreaking vaccines geographic expansion marketed vaccines remain forefront vaccines science leverage new classify new commercial assets vaccine disruptive technologies within rd culture built smart candidates potential make greatest contribution risk taking attracts develops retains best commercial success future 'new global health people partners leading experts assets ' vaccine candidates highest potential impact global health threats development innovative assets clinical development global health assets using science including key data readouts several candidate vaccines expected proprietary technology platforms focusing investment classify vaccine pipeline three categories maximum impact ensuring development lifecycle management new commercial assets global sustainable backed strong partnerships see trust health assets ensure allocate appropriate resources priority vaccine development programmes deliver best value society support groups strategy gsk annual report vaccines continued accelerated development candidate three rsv candidate vaccines tailored meet vaccines respiratory syncytial virus rsv specific needs target group maternal paediatric advanced therapeutic candidate vaccine chronic older adults given promising early results obstructive pulmonary disease copd progressed four strong medical need three rsv candidate vaccines new strategic candidate vaccines human trials one fda fast tracked phase iii trials rsv older adults second clostridium difficile key data readouts expected could help address antimicrobial resistance third maternal rsv candidate based recombinant testing sam technology rabies model fourth prefusion antigen paediatric rsv candidate harnesses therapeutic candidate vaccine chronic hepatitis b adenovirus vector technology older adult rsv focus work also terminated hepatitis c candidate people leverages recombinant virus universal flu programmes met prefusion antigen combined adjuvant system expectations work hiv candidate vaccine key ingredient shingrix enabling efficacy developing countries discontinued clinical results success market showed lack efficacy also transferred candidate vaccines ebola marburg viruses sabin copd vaccine institute see one deaths globally caused copd vaccine currently exists prevent disease copd expertise vaccines advanced technology candidate therapeutic vaccine aimed reducing allowed us focus technologies therapeutic frequency acute exacerbations slowing disease antimicrobial resistance candidate vaccines also puts progression copd sufferers contains four bacterial us strong competitive position new era therapeutic antigens adjuvant system programme vaccines pipeline increasingly expand prophylactic complements leadership medicines respiratory assets include therapeutic assets provide benefits diseases date demonstrated adjuvanted throughout course life investing several copd vaccine candidate safe highly immunogenic therapeutic assets including moving candidate vaccine enrolment phase iib study adults chronic hepatitis b phase iii clinical development completed ahead plan study results due additional benefit accelerated delivery typically involve shorter regulatory lead times allow accelerated clinical testing lifecycle management shingles meningitis balance focus strong pipeline active vaccines scientists foundation innovation lifecycle management marketed vaccines enables success continue evolve culture focus us deliver new presentations reach populations creating environment people take accountability geographies established vaccines ensuring smart risks focus accelerating development timelines continue play strong role business performance simplified governance process six pipeline programmes evolutions existing implemented single point decision making early products franchises announced proposal create development organisation gsk rd part twoyear shingles programme create new gsk common rd shingrix marks step change prevention shingles approach made progress accelerating priority painful potentially serious illness vaccine addresses pipeline assets including accelerating delivery agerelated decline immunity achieving rsv portfolio achieved challenging efficacy across age groups first nonlive shingles approach regulatory engagement using techniques vaccine combine specific antigen adjuvant adaptive clinical trial design quality design sustain immune response published new reduce manufacturing scaleup time clinical data supporting use shingrix adults greater risk shingles due conditions cancer organ developing delivering groundbreaking vaccines transplant currently exploring possibility rsv copd extending vaccines indication based results important factor determining development vaccine candidates pipeline burden disease shingrix received prestigious prix galien award every copd infections rsv high prevalence country available us best pharmaceutical medical need therefore key assets pipeline product germany best primary care product canada best innovative product prix galien considered rsv worlds leading award innovation excellence medical portfolio three different candidate vaccines products devices rsv common cause lower respiratory tract infection currently vaccine protects virus us alone leads hospitalisations adult deaths every year gsk annual report strategic report governance remuneration financial statements investor information vaccines continued meningitis partnerships market leader vaccines meningococcal partnerships central innovation strategy meningitis based revenue complementary efforts accelerate vaccine development collaborate portfolio bexsero targeting serogroup b menveo leading experts institutions companies access serogroups c w since launch external cuttingedge technology expertise aim bexsero become industryleading meningitis b vaccine scientific partner choice currently us licensed year olds phase iii external collaborations across multiple fields trial currently evaluating lowering age indication two continued building valuable partnerships including months simultaneously alternative liquid presentation one develop new vaccine prevent cervical cancer menveo progressing phase ii trials simplify vaccine innovax xiamen university china established preparation steps healthcare providers january collaboration vbi biotech company facilitate new england journal medicine published two independent development specialised therapeutic vaccine candidate meningitis b studies demonstrating real world impact patients recurrent glioblastoma also established bexsero reducing disease infants showing drop partnership viome company deep expertise cases uk three years need direct understanding gut microflora role chronic individual protection among adolescents us fda diseases facilitate vaccine development prevent approved indication single booster dose administration even treat conditions menveo individuals aged years continued risk meningococcal disease least four years vaccines pipeline elapsed since previous dose remain committed developing pentavalent phase indicationvaccine meningitis abcwy vaccine targeting five common registration shingrix immunocompromised meningococcal serogroups research efforts building rotarix liquid pcv free successful vaccines bexsero menveo combining phase iii bexsero infants us antigens two vaccines favourable safety mmr us efficacy profiles following completion phase ii studies discussion regulatory phase ii therapeutic copd authorities potential phase iii start key data rsv paediatric expected published menabcwy leveraging advanced technologies menveo liquid expertise capabilities developing applying advanced technologies important differentiator malaria fractional dose led industry adjuvant technology decades shigella continue innovate field rsv maternal adjuvant technology platforms lead enhanced phase iii rsv older adults immune response play key role innovation therapeutic chronic hepatitis b adjuvant technology key component six pipeline assets including rsv copd candidate vaccines clostridium difficile well enabling success licensed shingrix vaccine sam rabies model adjuvant technology made available partners including cepi collaborations strengthen global response coronavirus epidemic sarscov commercial assets global health assets lifecycle management sam platform started clinical investigation inlicense alliance relationship third party august potential significantly reduce porcine circo virus free formulation lead time vaccines research enable faster simpler manufacturing improve vaccine potency novel technologies progressing include bioconjugates generalised modules membrane antigens gmma used investigate two shigella candidates currently phase ii see trust section gsk annual report vaccines continued performance vaccines turnover million aer directed significant capital expanding supply cer primarily driven growth sales shingrix chain capacity meet demand shingrix working meningitis vaccines also contributed significantly growth creating new purposebuilt facility expect bring see group financial review full details line based strengthened manufacturing capacity achieved supply high teens millions doses future growth strategy year ahead original plans meantime ambition continue grow business ahead ensuring continuity supply across markets global vaccines market achieve objective already launched shingrix phased launches prioritising key assets shingrix bexsero focusing additional markets us china worlds two largest vaccines markets improve focus efficiency divested two shingrix manufacturing capacity increases sites ankleshwar india tianyuan china opportunity expand vaccines geographic footprint also transferred bavarian nordic two time year received regulatory approval travel vaccines rabies tickborn encephalitis shingrix china plan phased launch ensure continuity supply also potential expand supply performance reach shingrix increasing coverage eligible supply performance continued improve adults us extending indication younger demonstrated bexsero shingrix flu supply immunecompromised adults shipped million doses achieved strong ontime infull otif delivery key strategic asset bexsero already share global meningitis b vaccines market based part twoyear programme create new gsk revenue grow bexsero main geographic focus optimise vaccines manufacturing network eu us eu infant indication support commercial pipeline assets strong market advantage competitor product offers include investment lyophilisation facilities filling adolescent protection us short immunisation packaging technologies simplification schedule allows doses taken within one supply chain processes month particularly relevant local meningitis outbreaks vaccines sites inspected fda passed expand us besides shingrix bexsero belgium pertussis acellular manufacturing facility developing assets specifically us market passed fda preapproval inspection new including mmr vaccine pcvfree formulation rotavirus inactivated poliovirus vaccine unit track file vaccine currently phase iii testing china plan eu approval leverage established vaccine portfolio including cervarix digital transformation engerixb well licensing existing vaccines progressing towards goal becoming digital future datadriven organisation continued improve creating simpler competitive supply chain way harness technology developing new ways working worldclass network manufacturing sites drive performance increase ability deliver vaccines across countries gives us strategic global supply people around world leveraging data artificial capability allows us produce deliver around intelligence digital models optimise research million vaccine doses every day development projects well supply network drive efficiencies across business gsk annual report strategic report governance remuneration financial statements investor information consumer healthcare worldleading consumer healthcare business combines science consumer insights create innovative everyday healthcare brands consumers trust experts recommend oral health pain relief cold flu allergy relief digestive health vitamins minerals supplements progress longterm priorities innovation performance trust first market launches across total turnover billion supply chain service levels categories including sensodyne aer cer continued improve pronamel intensive enamel repair proforma excellent ontime infull delivery tums chewy bites completed joint venture performance cooling sensation pfizer combined consumer helped children access new innovation rollouts healthcare businesses track free lifechanging cleft lip including sensodyne sensitivity deliver synergies million palate surgery comprehensive gum polident cushion total annual cost savings cleft care partnership comfort smile train read read pages read pages innovation closed deal pfizer combine two denture care consumer insights show denture consumer healthcare businesses making us number one wearers experience gum discomfort regular basis globally overthecounter otc medicines therapeutic significant impact lives address oral health giving us leading positions key geographies developed polident cushion comfort provides including us china better cushioning comfort tired tender gums well providing strong denture adhesive launched proportion sales products introduced markets including italy spain past three years pain relief gained approval fda february delivering bestinclass innovation voltaren arthritis pain otc product combine deep consumer insights scientific temporary relief arthritis pain voltaren arthritis pain first technical expertise deliver innovations across prescription strength nonsteroidal antiinflammatory nsaid categories example oral health launched topical gel arthritis pain available otc us nearly advanced formulation enamel care pronamel intensive million americans osteoarthritis enamel repair toothpaste us uk germany people globally risk enamel tums almost yearold brand continues innovate wear european adults aged already focusing improving fast heartburn relief one showing moderate signs enamel wear formula common heartburn symptoms burning sensation proven actively repair acidweakened enamel help mouth throat tums chewy bites always fast people strengthen protect teeth acting essential develop antacid consumers could also feel working address created another launch sensodyne sensitivity gum tums chewy bites cooling sensation goes work developed approximately one third adult seconds providing cooling sensation consumers population experience tooth sensitivity half cool fight heartburn fast also experiencing gum problems new offering provides dual relief sensitivity bleeding gums one daily toothpaste launched markets including uk turkey based nicholas hall 's db global otc database gsk annual report consumer healthcare continued building industryleading capabilities research found consumers india consumer sensory labs around world enable us china increasingly looking products combine listen understand meet needs consumers science natural traditional approaches leveraging every year carry research involving around insights developed sensodyne herbal multicare consumers either one three consumer sensory toothpaste relief sensitive teeth captures labs consumers homes gain deeper understanding flavours eucalyptus fennel consumer reactions products development increasing use digital technology revolutionising process help improve brands develop new ones way consumers buy use healthcare products using added consumer sensory lab facility joint venture pfizer opportunity build us joint venture plan digital innovation capabilities evolve digital innovation open new lab china enhance capabilities hub team develop innovations focused creating platforms business models meet future healthcare needs consumers performance consumer healthcare sales million creating worldleading consumer healthcare company aer cer proforma basis sales grew since completing transaction pfizer create new driven strong performance oral health category partly consumer healthcare joint venture july offset decline skin health mid year completed joint made good progress towards integrating two businesses venture pfizer creating leading consumer healthcare day joint venture completed legal closes business markets including two biggest markets us china together accounting pfizer consumer leveraging joint venture integration catalyst healthcare revenues following close business continuity accelerate growth drive innovation sharpening issues significant employee experience issues reported strategic resource allocation ensure focus investments completed appointment approximately critical right markets brands generate leadership roles end completed legal closes strongest growth highest returns power brand portfolio joint venture local markets continue expanded addition advil centrum alongside work towards local closes remaining markets seven power brands including sensodyne voltaren theraflu local star brands geographically time announcing joint venture announced concentrated one key markets tums intention separate consumer healthcare via demerger emergenc chapstick us caltrate fenbid within around three years closing transaction china together power brands local stars drive future ready programme planning work begun prepare performance consumer healthcare reinforce global future separation focused building key leadership pain relief respiratory wellness therapeutic technology infrastructure support functions necessary oral health operate standalone company work continue parallel integration joint venture delivery redefining operating model reflect global planned savings local nature brands moving accountabilities decision making closer consumers customers accelerate track deliver billion synergies speed market leverage scale expertise synergies expected achieved number areas global portfolio also investing key capabilities including network rationalisation logistics infrastructure digital data analytics sustainability unlock growth advertising marketing sales distribution functional ensure meet expectations consumers support cost savings generated intended customers reinvested joint venture support innovation growth opportunities overall consumer healthcare joint venture targeting adjusted operating margin percentage midtohigh work continuing secure required regulatory approvals proposed sale horlicks consumer health food drinks brands unilever announced december following strategic review nutrition portfolio also progressing proposed merger stake glaxosmithkline consumer healthcare limited india hindustan unilever limited would allow hindustan unilever limited sell distribute otc oral health brands india distribution arrangement transaction expected finalised around end q subject approvals gsk annual report strategic report governance remuneration financial statements investor information consumer healthcare continued leading growth winning shoppers customers experts create new business evolving culture expert endorsement builds trust brands drives put consumers customers heart every decision shopper purchase decisions sensodyne retains unequalled take build leadership capabilities drive performance number one leadership position dentists brand second half took steps define recommended often sensitivity markets behaviours mindsets required embed effective decision compete otc brands sold making clarity accountability courageous straight talk pharmacies continued prioritise relationships top leaders building strong ownership dentists pharmacists invest information acting culture ambassadors across business supports products expert sales representatives deployed streamlined decision making tool designed called dentists markets share relevant help identify single point accountability plan sciencebased information roll also implemented high shopper science labs uk us singapore performing team development programmes around use stateoftheart technology track shopper behaviour senior leadership teams emphasis straight talk real time provide us rich insights consumers decision making actively listening taking action shopping habits around world additional satellite employee feedback perception evolution lab facilities located canada south africa mexico culture integration planning engagement headquarters major us retail partners quarterly consumer healthcare pulse surveys annual gsk employee survey see pages leveraged shopper science labs strengthen customer relationships developing ecommerce digital transformation evaluation tool enables us overlay digital content putting digital technology heart business integrate digital prototyping tools key retailer websites aim deliver meaningful interactions consumers including amazoncom tescocom simulate realistic fuel brand growth achieve efficiency savings ecommerce shopping experience shoppers continued accelerate digital transformation prioritise building digital capabilities including hiring expert new talent creating simpler competitive supply chain continue drive strong improvement service launched threeyear asia pacific digital accelerator customers continued excellent ontime infull service levels programme drive sales digital commerce promote allowed supply chain focus opportunities digitalfirst culture within region programme integrates driving value business consumers external digital experts gsk consumer healthcares team environment eliminating waste packaging costs different countries across asia pacific enhance digital capabilities build internal capacity embed agile ways joint venture provided renewed focus cost saving working initiatives leaner structure nonmanufacturing site teams drive synergy savings increase speed decision making made progress transforming marketing model includes optimisation manufacturing network capabilities strategically important areas notably consolidating maximising capacity sites creation cuttingedge marketing services team streamlining number contract manufacturers cmos leverages technology solutions data strategic partnerships use ensure right balance trusted costefficient provide specialist marketing capabilities scale improve manufacturing clear business continuity plans place quality effectiveness marketing campaigns manage supply stability announced combining anonymised firstparty data googles closure agbara nigeria dehiwala sri lanka secondparty data leveraging additional technology supply chain consolidated accountability platforms identify signals help us target specific endtoend operations regions built closer audiences based behaviours dynamic partnerships local commercial rd teams drive relevant content across media platforms local innovation significantly improve supply chain agility rolled new technology platform markets making products frequently smaller batches enables us track media spend real time enabling allows less inventory enables us respond us optimise campaign performance target audiences quickly effectively changing consumer demand greater precision create valuable first party data together insights provided platforms delivering improved consumer experience personalised content efficiency savings gsk annual report trust trust one three longterm priorities essential achieve purpose drive longterm growth add value society shareholders commitments trust purpose help people feel better live longer using science making products modern technology address affordable available employer health needs new medical innovations pricing engaged people develop differentiated highquality improve health millions achieve maintain competitive needed medicines vaccines people year making employee engagement score consumer healthcare products products available responsible improve health prices sustainable inclusion diversity business global health accelerate progress inclusion improve global health impact product reach diversity aiming rd infectious diseases use access strategies reach female representation senior roles affect children young people million underserved people recognition global lgbt developing countries focusing developing countries indices hiv malaria tb products health wellbeing development health security healthcare access leading company help world better prepare partner improve disease support employee health wellbeing future disease outbreaks prevention awareness access personal development pandemic potential tackle healthcare services million antimicrobial resistance people responsible business reliable supply ethics values data engagement environment commit quality safety operate ethical values use data responsibly reduce environmental reliable supply driven culture transparently improve impact one quarter products patients issues responded patient scientific consumers swiftly transparently engagement society high expectations businesses people commitments seek address material topics rightly expecting companies behave responsibly relevant stakeholders business contribute tackling societal challenges operating designed help us respond challenges opportunities responsibly brings direct benefits society also creates within industry society broadly see pages value shareholders supports ability attract contribute many un sustainable retain talent manage costs build trust patients development goals sdgs scienceled global consumers customers payers stakeholders healthcare company biggest contribution towards goal influence licence operate mechanisms ensure healthy lives promote well ages help us identify respond different stakeholder corporate responsibility cr committee forms groups summarised pages important part boards oversight trust priority commitments detailed support trust committee provides ongoing scrutiny progress priority driving progress key areas commitments company addressing evolving make significant impact ensuring running views expectations broad range stakeholders business responsible way corporate executive team senior management oversee implementation trust commitments report regularly cr committee see pages gsk annual report strategic report governance remuneration financial statements investor information trust continued external benchmarking approach reporting djsi top pharmaceutical industry group trust section report progress dow jones sustainability index commitments also publish online detailed information atmi top access medicine index leading contribution sdgs along esg performance industry antimicrobial resistance benchmark summary current historical data un global compact communication progress global reporting ftsegood member ftsegood index since initiative index sustainability accounting standards board cdp received score b cdp climate index assurance statements change cdp water named cdp supplier engagement leader gskcom responsibility reports data contribution sdgs science technology committed using science technology final phase iib results candidate vaccine address health needs innovation core developed partnership iavi confirmed primary findings unique opportunity impact vaccine candidate showed reduced risk developing global health prevention treatment infectious pulmonary tb half hivnegative adults latent tb diseases urgent public health threats growing infection january announced licensing resistance antibiotics asset bill melinda gates medical research institute continued development low income countries new medical innovations high tb burden line global health strategy biggest impact scienceled global healthcare company successfully discover develop worldleading portfolio firstinclass medicines innovative products using cuttingedge science tb spanning different mechanisms combination technology develop differentiated highquality needed medicines may contenders transform medicines vaccines consumer healthcare products tb landscape part new tb regimen effective improve health read innovation within three patients even resistance currentlyavailable businesses pages tb medicines global health february joined partnership accelerate commitment improve global health impact new tb treatments pantb collaboration involving rd infectious diseases affect children young companies bill melinda gates foundation people developing countries focusing hiv malaria tb aims accelerate development treatment course early discovery work also allows us pursue promising form tb even multidrug resistant forms infection scientific leads developing world diseases create course shorter less complicated easier chagas disease leishmaniasis sleeping sickness tolerate existing options need ensure sustainable collaborative model malaria translating scientific discoveries benefit work fight malaria ranges developing medicines vulnerable patients ensure ongoing sustainability vaccines working partners strengthen health systems investment global health science interests rtss vaccine first vaccine help protect children products reaching patients quickly seek deadliest form malaria p falciparum development partnerships appropriate maximise whocoordinated pilot implementation programme led impact transfer technology third party organisations local ministries health partnership path right capability focus example gsk launched selected regions malawi ghana transferred ebola marburg vaccine candidates kenya every year least children sabin vaccines institute believe transfers expected receive vaccine committed help ensure vaccine candidate technologies donating million doses undertaking additional developed faster efficiently brought postapproval pharmacovigilance effectiveness impact need studies currently working path tuberculosis gavi potential funders ensure sustainable supply tb leading cause death infectious disease vaccine potential broad implementation beyond worldwide represents significant public health threat pilot effective vaccine tb marked impact tafenoquine krintafelkozenis single dose radical cure diseases control including drugresistant tb treatment p vivax malaria developed partnership interruption transmission also help medicines malaria venture received regulatory approval achieve world health organization target malaria endemic countries brazil thailand ending tb epidemic early gsk annual report trust continued hiv health security viiv healthcare committed developing using vaccines medicines scientific knowhow delivering hiv treatment formulations optimised specifically help world better prepare future disease outbreaks infants children age driven pandemic potential tackle antimicrobial resistance amr wholed paediatric arv drug optimisation priorities pandemic preparedness continued progress clinical development gsk committed playing part prepare programmes paediatric formulations dolutegravir respond pandemics work governments support partnership international maternal paediatric pandemic readiness plans support pandemic adolescent aids clinical trials network paediatric influenza preparedness agreement adopted member european network treatment aids states event declared pandemic provide realtime access pandemic december filed fda eu regulatory influenza vaccines antivirals worlds poorest submissions seeking approval firstever mg countries commitments combination donations dispersibletablet formulation dolutegravir well tiered prices depending countrys gross national simplified dosing regimen optimise use existing income gni gsk supports whos pandemic dolutegravir mg filmcoated tablet paediatric hiv patients preparedness activities including global influenza submissions gateway regulatory surveillance response system worldwide network submissions low middleincome countries well able rapidly identify respond influenza outbreaks providing regulatory references generic manufacturers including pandemic potential register paediatric formulations voluntary licensing agreements february gsk announced two new collaborations make established pandemic vaccine adjuvant platform publicprivate partnership clinton technology available enhance global efforts develop health access initiative unitaid two generic manufacturers vaccine novel coronavirus sarscov mylan macleods expediting development use adjuvant added vaccines enhance registration market entry generic formulations immune response particular importance pandemic paediatric dolutegravir resourcelimited settings aim situation since reduce amount antigen required per project reduce gap dispersible dose allowing vaccine doses produced made tablet formulation available generic dispersible available people first collaboration announced tablet formulations available children developing coalition epidemic preparedness innovations cepi countries months rather years university queensland second collaboration developing world diseases chinabased clover biopharmaceuticals pursue promising scientific leads areas addressing antimicrobial resistance beyond tb malaria hiv within gsk amr one biggest health challenges facing world tres cantos open lab spain gsk vaccines institute playing leading role industrys response global health gvgh italy gsk ranked first access medicine tres cantos open lab furthers rd diseases foundations amr benchmark performance developing world offering external researchers potential vaccines play critical role avoiding need antibiotics access gsks compound library screening tools preventing bacterial viral infections vaccines scientific expertise well supporting research tb diseases diphtheria meningitis pneumonia malaria projects include neglected tropical diseases pertussis protected tens millions individuals chagas disease leishmaniasis sleeping sickness bacterial infections major drivers direct antibiotic gvgh aims discover effective affordable vaccines prescribing highburden infectious diseases developing countries addition vaccines nonbacterial infections like around scientists focus translating laboratory concepts influenza rotavirus malaria also prevent unnecessary highquality vaccines current areas work include avoidable prescribing antibiotics due secondary shigella invasive nontyphoidal salmonella typhoid infections committed researching developing paratyphoid fever group streptococcus new vaccines prevent mitigate amr infections february indian health regulatory authorities reduce avoidable antibiotic use approved new vaccine help protect children one pharmaceutical companies typhoid fever first developed gvgh actively research develop new antibiotics treat resistant transferred indian vaccine company infections pharmaceutical pipeline gepotidacin biological e proofofconcept demonstrated first new chemical class antibiotics mechanism first licensing vaccine created gvghs distinct currently approved antibiotic progressed labs successfully developed brought market phase iii clinical research october effective partnership studied treat patients uncomplicated urinary tract gskcom inside gvgh infection urogenital gonorrhoea many contract strains resistant existing treatments gsk annual report strategic report governance remuneration financial statements investor information trust continued however rd many types bacterial infections survey antibiotic resistance soar economically sustainable current market conditions programme analyse antibiotic resistance local level governments recognise need financial support share findings healthcare professionals hcps partnered us governments biomedical public health bodies inform development local advanced research development authority antibiotic prescribing guidelines one defense threat reduction agency also support public companies sharing amr surveillance data publicly private partnerships aim speed discovery open data platform run wellcome trust open development new medicines treat prevent resistant data institute addition trained hcps bacterial infections collaboration capability across countries appropriate use antibiotics building started implement new global limits reducing antibiotic discharge manufacturing environment across antibiotic factories suppliers track meet new global limits end address pharmaceuticals environment see environment section gskcom preparing future disease threats affordability availability making products affordable available provided prescribed medicines vaccines people around world responsible pricing eligible uninsured patients strategic access programmes partnerships patient assistance programme pricing europe engage governments payers work aim improve health millions people year towards sustainable health systems support ongoing making products available responsible prices innovation example pricing trelegy ellipta reflects sustainable business economic value demonstrating costeffectiveness innovation within acceptable budget offering potential recognise pricing pharmaceutical medicines costsaving compared alternatives vaccines important issue developed developing countries understand patient payer concerns developing countries use innovative pricing structures affordability setting price medicines part access strategies extend product reach developed markets apply valuebased approach see pages tiered pricing model vaccines balance reward innovation access affordability example based four widely recognised world bank gni country classifications high income upper middle income aim bring truly differentiated innovative products lower middle income low income price ceilings price bring highlyeffective health outcomes patients payers floors exist tier ceilings floors progressively even products high cost bring value decreasing tiers high low income countries patients healthcare systems investing genetics genomics big data ai accelerating pace least developed lowincome countries file develop transformational medicines prioritising patents medicines enforce historic patents molecules higher probability success know allows generic companies manufacture supply geneticallyvalidated drug candidates twice likely generic versions gsk medicines countries become registered medicines improving productivity gskcom pricing access strategies rd investment price medicines according value outcomes product reach bring patients providers payers aim use access strategies reach million sensitive market societal expectations underserved people developing countries products strategies include tiered pricing product us pricing product launches including donations voluntary licensing agreements extend access recent launches dovato nucala autoinjector trelegy generic manufacturers since set target ellipta shingrix juluca incorporate specific market products reached million people dynamics unique product well profile new access strategies medicine vaccine context existing treatment options last five years average net price products tiered pricing principles mean reserve lowest us fallen per year average list price vaccines prices organisations gavi vaccine rose per year average net price across alliance supports countries gni per head less us portfolio decreased around average list example rotarix vaccine available price rose product level largest single gavi countries protect rotavirus increase list price taken resulted price discounts rebates allowances increase net price offer various types patient total excludes reach albendazole donations assistance help ensure appropriate access medicines assessed gsk annual report trust continued provided pneumococcal vaccine synflorix partnerships americares direct relief gavieligible countries discounted price reaching ihp uk map international nearly units gsk million people committed delivering million medicines distributed humanitarian emergency doses synflorix gavi via current advanced market response countries commitments contract gskcom pricing access strategies distributed around doses vaccine healthcare access cervarix zimbabwe support multiage cohort aim partner improve disease prevention awareness vaccination programme protecting around girls access healthcare services million people human papillomavirus also delivered million since set target reached nearly million doses oral polio vaccine unicef support global people partnerships polio eradication initiative reaching million children since viiv healthcare invested million continue innovate help improve access vaccines positive action grants address hiv stigma lowresource settings introduced support hiv education prevention alone new multimonodose blowfill seal presentation vaccine positive action children programme directly reached almost rotavirus introduced first time people committed supporting partnerships myanmar support gavi new presentation end aids viiv healthcares mission leaving helps reduce cold chain volume resulting lower person living hiv behind cold chain transportation costs partnering comic relief complement july viiv healthcare marked fifth anniversary efforts combat malaria rd see voluntary licensing agreements medicines patent projects africa south east asia aim improve pool aurobindo pharma agreements currently allow malaria awareness prevention efforts get treatment generic manufacturers produce sell low cost single people need together partnerships fixed dose combination products containing dolutegravir local international organisations reached adults children countries highest burden hiv million people including health workers private totals countries adult paediatric providers vulnerable populations pregnant agreements respectively addition country women children five granted patent force end least million people living hiv across countries partnerships amref health africa developing world access generic dolutegravir care international save children helped train containing product made possible licensing frontline health workers approximately two agreements million people directly reached health worker healthcare service health facility viiv healthcare continued donate several antiretroviral medicines venezuela country facing partnership save children aims help reduce profound shortage basic medicines first child mortality partnership reached approximately pharmaceutical company donate antiretrovirals children five almost million children since people living hiv humanitarian crisis since february interventions including widening immunisation donated packs antiretrovirals coverage accelerating access treatments strengthening gsk also donated vaccines colombia healthcare systems also launched new protect venezuelan migrants transit residing programme nigeria focused preventing infectious national territory rotavirus pneumococcus diphtheria disease children pertussis tetanus children received free lifechanging surgery since donated billion albendazole tablets comprehensive cleft care partnership including million support efforts smile train together world dental federation end lymphatic filariasis lf control intestinal worms smile train launched new twoyear project soil transmitted helminths schoolage children improve oral health guidance ongoing care children benefited patients countries around world gsk clefts india also funded smile train tollfree remains committed continuing donate albendazole tablets cleft helpline provides people information lf eliminated public health problem globally cleft treatment support people reachedprotected calculated dividing total number doses supplied gavi unicef number doses needed complete full schedule vaccination allowing estimates wastage health worker data estimated based reach partner programmes level funding final data expected available april gsk annual report strategic report governance remuneration financial statements investor information trust continued allied dengue campaign india south global contribution community health programmes east asia created bring together key stakeholders amounted million includes cash product partners prevent treat outbreaks dengue fever donations volunteering time employees help potentially fatal mosquitoborne disease improve healthcare access trained healthcare workers reached gskcom prevention awareness infrastructure people range programmes mobilise viivhealthcarecom positive action programmes communities promote behaviour change modern employer modern employer believe strong employee committed improving ethnic representation experience critical attract retain motivate levels gsk work new ethnicity council best people support business future remove barriers increase understanding ensure launched modern employer ambition focusing equal opportunities inclusion diversity health wellbeing employee goal recognised global lgbt indices development aim ensure people empowered lgbt rights group stonewall recognised gsk feel good keep growing gsk top global employers list uk stonewall also engaged people named employee resource group lgbt employees employee engagement important barometer gauge allies best uk us gsk named people feel working gsk aim achieve best place work lgbt equality fourth consecutive maintain competitive employee engagement score year human rights campaigns corporate equality index survey employees get feedback addition signatories uk department longterm priorities culture change international developments charter change joining good response rate surveys organisations common aim ensure rights freedoms april september achieved dignity inclusion people disabilities highest engagement score ten years april gender diversity maintained strong score september goal female continue drive engagement lets talk sessions representation senior roles executive teams workplace collaborative percentage women management continued online platform enables twoway informal communication rise gsk women represented collaboration discussing topics matter management roles senior employees gsk sharing knowledge perspectives management roles vp support greater understanding faster effective latest hamptonalexander review ftse companies decisionmaking across organisation given month found gsk third highest proportion women employees actively connecting platform board increase sixth female get work done reading content representation also found exceeded target company business unit groups women board direct reports inclusion diversity corporate executive team believe strongly inclusion diversity gsk one prominent healthcare life science right way business also leads business success companies join healthcare businesswomens association unleashing enormous potential differing knowledge gender parity collaborative us launched experiences styles people enhancing ability foster measurable gender parity progress industry respond differing needs patients consumers improving gender balance encouraging employees able bring authentic selves supporting women develop leaders work encouraged results employee provided highperforming female managers coaching survey september included question support accelerating difference programme authentic self working gsk also recruit support women early careers received favourable score said women representing apprentices feel respected work graduates result efforts develop gsk four diversity councils covering gender female employees year three women gsk ethnicity lgbt disability chaired executive included womens engineering society top women team member councils support inclusion diversity engineering current former apprentices gsk agenda input employee resource groups india named avtar among best companies women work figure includes contributions tesaro portfolio gsk annual report trust continued longstanding commitment fair equal pay consider mental wellbeing important conduct countrybased reviews ensure markets physical wellbeing raised awareness issue clear guidance tools support ensure pay equity world mental health day encouraging people seek unexplainable differences detected addressed support hour confidential employee assistance compensation processes programme resources also launched mental health matters training line managers published third uk gender pay gap report helping increase awareness skills knowledge gender pay gap permanent ukbased gsk employees better support teams mean outperforming national average remain committed improving gender balanced representation preventing injuries illnesses work also fundamental application fair equitable pay practices ensure peoples health wellbeing approximately equal opportunities equal pay equal work employees drive company sales business unfortunately one commercial salesforce died motor women management vehicle accident kenya try prevent sorts tragic accidents happening run driver safety programme svpvp help employees protect families director combining online learning practical road safety activities manager roughly drivers across countries employees trained driver safety reportable injury illness rate continued decline per hours worked employees gender number remains comparable male female total leading companies sector board employee development management want people keep growing every stage employees working lives management senior managers defined companies act strategic report directors report regulations includes expect employees development plan persons responsible planning directing controlling activities agreed manager support employees take company strategically significant part company ownership development employees access board including directors undertakings included consolidated accounts new development portal resources health wellbeing development relevant roles development needs interests aim leading company supporting employee health addition gsk continues meet commitment wellbeing development member club group uk companies committed health wellbeing hiring young people development programmes global comprehensive preventive healthcare package least uk roles currently people employees eligible dependants includes graduate mba programmes globally preventative healthcare services little extra cost apprenticeships uk us canada ireland singapore participants provide programmes help people belgium take control health manage energy levels strong focus improving effectiveness adopt healthier behaviours people managers one part performance system employees took part critical holding managers accountable energy resilience programmes also expanded manage performance development team personalised digital health platform original employees provide feedback manager employees belgium employees singapore questions measure leadership effectiveness mexico spain france switzerland australia new zealand three key areas knowing people delivering results maximising potential managers participated understand important employees one employees provided flexibility manage lives everyone thrive feedback manager great things work home largest markets formal flexible working carer policies markets also introduced new leadership development programme reviewing competitiveness area aim firstline leaders training consists five virtual modules differentiate example us strong emphasis conversations matter developing implemented care family member paid leave performance leading high performing teams industry standards us programme piloted leader participants programme rolled across gsk fourth year row gsk increased participation support continued leadership development levels virgin pulse global challenge participants across countries named gskcom employee engagement learning development active organisation people collectively taking billion steps gsk annual report strategic report governance remuneration financial statements investor information trust continued reliable supply ensuring highquality safe reliable supply products conducted audits suppliers quality patients consumers priority three processes audits clinical studies run behalf businesses see pages product shortages gsk assess quality safety identify happen variety reasons including supply disruptions areas require improvement engage relevant third unexpected demand parties develop improvement plans track progress significant issues identified remain unresolved robust quality management systems support continuous may choose suspend terminate work third party improvement helping us maintain high standards product quality safety comply relevant regulations detecting assessing understanding preventing adverse including good manufacturing practice good effects drugrelated problem pharmacovigilance laboratory practice good pharmacovigilance practice important evaluating safety pharmaceutical products good clinical practice external regulatory work partners enhance systems inspections pharmaceutical vaccines consumer reporting external collaborations healthcare manufacturing sites local operating companies transcelerate european federation pharmaceutical found issues resulted minor industries associations innovative medicines observations address every issue however minor initiative working others promote harmonised regulatory authorities accepted proposed approaches procedures clinical development plans corrective actions safety evaluation drugs implement key regulations late summer gsk contacted regulatory counterfeit products present risk patient safety support authorities regarding detection ndma potential efforts prevent manufacture distribution counterfeit human carcinogen zantac ranitidine products based gsk products working closely government bodies information received correspondence regulatory international organisations world customs authorities gsk made decision midseptember organization customs authorities industry initiate voluntary recall pharmacyretail level recall zantac associations also conduct investigations work products markets precautionary action since enforcement agencies tackle counterfeit gsk products number recalls initiated api suppliers well gsk implementing serialisation drive traceability across pharmaceutical companies hold market authority supply chain increased supply chain visibility various countries including us gsk discontinued increased communications government systems making selling prescription zantac tablets helping raise visibility products prevent theft discontinued making selling overthecounter zantac counterfeiting stock diversion also allow systems us several regulatory authorities reviewed authenticate product point dispense findings andor conducting tests including fda continuing work gskcom patient safety reliable supply ethics values committed creating ethical valuesdriven culture every gsk employee complementary worker required issues responded swiftly transparently complete living values expectations mandatory expect everyone gsk live values expectations training annually employees speak concerns engage appropriately complementary workers completed training stakeholders respect human rights also extend covering content including code conduct human ethical expectations third parties work safety information reporting reporting misconduct living values expectations employees fail complete course may face together values patient focus integrity respect disciplinary action defined permitted local transparency expectations courage accountability labour laws development teamwork help us create culture throughout assessed different parts want employee survey employees agreed business values maturity matrix understand work environment encouraged ethical behaviour even well values expectations embedded face pressures meet business objectives additionally individual areas business using insights assessments inform plans integrate values ways working gsk gsk annual report trust continued examples include increasing opportunities engagement political engagement leadership teams improve trust strengthening everyone working behalf gsk must follow people managers capability lead employees code conduct interactions political stakeholders times change delivering pace additionally selection process public policy groups includes criteria ensure groups share values mandatory antibribery corruption abac training tailored consisting two modules one highrisk spent million federal lobbying activities employees one everyone else modules focus us registered us federal lobbying principles help employees deepen understanding register spend includes cost operating office abac risks may lie recognising conflicts interest washington dc cost travel consulting cost report mitigate risks conflicts representing interests eu institutions published december employees contract eu transparency register million also publish workers completed abac training list memberships trade associations may lobby indirectly behalf gskcom ethics values gsk make corporate political contributions reporting investigating concerns us employees may support individual candidates political encourage people speak concerns groups financially political action committee relating unethical conduct behaviour inconsistent contributed state federal candidates values simply want ask question breakdown spend available online apply code conduct gskcom public policy patient advocacy trade association anyone inside outside gsk raise concerns speak membership list criteria working public policy groups independent third party integrity lines human rights confidentially anonymously without fear retaliation gsk committed upholding universal declaration take every reported concern seriously review human rights core standards set international one understand whether formal investigation labour organization strive ensure respect human warranted investigations show employee rights embedded integrated across global business breached policies take appropriate disciplinary action conduct regular assessments informed external experts employees accused misconduct human rights impacts associated activities reviewed cases initiated building findings corporatelevel human formal investigations relating rights assessment past year focused behaviour workplace result employees strengthening approach managing labour rights risks disciplined policy violations supply chain carried initial review labour dismissed voluntarily left organisation rights risks associated sourcing activities received documented warning support fair labour ngo verit building instances action short documented warning taken work identify parts supply chain represent employees disciplined breakdown types greatest potential modern slavery risks also updated policy violation thirdparty labour rights standards include expectation policy area recruitment costs borne employer behaviour workplace worker pay job practice lead mandatory training completion forced labour good manufacturing distribution practices progress priority human rights areas marketing promotional activities access healthcare research practices patient safety expenses environment health safety privacy outlined relevant sections report representative remaining policy violation types gskcom human rights modern slavery act statement increased focus completing mandatory training improved classification concerns altered distribution policy violations compared latest available figures figures expected available april submission eus transparency register gsk annual report strategic report governance remuneration financial statements investor information trust continued working third parties priority suppliers significant spend thirdparty oversight programme strengthens supply support significant revenue andor medically rd chain risk management driving improvements global critical business enabled us provide network third parties includes suppliers distributors proactive support engagement visits designed build organisations transfer value capability areas improvement identified ecovadis want ensure third parties work share assessments audits values ethical business standards thirdparty risk buying goods services transformation programme assessment mitigation programme embedded also delivering improved guidance integration compliance globally continues simplified refined internal gsk users third parties programme make easier engage third parties appropriately includes new sourcing platform launched making risk assessments completed easier suppliers engage us third parties identified high risk gskcom ethics values undergone detailed independent assessments ecovadis continued work thirdparty suppliers reduce environment health safety ehs risks conducted audits ehs ethics also expanded thirdparty ehs team include dedicated ehs professionals within team based countries priority suppliers located data engagement data becoming increasingly central business developed comprehensive approach privacy healthcare industry broadly digital data analytics including training drives understanding everyone strategy harnesses power data technology gsk personally responsible correct handling strengthen business make real difference patients personal information apply set privacy principles around world believe help scientists ensure use personal information kept develop innovative medicines quickly higher minimum necessary fair transparent accurate probability success ever enhance clinical secure studies improve interaction healthcare providers combined privacy training mandatory customers consumers code conduct training approximately individuals using data responsibly transparently completed privacy foundation training includes privilege using individuals personal information new hires contingent workers returning leave comes responsibility treating data ethically absence explains privacy principles help committed using data responsibly transparently understand apply daily work also raises engaging patients healthcare providers help meet awareness privacy matters handle patient needs includes managing data carefully sharing personal data results clinical studies integrating patient insights personnel handle personal information rd hr product development providing healthcare globally received tailored privacy training understand professionals relevant accurate information obligations binding corporate rules need enable internal transfer eu hr rd data across data privacy gsk affiliates throughout people key roles across recognise people increasingly concerned organisation continued undergo certification protection appropriate use personal information international association privacy professionals iapp particularly related health new regulations increase expertise enable us make informed decisions around world also increased requirements handling personal data number people companies use personal information loss inappropriate certification gsk increased use personal information could serious impact individuals affected businesses take responsibility data privacy seriously gsk annual report trust continued protection individuals data privacy high priority improve engagement patients involved clinical exclusive collaboration andme collaboration studies developed patient engagement plans key combines andmes genetic expertise advanced data assets set dedicated patient panel key part science skills gsks extensive scientific capabilities internal governance process allows patients input scale enhance discovery development entirely development research protocols improve patient new medicines potential cures andme customers experience study keep informed choose participate research contribute results study completed information unique dynamic database purpose ensure inclusion diverse populations clinical advancing scientific research participation voluntary studies data generate represents many people customers required consent affirmatively data possible including individuals different demographics used research choose participate age elderlyfrail paediatric groups sex ethnicity information aggregated individual race capture potential variability responses identifiable gsk medicines vaccines helps us characterise clinical trial transparency robust benefitrisk profile generate greater insight part longstanding commitment data transparency prescribing information ensure right patient gets clinical studies published clinical study right medicine particularly important move reports summaries results towards precision medicine positive negative studies made changes inhouse trials improve clinical study register diversity participants including ensuring teams develop also share anonymised patientlevel data studies plans target populations based sex age race external researchers listed studies data ethnicity need targeted recruitment stage sharing via wwwvivliorg wwwclinicalstudydatarequestcom lifecycle molecule also asked thirdparty launched six years ago facilitate innovative datadriven preferred vendors provide plan deliver research used multiple study sponsors improved recruitment retention diverse populations funders external researchers granted data access fullservice outsourced trials based review scientific merit research engagement healthcare professionals hcps proposal independent panel access gsk study aim provide information products way data approved proposals since best suits limited time new medicines gskcom online gsk privacy notice gsk clinical study register significant new data allow payment experts speak scientific evidence diseases treat patient scientific engagement clinical experience disclose annually individual improve delivery groundbreaking new therapies level payments hcps legally permitted otherwise strengthening focus patients needs seeking aggregate basis insights across business continue support also updated salesforce incentives policy several initiatives empowering patients get portfolio evolved growing shift towards innovative involved development medicines training specialty care medicines area requiring high levels tools dialogue european patients academy expertise deliver information specialised hcps therapeutic innovation eupati one strong competition talent see held patient advocacy leaders summits details policy change portugal japan switzerland representatives patient organisations also provide insights european gskcom operating responsibly health advisory board respiratory health board new patient panels covering hepatitis chronic kidney disease rheumatoid arthritis well oncology patient council new methodology introduced gsk annual report strategic report governance remuneration financial statements investor information trust continued environment committed reducing environmental impact carbon emissions plus intensity ratios per regulations one quarter cutting greenhouse gas emissions tonnes coe reducing water impact redirecting waste beneficial use scope emissions commitment underpinned five environmental scope emissions commitments set baseline scope emissions available reduce operational carbon emissions scope report intensity ratios reduce value chain carbon emissions scope scope emissions per billion revenue sales revenue tonnes co em source electricity renewable sources interim target scope emissions fte tonnes co efte reduce total water use highrisk site scope emissionsbn available ensure waste repurposed beneficial uses revenue million tonnes report co ebn revenue carbon committed playing part address climate emissions use inhaler products fell change overall value chain carbon footprint made mainly reduction amount ventolin scope emissions operations produced new portfolio inhaled medicines delivered scope emissions supplier base via ellipta dry powder inhaler dpi lifecycle logistics use products mostly carbon footprint around times lower propellantbased metered dose inhalers inhaler accredited science based targets initiative support efforts promote low carbon inhalers set scope targets line level possible uk example nhs adopted decarbonisation required keep global temperature commitment increase dpi prescribing longterm plan increase c made good progress gsk ran public information campaign commitments different footprint inhalers wwwlowcarboninhalerscouk lowered scope emissions encouraging patients discuss inhaler options continued deployment energy efficiency programmes healthcare professional gsk also supporting similar low across operating sites globally around electricity carbon inhaler initiatives belgium sweden came renewable sources plan expand benchmark performance externally combination green certificates onsite scored b cdp climate renewable generation global electricity needs climate resilience decarbonised across uk us europe carried scenario analyses five products latest available data absolute scope emissions supply chains task force climate decreased vs per billion revenue related financial disclosures tcfd framework guidelines mainly reduced emissions associated raw materials used business usual scenario low carbon represents reduction per billion revenue scenario identify potential areas risk opportunity since baseline year recognise achievements climate change presents business see suppliers reduce environmental impacts annual supplier environmental sustainability awards winners supplier encourages excellence agricultural practices india uk energy provider creates clean energy inspiring next generation scientists engineers innovative tackling climate change reductions existing portfolio excluding pfizer sites joined august figures expected available carbon emissions calculated according greenhouse gas protocol corporate accounting reporting standard revised edition figures scope emissions electricity restated based updated iea emission factors published one year 's treatment use propellantbased inhalers results carbon footprint kg coe compared kg coe using ellipta dry powder inhalers gsk annual report trust continued water plastic goal reduce total water use highrisk packaging products plays important role site climate change must tackled delivering safe stable trusted medicines vaccines global level water challenges much localised consumer healthcare products however recognise vaccine pharmaceutical consumer healthcare impact plastic packaging environment manufacturing sites completed risk assessments working plan reduce plastic packaging implementing actions ensure compliance water making recyclable exploring increase use stewardship standard assessments identified recycled plastic content recognising medical regulations highrisk sites used million cubic metres water around world place significant constraints use total water use risk rating based recycled materials vaccines business removing pvc water scarcity local water quality health social risks packaging end developed regulatory reputational risks new pump flonasesensimist reduces amount sites working strategies reduce water plastic used device impact making good progress example site completed review plastic use across cape town south africa area affected drought business found plastic footprint initiated water recovery rainwater harvesting projects associated consumer healthcare products took water saving measures across year saved place integration pfizer consumer healthcare water sites annual water use one sites business updating include impact karachi pakistan also successfully implemented projects joint venture also implementing initiatives reduce reduce water used cooling towers shorten cleaning remove possible single use plastics across gsk cycles excess water used activities offices worldwide already eliminated million items decreased amount water used cleaning plastic food refreshment outlets helped reduce sites water footprint pharmaceuticals environment waste committed ensuring compounds end aim sites send adversely affect people environment carry zero waste landfill avoids harmful environmental impacts environmental testing pharmaceuticals use landfill keeps materials solvents circulation data risk assessments evaluate potential harm use new products less waste take steps minimise risk active pharmaceutical sent landfill excluding newlyjoined pfizer consumer ingredients including antibiotics entering environment healthcare sites sites achieving maintaining zero result manufacturing processes waste landfill cut amount waste produce since generating total tonnes gsk part amr industry alliance launched includes tonnes hazardous waste signatory industry roadmap progress tonnes sent landfill combating amr efforts combat amr see publicly committed minimise antibiotic longerterm goal waste discharge supply chain ensure manufacturing directed beneficial use either recycling incinerating related discharges negligible end waste energy recovery waste pharmaceutical supply chain initiative shared recycled incinerated energy recovery guidance best practice managing antibiotic discharges paper palm oil manufacturing suppliers committed moving towards deforestationfree gskcom environment sourcing key commodities purchased directly gsk indirectly behalf challenge due complex nature supply chains reached paper packaging palm oil sustainable sources volume working roundtable sustainable palm oil purchase book claim credits rainforest alliance audit assure supply chain date focused paper packaging palm oil palm oil derivatives developed supplier selection criteria well sourcing standards conjunction rainforest alliance gsk annual report strategic report governance remuneration financial statements investor information risk management risk management framework well embedded continually reviewed boardlevel oversight provided audit risk committee assisted risk oversight compliance council framework enables board identify evaluate year cet conducts formal risk review consider manage principal risks designed support longterm emerging risks whether sufficient information available priorities framework provides effective hierarchy support inclusion principal risks list review risk management compliance boards within supported extensive analysis external trends insights businesses promotes tone top establishes senior level interviews recommendations gsks key risk culture oversees effective cascade risk intelligence groups risk management boards escalation information regarding internal controls cet agreed escalate two new risks along values expectations speak processes standalone principal risks environmental ensures risks associated business activities sustainability nonpromotional engagement work actively effectively identified mitigated provides also underway establish appropriate reporting reasonable assurance material misstatement loss transformation risk recognition significant conduct annual confirmation exercise ensure transformation associated intention separate risk management approach consistent across gsk gsks consumer healthcare business reinforces leader accountability list principal risks pages audit risk committee considered assessment external macro environment risk gsks risks strategies address exposure following mitigation risks order drew annual business unit risk assurance update significance reports strategy papers significant risks annual risk review risks associated proposed separation gsks consumer healthcare business principal risk overseen cetlevel risk owner separation consumer healthcare business may ensure proportionate controls place clear plans dependent number factors outside gsks assigned address gaps control including required shareholder regulatory gsk considers current emerging risks part approvals favourable conditions public equity markets risk management framework gsk defines emerging risks public private debt markets changes applicable threeyear horizon may yet law regulation therefore certainty adequate information impact likelihood separation completed proposed therefore may warrant investigation addition separation completed inclusion list principal risks assurance either gsk consumer healthcare emerging risk assessments performed part remit realise expected benefits separation separation risk management compliance boards levels adversely affect gsk consumer healthcare organisation additionally global level perform value liquidity respective shares annual pestle analysis political economic social risks associated coronavirus outbreak technological legal environmental trends external potential impact coronavirus outbreak gsk 's environment identify emerging risks trading performance supply continuity remains uncertain date report outbreak material impact trading results group however continue monitor situation closely including potential impacts trading results supply continuity employees situation could change time assurance coronavirus outbreak material adverse impact future results group viability statement see arc report see principal risks uncertainties see internal control framework see gsk annual report risk management continued risk assessment mitigation activities patient safety macro risk level remains high developments data interrogation present potential benefits patient safety volume data analysed presents significant challenge intensifies coupled fragmented regulatory requirements increasing expectations technology deliver safer innovative medicines less risks gsk 's exposure remains unchanged deployed new operating model safety activities involving simpler central safety organisation outsourcing local pharmacovigilance activities deployments passed successful audits indicating expect lower risk steady state h product quality macro risk level remains unchanged despite continued concerns drug shortages security uncertainty complexity associated brexit gsks exposure remains unchanged benefits ongoing investment improvement initiatives manufacturing facilities operating systems training reflected quality performance metrics inspection outcomes financial controls macro risk level increased significant political uncertainty increasing societal expectations financial reporting role auditors well reporting highly sophisticated fraudsters enabled speed technological change gsks exposure maintained current levels despite increase external risk exposure result benefits previous transformation programmes strengthening controls leveraging technology centralising processes enhancing monitoring maintaining effective tax treasury strategies antibribery macro risk level remains unchanged continue see legal frameworks similar corruption abac uk us develop emerging economies high standards expected individuals corporations aided improved technology increased enforcement gsk exposure remains unchanged appropriate controls place training awareness raising strong monitoring around transactions payments third parties plan continue pre posttransaction abac due diligence increasing capabilities business monitoring oversight red flag resolution third parties continue understand assess moneylaundering risk exposure mitigate existing risk commercial practices macro risk level increasing increased pricing pressure greater retailer online competition broader set competitors evolving digital landscape increased scrutiny marketing practices industry gsks exposure marginally increased integrate tesaro consumer healthcare joint venture pfizer continue invest proportionate controls training monitoring embed new hcp engagement model salesforce incentives programme see gsk annual report strategic report governance remuneration financial statements investor information risk management continued risk assessment mitigation activities privacy macro risk level increased due diversity data privacy legislation limited harmonisation occurring despite europes adoption gdpr multinationals challenges standardise data privacy approach high local variation rise enforcement regulators gsks exposure remains constant following successful deployment privacy operating model eu prioritised deployment rest world progressing well research practices macro risk level increased regulators adapting new technological advancements well introducing changes regarding data privacy animal welfare human biological samples yet fully announced requirements implementation understood gsk 's exposure remains unchanged increasing regulatory expectations offset risk mitigation actions embed monitor additional controls enhance monitor quality culture particular focus data integrity access benefit sharing nagoya protocol third party oversight macro risk level increased due growing numbers countries varying regulation manufacturing standards requiring local production increases number third parties assess continuously oversee gsk exposure remains unchanged thirdparty risk assessment mitigation programme embedded continues simplified refined make easier engage third parties appropriately environment macro risk level increased due greater emphasis environmental controls health safety regulators activists stakeholders across direct operations supply sustainability chain emerging area focus postconsumption waste associated medicines evermore stringent regulations standards developed well developing countries gsk risk exposure remains unchanged continue focus appropriate control supply chain particularly active pharmaceutical ingredient api suppliers information security macro risk level continues increase result increasing digital footprint reflecting large multinational organisation combined sophisticated hacking threats gsk risk exposure remains unchanged development controls increase cyber operations threat intelligence capabilities mitigation protect critical information systems applications enhancements security operational technology systems networks offsetting risk supply continuity macro risk level remains unchanged ongoing evolution stringent regulatory expectations including continued regulatory focus contract manufacturers brexit continues provide uncertainty gsk risk exposure level remains unchanged improved risk management supplier portfolio reduced complexity networks improved crisis continuity management framework however reduced inventories threats posed cyberattacks global emergencies coronavirus outbreak quality incoming materials present ongoing supply risks gsk annual report risk management continued climaterelated financial disclosure provide gsks first voluntary disclosure analysis showed scenarios likely recommendations taskforce climaterelated financial financial risks would need managed disclosure tcfd initiative financial stability board none would materially impact business model promotes disclosure climate change risk key impacts scenarios governance floodrelated disruptions manufacturing sites board oversight responsibility management supply chain climate change risks support cet boards water stress leading increased expenditure disruption corporate responsibility committee crc oversees gsks manufacturing sites supply chain environmental sustainability enterprise risk progress higher temperatures affecting quality availability environmental targets see crc report raw materials increased costs fossil fuels regis simard president pharmaceuticals supply chain findings represent initial assessment plan management responsibility environment health safety use understand impacts develop sustainability including climate change risk action plans help mitigate risks embed sustainability cet reports directly ceo strategy review opportunities strategy risk management trust one three longterm priorities reducing environmental sustainability includes climate environmental impact important part trust priority change risks became standalone principal risk see metrics targets business previously managed subrisk gain better understanding climate change might environment health safety sustainability see impact business completed scenario analyses risks related climate change managed different levels five key products across vaccines pharmaceuticals organisation depending nature risk consumer healthcare businesses two scenarios risks opportunities associated gsks energy water businessasusual assumed little mitigation waste reduction programmes managed climate leading c warming change energy reduction team representatives lowcarbon assumed global temperature gsks three business units relevant support increase limited well c rapid functions meeting quarterly changes legislation technology operational risks opportunities asset site level study conducted independent third party identified assessed managed gsks business units used internationally recognised data sets risk management teams intergovernmental panel climate change potential physical risks changing climate flooding well metrics targets risks associated transition lowcarbon goal reduce environmental impact one quarter economy international climate policy carbon goal underpinned five environmental targets pricing analysed analysis looked implications carbon scopes renewable electricity sources gsk manufacturing facilities suppliers raw materials water waste see pages providers five products assessment accredited science based targets consider actions gsk might take mitigate initiative set scope targets line adapt findings decarbonisation required keep global temperature increases oc also committed moving towards deforestationfree sourcing key commodities working partners roundtable sustainable palm oil rainforest alliance detail progress making towards achieving targets found public response cdp questionnaire gsk annual report strategic report governance remuneration financial statements investor information risk management continued viability statement accordance provision revision following hypothetical downside scenarios code gsk assessed prospects evaluated company longer period months required scenario business performance risks include key going concern provision directors confirm performance risks including lower sales new products reasonable expectation gsk continue greater adverse impact generic competition operate meet liabilities fall due next competitive launches gsk products well three years directors assessment made possible supply manufacturing challenges reference gsks current position prospects strategy boards risk appetite gsks principal risks scenario external macroeconomic risks scenario managed detailed pages reflects incremental risks business driven outside strategic report factors intense competition increased pricing pressure us europe well potential board reviews internal controls risk management impact material negative changes macroeconomic policies approves governance structure code healthcare environment conduct also appraises approves major financing investment licensing decisions evaluates monitors scenario principal risks scenario includes severe performance prospects gsk whole focus assessment potential loss impact principal largely improving longterm financial performance risks related patient safety product quality supply chain delivery company three business strategies continuity well antibribery corruption aligned innovation performance trust priorities consequent regulatory actions fines could fundamentally threaten operations would include board reviews gsks strategy makes significant potential severe impact coronavirus materialise capital investment decisions longterm time horizon risks managed mitigating activities described based multiyear assessment return capital pages performance company three business units market opportunity pharmaceutical vaccines scenario put option exercise scenario evaluates consumer sectors approach aligned gsks model additional funding requirements assuming earliest potential achieving balanced growth investing high quality exercise outstanding put option held partner innovative products patients consumers healthcare hiv business providers however since many internal external parameters future separation consumer healthcare joint venture become increasingly unpredictable longer time horizons pfizer approved board may potentially occur gsk focuses detailed bottomup plan threeyear cycle within period covered viability assessment plan reviewed least annually directors considered scenario concluded approve business forecasts showing expected financial impact material impact viability group resultant separate directors believe threeyear assessment period companies threeyear period assessment viability statement appropriate aligns threeyear review also makes certain assumptions companys well established business planning processes normal level capital recycling likely occur considers balance longterm nature investments whether additional financing facilities required pharmaceutical vaccines consumer sectors respective level funding flexibility headroom assessment period analysis nearterm business performance realistically visible results stress testing show certain combinations hypothetical scenarios could increase funding plan stress tested series robust operational demands gsk require mitigating changes principal risk downside scenarios part boards groups funding strategy however light liquidity review risk include potential effects brexit available group based analysis directors expected material although may reasonable expectation even shortterm disruption downside scenarios consider severe stress tests company able continue gsks cash flows sustainability dividends funding strategy operation meet liabilities fall due insurance provision recovery well key financial threeyear period assessment ratios period metrics subject sensitivity analysis involves flexing number main assumptions underlying forecasts individually combination along mitigating actions could realistically taken avoid reduce impact occurrence underlying risk gsk annual report risk management continued preparations brexit preparing uks exit eu brexit anticipate subsequent ongoing costs arising overriding priority maintain continuity supply brexit could include customs duties include medicines vaccines consumer healthcare products cost duplicate testing release products people uk eu took riskbased approach continue estimate potential costs approximately planning mitigation place new post million per year details emerge brexit operating model part new model business need adapt future ukeu relationship arranged retesting certification medicines assumptions underlying forecasts could change consumer products europe required consequent adjustments part brexit completed relevant marketing authorisation transfers updated process gsk engaging governments packaging secured additional warehousing uk eu well brussels institutions discuss products continue support employees obtaining preparations alongside ambitions new ukeu settled status equivalent uk europe normal relationship continue review plans change processes used manage outstanding tax potential financial impact negotiations regulations customs activities depend new borders develop remain ready outcomes december place uk eu longer term continue believe brexit material impact business nonfinancial information statement following aligns nonfinancial reporting requirements contained sections ca cb companies act description business model human rights policy due diligence outcomes create value human rights summary principal risks social matters data engagement principal risks uncertainties third parties viability statement global health anticorruption bribery audit risk committee report health security nonfinancial key performance affordability availability living values expectations indicators employees reporting investigating concerns antibribery corruption key performance indicators employee engagement environmental matters policies diversity wellbeing development carbon water waste public policies codes gender pay gap standards available gskcom living values expectations board diversity gsk annual report strategic report governance remuneration financial statements investor information group financial review section reporting framework approach tax financial performance adjusting items cash generation conversion financial position resources treasury policies critical accounting policies ggsskk aannnnuuaall rreeppoorrtt group financial review reporting framework total adjusted results costs ordinary course smaller scale restructuring group financial review discusses operating legal charges expenses retained within total financial performance group cash flows financial adjusted results position resources results year adjusted results include benefits major restructuring compared primarily results preceding year programmes exclude significant costs significant total results legal major restructuring transaction items total reported results represent groups overall regarded complete picture groups financial performance performance presented total results exclusion adjusting items may result adjusted gsk also uses number adjusted nonifrs measures earnings materially higher lower total earnings report performance business adjusted results particular significant impairments restructuring nonifrs measures may considered addition charges legal costs excluded adjusted earnings substitute superior information presented higher total earnings accordance ifrs adjusted results defined nonifrs measures defined gsk undertaking number major restructuring programmes response significant changes groups gsk believes adjusted results considered together trading environment overall strategy following material total results provide investors analysts acquisitions costs cash noncash stakeholders helpful complementary information programmes provided individual elements understand better financial performance position approved meet accounting recognition criteria group period period allow groups result charges may incurred number years performance easily compared majority following initiation major restructuring programme peer companies measures also used management planning reporting purposes may group also initiated twoyear separation preparation directly comparable similarly described measures programme prepare gsk separation two new used companies leading companies biopharma consumer healthcare gsk encourages investors analysts rely time time group divests noncore investments single financial measure review gsks annual reports products businesses records profit loss including financial statements notes entirety disposal adjusting item notable divestment past five years disposal oncology business gsk committed continuously improving financial one element threepart transaction novartis reporting line evolving regulatory requirements best practice significant legal charges expenses arising adjusted results settlement litigation government investigations adjusted results exclude following items total results normal course materially larger together tax effects items regularly occurring individual matters also include certain amortisation intangible assets excluding computer major legacy matters software reconciliations total adjusted results providing impairment intangible assets excluding computer information key adjusting items software goodwill set five years set pages major restructuring costs include impairments tangible assets computer software specific gsk provides earnings guidance investor community boardapproved programmes structural basis adjusted results line peer companies significant scale costs individual related expectations investor community supporting easier projects exceed million including integration costs comparison groups performance peers gsk following material acquisitions able give guidance total results reliably transactionrelated accounting adjustments related forecast certain material elements total results significant acquisitions particularly future fair value movements contingent consideration put options given rise proceeds costs disposals associates products significant adjustments driven external factors businesses significant legal charges net insurance currency movements capital markets recoveries expenses settlement litigation government investigations operating income royalty income items gsk annual report strategic report governance remuneration financial statements investor information group financial review continued reporting framework continued historical record adjusting items reconciliations total adjusted operating profit last five years summarised follows total operating profit intangible asset amortisation intangible asset impairment major restructuring transactionrelated items divestments significant legal items us tax reform adjusted operating profit analysis impact transactionrelated items operating profit last five years follows novartis consumer healthcare joint venture put option contingent consideration former shionogiviiv healthcare jv including shionogi preferential dividends viiv healthcare put options pfizer preferential dividends contingent consideration former novartis vaccines business release fair value uplift acquired pfizer inventory adjustments transactionrelated items full reconciliations total adjusted results set pages explanations adjusting items reported noncontrolling interests viiv healthcare viiv healthcare also agreed pay additional future cash trading profit allocations consideration shionogi contingent future sales viiv healthcare subsidiary group performance products developed joint operating results turnover operating profit profit tax venture principally dolutegravir ifrs business included within group income statement combinations gsk required provide estimated portion earnings allocated noncontrolling fair value contingent consideration time interests owned shareholders line acquisition required update liability latest respective equity shareholdings pfizer shionogi estimate fair value subsequent period end shareholders including gsk also entitled liability contingent consideration recognised preferential dividends determined performance balance sheet date acquisition million certain products shareholder contributed subsequent remeasurements reflected within relative performance products changes time operating incomeexpense within adjusting items proportion overall earnings viiv healthcare income statement period december allocated shareholder change particular liability discounted stood increasing proportion sales dolutegravircontaining million posttax basis products favourable impact proportion cash payments settle contingent consideration preferential dividends allocated gsk adjusting items made shionogi viiv healthcare quarter based allocated shareholders based equity interests actual sales performance relevant products gsk entitled approximately total earnings previous quarter payments reduce balance sheet adjusted earnings viiv healthcare liability hence recorded income statement remeasurements liabilities preferential dividends cash payments made shionogi viiv healthcare allocated pfizer shionogi included within million operating income liability required recorded fair value acquisitionrelated arrangements estimated future payments significant timing consideration acquisition shionogis interest difference charges recorded total former shionogiviiv healthcare joint venture income statement reflect movements fair value shionogi received equity stake viiv healthcare liability actual cash payments made settle liability gsk annual report group financial review continued reporting framework continued cash payments reflected cash flow statement however q gsk notified shionogi partly operating cash flows partly within investing irrevocably given right accordingly recognised activities tax relief payments reflected liability put option groups balance sheet groups adjusting items part tax charge part q initial value million q payment relating original estimate fair value shionogi irrevocably agreed waive put option contingent consideration acquisition result gsk derecognised liability put option shionogiviiv healthcare joint venture million groups balance sheet directly equity value reported within investing activities cash flow statement liability million derecognised part payment relating increase gsk also call option shionogis shareholding liability since acquisition reported within operating cash viiv healthcare original agreements flows exercisable sixmonth windows commencing movements contingent consideration payable shionogi gsk irrevocably agreed waive first follows two exercise windows last sixmonth window remains call option fair value value accounting purposes contingent consideration beginning year remeasurement income statement free cash flow cash payments operating cash flows free cash flow defined net cash inflow operating cash payments investing activities activities less capital expenditure property plant equipment intangible assets contingent consideration contingent consideration end year payments net finance costs dividends paid non contingent consideration payable posttax basis controlling interests plus proceeds sale property shionogi december million december plant equipment intangible assets dividends million expected paid within one year received joint ventures associates used management planning reporting purposes exit rights discussions presentations investment analysts pfizer may request ipo viiv healthcare time rating agencies free cash flow growth calculated either gsk consent ipo offering reported basis reconciliation net cash inflow completed within nine months pfizer could require gsk operations free cash flow set acquire shareholding original agreements gsk unconditional right long made subsequent cer aer growth distribution shareholders withhold consent order illustrate underlying performance groups exercise pfizer put option result accordance practice discuss results terms constant exchange ifrs gsk recognise liability put option rate cer growth represents growth calculated balance sheet however q gsk notified exchange rates used determine results overseas pfizer irrevocably given right accordingly companies sterling remained unchanged recognised liability put option groups balance used comparative period cer represents growth sheet q initial value million constant exchange rates aer represents growth consistent revised treatment end q actual exchange rates gsk also recognised liabilities future preferential proforma growth dividends anticipated become payable pfizer shionogi acquisition pfizer consumer healthcare business groups balance sheet completed july gsks reported results closing balances liabilities related pfizers include five months results former pfizer consumer shareholding follows healthcare business august group presented proforma growth rates cer turnover adjusted operating profit operating profit pfizer put option business taking account transaction proforma growth pfizer preferential dividend rates cer calculated comparing reported results calculated applying exchange rates used original agreements shionogi could also comparative period results adjusted requested gsk acquire shareholding viiv healthcare include equivalent five months results former sixmonth windows commencing pfizer consumer healthcare business consolidated us gsk unconditional right long made included pfizers us gaap results subsequent distribution shareholders withhold consent exercise shionogi put option result gsk recognise liability put option balance sheet gsk annual report strategic report governance remuneration financial statements investor information group financial review continued approach tax understand responsibility pay appropriate amount ongoing public focus tax affairs tax fully support efforts ensure companies multinational companies included major project appropriately transparent tax affairs organisation economic cooperation development managed tax important element economic oecd addressing tax challenges digitalisation contribution bring countries operate economy gsk welcomes oecds efforts identify engage artificial tax arrangements without longterm sustainable consensus driven solution business commercial substance seek avoid tax challenges resulting digitalisation active tax use tax havens transactions would fully providing relevant business input assist successful disclose tax authority zero tolerance approach delivery aims project order create long tax evasion facilitation tax evasion lasting stable certain business environment taxpayers governments multilateral consensusbased substantial business employment presence approach grounded clearly defined accepted principles many countries around globe pay significant critical incentive innovate must diluted amount tax including corporation business taxes well tax associated employees time continued focus tax reform driven responsibility shareholders financially oecds base erosion profit shifting beps project efficient deliver sustainable tax rate part european commission initiatives fiscal state aid approach look align investment strategies investigations introduction mandatory disclosure countries already substantial economic activity rules outputs oecd beps projects clarified government policies promote regimes important principle tax paid profits throughout attractive business investment rd activity supply chain profitmaking activity takes place transparent intent available relevant tax payers gsk subject taxation throughout supply chain examples include uk patent box research gsk supports beps proposals particular development expenditure credit implementation oecds recommendations country tax risk managed robust internal policies country reporting including exchange data processes ensure alignment across tax authorities data validated existing business compliance tax legislation audit risk information held taxpayers support ability ensure committee board responsible approving multinational groups pay appropriate amount tax tax policies risk management approach seek detailed tax implications brexit dependent maintain open positive relationships governments outcome negotiations uk eu tax authorities worldwide welcome constructive therefore currently unknown continue work debate taxation policy government ensure uk retains trading relationship group corporate tax charge million eu allows us supply products swiftly million profits tax million today patients consumers zero tariffs million representing effective tax rate goods minimal customs procedures vat cash flow made cash tax payments cost crossborder trade direct tax implications million year million addition particular expected limited gsk indirect taxes pay profits pay duties levies tax implications may significant including potential transactional employment taxes customs duty costs additional transaction administrative costs associated managing import export obligations adjusted tax rate movement goods uk eu rate benefitted settlement open tax ukeu rest world approach positions key territories subject material changes brexit set product mix material changes tax regulations laws countries operate groups tax strategy set detail within public policy average effective adjusted tax rate medium term positions section website details expected around corporate tax charges year set groups total tax rate lower adjusted tax rate total tax charge includes tax effect fair value accounting movements groups put option liabilities viiv healthcare hedges shares hindustan unilever limited received disposal horlicks consumer healthcare brands reassessment estimates uncertain tax positions following settlement number open issues tax authorities gsk annual report group financial review continued financial performance group turnover bn gsk uses number adjusted nonifrs measures report proforma performance business adjusted results bn aer growth cer growth cer growth nonifrs measures may considered addition substitute superior information presented accordance ifrs adjusted results nonifrs measures defined pages total results group set growth turnover turnover cer turnover cost sales selling general administration total operating profit bn research development royalty income bn aer growth cer growth operating incomeexpense operating profit net finance costs profit disposal interest associates share aftertax profits associates joint ventures profit taxation taxation profit taxation year adjusted operating profit bn profit attributable shareholders proforma earnings per share p bn aer growth cer growth cer growth earnings per ads us adjusted results group set reconciliations total results adjusted results set growth turnover turnover cer turnover cost sales selling general administration research development royalty income adjusted operating profit adjusted profit attributable shareholders adjusted earnings per share p gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial performance continued group turnover pharmaceuticals group turnover business turnover bn growth growth cer bn aer growth cer growth pharmaceuticals vaccines group turnover consumer healthcare group turnover corporate unallocated turnover proforma growth group turnover geographic region growth growth cer us pharmaceuticals turnover europe revised growth growth international cer respiratory group turnover year increased aer cer hiv million growth delivered vaccines immunoinflammation consumer healthcare pharmaceuticals flat cer oncology proforma turnover growth group cer established pharmaceuticals pharmaceuticals turnover year million aer flat cer hiv sales aer pharmaceuticals turnover year million cer million respiratory sales aer flat cer hiv sales aer cer aer cer million sales established million growth juluca dovato partly offset pharmaceuticals million aer cer declines triumeq tivicay respiratory sales aer cer million growth trelegy vaccines turnover grew aer cer million ellipta nucala sales established pharmaceuticals primarily driven growth sales shingrix meningitis million aer cer including impact vaccines also contributed significantly growth loss exclusivity advair pharmaceuticals vaccines innovation sales sales us sales declined aer cer continued growth products launched last five years amounted nucala trelegy ellipta benlysta offset billion driven sales shingrix trelegy decline established products including loss ellipta nucala exclusivity advair excluding advair relvarbreo ellipta consumer healthcare sales grew aer cer impacted genericisation icslaba million proforma basis sales grew driven market growth aer cer europe sales grew strong performance oral health category partly offset aer cer strong growth respiratory partly decline skin health offset decline established pharmaceuticals international consumer healthcare innovation sales sales products grew aer cer growth therapy areas new market last three years amounted consumer healthcare sales reflecting continued focus oral health innovations gsk annual report group financial review continued financial performance continued respiratory us following launch dovato april total respiratory sales aer cer combined sales twodrug regimens million strong growth regions ellipta product sales grew total dolutegravir sales grew aer flat cer aer cer europe aer cer reflecting yearonyear share decline business international aer cer trelegy relvar transitions new twodrug portfolio offset net price breo growth nucala aer cer europe benefit europe total dolutegravir sales flat aer aer cer international us trelegy flat cer strong growth market share offsetting price ellipta nucala growth offset decline relvarbreo erosion higher clawback payments dovato juluca ellipta post generic icslaba price pressure reported combined sales million international grew strongly total dolutegravir sales growth aer sales nucala million year grew cer driven tivicay triumeq aer cer us sales million aer cer including impact new athome use oncology application sales zejula million period date sales ellipta products aer cer acquisition comprising million us million million driven growth europe international europe regions us sales grew aer flat cer immunoinflammation reflecting continued competitive pricing pressures ics sales benlysta year aer cer labas post generic advair europe sales grew aer million including sales subcutaneous formulation cer international aer cer sales million us benlysta grew aer cer trelegy ellipta contributed million globally year million driven increase us market share relvarbreo ellipta sales aer cer established pharmaceuticals driven us relvarbreo ellipta declined aer sales established pharmaceuticals year cer result competitive pricing pressures million aer cer impact generic advair us icslaba market established respiratory products declined aer europe international relvarbreo ellipta continued cer million decline advairseretide grow aer cer europe aer partly offset higher sales ventolin flovent allergy cer international products us generic version advair launched february resulting aer cer decline year hiv europe seretide sales aer cer hiv sales grew aer cer million year million reflecting continued competition generic dolutegravir franchise grew aer cer delivering products transition respiratory portfolio newer sales million remaining portfolio million products international sales seretide flat aer total hiv sales declined aer cer cer globally ventolin grew aer reduced overall hiv growth two percentage points cer driven strong uptake authorised generic aer one percentage point cer version us sales dolutegravir products million remainder established pharmaceuticals portfolio triumeq tivicay delivering sales million declined aer cer million including million respectively twodrug regimens juluca lamictal aer cer million generic dovato delivered sales million year competition lower sales viread international combined growth offsetting decline declines partly offset augmentin aer threedrug regimen triumeq reflected impact cer million year driven strong growth competition well transition business international new portfolio gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial performance continued vaccines influenza fluarixflulaval sales aer cer million reflecting strong sales execution us turnover bn partly offset increased price competition us bn aer growth cer growth lower demand europe shingles group turnover shingrix recorded sales million primarily driven continued strong uptake favourable benefit priorperiod rebate adjustments us germany canada also contributed growth established vaccines sales dtpacontaining vaccines infanrix pediarix boostrix grew aer cer infanrixpediarix sales grew aer cer million reflecting favourable yearonyear us cdc stockpile movements stronger vaccines turnover demand international partly offset competitive pressures europe boostrix sales aer cer growth growth cer million mainly due strong demand international meningitis together share gains higher demand us influenza hepatitis vaccines grew aer cer million shingles primarily due favourable yearonyear cdc stockpile established vaccines movements continued benefit competitor supply shortage us partly offset supply constraints lower demand europe vaccines turnover grew aer cer million primarily driven growth sales shingrix meningitis synflorix sales grew aer cer million vaccines also contributed growth mainly due bexsero primarily due stronger demand international demand share gains us together stronger rotarix sales aer cer million demand international established vaccines grew aer reflecting stronger demand international us cer million primarily reflecting strong growth together favourable phasing international boostrix hepatitis vaccines synflorix infanrixpediarix partly offset lower cervarix sales international supply mmrv vaccines sales declined aer cer constraints mmrv vaccines million largely driven supply constraints europe international meningitis cervarix sales aer cer million meningitis sales grew aer cer million reflecting lower demand expected returns due competitive bexsero sales grew aer cer million pressure china together lower demand elsewhere driven demand share gains us together international stronger demand international europe partly offset completion vaccination catchup cohorts certain markets europe menveo grew aer cer primarily reflecting improved supply higher demand international gsk annual report group financial review continued financial performance continued consumer healthcare wellness wellness sales grew aer cer million year proforma basis sales flat growth turnover bn proforma pain relief offset decline respiratory phasing bn aer growth cer growth cer growth lowmargin contract manufacturing pain relief benefited continued strong performance panadol advil latter reflecting ongoing recovery resolved group turnover supply issues voltaren saw weaker performance also impacted retail stock movements respiratory sales declined growth flonase offset weaker performance theraflu following strong cold flu comparator growth also impacted decline respiratory brands oral health oral health sales grew aer cer million sensodyne saw doubledigit broadbased growth strong consumer healthcare turnover performance us india benefiting new product growth growth innovations gum health grew double digits broadbased cer growth denture care grew midsingle digits oral wellness health growth also impacted decline sales oral health nonstrategic brands nutrition skin health nutrition nutrition sales grew aer cer million largely due inclusion pfizer vitamins minerals supplements portfolio proforma basis sales flat growth growth reflecting strong performance horlicks offset declines cer us nutrition products due alignment inmarket europe inventory levels pfizer brands growth also impacted divestment horlicks maxinutrition international uk proforma growth skin health consumer healthcare sales grew aer cer skin health sales grew aer cer million million proforma basis sales grew largely due addition chapstick pfizer portfolio driven strong performance oral health category partly proforma basis sales declined midsingle digits largely offset decline skin health regional level growth due divestments small tail brands us uk driven us international following acquisition pfizer portfolio proforma basis growth driven primarily international region strong performance india china divestments phasing lowmargin contract manufacturing negative impact proforma growth approximately one percentage point sales consumer healthcare business included five months pfizer brand sales arising creation joint venture pfizer brands included existing categories geographic regions used report consumer healthcare sales gsk expects revise category structure reporting q onwards gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial performance continued cost sales partly offset continuing benefit restructuring growth growth pharmaceuticals tight control ongoing costs cer particularly nonpromotional spending across three total cost sales businesses adjusted cost sales research development total cost sales percentage turnover growth growth percentage points higher aer percentage points cer higher cer terms compared reflected total research development increase costs major restructuring programmes adjusted research development primarily result writedowns number manufacturing total rd expenditure million turnover sites unwind fair market value uplift inventory aer cer adjusted rd expenditure arising completion consumer healthcare joint venture million turnover higher aer pfizer increased amortisation intangible assets higher cer proforma basis adjusted excluding adjusting items adjusted cost rd expenditure grew cer compared sales percentage turnover percentage pharmaceuticals rd expenditure million points higher aer percentage points higher cer aer cer significant increase study compared proforma basis adjusted cost clinical trial material investment oncology compared sales percentage turnover percentage reflected progression assets tesaro points higher cer reflected continued acquisition primarily zejula dostarlimab number adverse pricing pressure pharmaceuticals particularly programmes including belantamab mafodotin nyeso respiratory unfavourable product mix pharmaceuticals icos bintrafusp alfa well increased spending number nonrestructuring related writedowns progression key nononcology assets agmcsf manufacturing sites partly offset favourable rheumatoid arthritis partly offset savings product mix vaccines primarily due growth shingrix early phase portfolio reprioritisation late rd us favourable impact inventory adjustments vaccines expenditure vaccines consumer healthcare contribution integration restructuring million million respectively savings pharmaceuticals consumer healthcare selling general administration royalty income royalty income million million growth growth cer aer cer primarily reflecting increased royalties total selling general sales gardasil administration adjusted selling general operating incomeexpense administration net operating income million million expense primarily reflected profit disposal total sga costs percentage turnover rabies tickborne encephalitis vaccines million percentage points higher aer percentage points number asset disposals together increase higher cer compared included increased value shares hindustan unilever limited received significant legal charges arising settlement existing disposal horlicks consumer healthcare matters provisions ongoing litigation costs related brands cumulative increase value since signing acquisition pfizer consumer healthcare business proposed transaction million reversal indemnity receivable novartis following tax settlement equivalent release tax provision income also included accounting credits million reflected tax charge well increased million expense arising restructuring costs remeasurement contingent consideration liabilities related acquisitions former shionogiviiv healthcare joint excluding adjusting items adjusted sga venture former novartis vaccines business costs percentage turnover percentage liabilities pfizer put option pfizer shionogi point higher aer percentage point preferential dividends viiv healthcare included higher cer basis proforma basis adjusted sga remeasurement charge million million costs percentage turnover percentage contingent consideration liability due shionogi points higher cer compared primarily arising unwind discounting partly offset growth adjusted sga costs aer cer changes exchange rate assumptions sales forecasts cer proforma basis reflected increased also included remeasurement charge million investment resulting acquisition tesaro relation consumer healthcare put option promotional product support particularly new launches vaccines respiratory hiv well increased costs number legal settlements gsk annual report group financial review continued financial performance continued operating profit partly offset continued benefit restructuring total operating profit million compared tight control ongoing costs benefits million reduced remeasurement charges reprioritisation rd portfolio contingent consideration liabilities consumer vaccines operating profit million aer healthcare put option charge increased profits disposals cer higher turnover increase cer increase value shares hindustan unilever operating margin percentage points limited received disposal horlicks higher aer percentage points higher consumer healthcare brands partly offset increased cer basis primarily driven enhanced operating charges major restructuring primarily arising write leverage strong sales growth particularly shingrix downs number manufacturing sites costs integrate us improved product mix higher royalty income increased consumer healthcare joint venture increased sga investment support business growth partly offset significant legal charges income oneoff settlements excluding adjusting items adjusted operating consumer healthcare operating profit million profit million higher aer aer cer higher turnover increase flat cer turnover increase cer adjusted cer proforma basis operating profit million operating margin percentage points lower cer higher turnover increase cer aer percentage points lower cer basis operating margin percentage point higher proforma basis adjusted operating profit aer percentage points higher cer basis lower cer turnover increase cer adjusted proforma operating margin proforma operating margin percentage percentage points higher cer basis primarily points lower cer basis reflected continued manufacturing restructuring savings reduction proforma adjusted operating profit primarily improved growth higher margin power brands reflected continuing price pressure particularly respiratory divestment lower margin tail products well tight control including impact launch generic version advair operating expenses partly offset increased us february investment rd including investment promotion significant increase oncology investment partly net finance costs assets tesaro acquisition investments promotional product support particularly new launches revised vaccines hiv respiratory partly offset finance income benefit sales growth particularly vaccines interest income favourable mix vaccines consumer healthcare fair value movements favourable inventory adjustments vaccines continued benefit restructuring tight control ongoing costs across three businesses finance expense interest expense contingent consideration cash payments made unwinding discounts provisions shionogi companies reduce balance sheet remeasurements fair value movements liability hence recorded income statement total contingent consideration cash payments finance expense lease liabilities amounted million million including finance expense payments shionogi million million total net finance costs million compared operating profit business million adjusted net finance costs pharmaceuticals operating profit million million compared million increase aer cer turnover flat cer operating primarily reflected higher debt levels following acquisition margin percentage points lower aer novartis stake consumer healthcare joint percentage points lower cer basis venture june acquisition tesaro january primarily reflected increase cost sales percentage well adverse comparison oneoff due continued impact lower prices particularly accounting adjustment million amortisation interest respiratory including impact launch generic charges partly offset benefit older version advair us february unfavourable bonds refinanced lower interest rates fair value gain product mix primarily result decline advair interest rate swaps interest million q growth lower margin products significant increase historic tax settlement following introduction ifrs oncology rd investment new product support leases finance costs included unwind discount targeted priority markets together number non lease liability million year restructuring related writedowns manufacturing sites higher legal costs gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial performance continued share aftertax profits associates joint ventures earnings per share share aftertax profits associates million total earnings per share p compared p million included oneoff adjustment increase earnings per share primarily reflected million reflect gsks share increased aftertax profits reduced remeasurement charges contingent innoviva primarily result nonrecurring income tax consideration liabilities put options increase benefit value shares hindustan unilever limited received disposal horlicks consumer healthcare profit tax brands reduced effective tax rate increased share taking account net finance costs share profits aftertax profit associate innoviva associates profit taxation million compared million adjusted eps p compared p aer cer adjusted operating profit flat cer taxation improvement primarily resulted reduced effective tax rate increased share aftertax profits associates result nonrecurring income tax benefit innoviva partly offset increased net finance costs higher uk current year charge noncontrolling interest allocation consumer healthcare rest world current year charge profits charge respect prior periods total current taxation dividends total deferred taxation board declared four interim dividends resulting total taxation total profits dividend year pence line dividend declared see note financial statements charge million represented effective tax rate dividends total results reflected different tax effects various adjusting items tax dividend policy adjusted profit amounted million represented gsk recognises importance dividends shareholders effective adjusted tax rate reflecting aims distribute regular dividend payments impact settlement number open issues determined primarily reference free cash flow tax authorities generated business funding investment necessary support groups future growth issues related taxation described note financial statements taxation group continues believe board intends maintain dividend made adequate provision liabilities likely arise current level p per share subject material change periods open yet agreed tax external environment performance expectations authorities ultimate liability matters may vary time free cash flow strengthens intends build amounts provided dependent upon outcome free cash flow cover annual dividend target range agreements relevant tax authorities x returning dividend growth noncontrolling interests outlook allocation total earnings noncontrolling interests outlook reflects expectations growth key amounted million million increase new products start twoyear period primarily due increased allocation viiv healthcare continue increase investment products profits million million higher net rd pipeline alongside implementation new programme profits groups entities noncontrolling prepare group separation interests partly offset lower allocation expect adjusted eps decline range consumer healthcare profits million cer guidance excludes impact million following buyout novartis interest june material divestments beyond previously completion new consumer healthcare joint announced potential impact business venture pfizer july included coronavirus outbreak unwind fair value uplift acquired inventory expectations guidance targets regarding future allocation adjusted earnings noncontrolling interests performance dividend payments read together amounted million million increase cautionary statement regarding forwardlooking allocation reflected increased allocation consumer statements assumptions related outlook healthcare profits million million inside back cover increased allocation viiv healthcare profits million million higher net profits groups entities noncontrolling interests gsk annual report group financial review continued adjusting items divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs profit disposal associates share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions gsk annual report strategic report governance remuneration financial statements investor information group financial review continued adjusting items continued major restructuring integration analysis major restructuring charges income within pharmaceuticals sector highlyregulated statement line follows manufacturing operations supply chains long lifecycle business mean restructuring programmes particularly involve rationalisation closure manufacturing cost sales rd sites likely take several years complete selling general administration research development major restructuring costs related specific board approved major restructuring programmes excluded operating incomeexpense adjusted results major restructuring programmes total major restructuring charges including integration costs following material acquisitions combined restructuring integration programme structural significant scale delivered incremental annual cost savings year costs individual related projects exceed million billion major restructuring programme delivered ordinary course smallerscale restructuring costs retained incremental cost savings year billion within total adjusted results total cash charges combined restructuring total major restructuring charges incurred integration programme expected approximately million million analysed follows billion noncash charges billion total billion represents reduction billion non non originally approved billion programme cash cash total cash cash total delivered approximately billion annual savings including major estimated currency benefit billion programme restructuring expected deliver end total annual savings programme billion constant currency basis including incl tesaro estimated benefit billion currency basis consumer average exchange rates programme substantially healthcare joint complete therefore gsk cease external reporting venture integration total costs benefits combined restructuring programme integration programme onwards combined restructuring group acquired tesaro january expected integration incur around million integration restructuring programme cash costs leading annual costsaving benefits around million added reported part cash charges primarily arose restructuring existing major restructuring programme manufacturing organisation rd administrative major restructuring programme including functions well integration tesaro tesaro expected cost billion period major restructuring programme integration costs cash costs billion noncash costs consumer healthcare joint venture integration programme billion expected deliver annual savings around noncash charges major restructuring million rates savings programme primarily related announced plans restructure intended fully reinvested help fund targeted increases manufacturing network rd commercial support new products total cash payments made million completion new consumer healthcare joint venture million existing combined restructuring pfizer expected realise substantial cost synergies integration programme million million generating total annual cost savings billion million major restructuring expected cash costs billion noncash charges programme including settlement certain charges accrued billion plus additional capital expenditure billion previous quarters million relating cost savings intended reinvested consumer healthcare joint venture integration programme business support innovation growth analysis major restructuring charges business opportunities follows group initiated twoyear separation preparation programme prepare separation gsk two companies new gsk biopharma company rd pharmaceuticals vaccines approach focused science related immune system use genetics new technologies new leader consumer healthcare consumer healthcare corporate central functions total major restructuring charges gsk annual report group financial review continued adjusting items continued programme aims divestments significant legal charges items drive common approach rd improved capital divestments items included profit disposal allocation rabies tickborne encephalitis vaccines million align improve capabilities efficiency global gain year million arising increase value support functions support new gsk shares hindustan unilever limited received disposal horlicks consumer healthcare optimise supply chain product portfolio brands well equity investment impairments certain including divestment noncore assets strategic adjusting items together profit number review prescription dermatology underway asset disposals charge million million prepare consumer healthcare operate standalone significant legal matters included settlement existing company matters well provisions ongoing litigation significant programme target delivery billion annual legal cash payments million million savings billion total costs estimated billion billion expected proforma growth reconciliations cash costs proceeds anticipated divestments tables set reconciliations reported cer largely expected cover cash costs programme growth rates proforma cer growth rates additional onetime costs prepare consumer healthcare reported margin percentages proforma margin percentages separation estimated million excluding adjustment transaction costs include august december transactionrelated adjustments results transactionrelated adjustments resulted net charge pfizer reported consumer proforma million million included net growth rate healthcare growth rate million accounting credit remeasurement cer business cer contingent consideration liabilities related acquisitions group former shionogiviiv healthcare joint venture turnover former novartis vaccines business liabilities adjusted cost sales pfizer put option pfizer shionogi preferential adjusted selling general dividends viiv healthcare administration adjusted research development chargecredit adjusted operating profit consumer healthcare joint venture put option consumer healthcare contingent consideration former shionogiviiv turnover healthcare joint venture including shionogi wellness sales preferential dividends nutrition sales viiv healthcare put options pfizer preferential skin health sales dividends operating profit contingent consideration former novartis vaccines business proforma financial information used basis release fair value uplift acquired pfizer proforma growth rates calculated follows inventory adjustments august december total transactionrelated charges results gsk pfizer million charge relating contingent consideration reported consumer proforma results healthcare results former shionogiviiv healthcare joint venture represented business increase valuation contingent consideration due bn bn bn shionogi primarily result million unwind group discount partly offset updated exchange rate assumptions turnover adjustments sales forecasts million credit adjusted cost sales relating viiv healthcare put options pfizer preferential adjusted selling general dividends represented reduction valuation put administration option result adjustments multiples sales forecasts adjusted research development well updated exchange rate assumptions adjusted operating profit consumer healthcare adjustments included transaction costs arising turnover completion consumer healthcare joint venture pfizer wellness sales well reversal indemnity receivable novartis nutrition sales following tax settlement equivalent release skin health sales tax provision explanation accounting operating profit noncontrolling interests viiv healthcare set gsk annual report strategic report governance remuneration financial statements investor information group financial review continued cash generation conversion summary consolidated cash flow statement set reconciliation net cash inflow operating activities free cash flow reconciliation net cash inflow operating activities closest equivalent ifrs measure free cash flow net cash inflow operating activities shown net cash outflow investing activities net cash outflow financing activities increasedecrease cash bank overdrafts net cash inflow operating activities purchase property plant equipment cash bank overdrafts beginning year purchase intangible assets increase cash bank overdrafts proceeds sale property plant equipment exchange adjustments proceeds disposal intangible assets cash bank overdrafts end year interest paid cash bank overdrafts end year comprise interest received cash cash equivalents dividends associates joint ventures cash cash equivalents reported assets contingent consideration paid reported held sale investing activities overdrafts contribution noncontrolling interests distributions noncontrolling interests capital expenditure financial investment free cash flow cash payments tangible intangible fixed assets future cash flow amounted million million long term expect future cash generated disposals realised million million operations sufficient fund operating debt cash payments acquire equity investments amounted servicing costs normal levels capital expenditure obligations million million primarily relating existing licensing agreements expenditure arising lyell immunopharma sales equity investments realised restructuring programmes routine outflows including million million tax pension contributions dividends subject free cash flow principal risks uncertainties discussed pages free cash flow amount cash generated group may time time additional demands meeting obligations contingent consideration finance acquisitions including potentially acquiring interest tax dividends paid noncontrolling interests increased ownership interests viiv healthcare business capital expenditure property plant equipment minority shareholders hold put options access intangible assets multiple sources liquidity short longterm capital markets financial institutions needs addition cash flow operations free cash inflow investment appraisal capital allocation reduction free cash flow primarily reflected adverse strong framework capital allocation including timing payments returns rebates well initial board govern allocation capital stepdown impact us advair generic competition businesses utilise consistent cash return invested increased capital expenditure including acquisition capital croic methodology prioritise investment across intangible assets higher restructuring payments higher group whole effectively compare significant legal costs partly offset improved returns businesses allocate capital operating profits including currency benefits reduction also consider impact eps inventory lower increase trade receivables lower credit profile relevant contingent consideration payments compared included milestone payment novartis lower dividend payments noncontrolling interests reclassification lease payments operating financing activities following transition ifrs total cash payments shionogi relation viiv healthcare contingent consideration liability year million million million recognised cash flows operating activities million recognised contingent consideration paid within investing cash flows payments deductible tax purposes gsk annual report group financial review continued financial position resources acquisition pfizer consumer healthcare business acquisition pfizer consumer healthcare business assets noncash transaction resulted increase net noncurrent assets assets billion including intangible assets property plant equipment billion goodwill billion reflected right use assets recognition pfizers noncontrolling interest consumer goodwill healthcare joint venture billion gain retained intangible assets earnings billion representing difference investments associates joint ventures fair value book value gsks consumer investments healthcare business transferred pfizer deferred tax assets derivative financial instruments property plant equipment noncurrent assets business sciencebased technologyintensive highly total noncurrent assets regulated governmental authorities allocate significant financial resources renewal maintenance current assets property plant equipment minimise risks interruption inventories production ensure compliance regulatory standards current tax recoverable number processes use hazardous materials trade receivables derivative financial instruments total cost property plant equipment december million net book value liquid investments million land buildings represented cash cash equivalents million plant equipment million assets assets held sale construction million invested total current assets million new property plant equipment mainly total assets related large number projects renewal liabilities improvement expansion facilities various worldwide current liabilities sites support new product development launches well shortterm borrowings improve efficiency existing supply chains property contingent consideration liabilities mainly held freehold new investment financed trade payables liquid resources december contractual derivative financial instruments commitments future capital expenditure million current tax payable believe property plant facilities adequate shortterm provisions current needs total current liabilities observe stringent procedures use specialist skills manage environmental risks activities environmental noncurrent liabilities issues sometimes dating operations modified longterm borrowings discontinued reported environment corporation tax payable note financial statements legal proceedings deferred tax liabilities pensions postemployment benefits right use assets provisions right use assets amounted million december derivative financial instruments compared million january contingent consideration liabilities following implementation ifrs decrease noncurrent liabilities year reflected impact depreciation disposals total noncurrent liabilities million million respectively partly offset total liabilities additions including business combinations net assets million total equity goodwill goodwill increased million december million primarily reflecting additions million arising acquisition pfizer consumer healthcare business million acquisition tesaro inc gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial position resources continued intangible assets derivative financial instruments liabilities intangible assets include cost intangibles acquired held current noncurrent derivative financial liabilities third parties computer software net book value fair value million million primarily intangible assets december related foreign exchange contracts designated million million increase primarily designated accounting hedges reflected additions million acquisition trade payables pfizer consumer healthcare business million december trade payables acquisition tesaro inc million compared million investments associates joint ventures december increase primarily reflected higher held investments associates joint ventures payables consumer healthcare following pfizer carrying value december million acquisition year partly offset exchange movements million market value december provisions million million largest carried deferred tax provisions shortterm investments innoviva inc book value noncurrent provisions million december december million million million provisions yearend market value million see note financial included million million related legal statements investments associates joint ventures disputes million million related investments major restructuring programmes provision made held investments carrying value legal disputes indemnified disposal liabilities december million million employee related liabilities costs restructuring highest value investments held december programme extent balance sheet date legal andme book value december constructive obligation existed could reliably estimated million million progyny inc pensions postemployment benefits book value million million theravance account pension postemployment biopharma inc book value december arrangements accordance ias net deficits million million investments million million pension arrangements included equity stakes companies million million unfunded research collaborations provide access postemployment liabilities see note financial biotechnology developments potential interest interests statements pensions postemployment benefits companies arise business divestments noncurrent liabilities derivative financial instruments assets noncurrent liabilities amounted million current derivative financial assets held fair value december million million million noncurrent derivative financial assets held fair value million contingent consideration liabilities million million current derivative financial assets contingent consideration amounted million related derivative embedded agreement divest december million horlicks nutritional brands unilever plc see note million million represented estimated information majority remainder present value amounts payable shionogi relating viiv financial instruments related foreign exchange contracts healthcare million million represented designated designated accounting hedges estimated present value contingent consideration payable novartis related vaccines acquisition inventories inventory million increased million liability due shionogi included million respect primarily reflecting higher inventory consumer preferential dividends liability preferential dividends healthcare following pfizer acquisition year partly due pfizer december million offset impact exchange movements million explanation accounting non controlling interests viiv healthcare set trade receivables trade receivables million increased contingent consideration payable posttax basis million primarily reflecting impact higher december million million sales particularly vaccines partly offset better collections expected paid within one year consideration payable exchange movements expected paid number years result total estimated liabilities discounted present values deferred tax assets posttax basis using posttax discount rates shionogi deferred tax assets amounted million viiv healthcare contingent consideration liability discounted million december novartis vaccines contingent consideration liability discounted partly partly gsk annual report group financial review continued financial position resources continued maturity profile bond debt equivalent gbp bonds eur bonds usd bonds net debt cash liquid investments billion billion held centrally december analysis cash gross debt effects hedging cash cash equivalents liquid investments follows cash cash equivalents reported assets held sale borrowings repayable within one year cash liquid investments borrowings repayable one year gross debt fixed net debt floating december net debt billion compared noninterest bearing billion december comprised gross net debt debt billion cash liquid investments includes billion equivalent notes swapped floating fixed rates via interest billion including billion reported within assets held rate swaps sale net debt increased due billion acquisition movements net debt tesaro inc well billion tesaro net debt together billion impact implementation ifrs dividend paid shareholders billion net net debt beginning year investing activities billion partly offset billion net implementation ifrs favourable exchange impacts translation nonsterling net debt beginning year adjusted denominated debt exchange financing items increase cash bank overdrafts billion free cash flow decrease liquid investments december gsk shortterm borrowings increase longterm loans including overdrafts lease liabilities repayable within net repayment shortterm loans months billion loans billion repayable repayment lease liabilities subsequent year debt subsidiary undertakings acquired exchange movements december gsks cash liquid investments movements held follows net debt end year bank balances deposits bank balances deposits reported assets held sale us treasury treasury repo money market funds liquidity funds cash cash equivalents liquid investments government securities gsk annual report strategic report governance remuneration financial statements investor information group financial review continued financial position resources continued interest rate benchmark reform total equity interest rate benchmark reform amendments ifrs december total equity increased ias ifrs issued iasb september million december million amendments modify specific hedge accounting summary movements equity set requirements allow hedge accounting continue affected hedges period uncertainty hedged items hedging instruments affected current interest total equity beginning year rate benchmarks amended result ongoing implementation ifrs interest rate benchmark reforms implementation ifrs december group directly exposed implementation ifrs interest rate benchmark reform held interest rate total equity beginning year adjusted derivatives referenced libor matured end total comprehensive income year floating rate bonds due mature dividends shareholders end recognition interest consumer healthcare joint venture group closely monitored market output various industry working groups managing ordinary shares issued transition new benchmark interest rates includes changes noncontrolling interests announcements made libor regulators including derecognition liabilities noncontrolling interests financial conduct authority fca us commodity sharebased incentive plans futures trading commission regarding transition away libor including gbp libor usd libor tax sharebased incentive plans euribor sterling overnight index average rate contributions noncontrolling interests sonia secured overnight financing rate sofr distributions noncontrolling interests euro shortterm rate str respectively fca total equity end year made clear end longer share purchases seek persuade compel banks submit libor shares repurchased company group undertaking interest rate benchmark transition december gsk held million shares programme identify potential exposures within business treasury shares million shares cost deliver smooth transition appropriate alternative million million benchmark rates deducted retained earnings ordinary shares purchased period january february company expect make ordinary share repurchases remainder million treasury shares transferred employee share ownership plan esop trusts shares held trusts satisfy future exercises options awards group share option award schemes proportion shares held trusts respect awards rules scheme require us satisfy exercises market purchases rather issue new shares shares held trusts matched options awards granted december esop trusts held million million gsk shares future exercise share options share awards carrying value million million deducted reserves market value shares million million gsk annual report group financial review continued financial position resources continued contractual obligations commitments reached agreement trustees financial commitments summarised note uk pension schemes make additional contributions financial statements commitments assist eliminating pension deficit identified part december actuarial funding valuation table following table sets contractual obligations includes commitment excludes normal commitments december fall due ongoing annual funding requirement uk approximately payment million information pension obligations total yr yrs yrs yrs see note financial statements pensions postemployment benefits loans interest loans contingent liabilities finance lease obligations contingent liabilities set note financial future finance charges statements contingent liabilities intangible assets following table sets contingent liabilities comprising property plant equipment discounted bills performance guarantees letters credit investments items arising normal course business purchase commitments expected expire pensions total total yr yrs yrs yrs commitments respect loans future interest payable guarantees loans disclosed taking account effect contingent liabilities derivatives total entered number research collaborations normal course business provided various develop new compounds pharmaceutical companies indemnification guarantees respect business disposals terms arrangements include upfront fees legal disputes subsequently arisen equity investments loans commitments fund specified provision made outflow resources considered levels research addition often agree make probable reliable estimate made likely payments future milestones achieved outcome dispute included note agreements relate compounds early financial statements provisions stages development potential obligation make provide outcome tax legal disputes milestone payments continue number years outflow resources considered probable compounds move successfully development reliable estimate outflow may made december process generally closer product marketing disputes provision approval greater probability success amounts made possible make reliable estimate shown within intangible assets represent maximum potential outflow funds might required settle would paid milestones achieved include disputes possibility outflow billion relates externalised projects remote discovery portfolio increase commitments ultimate liability matters may vary significantly result number new rd collaborations amounts provided dependent upon negotiations including merck kgaa lyell immunopharma relevant tax authorities outcome litigation proceedings relevant discussed principal risks uncertainties pages note financial statements legal proceedings gsk annual report strategic report governance remuneration financial statements investor information group financial review continued treasury policies report sterling pay dividends sterling cash interest rate risk management flows role treasury monitor manage gsks objective minimise effective net interest cost groups external internal funding requirements financial balance mix debt fixed floating interest rates risks support strategic objectives gsk operates time policy interest rate risk management limits global basis primarily subsidiary companies net amount floating rate debt specific cap reviewed manage capital ensure subsidiaries able agreed less annually board operate going concerns optimise returns foreign exchange risk management shareholders appropriate balance debt objective minimise exposure overseas equity treasury activities governed policies approved operating subsidiaries transaction risk matching local annually board directors recently currency income local currency costs possible october treasury management group tmg foreign currency transaction exposures arising external meeting chaired chief financial officer takes place internal trade flows selectively hedged gsks internal regular basis review treasury activities members trading transactions matched centrally manage receive management information relating activities intercompany payment terms reduce foreign currency risk treasury operations possible manage cash surpluses borrowing objective gsks treasury activities minimise requirements subsidiary companies centrally using forward posttax net cost financial operations reduce volatility contracts hedge future repayments back originating order benefit earnings cash flows gsk uses variety currency financial instruments finance operations derivative order reduce foreign currency translation exposure financial instruments manage market risks seek denominate borrowings currencies operations derivatives principally comprise foreign exchange principal assets cash flows primarily forward contracts swaps used swap denominated us dollars euros sterling borrowings borrowings liquid assets currencies required swapped currencies required group purposes well interest rate swaps used manage exposure financial risks changes borrowings denominated swapped foreign interest rates currencies match investments overseas group assets may treated hedge relevant assets forward derivatives used exclusively hedging purposes relation contracts major currencies also used reduce exposure underlying business activities trading groups investment overseas group assets tmg speculative instruments reviews ratio borrowings assets major currencies capital management regularly gsks financial strategy implemented groups counterparty risk management financial architecture supports gsks strategic priorities set global counterparty limits banking regularly reviewed board manage capital investment counterparties based longterm credit ratings structure group appropriate mix debt moodys standard poors treasurys usage equity continue manage financial policies credit limits monitored daily treasury compliance officer profile particularly targets shortterm credit ratings tco operates independently treasury breach p maintaining single longterm ratings consistent limits would reported cfo immediately targets tco also monitors credit rating counterparties gsks longterm credit rating standard poors changes ratings occur notifies treasury negative outlook moodys investor services changes made investment levels authority limits moodys negative outlook shortterm credit appropriate addition relationship banks credit ratings p standard poors moodys ratings reviewed regularly report presented annually respectively tmg approval liquidity risk management gsks policy borrow centrally order meet anticipated funding requirements cash flow forecasts funding requirements monitored tmg regular basis strategy diversify liquidity sources using range facilities maintain broad access financial markets day sweep cash number global subsidiaries central treasury accounts liquidity management purposes gsk annual report group financial review continued critical accounting policies consolidated financial statements prepared us medicaid programme stateadministered accordance ifrs adopted use european programme providing assistance certain poor union also ifrs issued international vulnerable patients medicaid drug rebate accounting standards board iasb following accounting program established reduce state federal policies approved board described note expenditure prescription drugs patient financial statements accounting principles policies protection affordable care act became law participate providing rebates states accruals required make estimates assumptions medicaid rebates calculated based specific affect amounts assets liabilities revenue expenses terms relevant regulations patient protection reported financial statements actual amounts affordable care act results could differ estimates cash discounts offered customers encourage critical accounting policies relate following areas prompt payment accrued time turnover invoicing adjusted subsequently reflect actual taxation note experience legal disputes notes record accrual estimated sales returns applying historical experience customer returns amounts contingent consideration put option liabilities invoiced together marketrelated information notes stock levels wholesalers anticipated price increases pensions postemployment benefits note competitor activity information judgements estimates made reconciliation gross turnover net turnover us areas given note financial statements key pharmaceuticals business follows accounting judgements estimates turnover margin margin margin respect turnover accounting policy largest gross turnover business us pharmaceuticals us market complex arrangements rebates discounts marketdriven segments allowances following briefly describes nature government arrangements existence us pharmaceuticals business mandated arrangements certain indirect customers state programmes whereby customer able buy products cash discounts wholesalers reduced prices chargeback represents customer returns difference invoice price wholesaler prior year adjustments indirect customers contractual discounted price prior year items accruals estimating chargebacks calculated based items terms agreement historical experience total deductions product growth rates net turnover customer rebates offered key managed care marketdriven segments consist primarily managed care group purchasing organisations direct indirect medicare plans negotiate contract pricing customers arrangements require customer honoured via rebates chargebacks mandated segments achieve certain performance targets relating value consist primarily medicaid federal government product purchased formulary status predetermined market programmes receive governmentmandated pricing via shares relative competitors accrual customer rebates chargebacks rebates estimated based specific terms agreement historical experience product growth rates gsk annual report strategic report governance remuneration financial statements investor information group financial review continued critical accounting policies continued increased deductions marketdriven segments position could change time therefore gross turnover net turnover reconciliation primarily assurance losses result outcome reflected higher rebates chargebacks respiratory legal proceedings exceed material amount products advair particular generic version amount provisions reported groups financial advair launched february year statements advair accounted us pharmaceuticals turnover like many pharmaceutical companies faced approximately total deduction rebates various complex product liability antitrust patent litigation returns respiratory portfolio whole including well investigations operations conducted various established respiratory products accounted approximately governmental regulatory agencies throughout year total deduction year general counsel group head groups legal balance sheet accruals rebates discounts allowances function senior vice president head global returns us pharmaceuticals vaccines businesses litigation group responsible litigation managed combined basis december government investigations routinely brief chief executive total accrual amounted million million officer chief financial officer board directors significant litigation pending group monthly process operated monitor inventory levels governmental investigations group wholesalers abnormal movements process uses gross sales volumes prescription volumes based third party meetings appropriate detail status significant data sources information received key wholesalers litigation government investigations review matters aim maintain inventories consistent level number claims notified us information year year based pattern consumption potential claims yet notified assessment validity claims progress made settling claims recent settlement basis us pharmaceuticals vaccines inventory levels potential reimbursement insurers levels wholesalers distribution channels december estimated amount approximately meetings also include assessment whether four weeks turnover calculation uses third party sufficient information available us able make information accuracy totally verified reliable estimate potential outcomes disputes believed sufficiently reliable purpose often external counsel assisting us various litigation matters investigations also assist briefing legal disputes board senior management following discussions respect accounting policy legal disputes matters possible make reliable estimate following briefly describes process amount provision may required determine level provision necessary level provision legal disputes reviewed accordance requirements ias provisions adjusted appropriate matters discussed contingent liabilities contingent assets provide note financial statements legal proceedings anticipated settlement costs outflow resources considered probable reliable estimate may made likely outcome dispute legal expenses arising claims group may become involved significant legal proceedings respect possible make reliable estimate expected financial effect could result ultimate resolution proceedings cases appropriate disclosure cases would included annual report provision would made gsk annual report group financial review continued strategic report strategic report approved board directors march iain mackay chief financial officer march gsk annual report ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn corporate governance section chairmans governance statement board corporate executive team responsible leadership division responsibilities composition succession evaluation nominations committee report audit risk internal control audit risk committee report science committee report corporate responsibility committee report section statement directors report ggsskk aannnnuuaall rreeppoorrtt chairmans governance statement pleased present corporate governance report overview changes governance arrangements work towards separation group last year important one gsk board led board governance architecture sir philip hampton emma reset strategic direction given company embarking period transition company honoured opportunity join last two years particular period significant board lead separation create two new change board senior executive perspective worldclass businesses particularly excited work decided undertake external review gather views emma brought real clarity decision making board cet members ready us task pharma veteran might less dispassionate ahead review together insights also attracted best industry form top team introductory meetings investors feedback board focused supporting management employees met since joining helped us transforming group executing strategy refine board governance architecture help focus facilitate boards work support management beginning important journey company effective efficient possible delivering tenure gsk helpful first board meeting transformation pharmaceuticals vaccines business september last year included joint board cet strategy separation consumer healthcare business offsite session together able consider next steps plans way forward great start description review process carried jan hall follows statement understanding gsk informed robust induction process designed emma company review board agreed critical objectives secretary introductory meetings investors next three years towards separation board considered board review decided commission best distribute workload committees ensure optimal effectiveness board induction also increase time spends science given keen learn gsk started importance strengthening pipeline understanding rd hal visiting rd sites us uk including tesaro meeting andme agreed board conducted annual important collaboration look forward review groups enterprise risks deeper enterprise visiting group due course risk oversight undertaken board committee focuses aspect business closely since joining met individual basis board enhancements also considered ways working cet members key executives also attended governance architecture boards committees meetings board committees assess included understand board culture dynamics companys corporate governance arrangements audit risk committee arc arc continue strong focus financial introductory meetings investors reporting well monitoring dashboard gsks wanted hear shareholders think gsk enterprise risks process identified held meetings range investors making prioritised part oversight internal control approximately register comprised mix framework conduct detailed reviews gsks top uk us shareholders plus key investors also led financial controls reporting antibribery corruption annual governance meeting december commercial practices privacy information security noted following points enterprise risks well receiving business unit risk reports clear support emma demonstrate pipeline progress pharmaceuticals vaccines consumer healthcare hal top team ahead separation global support functions addition responsible support separation managing capital allocation debt oversight financial components work towards group dividend business development separation positive progress evidence positive shift innovation date performance culture rd culture transformed gsk annual report strategic report governance remuneration financial statements investor information nominations committee board mindful financial reporting councils remit nominations committee expanded frc uk corporate governance code code encompass corporate governance matters therefore freeing indicates nonexecutive directors serve time board committee renamed nine years however board considers nominations corporate governance committee non appropriate way proceed longterm best interests executives invited participate meetings shareholders believes following rigorous review committee considers succession talent judy continues act utmost independence despite length tenure transformation separation committee transformation separation committee established nominations committee continues oversee succession support advise managements work transforming planning board cet due course separating group chair committee whose consider needs post separation boards members include senior independent director sid non executive directors fees chairs arc remuneration corporate reviewed nonexecutive directors fee responsibility committees meet required arrangements part three year remuneration policy expected active near separation review nonexecutive director fees last increased rd board science committee following review concluded given critical importance strengthening pipeline appropriate make increases fees bring line board increase time spent rd strategy comparator group also taken opportunity science committee focus science deeper level update policy able remunerate workforce support boards understanding provide engagement director considerable work undertakes reassurance guidance required part new expanding role investors consulted changes supportive full science committee three broad objectives details found scientific assumptions driving strategy technical assurance risk oversight support board confirm company complied understanding agreed rd strategy external requirements code copy code transactions performing deep review underlying found wwwfrcorguk scientific assumptions addition oversight commend report stakeholders rds enterprise significant risks board feels enhancements governance improve effectiveness support sir jonathan symonds us separation process chairman succession planning march first task nominations committee chair focus search judys successor chair arc made good progress date look forward announcing conclusion search considered ideal transition important role pleased judy confirmed stay board year despite served nine years step board annual general meeting facilitate smooth transition judy continue chair annual report completed successor chair arc gsk annual report board board governance architecture board carries evaluation performance full commitment board whole support committees every year evaluation normally overarching strategy creating two great companies facilitated externally every third year last external evaluation board confident cet focused driving facilitated two years ago ffion hague independent performance next three years board evaluation action points reasons given chairmans governance statement meetings organisation improve balance pages board agreed would helpful presentation discussion create time carry external evaluation included review debate governance architecture board dynamics individual contribution facilitate appointed board undertake review even greater individual contribution creating connection company discussion time individual board directors committees review remit attendees preparation boards committee meetings ensure fit met chairman ceo advance agree purpose beyond objectives scope evaluation exercise timetable activities company secretary provided risk agree board committee ensure deeper access board committee materials part oversight review groups enterprise risks preparatory work strategy performance conduct deep dives interviews key strategic areas ensure focus supporting november december conducted management execute agreed strategy confidential detailed person interviews board board knowledge deepen boards knowledge cet member well meeting company understanding latest scientific developments secretary seek views boards effectiveness meetings based agreed discussion stakeholders within business board guideline included topics highlighted frc continue focus key areas focus cet guidance board effectiveness also reflected namely strengthening rd pipeline growth relevant requirements frcs code discussion transformation delivery gsks trust business priority guideline sent participant advance also externally board maintain strong relationships telephone meetings external remuneration adviser communication shareholders key auditor stakeholders seek input keep well informed progress review output evaluation presented discussed succession planning complete appointment board collectively summary report including arc chairs successor suggested next steps compiled governance build gsks commitment discussed chairman ceo subsequently environmental social governance esg matters sid summary report presented board january proposal implementation suggested recommendations board review feedback summary review concluded board operating effectively new chairman seen made excellent start business entering period significant positive change opportunity board feels confident cet individual board directors bring relevant experience skills collectively appropriate gsks mission producing products help people feel better live longer remains heart values culture gsk annual report strategic report governance remuneration financial statements investor information board continued board composition international experience gender diversity composition board executive global male nonexecutive us female tenure nonexecutive europe executive years emap male years female years nonexecutive male female sir jonathan symonds cbe skills experience nonexecutive chairman jon extensive international financial life sciences governance experience jon served independent nonexecutive director hsbc holdings plc april age deputy group chairman august retirement board february nationality british previously chairman hsbc bank plc hsbcs european subsidiary offers appointed september services clients uk continental europe jon chief financial officer novartis ag joining novartis partner managing director goldman n sachs chief financial officer astrazeneca plc partner kpmg governance experience includes roles nonexecutive director chair audit committees diageo plc qinetiq group plc external appointments jon currently chairman proteus digital health inc nonexecutive director rubius therapeutics inc also nonexecutive director genomics england limited previously served chairman jon fellow institute chartered accountants england wales emma walmsley skills experience chief executive officer prior appointment gsks ceo emma ceo gsk consumer healthcare joint venture gsk novartis creation march emma joined gsk age loreal worked years variety roles paris london new york nationality british shanghai emma previously nonexecutive director diageo plc appointed january emma holds classics modern languages oxford university chief executive officer april external appointments emma joined board microsoft inc independent director december honorary fellow royal society chemistry iain mackay skills experience chief financial officer prior joining gsk iain group finance director hsbc holdings plc position held eight years chartered accountant iain worked asia us europe hsbc age general electric schlumberger dowell price waterhouse nationality british external appointments appointed january iain trustee british heart foundation chair audit risk committee chief financial officer april member court university aberdeen group iain holds business studies accounting honorary doctorate aberdeen university scotland key c ommittee chair n nominations audit risk r remuneration science c c orporate responsibility gsk annual report board continued dr hal barron skills experience chief scientific officer prior joining gsk hal president rd calico llc california life company alphabet funded company uses advanced technologies increase understanding lifespan biology president rd prior hal executive vice president head global product development chief age medical officer roche responsible products combined portfolio roche nationality american genentech genentech senior vice president development chief medical officer appointed january hal nonexecutive director chair science technology committee juno chief scientific officer president therapeutics inc march acquired celgene corporation rd april external appointments hal associate adjunct professor epidemiology biostatistics university california san francisco also nonexecutive board director grail inc early cancer detection healthcare company member advisory board verily life sciences llc subsidiary alphabet inc manvinder singh vindi banga skills experience senior independent nonexecutive prior joining gsk vindi spent years unilever plc last role amongst several senior positions president global foods home personal care businesses member director unilever executive board vindi sat prime minister indias council trade industry age board governors indian institute management iim nationality british ahmedabad vindi also recipient padma bhushan one indias highest civilian honours vindi nonexecutive director confederation british industry cbi thomson appointed september reuters corp chairman supervisory board mauser group chairman kalle gmbh senior independent nonexecutive director senior independent director marks spencer group plc may external appointments n r vindi partner private equity investment firm clayton dubilier rice director high ridge brands co member holdingham international advisory board vindi sits governing board indian school business hyderabad global leadership council sad business school oxford member indo uk ceo forum vindi chair board trustees marie curie dr vivienne cox cbe skills experience independent nonexecutive director vivienne wide experience business gained energy natural resources publishing sectors also deep understanding regulatory government relationships workforce engagement director worked bp plc years britain continental europe posts including executive vice age president chief executive bps gas power renewable business alternative energy nationality british unit vivienne previously nonexecutive director bg group plc rio tinto plc lead independent director uk governments department international development vivienne appointed july appointed commander order british empire new year honours services uk economy sustainability r c external appointments viviennes main roles senior independent director pearson plc chairman supervisory board vallourec also nonexecutive director stena ab vivienne holds advisory positions advisory board member african leadership institute vice president energy institute member advisory board montrose associates vivienne chair rosalind franklin institute vice chair sad business school oxford sits global leadership council also patron hospice st francis lynn elsenhans skills experience independent nonexecutive director lynn wealth experience running global business significant knowledge global markets gsk operates served chair president chief executive officer age sunoco inc prior joining sunoco president chief executive nationality american officer lynn worked royal dutch shell joined held number appointed july senior roles including executive vice president global manufacturing lynn previously nonexecutive director flowserve corporation first tee greater houston trustee united way greater houston c n external appointments lynn nonexecutive director baker hughes company board director saudi aramco director texas medical center key c ommittee chair n nominations audit risk r remuneration science c c orporate responsibility gsk annual report strategic report governance remuneration financial statements investor information board continued dr laurie glimcher skills experience independent nonexecutive director addition number senior leadership positions held harvard medical school harvard school public health laurie also served stephen suzanne weiss dean professor scientific medical expert medicine weill cornell medical college attending physician new york presbyterian age hospitalweill cornell medical center laurie stepped board bristolmyers squibb co nationality american bms serving years board laurie cofounder chair scientific advisory board quentis therapeutics inc laurie brings scientific public health expertise appointed september boards deliberations wealth global publicly listed pharmaceutical business experience external appointments laurie currently professor medicine harvard medical school ceo president attending physician danafarber cancer institute laurie member us national academy sciences national academy medicine member scientific steering committee parker institute cancer immunotherapy nonexecutive director waters corporation also serves corporate governance committee addition laurie scientific advisory board member repare therapeutics inc abpro therapeutics kaleido biosciences inc dr jesse goodman skills experience independent nonexecutive director jesse previously served senior leadership positions us food drug administration fda including recently fdas chief scientist previously deputy commissioner science scientific medical expert public health director center biologics evaluation research cber age jesse played leadership role developing fdas regulatory science medical countermeasures nationality american initiatives worked collaboratively industry academia government global public health appointed january regulatory partners prepare respond major public health threats including emerging infectious diseases disasters terrorism led fdas response west nile virus hn c influenza pandemic served senior leadership team white house medical countermeasure review jesse previously member scientific advisory committee regulatory legal working group coalition epidemic preparedness innovations cepi brings scientific public health expertise boards deliberations external appointments jesse currently professor medicine georgetown university directs georgetown university center medical product access safety stewardship compass active clinician serves attending physician infectious diseases also serves president member board united states pharmacopeia usp member board scientific counselors infectious diseases centers disease control prevention cdc jesse also member board intellia therapeutics cambridge member us national academy medicine judy lewent skills experience independent nonexecutive director judy extensive knowledge global pharmaceutical industry corporate finance joined merck co served chief financial officer age retired judy served nonexecutive director dell inc quaker oats company motorola inc nationality american held nonexecutive directorships purdue pharma inc napp pharmaceutical holdings limited appointed april certain mundipharma international limited companies external appointments n r judy nonexecutive director thermo fisher scientific inc motorola solutions inc also trustee rockefeller family trust life member massachusetts institute technology corporation member american academy arts sciences member business advisory board twoxar member advisory board path inc board determined judy recent relevant financial experience agreed appropriate qualifications background audit committee financial expert urs rohner skills experience independent nonexecutive director urs broad range business legal experience served chairman number boards recently credit suisse worldleading financial services company prior joining age credit suisse urs served chairman executive board ceo prosieben nationality swiss prosiebensat media ag followed number years private practice major law firms appointed january switzerland us admitted bars canton zurich switzerland state new york us r n external appointments urs chairman board credit suisse group ag governance nominations committee conduct financial crime control committee also chairman member board trustees credit suisse research institute credit suisse foundation urs appointed vicechairman governing board swiss bankers association sir philip hampton joined board january deputy chairman april nonexecutive chairman may retired board effect august simon dingemans joined board january became chief financial officer april retired company may key c ommittee chair n nominations audit risk r remuneration science c c orporate responsibility gsk annual report corporate executive team skills experience dr hal barron hal joined gsk cet see board biographies chief scientific officer president rd roger connor roger joined cet appointed president gsk global vaccines president global vaccines addition leadership vaccines business responsible gsks global procurement organisation previously president global manufacturing supply vice president office ceo corporate strategy roger joined gsk astrazeneca roger holds degree mechanical manufacturing engineering queens university belfast masters manufacturing leadership cambridge university chartered accountant diana conrad diana appointed senior vice president human resources hr member cet senior vice president april previously senior vice president hr pharmaceuticals rd played key strategic role leader rd people culture agenda support human resources hr transformation diana joined gsk canadas hr team held several roles increasing responsibility becoming senior vice president hr consumer healthcare prior joining gsk held hr roles companies including ge capital gennum corporation zenon environmental laboratories diana honours bachelor arts mcmaster university canada james ford james joined cet appointed senior vice president general counsel senior vice president joined gsk served general counsel consumer healthcare general counsel global pharmaceuticals vice president corporate legal acting head global ethics general counsel compliance prior gsk james solicitor clifford chance dla holds law degree university east anglia diploma competition law kings college qualified solicitor england wales attorney new york state bar james based london practised law lived us singapore hong kong james cochair us based civil justice reform group nick hirons nick appointed cet senior vice president global ethics compliance senior vice president responsible compliance risk management corporate security investigations nick joined gsk international auditor later head audit assurance global ethics compliance combined five audit functions independent team common riskbased methodology nick relocated china establish governance model china business created consistent approach compliance nick fellow chartered institute management accountants sally jackson sally joined cet march senior vice president global communications ceo senior vice president office responsible communications government affairs three global businesses markets well employee engagement across group also global communications ceos chief staff prior sally senior vice president office ceo cfo ceo office previously served head investor relations joined gsk sally holds degree natural sciences university cambridge iain mackay iain joined gsk cet see board biographies chief financial officer brian mcnamara brian joined cet appointed ceo gsk consumer healthcare ceo gsk consumer healthcare joined gsk head europe americas gsk consumer healthcare following creation previous joint venture gsk novartis previously head novartis otc division brian began career procter gamble brian board member former chairman global selfcare federation gscf board member consumer goods forum earned undergraduate degree electrical engineering union college new york mba finance university cincinnati gsk annual report strategic report governance remuneration financial statements investor information corporate executive team continued skills experience luke miels luke joined gsk cet president global pharmaceuticals responsible president global pharmaceuticals commercial portfolio medicines vaccines luke also cochairs portfolio investment board hal previously worked astrazeneca executive vice president european business prior executive vice president global product portfolio strategy global medical affairs corporate affairs head asia roche based shanghai singapore prior held roles increasing seniority roche sanofiaventis us europe asia luke holds bachelor science degree biology flinders university adelaide mba macquarie university sydney david redfern david joined cet chief strategy officer responsible corporate development chief strategy officer strategic planning previously senior vice president northern europe responsibility gsks pharmaceutical businesses region senior vice president central eastern europe joined gsk david appointed chairman board viiv healthcare limited nonexecutive director aspen pharmacare holdings limited board bachelor science degree bristol university chartered accountant regis simard regis joined cet became president pharmaceuticals supply chain president pharmaceuticals responsible manufacturing supply gsks pharmaceutical products also leads quality environment health safety sustainability corporate level regis joined supply chain gsk site director france rising become senior vice president global pharmaceuticals manufacturing current role previously held senior positions sony konica minolta tyco healthcare member board viiv healthcare mechanical engineer holds mba karenann terrell karenann joined gsk cet chief digital technology officer responsible chief digital technology officer technology digital data analytics strategy previously worked walmart chief information officer prior baxter international chief information officer daimler chrysler corporation karenann began career general motors member board trustees new york hall science became nonexecutive director pluralsight llc earned graduate postgraduate degrees electrical engineering kettering purdue universities respectively phil thomson phil joined cet appointed president global affairs responsibility president global affairs groups strategic approach reputation policy development stakeholder engagement global health previously phil senior vice president communications government affairs phil chairman whitehall industry group board member chinabritain business council earned degree english history russian studies durham university emma walmsley emma joined cet see board biographies chief executive officer deborah waterhouse deborah appointed cet january became chief executive officer ceo viiv healthcare viiv healthcare april deborah joined gsk recently senior vice president primary care within companys us business prior led us vaccines business strong track record performance specialty primary care deborah led hiv business uk heading hiv centre excellence pharma europe held international roles general manager australia new zealand senior vice president central eastern europe claire thomas member cet svp human resources april retired company september gsk annual report responsible leadership boards role promote longterm sustainable leadership capability success gsk drive longterm growth shareholders employee engagement whilst seeking add value key stakeholders strategic report pages seeks demonstrate ways working able achieve practice corporate board also receives regular updates head governance report pages explains human resources analyse progress governance contributes delivery strategy dashboard indicators innovation performance trust ipt priorities board supports approach culture change purpose values culture employed management seeking appoint promote purpose improve quality human life helping right people enhancing companys governance controls people feel better live longer underpinned processes support incentivise right values patient focus integrity respect transparency behaviours training developing employees purpose values always source great companys code conduct embodies values pride board management employees help expectations corporate standards employee attract retain talented people individuals want policies aligned include longstanding speak part group contributes meaningfully society arrangements employees raise matters confidentially also drive quality relationships anonymously without fear reprisals living patients consumers key stakeholders ultimately values expectations right thing board enable swifter progress getting new medicines audit risk committee regularly reviews speak vaccines consumer healthcare products patients reports provided global ethics compliance gec consumers around world culture set board speak channels cases managed independent intended deliver high standards business conduct third party cases investigated gec promote longterm success company code conduct available gskcom kept purpose values supported expectations review board refreshed least every courage accountability development teamwork year updated version due published evolving culture foster increased pace performance edge board receives regular reports ceo cfo details enable culture change well head human resources global businesses invest reward workforce described pages update progress alignment strategy respectively performance valuesbased culture way stakeholders board assures described engagement companys main stakeholder groups year board focused culture discussions including patients shareholders consumers customers employees experience gsk ways working audit employees levels organisation across risk committee considered risk compliance aspects enterprise summarised pages strategic culture change performance line gsks trust report priority board considered progress culture change section corporate governance report sets research corporate reputation insights companys key stakeholders interests considered reflections key external stakeholders board discussions decisionmaking culture change complex global organisation gsk year read conjunction section takes time sustained effort board fully committed statement areas statement work healthy culture vital tool unlocking crossreferences annual report provide holistic protecting value board acknowledges biggest view board discharges duty driver culture leadership company stakeholders rightly high expectations us culture shift underway continues role modelled dynamic environment operate presents challenges cet board words actions behaviours opportunities board seeks respond whilst set tone employees wider workforce board remaining commercially successful upholding reputation members seek lead example undertaking living maintaining licence operate building trust ensure values expectations training alongside rest able identify respond expectations workforce training explores particular values effectively board engages many key stakeholders expectations culture application companys directly seeks understand views means operations ways working ensure stakeholder sentiment appropriately board receives results regular employee surveys considered deliberations decisionmaking principal means assessing shift culture influence importance different stakeholder groups embedding organisation culture dashboard also board discussions vary depending matter introduced four quantifiable indicators progress consideration indeed different stakeholders interests people culture transformation namely conflict requiring balanced judgments exercised appoint promote right people board arrive final decision gsk annual report strategic report governance remuneration financial statements investor information responsible leadership continued stakeholder engagement feedback provides important maintain continual active dialogue means identifying emerging issues brought institutional shareholders performance plans attention board enables us consider objectives programme regular meetings activities enable us deliver purpose year held individual meetings major ultimately goal become one worlds shareholders hosted total nearly group innovative bestperforming trusted healthcare companies meetings major shareholders potential major shareholders principal board committees cet delegated powers enable indepth assessment senior independent director sid vindi banga conducted understanding impacts companys actions plans series meetings investors advisers seek stakeholders engagement briefings views chairman succession process particular boards knowledge informed work key part induction new chairman jonathan corporate responsibility committee described symonds wanted hear shareholders thought detail gsk jon held introductory meetings range investors comprising third companys share register improve understanding stakeholder matters keen meet fund portfolio managers well board members also encouraged individual level seeing governance professionals could gain fuller meet employees shareholders key stakeholders picture major shareholders views perspectives part induction thereafter ongoing basis gsk feedback received summarised business awareness encouraged report governance statement informed board experiences relevant material board review board also advised stakeholder views number annual governance meeting different ways including addition board also holds annual governance event ceos board report institutional shareholders key investment industry bodies monthly stakeholder perception reports proxy advisory firms years event held december london hosted chairman businesses updates sid committee chairs business development analysis justifications jon shared updates joined board key areas board committee evaluations focus board including remuneration policy reviews wider workforce pay induction shareholder meetings initial impressions perspective gsk culture succession planning updates audit risk committee chair succession process workforce engagement directors updates board review potential changes governance architecture annual governance meeting also provided update behalf workforce annual general meeting engagement director unable attend employee survey reports urs rohner remuneration committee chair also took briefings annual strategy meetings opportunity discuss progress remuneration annual budget business planning process committees review executive remuneration ahead remuneration policy vote annual general meeting corporate governance regulatory development updates may judy lewent audit risk committee chair year board received considered lynn elsenhans corporate responsibility committee chair independent research stakeholder perceptions dr jesse goodman chairs science committee gsks corporate reputation views approach also provided overviews work respective esg issues committees year shareholder engagement annual governance meeting well received board seeks directly engage private retail number thoughtful incisive questions asked institutional shareholders several ways includes regular board members present gsks rd capabilities strategy communications annual general meeting annual plans separation group listening views governance meeting well work investor shareholders receiving feedback provided relations team company secretary additional direct insights shared rest year publication quarterly results board next meeting ceo emma walmsley cfo iain mackay give presentations institutional investors analysts media webcast teleconference presentations made available gskcom gsk annual report responsible leadership continued annual general meeting workforce engagement shareholders invited attend annual general described last years annual report meeting held may sofitel london board chosen designate dr vivienne cox heathrow hotel see details workforce engagement director gather views people board believed would provide direct annual general meeting good level effective form engagement gsk vivienne pleased attendance engagement shareholders provided share views inaugural year role helpful insights board issues concerning proposed resolutions approved shareholders board also takes opportunity engage employees directly via receptions held around board meetings level support ranged full voting nonexecutive directors also attend internal meetings outcomes available gskcom annual general visit group sites report back findings meeting provides opportunity shareholders put questions board chairs board committees formal proceedings providing shareholders chance meet informally directors make available meeting workforce engagement director careful ensure could engage diverse year since board appointed role crosssection workforce terms seniority gender learned great deal rich dialogue enjoyed ethnicity tenure employment job types pleased meeting variety enthusiastic dedicated meeting generated wideranging exchanges employees opinion insights started comprehensive briefing group also pleased briefings hr head human resources perspective agreed data collected gsks employee surveys understand make visits employees work principal feedback generate different businesses businesses allowed gain understanding employee groupings provides helpful insights workforces views attitudes range meaningful used input determine locations visit whether issues ipt priorities culture shift underway person virtually organisation ways working employee standing item board agenda share surveys one manager feedback accountability feedback substance workforce engagements approaches global health modern employer board uses reports non agenda also importantly eventual separation executive directors visits gsk sites measure group create two new companies progress companys modern employer agenda grateful assisted head human resources focuses inclusion diversity employee health company secretary devising programme wellbeing development visits noted consisted visits three key gsk sites given clear consistent support groups strategy ipt exposure across group countries priorities commitment employees feel company significant presence good keep growing rd upper providence pennsylvania usa one work separate group working gsks major pharmaceutical rd hubs provide voice workforce important input board looking forward developing role vaccines wavre belgium utilising technology via virtual meetings using consumer healthcare warren site new jersey employee forums explore perspectives planning met cross sections new workforce including undertake one event quarter possible former pfizer employees new joint venture business align board visits held virtually look forward local management welcomed sites reporting progress next year great job introducing members workforce finally also enlisted input feedback fellow explained nature sites operations enabled nonexecutive directors also active visiting gsk hold direct open honest conversations meetings sites meeting employees continue held without management present individually build holistic view perspectives sentiment group settings gain insights workforce workforce across group experiences concerns perspectives done partly use lets talk gsk initiative whose use discussed annual report dr vivienne cox encourages workforce talk share different points nonexecutive director view informal setting gsk annual report strategic report governance remuneration financial statements investor information responsible leadership continued table sets list principal decisions taken either board committees regard stakeholder interests impacts stakeholder groups boardcommittee section principal decision made decisions regard stakeholder interests duties considered board board committees sales force incentive sfi audit risk committee considered stakeholders hcps committee recommended programme recommended board changes medical experts employees implementation limited sfi sfi programme certain countries investors governments programme changes board reflect growing shift gsks regulators patients approval portfolio certain innovative specialty consumers safeguard key stakeholder interests care products including oncology duties new sfi programme implemented particular examined value longterm results controlled phases across markets review changes means workforce business robustness programmes attracting retaining best sales relationships reputation governance arrangements presented force talent committee later year enhancing quality dialogue details available healthcare professionals hcp helping company better serve patients committee also stipulated implementation robust governance arrangements underpin changes uphold ethical valuesled approach hcp engagement business development science committee stakeholders patients science committee recommended collaborations board reviewed several business consumers employees collaborations scientific perspective development deals collaborations investors prior board approving year included duties collaborations lyell immunopharma longterm results university california help workforce business gsk obtain competitive advantage relationships adding pipeline optionality enabling us gain access key technologies arrangements considered context promise help gsk deliver transformational medicines patients capabilities talent made available company esg insights corporate responsibility committee stakeholders committee decided include sasb received considered perception investors governments disclosures companys esg study investors specifically interested regulators non performance summary available esg aspects activities governmental organisations gskcom make first voluntary better understand rapid rise interest multilateral organisations tcfd disclosure annual report investors area chief see duties concerns longterm results committee raised remuneration committee noted discussed business relationships committee chair remuneration investors desire see sustained delivery community committee increasing importance trust commitments increased environment reputation demonstrating link esg reporting aligned sustainability performance remuneration outcomes accounting standards board sasb executive directors cet taskforce climaterelated financial remuneration committee noted disclosures tcfd importance stressing link esg delivery gsks bonus awards executive directors agreed devising new remuneration arrangements two businesses post separation would look holistically could highlight incentivise importance esg success business minimise impact environment gsk annual report responsible leadership continued boardcommittee stakeholder groups principal decision made decisions regard stakeholder interests section duties considered board board committees board governance board engaged undertake stakeholders employees board agreed changes governance architecture external evaluation included review investors patients architecture improve board governance board architecture consumers effectiveness support management duties effective efficient possible longterm results delivering transformation reputation pharmaceuticals vaccines business separation consumer healthcare business details available pages remuneration policy prior developing new stakeholders employees committee approved new policy review remuneration policy new policy investors governments subject binding shareholder vote behalf remuneration committee regulators proxy annual general meeting chair met head human advisers includes measures align executive resources hr leads directors pension arrangements duties area business hear views wider workforce longterm results remuneration arrangements gsk specific area focus investors workforce reputation consider executive wider proxy advisers workforce pay alignment opportunities details available pages chair consulted investors proxy advisers new policy proposals committee following engagement carefully considered feedback finalising design new policy gsk annual report strategic report governance remuneration financial statements investor information responsible leadership continued board programme board responsible longterm success company authority accountable shareholders ensuring group appropriately managed achieves strategic objectives sets performance duties regard interests gsks key stakeholders potential impact decisions makes stakeholders board discharges responsibilities annual programme meetings year focused number specific areas outlined table line longterm ipt priorities underpinned continuing shift culture addition year ceo met nonexecutive directors discuss various matters including progress companys strategy succession planning continuing regulatory investigations areas focus longterm priorities link strategy boards oversight execution strategy included receiving discussing reports three principal businesses pharmaceuticals vaccines consumer p c healthcare holding joint board cet strategy day discuss ipt priorities external landscape changes business p c performance competitors governance arrangements receiving ceo cfo cso quarterly reports p c performance boards focus performance included evaluating ceos performance setting objectives p c setting reviewing agreeing annual budget plan forward looking three year forecast p annual talent succession plan p c scrutinising groups financial performance p reviewing quarterly financial results dividend proposal earnings guidance investor materials results p announcements confirmation viability statement going concern p approval statutory accounts p governance boards approach discharging corporate governance duties included receiving reports board committees receiving reports external auditor p chairman succession appointment new chairman p approving annual report form f reviewing annual general meeting preparation approving notice annual general meeting calling general meeting approve joint venture pfizer inc overseeing execution deal receiving reports corporate governance regulatory developments receiving secretarys report considering observations agreeing actions evaluation boards performance p annual setting boards priorities p c approval modern slavery statement approval gender pay gap disclosure receiving annual quality update c cultural receiving cultural transformation updates p c transformation engagement boards regard stakeholder impacts included reviewing board governance architecture p c receiving updates workforce engagement director p c reviewing employee survey results updates p c corporate reputation research review p c investor perception research review p c link longterm priorities innovation performance p trust culture c gsk annual report division responsibilities corporate governance framework corporate governance framework operation established board set designed clearly define responsibilities accountabilities framework designed safeguard enhance longterm shareholder value provide platform realise groups strategy gsks longterm priorities ipt consistent culture values expectations internal control risk management arrangements described pages integral part governance framework following board review gsks board governance architecture reviewed enhanced summary changes introduced following review provided chairmans statement pages board chief nominations audit risk remuneration science corporate executive committee committee committee committee responsibility officer committee corporate executive r ead read read read read team see gskcom terms reference board committee scheduled board committee attendance corporate board nominations audit risk remuneration science responsibility total number scheduled meetings members attended attended attended attended attended attended sir jonathan symonds emma walmsley iain mackay dr hal barron vindi banga dr vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent urs rohner sir philip hampton retired august simon dingemans retired may number adhoc meetings directors served part year numbers brackets denote number meetings directors eligible attend see committee reports attendees committee meetings chairman ceo executive directors work committees year reports included later corporate governance report gsk annual report strategic report governance remuneration financial statements investor information division responsibilities continued clear division board roles responsibilities leadership independent oversight rigorous challenge chairman nonexecutive directors jonathan symonds provide strong independent element board leads manages business board constructively support challenge management provides direction focus scrutinise performance meeting agreed ensures clear structure effective operation deliverables board committees shape proposals strategy offer specialist advice sets board agenda ensures sufficient time management allocated promote effective debate support sound letter appointment setting terms decision making conditions directorship ensures board receives accurate timely clear devote time necessary proper information performance duties meets nonexecutive director annual expected attend meetings required basis discuss individual contributions independence statement performance together training development needs board considers nonexecutive directors shares peer feedback provided part identified pages independent board evaluation process assessed circumstances set meets regularly nonexecutive directors provision code review independently executive directors explanation continuing independence maintains dialogue shareholders commitment judy lewent april governance company served board nine years described chairmans role description available gskcom senior independent director chief executive officer vindi banga emma walmsley acts sounding board chairman trusted responsible management group intermediary directors three businesses together nonexecutive directors leads develops groups strategic direction annual review chairmans performance taking consideration approval board account views executive directors implements agreed strategy discusses results chairmans effectiveness supported members cet review chairman maintains continual active dialogue leads search appointment process makes shareholders respect companys performance recommendation board new chairman acts additional point contact shareholders chief executive officers role description available gskcom maintains understanding issues concerns major shareholders briefings company secretary investor relations senior independent nonexecutive directors role description available gskcom company secretary secretary board board committees victoria whyte supports board committee chairs annual agenda planning ensures information made available board members timely fashion supports chairman designing delivering board inductions coordinates continuing business awareness training requirements nonexecutive directors undertakes internal board committee evaluations request chairman advises directors board practice procedures corporate governance matters chairs groups disclosure committee operates boardapproved appointments policy reflects board external appointment requirements code point contact shareholders corporate governance matters gsk annual report composition succession evaluation nominations committee report pleased present first report nominations jonathan symonds committee chair nominations committee chair year focus committee chairman succession sid vindi banga led process resulted appointment report process outlined role comment work committee committee reviews recommends board year structure size composition board board changes appointment directors committee members since joined board committee focused succession board cet search judy lewents successor chair audit risk committee made good progress look forward reporting conclusion search due course membership committee appointed egon zehnder korn ferry committee members committee member since assist appointment broad selection criteria used sir jonathan symonds chair september september focusing potential candidates following vindi banga january characteristics lynn elsenhans january someone ideally pharmaceuticals industry judy lewent may strong preference former cfo andor candidates urs rohner january audit committee experience broaden diversity philip hampton january former committee chair august talent pool sought ideally qualified accountant details committee members skills experience given biographies board pages see committee also considered ideal transition committee member attendance levels important role pleased judy lewent agreed company secretary secretary committee remain post year despite nine years attends meetings attendees committee service stepping board meetings may include annual general meeting help facilitate smooth transition especially given recent change cfo regular attends attendees attendee required auditor work underway transform separate chief executive officer group committee mindful code head human resources indicated nonexecutive directors serve appropriate external advisers nine years however engagement shareholders recommended board appropriate way proceed longterm interest advisory services shareholders board confirmed despite nine years year egon zehnder korn ferry provided service judy continues demonstrate characteristics recruitment consultancy services committee independence carrying role board addition recruitment hr services provide company egon zehnder provides executive iain mackay started role chief financial officer coaching services certain directors committee april appointed board august supports engagement executive search firms joined board january elected egon zehnder korn ferry signed annual general meeting may simon dingemans voluntary code conduct gender diversity retired company following annual general best practice egon zehnder korn ferry meeting following eight years service chief financial number executive search firms received officer process committee followed iain mackays accreditation enhanced code recruitment described last years report conduct meeting exacting performance criteria best practice standards genderbalanced selection ftse boards gsk annual report strategic report governance remuneration financial statements investor information composition succession evaluation continued nominations committee report continued cet succession progress towards female board representation year committee reviewed following combined executive committee direct reports targets internal senior executive appointments cet least published ftse women recommendation ceo leaders report reproduced diana conrad appointed svp human resources female representation june report female april succeeding claire thomas performed representation metrics board combined role years ftse target sally jackson appointed expanded role senior gsk vice president global communications ceo office average ftse joined cet march highest date report women deborah waterhouse ceo viiv healthcare joined board women cet cet january board composition tenure diversity board sought balance composition tenure closing gap board cet gender committees refresh progressively representation increasing pipeline female time benefit experience longer direct reports cet achieve target serving directors fresh external perspectives particular area attention pleased good progress insights newer appointees made stage exceeded target combined executive committee direct nonexecutive directors drawn wide range reports representation women management industries backgrounds including pharmaceuticals positions gsk illustrated part industry rd vaccines consumer products gender diversity gsks global workforce healthcare medical research academia insurance financial services wealth experience complex also pleased report line parker organisations global reach many board members reports recommendation experience longcycle industries great committee met nonexecutive directors present assistance understanding industry operate receive consider succession plans management committed diversity boardroom executive directors ensure diverse pipeline gsk committed equal opportunities employees potential successors available committee also wider workforce levels organisation regularly reviews succession planning nonexecutive board management seek encourage diverse members board inclusive culture throughout gsk committee evaluation committees annual evaluation exercise externally key requirement effective board comprises facilitated interviewed committee members range balance skills experience knowledge ethnicity behalf concluded committee continued gender socialeconomic backgrounds independence operate effectively individuals prepared challenge work effective team needs backed diversity agreed committees role expanded personal attributes including character intellect sound encompass corporate governance matters therefore freeing judgement honesty courage time board committee therefore renamed nominations corporate governance committee support promoting long term success company addition nonexecutive directors invited committee responsible developing measurable participate meetings committee considers objectives assist implementation boards diversity succession talent policy including gender ethnic diversity monitoring progress towards achievement objectives diversity policy line measurable targets set sir jonathan symonds nominations committee chair hamptonalexander review increase number march women senior leadership positions ftse companies parker review commissions report beyond one increase ethnic diversity appointments boards ftse companies gsk annual report composition succession evaluation continued chairman succession report chairman succession following key personal attributes identified job beginning announced sir philip specification hampton informed board intention step proven respected chair senior executive chairman would continue role new considerable nonexecutive director senior chairman selected joined board independent lead independent director experience good time transition company delivering businesses scale complexity improved operating performance developed clear experience uk capital markets appreciation new strategy next years us international shareholders selection process led boards sid good understanding uk corporate governance nominations committee expanded comprise experience businesses significant portfolio change nonexecutive directors supported head including mergers acquisitions divestments human resources company secretary addition experience global scale international markets sought input ceo emma walmsley life sciences experience preferable mandatory process appropriate experience regulated industry committee began developing agreeing job reputation stature authority command respect specification role chairman included externally internally skillset experience key leadership characteristics required lead gsk board next stage whilst deciding job specification described also company engaged egon zehnder korn ferry engaged several shareholders advisers secured specialise recruitment high calibre input advice chairs board directors using firms ensured pool suitable candidates began long list process would truly global search embrace due consideration reduced shortlist briefing broad talent pool possible work validated reports shortlisted candidates reviewed timetotime ensure gaps search candidates met board process committee receiving best members possible market advice key appointment process resulted nominations committee job specification emphasised new chairman believing jonathan symonds suitable would lead board companys next phase candidate gsks next chairman july development would involve accordance nominations committees terms continuing drive gsks strategy building sustainably reference good governance chaired meeting growing pharmaceuticals vaccines business recommended jons appointment nonexecutive strengthening rd delivery pipeline consolidating director next chairman also chaired board tesaro acquisition undertaking business meeting day sir philip recused development recommendation approved unanimously july pleased announce jon would join successfully integrating pfizer consumer healthcare board nonexecutive chairman effect business gsk consumer business whilst september sir philip stepped board completing divestment horlicks india would effect august thereby prepare company creation two separate listed entities separate governance jon met independence requirements set structures pharmaceuticals vaccines consumer code appointment required boardapproved healthcare external appointments policy significant existing commitments indication time involvement whilst continuing improve companys operating disclosed taken consideration prior performance appointment board noted particular jon would envisaged chair would remain gsk step role deputy chair director pharmaceutical vaccine company provide appropriate hsbc february stability continuity subject performance board pleased welcome jon exceptional ratified board appropriate time experience life sciences financial management governance complex regulated global companies throughout career jon demonstrated passion science known integrity professionalism vindi banga senior independent director gsk annual report strategic report governance remuneration financial statements investor information composition succession evaluation continued external evaluation board details independent external evaluation board conducted set progress board evaluation progress conclusions board evaluation review set areas focus progressachievements succession planning board sid running search process next chairman supported comprehensive process led sid resulting appointment global executive search firm attendance nominations committee jonathan symonds described sid process expanded include nonexecutive directors nominations committee also progressing search nominations committee also focused search judy successor judy lewent chair audit risk committee lewents successor good progress made date details given oversight rd pipeline revival key business development transactions proposed consumer healthcare joint venture pfizer board would continue monitor performance rd pipeline board committees monitored overseen successful integration operation key business development integration operation recent transactions transactions including tesaro andme merck kgaa darmstadt board also pleased oversee early completion consumer germany would also reviewing overseeing arrangements healthcare joint venture pfizer continue monitor managements proposed consumer healthcare joint venture pfizer progress integrating growing business building board relationships culture line ceos culture work across group continuing evolution boards culture building relationships good progress made evolving boards culture noted membership changed important area focus especially board review undertaken see impending chairman succession enhancing boards decisionmaking ways working opportunities enhance boards decisionmaking ways implementation agreed enhancements ways working working would continue considered ensure board governance architecture board committees described operate effectively possible chairman governance statement pages gsk annual report audit risk internal control audit risk committee report following pages report aim share insights judy lewent activities undertaken overseen committee audit risk committee chair year committee worked largely recurring structured programme activities devise programme company secretary agree content management role external auditors start year committee reviews responsible adapted appropriate year progresses financial internal reporting processes financial reporting integrity financial statements including integrity financial statements including annual annual report quarterly results announcements report quarterly results announcements key focus committee includes committees assessment system internal controls effectiveness internal controls financial reporting identification management risks external committee reviewed least quarterly companys internal audit processes significant accounting matters including contingent initiating audit tenders selection appointment consideration liabilities revenue recognition accruals external auditor setting remuneration returns rebates restructuring tax accounting exercising oversight work significant transactions well impact changes accounting standards committees position always aim clear membership transparent financial disclosure gsks financial reporting committee members committee member since support proactive approach step ahead judy lewent april guidance requirements regulators line prior chair january years committee continued review compliance vindi banga january latest guidance lynn elsenhans january dr laurie glimcher september committee auditor discuss significant issues relation financial statements committee details committee members financial accounting scientific experience expertise given biographies considers periodically year areas particular board pages see committee member audit focus outcomes overlapping areas attendance levels attention disclosed separately pages company secretary secretary committee annual report attends meetings entire board invited audit reform external auditors attend committee meetings attendees reviews external audit industry acknowledged include diversity stakeholders make use companys audited accounts statements poor quality audits regular attends attendee attendee required significant negative repercussions upon economy general counsel society whole albeit auditors responsibility law group financial controller shareholders whole associated reform head audit assurance external audit market therefore area regulatory head global ethics compliance development committee monitoring closely chief medical officer another key activity committee monitor chief product quality officer performance deloitte second year deloitte external auditor served gsks external auditor extensive accordance frcs code board change management process including formal handover determined judy lewent recent relevant observation previous auditor deloitte took financial experience board also agreed action review deloittes first audit appropriate qualifications background audit completed part approximately key members committee financial expert defined sarbanesoxley management interviewed gather feedback act determined independent respect deloittes first audit within meaning securities exchange act amended committee whole competence relevant sector company operates gsk annual report strategic report governance remuneration financial statements investor information audit risk internal control continued audit risk committee report continued learnings efficiencies identified action review committee considered detail rationale around incorporated audit plan objectives limited changes sfi programme robust audit set agreed continue monitored governance arrangements underpinning within committee information effectiveness context gsks ipt priorities recommending years audit process given implementation policy changes board may new sfi policy implemented controlled committee discussed deloitte examples phases across markets committee received use analytical tools insights supported report december outcome ibm monitoring improved efficiency effectiveness audit work sfi activities controls performed gec business development transactions managing change sfi programme continue oversight tesaro transaction consumer significant activity committee given potential healthcare jv pfizer key priority associated risks therefore gec committed performing committee given importance success full ibm review sfi changes gain traction across transactions accelerate groups strategy reshape markets present findings business committee received regular reports learnings committee end year integration management tesaro included fundamental success new sfi programme reviewing rd risks deal monitoring strong leadership continue drive culture performance known operational compliance reputational risks trust enforced measured governance controls associated mitigation plans integration across zero tolerance abuse committee regularly monitors commercial medical functions progressed well reviews internal controls also held deepdive completed effect january session leaders gsks principal businesses committee also exercised responsibility monitoring discuss individual engagement accountabilities overseeing consumer joint ventures risk management views balancing performance trust priorities post day one due diligence jv operates businesses extremely competitive changing environment internal framework control risk management committee focused management three enterprise developments risks relevant delivery joint ventures risk management framework well embedded strategic priorities commercial practices supply chain continually reviewed committee enables board continuity portfolio ingredient risk committee identify evaluate manage hcp sfi changes principal risks designed support innovation committee devoted significant time year performance trust priorities cultural transformation reviewing design governance arrangements formed framework provides effective hierarchy risk part hcp engagement policy sfi programme management compliance boards rmcbs within changes move promotion speciality medicines gsks businesses promotes tone top underpinned hcp sfi changes well establishes risk culture oversees effective cascade executed received positively externally internally escalation information regarding internal controls however presents increased risk potential unethical along gsks values expectations speak behaviour comprehensively controlled processes ensures risks associated business mitigated activities actively effectively agreed mitigated end committee received presentation provides reasonable assurance material misstatement results hcp engagement theme review conducted loss gec conducted annual confirmation exercise global ethics compliance gec independent ensure risk management approach consistent business monitoring ibm across markets covering one across gsk reinforce leadership accountability third eligible markets review identified several year committee considered gsks risks process learnings embedded across strategies address drawn markets covered hcp engagement programme annual business unit risk strategy papers also assurance update reports provided audit assurance aa gsks significant risks annual internal control risk management effectiveness review gec gsk annual report audit risk internal control continued audit risk committee report continued principal risk overseen cet member level risk business reported committee key internal owner ensure proportionate controls place clear control framework icf improvements simplification plans assigned address gaps committee considers activities improve manage risks current emerging risks part oversight summarised gsks risk management framework pharmaceuticals along embedding hcp emerging risks defined visible engagement model noted general manager organisation threeyear horizon emerging risk confirmation forms component cet confirmation assessments performed part remit rmcbs process continues important review risks levels organisation additionally annual analysis mitigation plans allows detailed area regional oversight political economic social technological legal confirmation allowed targeted discussions environmental pestle trends external environment rmcbs better understanding deployment performed aa team identify emerging risk operating model changes mitigation actions accountability gsks known enterprise risk areas year cet local control efforts risk oversight compliance council rocc conduct vaccines year vaccines business worked formal risk review consider emerging risks whether increase icf maturity improve effectiveness sufficient information available support inclusion rmcbs new rd governance model built around gsks principal risks list principles faster decision making smart risktaking review supported extensive analysis external trends approach vaccines continued perform comprehensive insights senior level interviews recommendations asset risk assessments complementing implementation gsks key risk intelligence groups risk management new enterprise risk management framework boards based review committee agreed consumer healthcare better understand risks incountry cet recommendation escalate environmental country risk radar launched helps sustainability standalone principal risk given proactively identify higher risk countries looking culture significance gsk previously managed commercial kpis qualitative aspects provides judgement subrisk environment health safety sustainability specific action plans necessary mitigate risk risks require focus going forward improved management monitoring toolkit also include transformation pricing pressures nonpromotional developed support general manager selfassessments engagement enhance control maturity enterprise risk management enhancements committee consumer healthcare distribution activity risk management overseen embedding gec new enterprise risk framework developed allow markets understand management cycle distributor activity risk dependent type services enterprise risk plans completed delivered service provider tool provides guidance enterprise risks communicated expected controls manage risk implemented businesses functions implementation globally end march provided greater clarity across organisation nature viiv healthcare one particular area focus viiv risks controls expect place improving effectiveness rmcbs driving robust businesses functions given assurance risk discussion clear risk owner accountability adopted enterprise risk plans adapted proportionate risk mitigation approval enterprise risk owner driving monitoring compliance activities consistency better oversight monitoring key part icf gec requirement cet confirmation introduced continued mature ibm framework abac across group important risk areas reinforcing commercial practices risks ibm conducted across leader accountability risk management measuring enterprise significant focus prioritising monitoring well controls set enterprise risk plans highest risk activities risk markets review implemented gaps addressed gec led ibm market visits across gsks principal businesses maturity gsks ibm programme helps new enterprise risk reports rocc provide greater confidence issues identified introduced focus data key risk indicators therefore addressed earlier leading better informed discussions risk exposure actions needed gsk annual report strategic report governance remuneration financial statements investor information audit risk internal control continued audit risk committee report continued gsk values expectations committee evaluation gsks values expectations high priority committees annual evaluation externally facilitated committee aa team conducted values assurance interviewed committee members behalf reviews vars assess well gsks values concluded committee continued operate expectations embedded organisation insights effectively terms enhancements committees vars identified two continuing areas focus deliberations following improvement points agreed creating environment people comfortable committee continue strong focus speaking issues challenging status quo financial reporting well monitoring dashboard raising awareness gsks expectations helping gsks enterprise risks process people understand mean context roles identified prioritised following review boards living values expectations year mandatory governance architecture committee conduct training strategy focused simplifying key messages detailed reviews gsks financial controls reporting behaviours gsk wanted communicate anti bribery corruption practices commercial practices compressing training smaller pieces facilitate learning privacy information security enterprise risks detailed retention driving conversations review gsks enterprise risks undertaken employees line managers board committee focused aspect business closely addition committee responsible data analytics building existing capabilities gec oversight financial components work towards established data analytics workstream focuses separation developing marketlevel key risk indicators designed signal may potential issues business activity audit risk committee chair succession improving quality gec data used approaching end tenure board however provide actionable insights assist business facilitate smooth transition successor agreed mitigating risk stay board year annual general meeting subject reelection annual monitoring technology infoprotect general meeting may look forward working committee continues monitor effectiveness handing successor announced risk management internal control use new technologies impact financial controls reporting enterprise risk given fast pace technological development including ability new technologies perform tasks traditionally undertaken humans judy lewent committee considered particular impact robotics audit risk committee chair artificial intelligence march finance function aims improve performance efficacy reduce costs manage risk better optimising use technology gsk continues develop cloud applications robotics visualisation tools advanced analytics governance frameworks place ensure new technology assessed developed piloted deployed monitored controlled manner infoprotect recognising potential impacts continuously evolving environment complexity gsks footprint key enterprise risk committee receive quarterly updates information security committee also overseeing introduction chief information security officer industry standard framework monitoring reporting information security gsk gsk annual report audit risk internal control continued committee areas committee focus items discussed frequency financial reviewed integrity draft financial statements appropriateness accounting policies going concern reporting assumptions considered approval process confirming recommending board annual report fair balanced understandable reviewed recommended board approval annual report form f reviewed recommended statutory accounts reviewed major restructuring reports reviewed recommended approval quarterly preliminary results announcements dividends earnings q guidance reviewed significant issues relation quarterly preliminary results q reviewed approved directors expenses reviewed recommended inclusion viability statement annual report reviewed appropriateness accounting policies q reviewed accounting developments impacts well key accounting issues p reviewed financial reporting framework disclosure arrangements p external performed evidencebased assessment external auditor effectiveness external audit auditor considered qualifications expertise independence external auditor reviewed approved auditnonaudit expenditure incurred approved audit plan fee proposal set performance expectations auditor year considered nonaudit services fees audit budget considered auditors report annual results considered initial results external audit considered external auditor review report progress report key judgemental items considered internal controls financial reporting p global internal reviewed assurance reports global pharmaceuticals including viiv rd sfi programme update control vaccines consumer healthcare well global support functions compliance confirmed compliance sarbanesoxley act received litigation reports updates p received reports continuing investigations antibribery corruption issues reviewed gsks internal control framework controls financial reporting p reviewed audit assurance work approved work plan reviewed tesaro integration plan p reviewed general data protection regulation update p reviewed internal audit reports p risk reviewed risk management framework compliance reviewed risk elements group treasury pensions risk insurance tax policies considered emerging risks p received status reports companys enterprise risks risks disclosed pages xx xx p received fraud site security cyber security risk assessment updates p received rocc meeting updates p governance review new provisions confirmation compliance code matters reviewed committees terms reference confirmed adhered reviewed reports disclosure committee p reviewed committees performance effectiveness received corporate governance updates p reviewed groups modern slavery act statement reviewed companys gender pay gap disclosures p considered sfi programme reviewed technology audit assurance p reviewed balance performance trust met privately separately heads gec aa general counsel p met privately external auditor end meeting appropriate committee activity key annually q quarterly p periodically standing gsk annual report strategic report governance remuneration financial statements investor information audit risk internal control continued significant issues relating financial statements considering quarterly financial results announcements financial results contained annual report committee reviewed significant issues judgements made management determining results committee reviewed papers prepared management setting key areas risk actions undertaken quantify effects relevant issues judgements made management appropriate accounting required address issues financial statements significant issues considered relation financial statements year ended december set following table together summary financial outcomes appropriate addition committee external auditor discussed significant issues addressed committee year areas particular audit focus described independent auditors report pages significant issues considered committee relation financial statements issue addressed committee going concern basis preparation committee considered outcome managements halfyearly reviews current forecast net financial statements debt positions various financing facilities options available group following review risk potential impact unforeseen events committee confirmed application going concern basis preparation financial statements continued appropriate revenue recognition including returns committee reviewed managements approach timing recognition revenue accruals rebates rar accruals customer returns rebates us pharmaceuticals vaccines accrual returns rebates billion december committee reviewed basis accrual made concurred managements judgements amounts involved fuller description process operated us pharmaceuticals vaccines business determining level accrual necessary set critical accounting policies provisions legal matters including committee received detailed reports actual potential litigation internal external investigations groups legal counsel together number detailed updates investigations groups commercial commercial practices practices management outlined levels provision corresponding disclosure considered necessary respect potential adverse litigation outcomes also areas yet possible determine provision necessary amount december provision legal matters billion set note financial statements provisions provisions uncertain tax positions committee considered current tax disputes areas potential risk concurred managements judgement levels tax contingencies required december tax payable liability billion including provisions uncertain tax positions recognised groups balance sheet acquisitions tesaro pfizer committee considered judgements made management acquisition date valuations consumer healthcare business assets liabilities acquired particular valuations intangible assets intangible assets acquired tesaro valued billion pfizer consumer healthcare business billion committee concurred managements valuation judgements details provided note financial statements acquisitions disposals impairments intangible assets committee reviewed managements process reviewing testing goodwill intangible assets potential impairment committee accepted managements judgements intangible assets required writing resulting impairment charge million see note financial statements intangible assets details valuation contingent consideration committee considered managements judgement unwind discount liability relation viiv healthcare largely offset updated exchange rate assumptions adjustments sales forecasts cash payments nearly billion year december groups balance sheet included contingent consideration liability billion relation viiv healthcare see note financial statements contingent consideration liabilities details viiv healthcare put option committee reviewed agreed accounting pfizer put option concurred managements judgement valuation put option billion december gsk annual report audit risk internal control continued auditors reappointment external auditor clarity communication auditor ways following audit tender process conducted committee working concluded december deloittes appointment alignment audit groups investment auditor company group approved sap shareholders annual general meeting may quality audit teams leadership contractual similar obligations restricting groups choice external auditor skills experience audit team committee considers company committe chair regularly meets independently complied mandatory audit processes audit audit partners addition end face face committee responsibility provisions competition meeting committee meets auditor exchange markets authority statutory audit services order views progress date appropriate effectiveness quality external audit process reviewed feedback noted areas committee committed ensuring ongoing improvement implemented respect audit team basis gsk receives high quality effective audit audit committee satisfied external auditor evaluating deloittes performance effectiveness auditor external audit process prior making recommendation reappointment early committee reviewed auditors independence qualifications objectivity expertise effectiveness performance criteria resources agreed conjunction management beginning criteria set committee therefore agreed recommend board reappointment deloitte forthcoming annual undertaking review committee considered general meeting overall quality audit independence deloitte whether exhibited appropriate level challenge scepticism work deloitte recently appointed gsks auditor length tenure taken account assessing independence objectivity however committee consider overall effectively deloitte assumed role auditor finally committee considered feedback external audit survey sought views committee members financial management team corporate business unit level covered effectiveness challenge auditor deloittes integrity transparency reporting management committee gsk annual report strategic report governance remuneration financial statements investor information audit risk internal control continued auditors reappointment continued detailed criteria committee used judging effectiveness deloitte external auditor overriding responsibility deliver smoothrunning thorough efficiently executed audit set performance expectations gsks external auditor audit approach leverage centrally controlled audit approach ensuring gsk group joint venture local statutory entities audited strategy refine consistent technologyled audit enhanced risk assessment analytical procedures providing insights combined data trend analysis process cycle pathways identification audit risks ensuring wellinformed efficient audit deliver focused consistent audit approach globally reflected local risks materiality high quality adhere independence policies gsks frcs revised ethical standard applicable sec standards independent maintain relentless focus audit quality deloittes internal quality control procedures audit provide timely clarity assessments accounting treatments ensure consistency advice levels maintain forwardthinking approach raising potential issues concerns soon identified provide timely uptodate knowledge technical governance issues including evolving market practice viability statement requirements esmasec guidelines new ifrss ie ifrs serve industry resource communicating best practice trends reporting integrated reporting provide high quality succession planning key staff members deloitte ensure technical skillsets continuously enhanced effective deliver smooth running thorough efficiently executed audit partnership discussing approach areas focus advance early engagement understanding implications new operating model ensuring sarbanes oxley scope additional procedures discussed understood management communicated timely basis within gsk deloitte timely reporting issues levels within group early engagement provision impact assessments key judgements ensuring clarity roles responsibilities local deloitte finance services responding issues raised management timely basis meeting agreed deadlines providing sufficient time management consider draft auditor reports respond requests queries consistent timely communication engagement local central audit teams across gsk stakeholder groups liaise aa avoid duplication work gec ensure common understanding audit findings adopting collaborative approach solving issues ultimately provide highquality service board shareholders relevant stakeholders scrupulous scrutiny group act utmost integrity value work closely management agree scope changes overruns efficiencies set clear milestones continuous money monitoring provide transparency audit time cost incurred analysis budget identifying areas enable reduction audit hours without compromising audit quality commensurately reducing audit fees gsk annual report audit risk internal control continued nonaudit services presumption nonaudit services provided prohibitions gsks policy includes black list prohibited accountancy firms nonaudit services however external auditors skills experience preapproval categorywide preapproval process reflects make suitable supplier nonaudit service restrictions frcs guidance audit may authorised provide nonaudit services committees nonaudit services auditrelated tax services accordance gsks preapproved committee chair policy committee ensures auditor objectivity cfo delegated committee independence safeguarded reviewing pre preapproved approving services group financial controller following core policy guidelines engaging external approved designate group auditor provide nonaudit services observed financial controller process nonaudit services put fees paid companys auditor associates set competitive tender financial service providers details given note financial external auditor line groups procurement statements operating profit process unless skills experience external auditor make suitable supplier safeguards ensuring adequate safeguards place audit services comparisonm objectivity independence group audit threatened compromised deloitte fee cap ensuring total fee payable nonaudit services exceed annual audit fee except special circumstances would clear advantage companys auditor undertaking dddeeellloooiiitttttteee additional work companys policy complies frcs revised ethical standard eu audit regulation pwc sarbanesoxley act companys policy contains following three guidelines fee cap cap annual audit fee audit assurance services services including tax regulatory compliance stringent frcs fee cap set treasuryrelated services average fees preceding threeyear period fair balanced understandable assessment one key compliance requirements groups financial code conduct reporting lines statements annual report fair balanced also number wellestablished policies including understandable coordination review groupwide code conduct available gskcom together contributions annual report follows wellestablished details confidential speak reporting lines documented process performed parallel reporting investigation unlawful conduct updated formal process undertaken external auditor version code conduct last published april committee received summary approach taken management preparation gsks annual report ensure met requirements frcs code enabled committee board confirm gsks annual report taken whole fair balanced understandable provides information necessary shareholders assess companys position performance business model strategy gsk annual report strategic report governance remuneration financial statements investor information audit risk internal control continued internal control framework board recognises obligation present fair balanced groups rocc team senior leaders mandated diligent assessment gsks current position board assist committee overseeing risk prospects board accountable evaluating management internal control activities also provides approving effectiveness internal controls including business framework risk management upward financial operational compliance controls risk escalation significant risks business unit risk management processes operated gsk board structure reports rocc business unit rmcbs responsible promoting local tone internal control framework framework top risk culture well ensuring effective oversight comprehensive enterprisewide risk management model internal controls risk management processes means gsk ensures reliability financial reporting compliance laws regulations principal risk assigned risk owner member framework supports continuous process boards senior management risk owner accountable identification evaluation management groups management hisher respective principal risk including principal risks required frcs code setting risk mitigation plans implementation designed manage risk achieving business reporting risk management approach progress objectives rocc committee every year rocc rmcbs assisted gec responsible fit purpose framework conjunction corporate advancing risk management across enterprise values expectations speak processes ensures development working practices riskbased risks associated business activities actively ethically sound gec actively promotes ethical behaviours effectively controlled line agreed risk appetite enabling members organisation operate believe framework provides reasonable accordance values comply applicable absolute assurance material misstatement loss laws regulations aa line agreed assurance plan provides framework independent assurance senior management board enterprise oversight effectiveness risk management across group independent assurance assurance helps senior management board meet oversight advisory responsibilities fulfilling independent business monitoring g othro eu r p ts kt er ha ote ldg eic r b aje c ati v dd u b au l rl ed pin og r tt ir nu gs li nw ei ih n tp oa tt hie en cts f ond disc ep nl fi rce ea mn ed nt b r ui ss ssk e nsm een st w cori ntt te ron ls standards p r pin sh r roi kd e n v c tt c io dh ip eoe ta h alc e r nm io gs aim kt srt oem sue w eit p srt ne e se ae c mnr e ei v ng oe tn e r ncr ee lg aa hu tn eel r tir n ee rp e na ro l n cs l cf nr r oo e tn rm ots r l ob eo lu nfs vs itn rig ohe n nes mss fi e c eu r nn en tit p ts rts p ro blemer ssp n ding activities training w ot fi r teh hni en g te eha e rc enh p tp oh reri n scc tp n ha erl cr li oek n va mir ita n te en e c cnl ou nd f cin lug e ewn sih n oa g nn tc th e em c ee fn fn et ss ci tt io era nt eio sn mom na toa rg ine gment communication anf nth ue li ln yt e inrn aa cl cc oo rn dtr ao nl c e en v wir ito hn tm e n ft ra cnd r ep rt c oo th ee p b roo va isr id ns board authority delegated committee conducted robust assessment groups principal risks includes consideration nature extent risk willing take achieving groups strategic gsk values expectations objectives board committee maintained oversight ensure effectiveness internal control environment risk management processes operation across group whole year date approval annual report gsk annual report internal control framework continued boards review focuses company subsidiaries review groups risk management approach extend material associated undertakings joint discussed risk management section strategic ventures investments although considers risk report pages management principal companys participation activities risk explained principal risks uncertainties pages established procedures controls place identify entities groups viability discussed group whose results must consolidated groups results financial review section strategic report believe process followed board committee reviewing regularly system internal controls risk management processes accordance guidance risk management internal control related financial business reporting issued frc governance structure risk management gsk annual report gnirotinom rof ytilibatnuocca responsibility implementing audit risk internal control continued board directors responsible system corporate governance strategy risk management financial performance responsible reviewing approving audit risk committee adequacy effectiveness risk management internal controls corporate executive team supports ceo managing business activities authorised board assist audit risk oversight risk committee overseeing risk compliance council management internal control activities group responsible system corporate business units governance strategy risk management financial performance ensures appropriate internal controls risk management implemented effective risk management compliance boards complemented country executive risk boards ensure consistent approach risk management across local territoriesstrategic report governance remuneration financial statements investor information science committee report pleased present third report chair science dr jesse goodman committee committee science committee chair committee worked support board dr barron cso considering science role technology culture part new rd strategy committee committee operated programme activities help undertakes periodic reviews rd strategy discharge responsibilities items considered included progress regular updates pharmaceuticals vaccines assesses overall performance including relevant assets financial metrics effectiveness competitiveness rd regular updates rd strategy helps identify critical emerging trends science scientific technical review business deals medicine potential impact company strengthen pipeline undertakes periodic reviews companys scientific oversight rd pipeline milestones including project capability talent portfolio governance gates progress rd goals reviews scientific opportunity specific large scale progress rds culture talent investments business transactions pharmaceuticals rd reviews output groups science advisory committee pleased observe pharma rds boards significant progress strengthening pipeline focus science related immune system use membership human genetics advanced technologies committee members committee member since creating culture fosters innovative mindset new dr jesse goodman january governance model embedded centralised key chair january functional capabilities changes included refocus dr laurie glimcher september smaller number promising projects move away judy lewent january discovery performance unit model three large research details committee members skills experience given units focusing priority areas immunology genetics biographies board pages see pipeline continues evolve assets progressing committee member attendance levels added terminations medicines approved company secretary secretary committee resulting medicines currently developed attends meetings attendees committee rd continues attract talented individuals work meetings may include rd help deliver new approach science x technology x culture regular attends attendee attendee required vaccines rd company chairman committee oversaw significant changes vaccines chief executive officer rd strategy secure growth existing portfolio chief scientific officer president rd unlock new emerging vaccines fields one key president global vaccines changes creation integrated development independent senior external scientific advisers organisation chief financial officer develop maintain greater insight company executives understanding vaccines business pleased visit wavre belgium rockville washington visits enjoyed meeting employees members rd brought life impressive scientific activities undertaken within vaccines gsk annual report science committee report continued collaborative approach committee evaluation committee pleased review scientific committees annual evaluation externally facilitated perspective new key collaborations strategic partners interviewed committee members behalf help enable gsk strengthen pipeline concluded committee continued develop well gain real advantages patients company given critical importance strengthening pipeline collaborations enable us obtain competitive advantage committee focus science deeper level support adding pipeline optionality enable us gain access boards understanding provide reassurance key technologies included guidance going forward committee three broad lyell immunopharma gsk entered fiveyear collaboration objectives develop new technologies improve cell therapies key scientific assumptions companys strategy cancer patients collaboration apply lyells technologies remain valid strengthen complement cell therapy pipeline technical assurance university california establishing stateoftheart laboratory crispr technologies laboratory risk oversight research practices patient safety genomics research new laboratory explore gene enterprise risks mutations cause disease develop new technologies using look forward reporting progress next year crispr rapidly accelerate discovery new medicines collaboration build gsks existing collaborations companies andme able deliver dr jesse goodman genetic information scale improving probability rd science committee chair success march positive outlookrd priority assets forward strategy addition committee pleased note number positive developments year underscore moves towards promising future outlook rd included rd pipeline achieved major approvals made submissions positive readouts pivotal studies progressed new assets pivotal studies pivotal study readouts included positive data key latestage oncology therapies zejula women ovarian cancer belantamab mafodotin patients multiple myeloma dostarlimab patients endometrial cancer national medical products administration approved shingrix vaccine use china largescale pilot implementation rtssas mosquirix malaria vaccine malawi ghana kenya gsk annual report strategic report governance remuneration financial statements investor information corporate responsibility committee report chair corporate responsibility committee lynn elsenhans committee pleased present committees corporate responsibility committee chair report committee forms important part boards oversight role companys trust priority ensuring cet working deliver longterm value shareholders society committee committee rolling agenda receives reports reviews issues potential serious cet members senior managers ensure actions impact upon gsks business reputation progress companys commitments reviewed oversight views interests internal regular basis includes monitoring company works external stakeholders engage effectively broad range stakeholders considers gsks trust priority annual governance responds high external expectations gsk global oversight progress gsks trust commitments healthcare company reflect important issues responsible areas focus sustainable business growth committee focused time areas membership material stakeholders longterm business success year work committee included scrutiny membership committee appointment progress commitments support companys dates set trust priority set context external trends committee members committee member since stakeholder expectations committee reviewed lynn elsenhans october approved companys reporting progress chair may commitments set trust section dr vivienne cox july pages dr jesse goodman may year management presented committee details committee members skills experience number topics across breadth trust priority given biographies board pages see committee member attendance levels science technology global health committee company secretary secretary committee reviewed areas significant progress attends meetings attendees committee companys new global health strategy led science meetings may include emphasises importance sustainable funding models committee discussed sustaining momentum regular attends good early progress made ensure best outcomes attendee attendee required patients company acknowledging commercial company chairman business benefits investment area chief executive officer chief scientific officer president rd affordability availability year continued general counsel focus access affordability companys president global affairs commitment making products available prices president pharma supply chain responsible sustainable business reviewed president global pharmaceuticals global pricing strategies pharmaceuticals business president global vaccines particular focus us environment companys ceo gsk consumer healthcare largest single market operating context svp human resources continues evolve svp corporate affairs modern employer committee reviewed progress vp trust global health companys commitments modern employer centre executives engaged people inclusion diversity health wellbeing development committee discussed good progress gender lgbt targets use employee assistance programme robust deployment one manager assessment tool identify issues help improve line managements performance gsk annual report corporate responsibility committee report continued responsible business committee reviewed progress committee evaluation made gsks commitments fundamentals committees annual evaluation externally facilitated responsible business included oversight ethics interviewed committee members behalf values responsible use data scientific concluded committee continued operate engagement also reviewed progress measures effectively reduce environmental impact one quarter given increasing importance esg factors emerging environmental risks including plastics usage need done regard coming years committee discussed assessment companys committee pleased boards support plastics footprint plans reduce use possible progress work area particular respect stakeholder engagement insights environmental sustainability committee pays close attention evolving views committee aims expectations companys broad range key stakeholders next year continue scrutinise monitor regular report stakeholder insights reviewed gsks material trust topics including one managements discussed meeting ensure committee considers key priorities continue building protecting companys issues may bearing companys reputation reputation strong focus innovation committee delivery responsible business agenda considers company well positioned committee also received update gsks reputation support continuing delivery trust priority research understand relevant insights strategy employee insights discussed relation companys lynn elsenhans modern employer agenda results employee corporate responsibility committee chair survey march year continued enjoy positive engagement investors approach performance trust work committee meet directly shareholders understand issues concerns may committee members also area responsibility items addressed external issues health safety update meet informally shareholders annual potential serious impact upon general meeting committee also reviewed perception regular reputational emerging gsks business reputation study investors interested esg aspects issues update activities better understand rising interest investors oversight corporate reputation area matters committee discussed research kpi perceptions strengths area including hcp engagement sfi changes management esg risks opportunities implementation well integrated strategy quality esg oversight stakeholder views stakeholder insights update disclosures strong committee noted investors desire engagement esg investor insights see sustained delivery trust commitments increased employee survey reporting aligned sustainability accounting standards shareholder meetings board sasb taskforce climaterelated financial disclosures tcfd company included sasb annual governance oversight approval trust section disclosures esg performance summary available progress gsks annual report online first voluntary tcfd disclosure given responsible business oversight progress commitments support trust commitments highlighted remuneration committee chair global health strategy emerging importance establishing link esg sustainable access affordability performance remuneration outcomes executive business conduct directors cet responsible use data finally committee pleased see company modern employer engagement perform well two key external benchmarks securing first culture position dow jones sustainability index environmental targets pharmaceutical industry continuing hold first position access medicine index since key hcp healthcare professional sfi sales force incentives esg enviromental social governance gsk annual report strategic report governance remuneration financial statements investor information section statement statement aligns section statement requirements engagement companys main stakeholder groups contained section cza companies act including patients shareholders consumers customers act employees levels organisation across enterprise summarised pages strategic statement focuses directors regard report year matters set section f act performing duties incorporating governance architecture processes company information areas annual report avoid operated ensure relevant matters considered unnecessary duplication board considers board principal decisionmaking means statement focuses risks opportunities contributing delivery gsks longterm priorities strategic importance gsk consistent size innovation performance trust summarised pages complexity group corporate governance report performance duty promote success table identifies annual report company board regard number matters information issues factors stakeholders including listening considering views shareholders board considered relevant disclosure complying companys key stakeholders build trust section f act set detail given ensure fully understands potential impacts decisions strategic importance gsk makes stakeholders environment communities operate board regard following matters information longterm results strategic report likely consequences decision long term business model chairmans statement ceos statement capital allocation longterm priorities key performance indicators risk management viability statement corporate governance report responsible leadership audit risk committee report b workforce strategic report interests groups employees business model culture modern employer stakeholder engagement page corporate governance report responsible leadership workforce engagement nominations committee report audit risk committee report remuneration report remuneration committee chairs statement gskcom gender pay gap report gsk annual report section statement continued board regard following matters information c business relationships strategic report importance developing groups business business model relationships suppliers customers others industry trends stakeholder engagement performance pharma vaccines consumer reliable supply working third parties risk management corporate governance report responsible leadership principal decisions audit risk committee report corporate responsibility committee report community environment strategic report impact groups operations trust section including community environment environment ehss risk pages climaterelated financial disclosure corporate governance report corporate responsibility committee report gskcom responsibility reports data e reputation strategic report desire maintain reputation high culture standards business conduct trust ethics values human rights reporting investigating concerns antibribery corruption nonfinancial statement approach tax corporate governance report corporate responsibility committee report gskcom modern slavery statement f fairness shareholders corporate governance report aim act fairly members shareholder engagement company investor information gsk annual report strategic report governance remuneration financial statements investor information directors directors powers determined uk legislation nominations committee reviewed register potential articles association contain rules conflict authorisations register conflicts january appointment replacement directors provide reported board conflicts directors may appointed ordinary resolution appropriately authorised process authorisation members resolution board provided continued operate effectively recommended approval appointed board director retires next register conflicts board subsequently annual general meeting following appointment approved except described note financial statements related party transactions end articles also provide directors required financial year director person closely associated seek reelection annually annual general meeting material interest contract significance accordance code group company director cease director articles prohibit director voting resolution becomes bankrupt concerning appointment terms termination ceases director virtue companies act appointment articles independent advice suffers mental physical ill health board resolves company agreed procedure directors take shall cease director independent legal andor financial advice companys expense deem necessary missed directors meetings continuous period indemnification directors six months without permission board resolves qualifying third party indemnity provisions defined shall cease director companies act force benefit directors prohibited director law former directors held office resigns offers resign board accepts offer approval signature annual report required resign board change control essential contracts contracts arrangements directors conflicts interest individually fundamental ability business directors duty companies act operate effectively neither company party material avoid situation could direct agreements would take effect altered terminate upon indirect conflict interest possible conflict change control following takeover bid company articles provide general power board agreements director would provide compensation authorise conflicts loss office employment resulting takeover board reviews new potential actual conflict except provisions companys share plans may recorded company secretary directors counted cause options awards granted plans vest quorum authorisation actual takeover potential conflicts nominations committee reviews details termination provisions executive directors register conflicts annual basis board service contracts given full version companys subsequently approves remuneration policy available wwwgskcom continuing basis directors responsible investors section updated new informing company secretary new actual remuneration policy set pages potential conflicts may arise changes annual report provided approved shareholders circumstances may affect authorisation previously companys annual general meeting given even provided authorisation director absolved statutory duty promote success company actual conflict arises postauthorisation board may choose exclude director receipt relevant information participation debate suspend director board last resort require director resign gsk annual report directors continued content directors report following information also incorporated directors purposes uk companies act report directors report glaxosmithkline plc year ended location annual report december comprises interest capitalised financial statements directors report notes section pages publication unaudited financial information group financial review corporate governance report details longterm incentive schemes remuneration report employee engagement waiver emoluments director applicable directors statements responsibilities waiver future emoluments director applicable investor information non preemptive issues equity cash applicable non preemptive issues equity cash applicable strategic report sets matters required unlisted major subsidiary undertaking disclosed directors report considered parent company participation placing applicable strategic importance listed subsidiary strategic report provision services controlling applicable shareholder section pages shareholder waiver dividends financial statements risk management objectives policies notes shareholder waiver future dividends financial statements notes likely future developments company agreements controlling shareholders applicable research development activities business relationships directors report diversity drawn presented accordance provision information consultations employees reliance upon english company law liabilities carbon emissions directors connection report shall subject section statement limitations restrictions provided law approved board directors march signed behalf sir jonathan symonds chairman march gsk annual report ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn remuneration section chairmans annual statement annual report remuneration remuneration policy summary remuneration policy report ggsskk aannnnuuaall rreeppoorrtt remuneration report chairmans annual statement behalf remuneration committee committee proposed new policy considered developed pleased present remuneration report context committees oversight wider workforce includes annual statement annual report pay met hr business leads exchange views remuneration updated remuneration policy executive remuneration arrangements align groups report setting proposed changes remuneration policy wider pay policy arrangements engagement described pleased insights generated performance engagement continue develop coming set elsewhere report gsk made years ensure alignment pay policy practices significant progress across three ipt priorities addition based external benchmark data internal innovation strengthened pipeline focusing projections committee able satisfy increasing investment rd exciting new companys remuneration arrangements remain appropriate developments oncology significant number positive given committees view design existing policy results across portfolio working effectively major structural changes proposed performance delivered growth sales earnings especially avoid distraction preparing separation well achieving strong cash generation improvements group however certain amendments included ensure operational execution prepare separation group policy implementation remain fit purpose trust continued make good progress innovations concluding necessary changes engaged global health tb malaria hiv ranked top major shareholders behalf committee pharmaceuticals sector dow jones sustainability index feedback received shareholders greatly valued remuneration outcomes carefully considered committee decided awards relation made accordance proceed finalising proposed new policy key changes approved remuneration policy key decisions made outlined committee follows pensions annual bonus outcomes determined reference alignment new executive directors pension performance agreed financial measure contributions wider workforce committee committees assessment executive directors considered levels pension directors context individual levels performance resulted bonus requirements frcs code feedback payment made target committee believes investors guidance investment association bonus outcomes appropriately reflect overall emerging market practice companys existing pension underlying performance arrangements wider workforce new policy future executive directors appointed uk us vesting lti awards based preagreed equally provide pension aligned opportunity available weighted measures rd new product performance broader employee population location see adjusted free cash flow relative tsr three years resulted overall vesting level alignment current uk executive directors pension see contributions wider workforce committee reduce pension provisions current uk based executive committee determined bonus lti outcomes directors align wider uk workforce levels included full assessment performance across january relevant measures exercise discretion part determination committee determined maintain current pension contribution dr hal barron cso review remuneration policy based us recognises contractual commitment committee reviewed remuneration appointment exceptional talent critical policy objective maintaining alignment importance making continued progress rd ipt priorities shift culture investor sentiment groups prospects coming years also recognises emerging market practice strong competitive dynamics market outset review committee careful ensure operates existing policy reflected factors set provision extension post employment cessation share frcs code applied consistently ownership requirement developed proposed new policy examples gsks current share ownership requirement sor mandates factors addressed new policy include executive directors must retain shareholding oneyear continuing simplify pay arrangements removing post employment cessation extended require years service condition termination mutual agreement sor held second year post cessation loss office policy employment gsk operates significant sors ceo would maintaining proportionate approach reducing ceos therefore required hold salary first year maximum lti award level base salary following cessation salary second year gsk annual report strategic report governance remuneration financial statements investor information reduction maximum lti award level ceo remuneration committee aware sensitivity amongst committee initially set emma walmsleys pay ceo stakeholders levels executive pay light given previous incumbent market reflect committee intention using headroom new role also first ceo position currently available reduce maximum award level since emma walmsleys leadership strong permitted new policy ceos lti awards progress made across gsks strategic priorities base salary proposed lti ipt supported shift companys culture new rd continues granted maximum opportunity strategy delivering significant progress technology although proposed increase lti award level emma pipeline strengthened targeted business walmsley implementation new policy development result company delivering strong set financial operating performance sales growth changes across three businesses growth total adjusted broadening malus clawback provisions consistent earnings per share growth free cash flow since common practice ftse proposing despite genericisation advair us extend scope triggering events existing implementation second step planned salary executive financial recoupment policy see increase emma walmsley reflect performance update termination policy proposing role committee agreed following engagement significant changes loss office payment policy shareholders progress pay levels implementing however manage succession proactively proposed twostep salary increase disclosed last year service condition removed years annual report second salary increase would termination mutual agreement policy bring new awarded subject continued development sustained policy line market standard performance full details proposed changes policy set committee considered emma walmsleys performance pages light continued progress developing remuneration policy implementation executing business strategy delivery financial new psp performance measure performance second salary increase awarded previously indicated shareholders intention january resulting base salary introduce measure recognise importance accelerating setting lti award level salary also strengthening pipeline reflecting innovation priority increasing emma walmsleys annual lti award level particular importance anticipation separation salary recognise development strong therefore introducing strategic pipeline progress performance competitive landscape gsk measure targeted reward progress strengthening operates increase lti award remains rd pipeline high quality assets achieving new reduced maximum proposed new policy approvals major markets key assets indications committee considered high regard focus metric achievement material held virtue performance considered milestones competitive positioning peers making adjustment new performance measure weightings lti lti awards enables emma walmsleys total compensation awards positioned broadly market median levels delivery relative tsr strong longterm performance adjusted free cash flow board changes innovation sales announced august iain mackay joined board pipeline progress cet january succeeded simon dingemans therefore future lti measures would reward chief financial officer april simon retired executive directors delivering immediate value outcomes company following agm may details shareholders based companys performance joining leaving arrangements described last remaining incentivising innovation commercialisation years report new assets agm introduction european benchmark peer group finally would like thank shareholders input committee replacing existing ukcross industry peer engagement remuneration policy review group new european peer group reflects feedback welcome shareholders feedback report look shareholders uk peer group forward receiving support proposed new becoming narrow change results group remuneration policy annual report remuneration reflective nature gsks business annual general meeting may methodology select new group based selecting companies within range gsks market capitalisation urs rohner ftse stoxx excluding companies remuneration committee chairman operate financial services extraction utilities industries march gsk annual report glance total remuneration following shows breakdown total remuneration paid executive directors office december respect emma walmsley iain mackay dr hal barron usm usm usm usm usm usm mackay joined board january remuneration shown date fixed pay salary benefits pension performance pay annual bonus ltis earned respect three year performance period pay performance annual bonus financial performance lti outcome performance period ended december overall vesting maximum target relative rd new target tsr product threshold target adjusted group pbit performance achieved vested adjusted maximum performance target lapsed free cash flow proposed executive remuneration policy implementation key changes policy alignment pensions wider new uk us executive directors pension contribution levels aligned wider workforce workforce current uk executive directors pension contribution levels aligned wider workforce january extension post employment share ownership requirements executive directors held second year post cessation cessation sor employment lti opportunity maximum reduced ceo award maximum reduced base salary implementation greater alignment lti measures greater alignment innovation business priority ipt business priorities introduction pipeline progress performance measure innovation measures comprise performance measures ceo remuneration implementation second step planned salary increase effective january increase ceos lti award level base salary following continued development sustained performance ee proposed nonexecutive directors remuneration policy gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration total remuneration audited fixed pay pay performance annual bonus vested lti awards maximum opportunity vesting measures salary measures rd new product adjusted group pbit afcf total benefits personal objectives relative tsr remuneration two year deferral plans could b pension gsk shares last dabp matching awards psp awards read pages read pages read read total remuneration audited emma walmsley iain mackay dr hal barron simon dingemans january may fixed pay salary benefits pension total fixed pay pay performance annual bonus vesting lti awards dabp matching awards psp total pay performance total remuneration notes details mandatory bonus deferrals deferred annual bonus plan dabp set matching awards ceased longer granted dabp dabp matching awards vested february valued based share price vesting vested amount relates share price appreciation performance period committee exercise discretion relation vesting awards share price changes ms walmsleys psp vest july valued based average share price threemonth period december vested amount relates share price appreciation performance period committee exercise discretion relation vesting awards share price changes committee may specific circumstances line stated principles apply clawbackmalus determines appropriate following due consideration committee recovery sums paid clawback reduction outstanding awards vesting levels malus applied respect executive directors see details vesting dabp matching awards psp awards details payments past directors gsk annual report annual report remuneration continued total remuneration audited continued following sections provide details element total remuneration including committee implemented approved remuneration policy year comparator groups pay relative tsr committee used two pay comparator groups considering executive pay global pharmaceutical comparator group also used measure relative tsr performance primary groups used executive director follows primary comparator group global pharmaceutical comparator group emma walmsley astrazeneca reckitt benckiser dr hal barron france us iain mackay bhp group rio tinto sanofi abbvie bp royal dutch shell switzerland amgen british american tobacco unilever novartis bristolmyers squibb diageo vodafone roche holdings eli lilly johnson johnson uk merck co astrazeneca pfizer bbvie amgen included remuneration benchmarking included tsr comparator group reviewing ceos remuneration committee also referenced pay group leading european companies whose selection based size complexity see changes comparator group ceo cfo fixed pay audited salary benefits table sets base salaries executive uk remuneration reporting regulations require company directors last two years compared increases add executive directors total benefits calculation uk us workforce items deemed tax authorities taxable benefit details set full following shareholder consultation january committee decided adjust ceos pay two tranches reflect development performance role details salary levels provided base salary change emma walmsley iain mackay na dr hal barron simon dingemans uk us employees gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued fixed pay audited continued pensions executive director member since pension arrangements emma walmsley base salary matching contributions first salary base salary iain mackay lieu pension salary excess dr hal barron dr barron member k plan open us employees executive supplemental savings plan essp savings scheme open us executives accrue benefits k plan limits completed one years service january dr barron receives combined contribution rate k essp plans core contributions plus match total base salary bonus less bonus deferred dabp dr barron also member us cash balance supplemental cash balance pension plans gsk makes annual contributions base salary line us senior executives members gsks cet simon dingemans base salary lieu pension member defined contribution plan emma walmsley iain mackay eligible receive matching award first salaries accordance terms plan emma walmsley iain mackay receive cash payments lieu pension base salary excess line gsks defined contribution pension plan rates simon dingemans received cash payment lieu pension base salary line gsks defined contribution pension plan rates following table shows breakdown pension values set pension remuneration figures calculated accordance methodology set large mediumsized companies group accounts reports amendment regulations remuneration regulations emma walmsley iain mackay dr hal barron simon dingemans janmay pension remuneration values uk defined contribution us defined benefit employer cash contributions total pension remuneration value uk defined contribution figure emma walmsley includes bonus sacrifice contribution details regarding pension values dr hal barron set table pensions figures disclosed dr barron member us style defined benefit plans accordance paragraph eii schedule remuneration regulations table shows accrued benefit ie annual pension accrued date accordance regulations pension remuneration calculated increase accrued benefit adjusted inflation multiplied reflect fact benefit received number years accrued pension pension remuneration december december value dr hal barron pension values us funded us unfunded total please see details changes pensions policy future policy table implementation gsk annual report annual report remuneration continued pay performance audited annual bonus individual annual bonus adjusted group pbit objectives performance targets financial measures weightings follows weighting adjusted group pbit performance positioning performance measure executive directors target outcome target adjusted group pbit individual objectives threshold maximum performance targets set target respectively adjusted group pbit target outcome purposes annual bonus calculation differ adjusted group pbit disclosed elsewhere annual report primarily target outcome numbers calculated applying gsk budget exchange rates actual exchange rates following table shows actual bonuses earned compared bonus opportunity bonus opportunity bonus outcome financial individual total total target maximum performance objectives bonus bonus bonus salary salary base salary salary salary salary emma walmsley iain mackay dr hal barron table provides detail delivery adjusted group pbit financial performance group turnover billion increase aer cer adjusted operating profit million higher aer flat cer turnover increase cer adjusted operating margin aer cer cer proforma basis total earnings per share increased p aer cer adjusted eps grew aer cer p strong cash generation achieved free cash flow billion dividend continued p gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued pay performance audited continued following table summarises performance scorecard individual objectives agreed committee executive director addition contribution financial performance individual objectives emma walmsley continued focus progress longterm ipt priorities supply chain transformation plans delivering brand robust commercial execution resulted strong performance network simplification building capacity support new product sales pharmaceuticals vaccines billion speciality pipeline supply chain reliability targets achieved consumer healthcare billion commercial medical progress building global reputation across ipt priorities speciality capability build track support upcoming launches including ranking dow jones sustainability index total respiratory sales billion shingrix sales billion met significant milestones global health strategy continuing drive transition drug regimens hiv including malaria tb paediatric hiv programmes strengthened pipeline execution rd strategy continued amr leadership science x technology x culture doubling number focused leadership development including two internal cet oncology assets clinical development significant progress promotions hr communications new role advanced technology approach establishing laboratory top enterprise key roles women senior genomic research collaboration lyell immunopharma vice president vice president level outstanding external hires functional genomics aiml recorded highest ever employee engagement april tesaro acquisition completed integrated positive data continued focus creating performance readouts zejula culture underpinned values expectations consumer healthcare jv pfizer completed ahead plan integration track preparation creation two new companies started iain mackay strong financial leadership group first year role key leadership role preparation separation two delivered financial operating performance plan companies group turnover operating profit free cash flow capital strengthened finance investor relations team expenditure cash restructuring structure high engagement period leadership company change dr hal barron rd strategy delivering strong pipeline progress assets tesaro integrated delivered efficiency pipeline advanced phase phase phase goals positive data readouts zejula terminations least registration decisions expected rebuilding gsks reputation innovation supported continued drive focus greater collaboration partner significant increase internal accountability decision making engagement innovation significant business development support advanced technology approach well strong capability build including external hires lead functional genomics aiml new talent key rd roles building oncology capability malus clawback policy line disclosure guidelines neither committee details policy malus clawback please refer recoupment committee exercised malus clawback companys remuneration policy report also available gskcom policies committee reviews discloses whether details existing policies recruitment remuneration recoupment committee exercised malus clawback loss office termination payments please refer disclosure made matter subject remuneration policy report pages public reports misconduct fully annual report available gskcom change resolved legally permissible disclose loss office policy remuneration policy report made without unduly prejudicing company proposed please refer therefore shareholders gsk annual report annual report remuneration continued pay performance audited continued value earned longterm incentives ltis following tables set performance achieved management targets set companys lti plans also include update performance outstanding awards line committees agreed principles measure applicable lti awards actual performance targets reviewed adjustments made appropriate ensure vesting outcome reflects genuine underlying business performance results delivered line trust business priority reflects companys position esg see details adjustments made provided time vesting awards performance period ended december committee reviewed performance psp awards dabp matching awards granted executive directors targets set details decision revise adjusted free cash flow afcf target set annual report psp awards dabp matching awards assessed performance measures changes afcf target addition changes targets set rd new product performance measure relative tsr performance measure psp awards psp valued based average share price threemonth period december vested amount ceo relates share price appreciation performance period committee exercise discretion relation vesting awards share price changes dabp matching awards valued based share price vesting vested amount ceo relates share price appreciation performance period committee exercise discretion relation vesting awards share price changes performance achieved three years december vesting levels set table outcome vesting level performance measures relative weighting performance targets outcome maximum award rd new product rd new product sales performance measures aggregate threeyear sales new bn performance products launched threeyear performance period preceding two renamed years ie innovation sales target vesting rd maximum bn bn bn threshold bn adjusted free line companys agreed principles afcf figures included adjustments bn cash flow number material distorting items including legal settlements exchange rate performance movements special pension contributions rd original revised target target vesting maximum bn bn bn bn bn bn threshold bn bn f urther details revised target set annual report relative tsr ranked th tsr ranking within comparator group vesting performance maximum st nd rd rd th th threshold median th th sr comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck co novartis pfizer roche holdings sanofi vesting schedule based delivering vesting median performance comparator group ten companies median falls two companies total vesting respect awards gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued pay performance audited continued update performance ongoing lti awards committee also reviewed performance psp awards granted executive directors following charts provide estimate vesting levels taking account performance december actual vesting levels determined based performance full threeyear performance periods indications therefore regarded predictions final vesting levels afcf targets associated vesting scales psp awards adjusted net overall impact reduction bn bn award bn bn award adjustments take account following items cash flow impact pfizer transaction impact vaccines rabipur encepur divestments operating profit impact separation preparation programme including restructuring programme costs savings operating profit separation costs changes targets set rd new product performance measure renamed innovation sales relative tsr performance measure awards performance updates award award ranked rd ranked rd bn threshold bn threshold maximum maximum commercially commercially median bn sensitive median bn sensitive threshold threshold tsr adjusted free rd new tsr adjusted free rd new rd cash flow product rd cash flow product rd rd rd rd estimated vesting level estimated lapsing level threshold performance award vest respect rd new product performance renamed innovation sales afcf measures relative tsr element award award vest median performance respectively tsr comparator group remains unchanged shown respect awards individual lti award levels appear annual report set lti awards years report historical vesting lti plans vesting year adjusted free rd new business total vested grant relative tsr cash flow product diversification lapsed dabp awards subject tsr performance awards subject performance measures psp awards gsk annual report annual report remuneration continued pay performance audited continued lti awards dabp awards respect deferral bonus psp awards shown table dabp awards psp awards total bonus number face value award level number face value deferred shares award base salary shares award emma walmsley shares shares iain mackay shares dr hal barron ads ads simon dingemans shares face values dabp awards calculated based share price ads price closing prices february day grant nilcost options uk executive directors restricted shares us executive director performance conditions attached dabp awards reflect mandatory deferrals respect annual bonus earned face values psp awards calculated based share price ads price closing prices march day grant conditional shares based three equally weighted measures rd new product performance renamed innovation sales ii adjusted free cash flow iii relative tsr performance measure vests threshold performance period psp awards january december iain mackay appointed board january simon dingemans dabp award vest normal three years date granted allemployee share plans dilution limits uk executive directors may participate hmrc approved awards made plans incorporate dilution allemployee share plans wider uk workforce ie limits consistent guidelines published share save share reward plans investment association limits rolling tenyear period plans rolling tenyear participants share save plan may save period executive share plans granted senior executives month three years end period estimated dilution existing awards made last ten option buy gsk shares discount share price years december follows start savings contract participants share reward plan contribute month purchase gsk gsk employee share plans shares company matches details see executive share plans actual limit gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued ceo pay comparison ceo total remuneration positioning supplementaladditional ratios gsks ceo pay ratio likely vary potentially significantly time since driven largely ceo variable pay outcomes line reward principles ceo larger portion pay based performance individuals p p global pharmaceutical p means depending gsks performance group ratio could increase decrease significantly committee believes senior executives significant european proportion pay directly linked performance crossindustry group light also provided supplemental ratios lti compensation excluded believe provides additional view ltis formed substantial percentage ceos total remuneration highly lower quartile median upper emma walmsleys median quartile current position variable dependent business performance ceo remuneration includes salary expected value incentives based total remuneration excluding long term incentive committees agreed benchmarking methodology compensation ceo pay ratios financial year methodology p p p lower upper quartile median quartile option methodology p p p total remuneration less vesting longterm incentive awards option historic ceo remuneration pay ratios calculated using actual earnings emma walmsley sir andrew witty ceo uk employees ceo total single figure remuneration total given report remuneration total remuneration uk fulltime equivalent employees annual bonus award company december calculated line single figure methodology reflects actual maximum earnings received excluding business expenses vesting lti awards used produce percentile calculation option remuneration regulations business expenses maximum excluded reimbursed employees ms walmsleys total remuneration includes pay period january sufficiently substantial value significantly impact march became ceo ratios sir andrew received prorata payment lieu variable bonus opportunity accordance remuneration policy gsk continues choose option psp dabp awards sir andrew granted vest april robust statistically accurate way company accordance terms executive financial recoupment policy calculate three ratios options available percentage change remuneration ceo remuneration regulations increase pay ratio emma walmsley uk employees due outcome psp award first award emma walmsley ceo change change set table base salary total pay salary benefits percentiles benefits annual bonus p p p wider uk employee population salary increase salary includes annual salary review well additional total pay changes year eg promotion uk employee benefits benefits unchanged previous year changes benefit policies levels reflect committee believes median pay ratio consistent changes level benefits individual may received companys pay reward progression policies result change role eg promotion uk base salaries employees including executive employee population considered relevant directors set reference range factors including comparison closely reflects economic environment market practice experience performance role encountered ceo gsk annual report annual report remuneration continued ceo pay comparison continued performance graph following graph sets performance company relative ftse index pharmaceutical performance comparator group tenyear period december indices selected comparison purposes reflect primary index gsk constituent industry operates gsk total return gsk pharma peers ftse total return index total return index index comprises astrazeneca bristolmyers squibb eli lilly johnson johnson merck co novartis pfizer roche holdings sanofi additional remuneration disclosures relative importance spend pay external appointments executive directors table shows total employee pay groups dividends board encourages executive directors hold one listed paid shareholders company external nonexecutive directorship equivalent change line frcs uk corporate governance code become established roles broaden total employee pay experience development may retain dividends paid year fees figures table reflect payments made appointments considered board line year impact movements exchange companys policy external appointments ascertain rates set pages however nature scope appointments ensure would dividends declared respect million cause actual potential conflict interest million increase individual executive director continues meet existing total employee pay based employees average commitments gsk number people employed ceo share repurchases made company year board approved emma walmsleys year nomination board microsoft corporation independent nonexecutive director joined board service contracts december shareholder approval expected table sets dates executive directors receive fees per annum service contracts available review companys delivered cash stock options registered office office hours gskcom microsoft corporations deferred compensation plan executive directors service contract contains month notice nonemployee directors received fees period set existing proposed new policy cfo date contract effective date expiry date iain mackay trustee british heart foundation emma walmsley member court university aberdeen iain mackay na group receive fees external dr hal barron appointments shareholder votes remuneration matters cso table shows recent shareholder votes board recognises importance ensuring hal respect remuneration report remuneration policy barron remains connected life sciences community votes total votes total votes total votes withheld therefore approved appointment board grail cast billion million inc private company nonexecutive director remuneration report earned fees agm remuneration policy agm gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued total benefits audited tables provide analysis total benefits received executive directors comprise employee benefits line policy employees may vary location role business related services provided employees assist enable carry role tax authority deemed taxable benefit individual business expenses company meets tax arises therefore items shown grossed tax split three areas business travel includes travel costs executive director appropriate spousepartner associated accompanying executive director gsk business deemed taxable benefits director accommodation whilst business travel benefits gross tax gross tax emma walmsley net uk us total net uk us total benefits available employees business related services business travel benefits total benefits gross tax gross tax iain mackay net uk us total net uk us total benefits available employees business related services business travel benefits total benefits gross tax gross tax dr hal barron net uk us total net uk us total benefits available employees business related services business travel accommodation whilst business travel benefits total benefits gross tax gross tax simon dingemans net uk us total net uk us total benefits available employees business related services business travel benefits total benefits notes b usiness related services tax regulations deem taxable benefit uk andor us uring gsk reviewed methodology allocating cost certain business travel using previous methodology dr barrons business travel would totalled approximately net conversely current methodology would resulted additional cost approximately bringing business travel approximately net r barrons place main business moved uk us resulting reduction cost gsk annual report annual report remuneration continued payments past directors audited vesting release lti awards past directors set annual report sir andrew witty dr moncef slaoui left board march mutual agreement accordance remuneration policy approved shareholders psp awards dabp awards vest original timescales subject original performance conditions dr moncef slaoui sir andrew witty number vested ads price equating number vested share price equating ads awarded shares awarded psp psp dabp dabp benefits grossed cost post employment benefits grossed cost post employment financial planning home security simon dingemans left may psp awards lapsed dabp matching awards may dabp awards award vest may terms executive financial recoupment policy awards vest february february respectively accordance standard vesting rules simon dingemans left board may voluntary leaver receive severance payment left company receive annual bonus respect outstanding ltis treated line approved remuneration policy set table payments loss office audited loss office payments made gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued implementation remuneration policy comparator groups pay relative tsr following feedback engagement shareholders committee decided replace uk crossindustry comparator group broader european crossindustry group ceo cfo european crossindustry group comprises ceo cfo europe crossindustry comparator group roche holding ag linde deutsche telekom novartis sanofi kering lvmh astrazeneca heineken anheuserbusch inbev diageo basf unilever siemens vinci sap christian dior adidas loreal inditex bayer novo nordisk bat safran airbus volkswagen reckitt benckiser cso relative tsr performance executive directors global pharmaceuticals comparator group global pharmaceuticals comparator group continue used csos remuneration measure relative tsr performance executive directors see composition group fixed pay salary committee considered average increases pension awarded employees level cet uk committee carefully considered engaged us due consideration agreed investors pension provisions new executive appropriate award increases line wider workforce directors light external focus area cso cfo ensure competitiveness remuneration proposed new policy changed remuneration could maintained following engagement review ceos continued development committee also committed reduce existing uk sustained performance following engagement executive directors pensions align wider workforce shareholders agreed second base salary january pension contributions cso increase outlined annual report pages retained given contractual commitment implemented appointment exceptional talent critical importance making continued progress rd group prospects base salary change coming years new usbased executive directors wider workforce pension aligned wider us workforce emma walmsley appointment iain mackay dr hal barron pension contribution emma walmsley base salary matching contributions based average increase budget employees level cet uk us iain mackay first salary accordance terms plan open employees base salary lieu pension salary excess benefits see details proposed new policy dr hal barron base salary benefits changes made executive directors addition line wider us workforce benefits january combined contribution rate k essp plans core contribution plus match total base salary bonus less bonus deferred dabp gsk annual report annual report remuneration continued implementation remuneration policy continued pay performance table provides details awards granted psp annual bonus psp award changes operation annual bonus change plan salary award level shares adss full details policy relation annual bonus plan emma walmsley please refer details new policy iain mackay dr hal barron bonus opportunity weighting salary performance measures increase award level ms walmsley delivered top adjusted scorecard award subject shareholder approval remuneration report agm group individual may target maximum pbit objectives awards granted price per share per ads emma walmsley lti performance measures iain mackay continuous consideration given introduction dr hal barron measure recognise importance accelerating strengthening pipeline support innovation setting assessing performance levels executive business priority even greater importance work directors committee considers performance towards separation group committee companys trust business priority see reflects engagement investors decided introduce strategic groups approach esg factors pipeline progress measure inevitably targets linked directly financial strategic pipeline progress measure plan commercially sensitive committee specifically targeted reward progress consider appropriate disclose annual bonus targets strengthening rd pipeline high quality assets year may result competitive harm however details achieving approvals major markets key assets performance targets usual disclosed indications focus metric achievement retrospective basis annual report material milestones deferred annual bonus plan dabp awards committee set targets based relevant milestones table provides details mandatory deferral commercial value delivered business end dabp annual bonus payments performance period associated awards granted shares awarded performance conditions must held three years pipeline progress measure based two equally regardless continued employment weighted elements key assets indications total bonus deferred dabp awards pipeline progress lti award shares shares ads pipeline progress measure measure emma walmsley pivotal trial starts iain mackay focuses mainly phase iii dr hal barron registrational trial starts may also include phase ii starts example oncology performance share plan psp awards following careful consideration engagement investors major regulatory approval milestones committee intends increase emma walmsleys annual psp award level salary recognise points allocated assets submeasure development role strong performance together based forecast commercial value peak year sales highly competitive landscape gsk operates end performance period award remains newly reduced maximum grant proposed new policy committee considered pipeline progress lti award threshold maximum particular high regard held virtue measure performance competitive positioning peers pivotal points points points points adjustment bring total compensation broadly trial starts market median level provided company delivers strong major points points points points longterm performance however compared global regulatory approval pharmaceuticals comparator group remains lower milestones median see easily differentiate existing rd new product sales measure renamed innovation sales measure otherwise unchanged gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued implementation remuneration policy continued weightings four lti measures onwards shareholdings versus share ownership requirement sor align interests executive directors shareholders required build maintain significant lti measure weighting holdings shares gsk time executive directors business priority measure previous new required continue satisfy share ownership innovation innovation sales requirements holding sor first months previously rd leaving gsk going forward executive directors also new product performance required hold least sor months leaving gsk pipeline progress performance relative tsr share ownership vs sor multiples base salary adjusted free cash flow emma walmsley x x trust business priority iain mackay x setting targets reviewing managements performance lti measures committee considers dr hal barron x x reflects companys trust business priority trust priority reflects companys approach esg factors x x x see sor december shareholding disclosure measures committee mindful investors concerns see executive directors shareholdings nondisclosure targets time grant committed february disclose targets full following end mr dingemans left gsk continues hold three performance period times previous base salary continue provide shareholders interim performance updates measures course performance period exercises rigour assessment performance measures enlist support science committee assessing performance new pipeline progress measure innovation targets innovation sales pipeline progress measures nature commercially sensitive time grant performance relative tsr continue measured gsks global pharmaceutical comparator group see adjusted free cash flow afcf targets afcf measure grant target vesting maximum bn bn bn threshold bn gsk annual report annual report remuneration continued remuneration governance role committee company secretary secretary committee role committee set companys remuneration attends meetings attendees committee include policy regard gsks workforce remuneration committee attendees gsk able recruit retain motivate executives regular attends remuneration policy regularly reviewed ensure attendee attendee required consistent companys scale scope operations ceo supports business strategy growth plans aligned cfo wider workforce helps drive creation shareholder head human resources value head reward committee adviser pwc terms reference committees terms reference available judy lewent vindi banga members audit risk companys website terms reference reviewed least remuneration committees provide input audit annually last revised december reflect best risk committees review groups performance practice developments oversight risk factors relevant remuneration decisions governance committee chair meets employees hr board considers members committee representatives understand employees views independent nonexecutive directors accordance remuneration addition dr cox gsks workforce code engagement director provides committee insights views wider workforce remuneration gsk membership members committee together appointment adviser committee dates set pricewaterhousecoopers llp pwc independent adviser committee since appointed committee members committee member since full commercial tender exercise concluded urs rohner january company pwc member remuneration chair chair since may consultants group voluntarily operates vindi banga january code conduct relation executive remuneration consulting uk code conduct found dr vivienne cox january wwwremunerationconsultantsgroupcom judy lewent january year pwc connection committee meetings usually include closed session committee members board directors however members committee present provide consulting assurance services individuals may also invited attend committee meetings company line protocols agreed set year executives committee attendees committee chair pwc provided advice involved decisions present committee satisfied advice objective discussions regarding remuneration independent details committee members skills experience given pwc provided independent commentary matters biographies board pages see consideration committee updates market committee member attendance levels practice legislative requirements pwcs fees advice year charged fixed time materials basis willis towers watson provided additional market data committee committee evaluation committees annual evaluation externally facilitated interviewed committee members committee chairs behalf concluded committee continued operate effectively gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued committee areas committee focus items discussed remuneration policy executive remuneration policy review recommendations committee sets broad structure remuneration remuneration impact major group restructuring policy determines remuneration executive engagement shareholders directors chairman corporate officers salary review review remuneration environment including wider employee committee periodically reviews considers trends remuneration environment executive directors cet executive director cet benchmarking competitiveness approving annual adjustments necessary regard gsk comparator groups remuneration wider workforce executive director cet company secretary salary review recommendations annual bonus ceo executive directors cet bonus recommendations committee responsible setting specific performance ceo bonus objectives measures annual bonus assessments performance lti plans lti performance outcomes vesting lti awards cet committee responsible approving lti plan rule changes grants assessments performance vesting lti awards confirmation lti grants cet executive directors cet including interim awards development new innovation pipeline measure governance areas focus review terms reference committee adheres robust remuneration governance committee evaluation annual review framework ensuring alignment internal actions remuneration report external reportingcompliance requirements confirmation group budget remuneration purposes remuneration considerations committee programme agm remuneration report feedback external remuneration environment performance target disclosure incentive plans approval new chairmans fees remuneration report disclosures including ceo pay ratio annual governance meeting key committee messages presentation remuneration policy consideration feedback received employer consultation employees employee representatives setting pay gender pay gap reporting gsk annual report annual report remuneration continued nonexecutive directors fees chairman nonexecutive directors nonexecutive directors fees company aims provide chairman non nonexecutive directors fees applied executive directors fees competitive set table paid companies equivalent size complexity per annum subject limits contained articles association standard annual fee supplemental fees chairmans fees chair audit risk committee chairman paid fee per annum senior independent director elected take gsk shares chairmans scientificmedical experts fees reviewed appointment new chair chairs remuneration corporate concluded remained appropriate responsibility science committees nonexecutive director undertaking intercontinental per meeting travel meetings implementation nonexecutive directors policy nonexecutive directors standard fees last increased january following review engagement shareholders agreed increase annual fees payable nonexecutive directors effect january standard annual fee senior independent director committee chairs including remuneration corporate responsibility science committees subject shareholder approval introduce supplemental fee effect january payable workforce engagement director authorise payment nonexecutive director amount paid committee chair undertaking additional duties exceptional unforeseen circumstances requiring significant additional time commitment changes proposed fees payable chair audit risk committee scientificmedical experts expect make increases fees payable nonexecutive directors new policy period increases described reflect time commitments roles nonexecutive directors continue required invest least total net fees gsk shares ads total fees audited audited table sets value fees benefits received nonexecutive directors form cash shares ads details nonexecutive directors share allocation plan set nonexecutive directors fees paid currency sterling converted using average exchange rate reviewed time time benefits comprise grossed cash value travel subsistence costs incurred normal course business relation attendance board committee meetings overseasbased directors includes travel meetings uk nonexecutive directors fixed fees fixed fees emoluments audited cash sharesads benefits total pay cash sharesads benefits total pay vindi banga dr vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent urs rohner sir jonathan symonds former directors professor sir roy anderson philip hampton sir deryck maughan dr daniel podolsky hans wijers professor sir roy anderson retired board may dr daniel podolsky sir deryck maughan retired board may hans wijers retired board may gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued directors interests shares audited interests directors company office persons closely associated pca shown tables total share plan interests december date leaving total directors interests sharesads options december january unvested unvested unvested unvested february date date subject subject subject subject vested exercised leaving appointment performance performance performance performance exercised year executive directors shares emma walmsley iain mackay simon dingemans ads dr hal barron share allocation plan nonexecutive directors total directors interests number shares ads december january dividends dividends reinvested reinvested february date date year december allocated december leaving appointment end paid year elected nonexecutive directors shares vindi banga dr vivienne cox urs rohner sir jonathan symonds philip hampton ads lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent u nvested options subject performance emma walmsley represent bonus deferrals share save options u nvested shares subject performance simon dingemans represent shares awarded end threeyear performance periods psp grants together subsequent reinvested dividends shares subject twoyear holding period ending february psp grant february psp grant unvested options subject performance mr dingemans represent bonus deferrals share save options share save options lapsed may left gsk unvested ads subject performance dr hal barron represent bonus deferrals u nvested shares subject performance simon dingemans represent psp awards granted lapsed may left gsk unvested options subject performance represent dabp matching awards granted lapsed may left gsk otal directors interests includes shares purchased glaxosmithkline share reward plan emma walmsley simon dingemans awarded shares respectively plan total number shares held within plan follows share reward plan shares february december january emma walmsley simon dingemans dr hal barron us employee eligible participate share reward plan open uk employees otal directors interests includes options shares ads resulting deferral bonus subsequent reinvestment dividends dabp totals shown table include bonus deferrals exclude unvested matching awards subject ongoing performance criteria last matching award granted amounts represent gross share ads balances prior sale shares ads satisfy tax liabilities december deferred annual bonus plan bonus deferrals february date leaving january emma walmsley shares iain mackay shares dr hal barron ads simon dingemans shares gsk annual report annual report remuneration continued directors interests shares audited continued otal directors interests february includes shares ads vested february due performance met dabp psp awards less sold satisfy tax liabilities vested amounts following table sets details options share option plan sop nilcost options dabp exercised executive directors number shares date market price gain exercise type award date grant option exercise grant price exercise emma walmsley sop dabp deferral dabp matching simon dingemans dabp deferral dabp matching respect options sop remuneration receivable executive director calculated date options first vest remuneration difference amount executive director required pay buy shares total value shares vesting date executive director chooses exercise options vesting date subsequent increase decrease amount realised due movements share price vesting date date exercise increase decrease value result investment decision executive director recorded remuneration respect nilcost options dabp bonus deferred director recorded remuneration annual bonus year relates gain recorded exercise nilcost option comprises remuneration total amounts received reinvested dividends prior vesting gains losses resulting movements share price dates grant exercise initial bonus amount deferred ii dates dividend reinvestment exercise reinvested dividends matching element dabp remuneration executive director recorded year performance period ends represents number vested shares multiplied share price vesting gain recorded exercise nilcost option comprises total remuneration gain loss resulting movement share price vesting exercise last matching award granted emma walmsley total gain following exercise options granted sop comprises remuneration respect share options granted july vested july vesting price investment gain gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp investment gain relating movement share price vesting exercise dates simon dingemans gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp investment gain relating movement share price vesting exercise dates nonexecutive directors total interests include shares ads received part fees nonexecutive directors share allocation plan dividends received shares ads plan january converted shares ads february imon dingemans retired board may sir philip hampton retired board august gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued directors senior management information provided compensation interests directors senior management group group purpose group defined nonexecutive executive directors members cet company secretary financial year following table sets aggregate remuneration group periods served capacity remuneration total compensation paid aggregate increase accrued pension benefits net inflation aggregate payments defined contribution schemes members group awarded shares ads companys various lti plans set table align interests senior management shareholders executive directors cet members required build maintain significant holdings shares gsk time cet members required hold shares equivalent multiple two times base salary must continue satisfy share ownership requirements minimum months leaving gsk awards dividend reinvestment awards awarded shares ads shares ads deferred annual bonus plan matching awards performance share plan deferred investment awards share value plan february group pcas following interests shares ads company interests awarded various lti plans described note financial statements employee share schemes interests february shares ads owned unexercised options deferred annual bonus plan performance share plan deferred investment awards share value plan n otional shares ads e xecutive directors eligible receive deferred investment awards participate share value plan deferred investment award granted emma walmsley vested granted prior becoming executive director gsk annual report remuneration policy summary remuneration policy review current remuneration policy policy approved create shareholder value shareholders annual general meeting may drive success company benefit patients receiving vote favour required customers key stakeholders remuneration regulations shareholders asked approve new policy annual general meeting may addition changes policy made ensure intended apply next three years implementation support delivery business strategy whilst delivering clear understandable appropriately committee considered policy competitive package attract retain motivate executive decisionmaking process committee followed talent determination review implementation proposed new policy set committee chairs statement pages committee developed new policy executive nonexecutive directors context oversight wider workforce pay however consult employees committees review policy sought ensure new policy consulted largest shareholders continues respect proposed changes took shareholders aligned companys business priorities culture feedback account finalising new policy shift wider workforce pay policies emerging best table provides overview main changes practice proposed respect new policy full policy shareholders asked approve set pages remuneration element proposed changes policy rationale change pension new executive director receive pension alignment shareholders aligned broader workforce contribution levels alignment code emerging market current uk executive directors similarly practice aligned january extension post cessation share sor executive directors held alignment shareholders ownership requirements second year post cessation role alignment code emerging market practice lti quantum reduction maximum award level permitted pay performance increase award level received feedback shareholders applied case ceo maximum award level permitted policy reduced previous increase target award ceo reflects strong performance role emma walmsley since appointment april malus clawback definition triggering event expanded alignment market practice include material misstatement results serious become common ftse companies reputational damage apply broader definition triggering event loss office payment policy years service condition termination simplification flexibility mutual agreement removed simplify policy allow greater flexibility board manage succession proactively nonexecutive directors fees introduction fee compensation additional duties designated workforce engagement director reflect work involved carrying new role effect january equivalent committee chair authority also sought nonexecutive director appropriately remunerate nonexecutive directors chairman remunerated work amount paid committee chairs simplification alignment shareholders undertaking additional duties exceptional allow direct reinvestment fees shares unforeseen circumstances requiring significant ads additional time commitment nonexecutive directors continue required invest least total net fees shares ads company gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report future policy table subject shareholder approval companys annual general meeting may remuneration policy remuneration element outlined table salary change purpose link strategy opportunity provide core reward role formal maximum limit ordinarily salary increases broadly line average increases wider set level appropriate secure retain high calibre gsk workforce individuals needed deliver groups strategic priorities however increases may higher reflect change operation scope individuals role responsibilities experience individuals role experience performance independently salary adjustments may also reflect wider market conditions sourced data relevant comparator groups considered geography individual operates determining salary levels details current salary levels set annual report salary increases typically take effect first quarter remuneration year performance measures salaries normally paid currency executive overall performance individual key consideration directors home country determining salary increases benefits change purpose link strategy executive director based outside uk levels set recruit retain high calibre individuals required travel uk fulfil responsibilities execute business strategy role attend board meetings may subject tax business travel expenses uk operation provision accommodation uk although reality executive directors eligible receive benefits line represents business expense tax treatment requires policy employees may vary location travel accommodation expenses included include limited car allowances healthcare benefits business context tax liabilities life assurancedeath service provided part covered company grossedup basis individuals pension arrangements personal financial advice contractual postretirement benefits line policy benefit provision tailored reflect market practice employees executive directors may eligible geography executive director based receive overseas relocation allowances international different policies may apply current future executive transferrelated benefits required executive directors directors based different country uk also eligible participate allemployee share opportunity schemes eg share save share reward plan formal maximum limit benefits costs fluctuate subject terms depending changes provider cost individual employees circumstances order recognise high business travel requirements details current benefits costs set annual role executive directors also entitled car travel report remuneration exceptionally may accompanied spousepartner performance measure business trips benefits include expenses incurred none ordinary course business deemed taxable benefits individual gsk annual report remuneration policy report continued future policy table continued pension change purpose link strategy new executive directors uk receive date pension arrangements provide competitive level retirement appointment income base salary contribution defined contribution plan matched contributions subject operation relevant cap line implementation principles pension arrangements structured accordance members plan plans operated country individual likely base salary cash payment lieu pension retire individual chooses become member contribution portion relevant cap pension plan cash lieu relevant pension contribution paid instead executive directors uk base salary cash payment lieu pension entitled either join defined contribution pension plan contribution receive cash payment lieu pension contribution us individual member gsk legacy defined cash balance supplemental cash balance pension benefit plan defined contribution plan alternative plans providing annual contributions base salary pension plan arrangement subsequently appointed split two plans appropriate board may remain member plan gsk k plan executive supplemental savings plan opportunity essp core contributions salary bonus policy current executive directors matched contributions salary bonus uk new executive directors us receive base salary contribution defined contribution plan cash balance supplemental cash balance pension matched contributions subject plans providing annual contributions base salary relevant cap line implementation principles bonus split two plans appropriate members plan gsk k plan essp core contributions base salary cash payment lieu pension salary bonus matched contributions contribution portion relevant cap salary bonus global base salary cash payment lieu pension eligible appropriate equivalent arrangement excess contribution usuk arrangements january current uk executive directors performance measures still role pension arrangements aligned none new executive directors arrangements follows n event change plans operated us similar value would provided successor arrangements introduced within market l ess bonus deferred dabp annual bonus change purpose link strategy committee may apply judgement making appropriate incentivise recognise execution business strategy adjustments bonus outcomes ensure reflect annual basis underlying business performance clawback andor malus provisions apply described rewards achievement stretching annual financial strategic business targets delivery personal objectives opportunity maximum bonus opportunity executive directors operation salary threshold performance bonus payout financial operational business targets set start financial measure nil target performance year committee bonus levels determined bonus payout maximum opportunity committee based performance targets performance measures individual objectives set start year based combination financial targets individual committee performance objectives strategic performance objectives majority bonus assessed committee assessed financial measures weighting executive directors required defer bonus different measures determined year earned shares ads appropriate three years according business priorities details including deferred bonus shares eligible dividend equivalents measures used financial year provided date vesting annual report remuneration gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report continued future policy table continued selection annual bonus measures annual bonus designed drive achievement majority annual bonus opportunity based gsks annual financial strategic business targets formal review performance stretching financial targets delivery personal objectives remainder bonus subject balanced scorecard strategic individual targets aligned annual bonus financial targets set reference companys key objectives financial year internal budget external consensus targets performance share plan psp change purpose link strategy clawback andor malus provisions apply described incentivise recognise delivery longer term business priorities financial growth increases opportunity shareholder value compared pharmaceutical normal maximum award limits may granted companies psp individual one year set table addition provide alignment shareholder interests retention element encourage longterm shareholding salary discourage excessive risk taking ceo operation cfo conditional awards made annually vesting dependent executive directors achievement performance conditions three years performance measures subject additional twoyear holding period psp based combination financial share price related targets set reference internal budget external strategic performance conditions aligned consensus targets companys strategic plan measures awards awards eligible dividend equivalents date vest threshold performance details including vesting release performance targets attached psp respect year weightings targets psp awards committee may adjust formulaic vesting outcome provided annual report remuneration either ensure overall outcome reflects underlying business performance vesting period w e announced annual report reducing threshold vesting level tsr measure order align performance measures selection longterm incentive measures committee selects performance measures focus major adjustment calculation performance executive directors longterm remuneration delivery measures disclosed shareholders vesting gsks key strategic priorities longer term addition audit risk committee chair members setting robust targets committee implemented also members remuneration committee number safeguards ensure targets met provide input audit risk committees review sustainable way performance reflects genuine achievement groups performance oversight risk factors targets therefore represents delivery value relevant remuneration decisions shareholders details rationale behind performance measures performance measure impact acquisition selected calculated set divestment quantified adjusted event annual report remuneration share ownership requirements change align interests executive directors minimum executive directors required maintain shareholders required build maintain significant share ownership requirements end holdings shares gsk time requirements first year following retirement company executive director follows end second year salary ceo executive directors gsk annual report remuneration policy report continued future policy table continued clawback malus expansion definition triggering event event triggering event ie significant misconduct respect financial year remuneration committee way violation regulation law significant gsk policy disclose whether recoupment committee code conduct material misstatement results exercised clawback malus disclosure made serious reputational damage company matter subject public reports ability claw back three years annual deferred misconduct fully resolved legally bonuses well vested unvested ltis addition permissible disclose made without respect psp awards made participant unduly prejudicing company therefore shareholders subject investigation vesting awards additionally continuity responsibility may delayed outcome investigation initiation adverse event emergence separate recoupment committee established problem adverse event taken account investigate relevant claims misconduct recoupment assessing annual bonus awards lti vesting levels committee exercises authority wider employee base year problem identified future periods comprises senior executives relevant oversight remuneration committee recoupment committee may appropriate experience including senior vice president make appropriate adjustments individual annual bonuses global ethics compliance senior vice president well grant vesting levels lti awards reflect general counsel approach recruitment remuneration change committee determines remuneration package new internal appointments entitlements existing executive directors casebycase basis depending remuneration elements continue including pension role market operate entitlements outstanding awards however experience total remuneration levels set reference already case internal appointments required relevant pay comparator group appropriate move executive director contractual terms including allow future development role termination provisions expected new executive directors participate committee mindful sensitivity relating short longterm incentive plans basis recruitment packages particular buying existing directors however exceptional circumstances rights relating previous employment therefore seek committee reserves flexibility set incentive limit minimise arrangements however certain new executive director additional circumstances enable recruitment exceptional talent existing limits committee may determine arrangements best interests company shareholders committee retains flexibility recognition high arrangements possible likeforlike basis levels variable pay gsks global pharmaceutical forfeited remuneration terms arrangements competitors however committee use flexibility therefore vary depending plans arrangements put considered best interests company place previous employer may form investors cash shares may may subject performance pension arrangements external recruit executive conditions explanations provided payments director set remuneration policy table made compensation previous remuneration forfeited remuneration arrangements newly appointed benefits provided line policy existing executive director disclosed soon practicable executive directors appointment required meet business needs relocation support provided line company policy gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report continued future policy table continued loss office payment policy change company policy fixed term contracts notice period termination employing company generally contracts new appointments expire line executive director calendar months applicable policy retirement age since ability impose month noncompete period nonsolicitation restriction executive director contracts existing executive directors expire considered important company ability dates shown protect groups intellectual property staff light committee believes would appropriate provide mitigation contracts termination employment event executive directors employment company terminates following policies payments apply element remuneration loss office payment policy termination termination notice months annual salary payable termination company prorated part notice period worked payment termination payment made respect part notice period extends beyond contract expiry date bonus element normally included termination payment however terms contracts seek balance commercial imperatives best practice redundancy termination notice uk statutory redundancy pay apply us general severance policy apply retirement death illhealth injury disability termination payment lti awards psp awards governed plan rules approved shareholders following provisions normally apply termination notice unvested awards lapse redundancy retirement death illhealth injury disability reason generally awards continue vest original timescales subject performance prorated time event change control psp awards vest taking account performance date normally taking account proportion performance period elapsed alternatively awards may exchanged new awards annual bonus termination notice individual individual serves notice termination date falls december bonus forfeited termination notice company redundancy retirement death illhealth injury disability termination date falls financial year eligible prorated ontarget bonus employed december bonus payable based actual results mandatorily dabp deferred bonus awards respect mandatorily deferred bonus amounts governed plan rules approved shareholders deferred following provisions normally apply bonus termination gross misconduct generally unvested awards lapse dabp reason generally awards vest full original vesting date event change control awards vest may exchanged new awards benefits generally benefits continue apply termination date committee may make payments connection existing legal obligation respect claim related cessation employment may include fees outplacement assistance legal andor professional advice termination notice company retirement us executives line policy applicable us senior executives may become eligible future date receive continuing medical dental insurance terminationretirement termination mutual agreement certain circumstances best interests company board manage proactively succession planning development senior talent pipeline circumstances board may therefore agree executives departure mutual agreement order apply committee need satisfied executive demonstrated performance line expectations required contributed orderly succession case executive director would treated good leaver purposes gsks longterm incentive plans termination date falls financial year would eligible prorated ontarget bonus employed december bonus payable would based actual results gsk annual report remuneration policy report continued loss office payment policy continued committee anticipate exercise discretion executive director leaves company provided psp dabp plan rules respect committee carry assessment individuals termination payments manner would benefit performance conduct time role executive director however may unforeseen determined individuals performance conduct circumstances best interests company contrary legitimate expectations company shareholders necessary exercise committee reserves right apply appropriate mechanisms discretion explanations provided clawback reduction lapsing outstanding incentive awards malus ensure termination payments best interests company shareholders see differences remuneration policy executive directors employees setting remuneration levels executive directors employees formally consulted respect committee considers prevailing market conditions remuneration policy urs rohner committee chair meets competitive environment comparison senior hr representatives across business remuneration executives companies similar size review employee feedback dr vivienne cox independent complexity international reach positioning nonexecutive director engages employees various relativities pay employment conditions across topics including remuneration role workforce broader gsk workforce engagement director particular committee considers range base wider organisation aligned performance salary rises workforces parts gsk reward systems innovation performance trust executive directors employed considered priorities values expectations performance relevant comparison populations reflect system evaluates employees need closely economic environments encountered also senior people individuals principles apply remuneration disincentivise unethical working practices using clawback policy executive directors employees although mechanism allows us recover performancerelated pay remuneration offered executive directors policy stronger emphasis performancerelated pay offered employees group salary benefits including pension tailored local market annual bonus plan applies wider employee population based business performance combination performancerelated restricted share plans apply wider employee population allemployee share plans available employees uk including hm revenue customs approved uk share save share reward plans gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report continued scenarios future total remuneration charts opposite provide illustrations future total remuneration executive directors respect emma walmsley remuneration opportunity granted proposed new policy range potential outcomes provided executive director underlying assumptions set scenarios base salary used benefits figures used ie based actual amounts received hal barron pension figures pension emma walmsley iain mackay based upon salaries amounts shown value psp awards based upon relevant multiples including proposed uplift emma walmsley salary fixed expected maximum maximum include amounts respect dividends reinvested share price factor changes share price vesting period increase except described fixed excludes pay performance ie annual bonus would iain mackay paid psp awards would vest expected includes fixed pay annual bonus assumed target performance achieved psp awards amounts reflect vesting levels maximum assumed annual bonus would payable maximum level awards psp would vest full maximum share price increase fixed expected maximum maximum share price elements maximum assuming increase increase share price appointed effect january dr hal barron fixed expected maximum maximum share price increase fixed pay annual bonus psp share price increase gsk annual report remuneration policy report continued nonexecutive director remuneration policy nonexecutive directors fees change element purpose link strategy operation chairmans fees provide inclusive flat rate fee formal maximum however fees reviewed annually set reference competitive paid review chairmans performance independently sourced market data companies equivalent size committee responsible evaluating making recommendations board complexity subject limits contained fees payable chairman chairman participate discussions gsks articles association respect fees fees paid cash chairman required invest least total net fees shares ads company basic fees formal maximum chairman fees reviewed annually set reference independently sourced data chairman ceo responsible evaluating making recommendations board fees payable companys nonexecutive directors fees paid cash directors required invest least total net fees shares ads company shares ads delivered released following retirement board supplemental compensate nonexecutive directors additional fees senior independent director committee chairs science fees chairman taking medical experts workforce engagement director role intercontinental travel additional board responsibilities company authority pay additional fee equivalent undertaking intercontinental travel committee chair supplement effect january nonexecutive director company require significant additional time commitment exceptional unforseen circumstances benefits facilitate execution responsibilities travel subsistence costs nonexecutive directors incurred normal duties required role course business relation meetings board committee matters gskhosted events overseasbased nonexecutive directors includes travel meetings uk event necessary business purposes whilst normal practice nonexecutive directors may accompanied spouse partner meetings events costs associated met company instances deemed taxable therefore treated benefits nonexecutive director approach recruitment remuneration change following policy principles apply roles nonexecutive directors chairman nonexecutive director fee levels new nonexecutive directors set basis existing nonexecutive directors chairman company subject local laws regulations fees fees set level competitive paid paid partly shares companies equivalent size complexity fees paid partly shares event nonexecutive director different role responsibilities appointed fee levels benchmarked set reference comparable roles companies equivalent size complexity loss office change chairman nonexecutive directors entitled receive payments respect fees loss office retire step board gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report continued operation scope remuneration policy remuneration policy policy set pages ii policy came effect provided terms annual report intended policy payment consistent shareholderapproved gsks executive nonexecutive directors operate remuneration policy force time agreed period three years date approval companys iii time relevant individual director annual general meeting may company opinion committee payment committee wrote policy principally relation consideration individual becoming director remuneration arrangements executive directors whilst company purposes payments includes taking account possible recruitment replacement committee satisfying awards variable remuneration additional executive director operation relation award shares ads terms policy committee intends policy operate payment agreed time award granted period set entirety however may due performance share plan deferred annual bonus plan consideration seek change policy period awards subject terms relevant plan rules believes appropriate longterm award granted committee may adjust success company consultation shareholders amend awards accordance provisions sought shareholder approval general meeting plan rules includes making adjustments reflect oneoff committee reserves right make remuneration corporate events change companys capital payments andor payments loss office including structure exercising discretions available connection committee may also make minor amendments policy payments notwithstanding line regulatory exchange control tax administrative purposes policy terms payment agreed take account change legislation without obtaining agm may date companys shareholder approval amendments first shareholderapproved directors remuneration policy came statement consideration shareholder views effect committee engages regular dialogue shareholders holds annual meetings gsks largest investors discuss take feedback remuneration policy governance matters gsk annual report remuneration policy report continued basis preparation annual report remuneration prepared annual report remuneration approved accordance companies act large board directors signed behalf mediumsized companies groups accounts reports amendment regulations regulations accordance regulations following parts urs rohner annual report remuneration subject audit total remuneration committee chairman remuneration figures executive directors including march details element remuneration salary benefits pension annual bonus longterm incentive awards nonexecutive directors fees emoluments received year directors interests shares including interests gsk share plans payments past directors payments loss office share ownership requirements holdings opinion thereon expressed remaining sections annual report remuneration subject audit pages referred within audited sections gsk annual report ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn financial statements section directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap ggsskk aannnnuuaall rreeppoorrtt directors statement responsibilities directors responsible preparing annual report directors responsible keeping adequate accounting remuneration report group parent company records sufficient show explain companys financial statements accordance applicable law transactions disclose reasonable accuracy time regulations financial position group enable ensure group financial statements remuneration uk company law requires directors prepare financial report comply companies act article statements financial year directors required ias regulation also responsible safeguarding prepare group financial statements accordance assets group hence taking reasonable steps international financial reporting standards ifrs adopted prevention detection fraud irregularities european union preparing group financial statements directors also elected comply group financial statements year ended ifrs issued international accounting standards december comprising principal statements board iasb directors elected prepare parent supporting notes set financial statements company financial statements accordance united pages report parent company kingdom accounting standards applicable law united financial statements year ended december kingdom generally accepted accounting practice comprising balance sheet statement changes company law directors must approve financial equity year ended december supporting statements unless satisfied give true notes set pages fair view state affairs group profit responsibilities auditor relation financial loss period statements set independent auditors report preparing financial statements directors required pages financial statements year ended december select suitable accounting policies apply included annual report published printed consistently form made available website directors responsible maintenance integrity annual make judgements accounting estimates report website accordance uk legislation reasonable prudent governing preparation dissemination financial state group financial statements comply ifrs statements access website available outside adopted european union ifrs issued uk comparable legislation may different iasb subject material departures disclosed current directors whose names functions explained group financial statements listed corporate governance section annual state regard parent company financial statements report confirms best knowledge applicable uk accounting standards group financial statements prepared followed subject material departures disclosed accordance ifrs adopted eu ifrs explained parent company financial statements issued iasb give true fair view assets prepare financial statements going concern basis liabilities financial position profit group unless inappropriate presume group strategic report risk sections annual report parent company continue business represent management report include fair review development performance business position company group taken whole together description principal risks uncertainties faces gsk annual report strategic report governance remuneration financial statements investor information directors statement responsibilities continued disclosure information auditor uk corporate governance code directors office date annual report board considers glaxosmithkline plc applies confirmed principles complies provisions uk corporate governance code maintained financial reporting far aware relevant audit council described corporate governance section information companys auditor unaware pages board considers taken steps ought annual report taken whole fair balanced taken director make aware understandable provides information necessary relevant audit information establish companys shareholders assess groups position performance auditor aware information business model strategy confirmation given interpreted required financial conduct authoritys listing rules accordance provisions section auditor considered directors statement companies act compliance relation points uk corporate governance code specified review going concern basis pages contain information performance annual report group financial position cash flows net debt position annual report year ended december borrowing facilities information including treasury comprising report directors remuneration risk management policies exposures market credit risk report financial statements additional information hedging activities given note financial investors approved board directors statements financial instruments related disclosures signed behalf assessed principal risks matters considered connection viability statement sir jonathan symonds directors considered appropriate adopt going concern chairman basis accounting preparing financial statements march internal control board audit risk committee reviewed assessment risks internal control framework operates gsk considered effectiveness system internal control operation group year covered annual report date approval board directors gsk annual report independent auditors report members glaxosmithkline plc report audit financial statements opinion basis opinion opinion conducted audit accordance international standards auditing uk isas uk applicable law financial statements glaxosmithkline plc parent responsibilities standards company subsidiaries group give true described auditors responsibilities audit fair view state groups parent financial statements section report companys affairs december groups profit year ended independent group parent company accordance ethical requirements relevant group financial statements properly prepared audit financial statements uk including financial accordance international financial reporting reporting councils frcs ethical standard applied standards ifrss adopted european union listed public interest entities fulfilled ifrss issued international accounting standards ethical responsibilities accordance requirements board iasb confirm nonaudit services prohibited frcs parent company financial statements properly ethical standard provided group parent prepared accordance united kingdom generally company noted audit risk committee report within accepted accounting practice including frs reduced corporate governance section annual report disclosure framework believe audit evidence obtained financial statements prepared accordance sufficient appropriate provide basis opinion requirements companies act audit scope execution regards group financial statements article ias regulation structured approach audit reflect group organised well ensuring audit audited financial statements comprise effective risk focused audit approach group summarised following areas enabled us obtain evidence required form opinion group consolidated balance sheet december parent company financial statements consolidated income statement year ended risk assessment audit planning group level consolidated statement comprehensive income central control common systems throughout year ended group enabled us structure audit centrally consolidated statement changes equity year addition appointing partners three ended businesses also partners coordinate component consolidated cash flow statement year ended legal entity audits country global business partners met regularly relevant management notes financial statements includes understand strategy matters arose throughout accounting principles policies year could impacted financial reporting regular meetings members internal parent company audit internal legal counsel global ethics balance sheet december compliance teams allowed us understand work statement changes equity year ended review reports enhance risk assessment notes financial statements includes significant changes audit scope group completed accounting principles policies two major transactions year acquisition shares tesaro inc tesaro financial reporting framework applied commercialstage oncology business preparation group financial statements applicable law ifrss adopted european union financial acquisition pfizer consumer healthcare reporting framework applied preparation business form new consumer healthcare joint venture parent company financial statements applicable law pfizer inc united kingdom accounting standards including frs result pfizer transaction pfizer reduced disclosure framework united kingdom generally consumer healthcare operations united states us accepted accounting practice china brought audit scope transactions required increased extent audit effort areas including need perform additional opening balance sheet testing consolidation work gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued audit work performed global shared service centres residual consists components legal entities significant amount groups operational processes annual revenue turnover less total group cover financial reporting undertaken shared service revenue entities components nonsignificant centres central team included senior individuals components individually aggregate present responsible global processes coordinated reasonable possibility risk material misstatement audit work shared service centres scope application materiality group audit ensure developed good understanding endtoend view key processes supported define materiality magnitude misstatement material account balances classes transactions financial statements makes probable economic disclosures within group financial statements decisions reasonably knowledgeable person would evaluated effectiveness internal controls financial changed influenced use materiality planning reporting processes considered implications scope audit work evaluating results remainder audit work work audit work executed component level individual based professional judgement determined legal entities following components subject materiality financial statements whole follows marketspecific audit procedures well assessment parent company internal controls financial reporting belgium group financial statements financial statements canada china france germany italy japan spain materiality million million switzerland united kingdom united states group million million audit team active dialogue throughout audit basis determining benchmark materiality component audit teams responsible audit work determining materiality considered determined using direction supervision group audit team materiality metrics used investors total assets benchmark readers financial included determining whether work planned statements particular performed accordance overall group audit considered statutory profit strategy requirements group audit instructions tax adjusted profit components part supervising work tax revenue net cash flows operations components senior group audit team members visited component countries well locations shared using professional judgement determined preliminary service centre audits materiality million audit procedures undertaken group level metric parent company addition also performed statutory profit tax audit work group parent company financial adjusted profit tax statements including limited consolidation revenue groups results preparation financial net cash inflow statements certain disclosures within directors operating activities remuneration report litigation provisions exposures reconciliation statutory addition managements entity level oversight controls profit tax adjusted profit tax detailed adjusting relevant financial reporting also carried analytical items section strategic report procedures confirm conclusion rationale given importance parent company significant risks material misstatement aggregated metrics used investors holds groups financial information remaining components benchmark readers financial statements investments subject marketspecific audit procedures applied concluded statutory profit profitoriented tax primary strength internal controls testing approach tested internal benchmark adjusted profit balance sheet key controls financial reporting across inscope entities tax revenue net cash measure financial entity level controls group level able inflow operating activities health important supporting benchmarks shareholders since place reliance controls planned primary concern efficient notwithstanding controls deficiencies component materiality parent company disclosed key audit matters section report allocated inscope payment components ranged mitigating controls existed allowed us continue dividends using million million take reliance controls planned benchmark total range materiality allocated assets therefore coverage obtained group scoping strategy across components audit appropriate metric summarised follows prior years group financial statements profit total benchmark revenue tax assets million million covered marketspecific procedures covered review group level gsk annual report independent auditors report continued report audit financial statements continued set performance materiality level lower materiality principal risks viability statement reduce probability aggregate uncorrected based solely reading directors statements undetected misstatements exceed materiality considering whether consistent knowledge financial statements whole group performance obtained course audit including knowledge materiality set group materiality obtained evaluation directors assessment audit determining performance materiality groups parent companys ability continue going considered factors including concern required state whether anything material add draw attention relation risk assessment including assessment groups overall control environment consider disclosures pages describe principal appropriate rely controls number business risks procedures identify emerging risks processes explanation managed mitigated past experience audit indicated low directors confirmation carried number corrected uncorrected misstatements robust assessment principal emerging risks identified prior periods facing group including would threaten business model future performance solvency liquidity agreed audit risk committee would report committee audit differences excess directors explanation million million well differences assessed prospects group period threshold view warranted reporting done consider period qualitative grounds also report audit risk appropriate statement whether committee disclosure matters identified reasonable expectation group able assessing overall presentation financial statements continue operation meet liabilities fall due period assessment including related conclusions relating going concern disclosures drawing attention necessary qualifications principal risks viability statement assumptions going concern also required report whether directors statement reviewed directors statement notes relating prospects group required listing rule financial statements whether considered r materially inconsistent knowledge obtained appropriate adopt going concern basis accounting audit preparing identification material confirm nothing material report add uncertainties groups parent companys ability draw attention respect matters continue period least twelve months date approval financial statements considered part risk assessment nature group business model related risks including relevant impact brexit requirements applicable financial reporting framework system internal control evaluated directors assessment groups ability continue going concern including challenging underlying data key assumptions used make assessment evaluated directors plans future actions relation going concern assessment required state whether anything material add draw attention relation statement required listing rule r report statement materially inconsistent knowledge obtained audit confirm nothing material report add draw attention respect matters gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued key audit matters key audit matters matters professional judgement significance audit financial statements current period include significant assessed risks material misstatement whether due fraud identified matters included greatest effect overall audit strategy allocation resources audit directing efforts engagement team matters addressed context audit financial statements whole forming opinion thereon provide separate opinion matters key audit matter description scope audit responded key audit matter valuation viiv healthcare shionogi contingent audit procedures performed consideration liability performed following audit procedures amongst others recent years group completed number significant related sales forecasts transactions resulted recognition material challenged managements evidence enquiries key contingent consideration liabilities key source individuals senior leadership team commercial strategy estimation uncertainty significant liabilities team key personnel involved budgeting viiv healthcare shionogi contingent consideration forecasting process obtaining objective evidence liability viiv ccl respect key inputs assumptions group completed acquisition remaining challenged us volume assumptions made management interest shionogiviiv healthcare joint venture estimate sales forecasts involves benchmarking market upon completion group recognised contingent share data external data total prescription consideration liability fair value expected future volumes new patient prescription volumes order assess payments made shionogi december sources contradictory evidence liability valued million challenged reasonableness us pricing assumptions identified viiv ccl key audit matter made management comparing forecasted returns significant estimates assumptions management makes rebates accruals rate product current rate related sales forecasts dolutegravirbased regimens assessing forecasted returns rebates used value viiv ccl forecasts based comparable products expected changes payer policy managements assessment expected launch dates ability shift market practice prescriber behaviour towards reviewed results clinical studies undertaken year drug regimens subsequent sales volumes pricing management key competitors order assess whether forecasts also required significant audit effort perform corroborative contradictory managements appropriate audit procedures challenge evaluate assumptions dolutegravir sales forecasts us reasonableness forecasts benchmarked managements forecasts analysts reports contingent consideration liabilities including viiv ccl developed range possible outcomes using analyst disclosed key source estimation uncertainty note forecast growth viiv healthcare consensus group financial statements disclosures analysts including bank america merrill lynch morgan provided notes matter also discussed stanley barclays credit suisse jefferies redburn audit risk committee report within corporate tested controls key inputs assumptions used governance section annual report valuation contingent consideration liability including management review controls sales forecasts dolutegravirbased regimens key observations communicated audit risk committee underlying sales forecasts dolutegravirbased regimens used valuation viiv ccl updated reflect changes hiv market viivs products market approach valuing viiv ccl consistent prior periods managements forecasts within benchmarked observable range satisfied valuation viiv ccl reasonable consistent ifrs gsk annual report independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation us returns rebates rar accruals audit procedures performed us group sells customers various commercial performed following audit procedures amongst others government mandated contracts reimbursement related management estimates rar accruals arrangements include rebates chargebacks right assessed historical accuracy managements estimates return certain pharmaceutical products revenue actual outcomes inform assessment current recognition reflects grosstonet sales adjustments year accrual adjustments known returns rebates rar accruals source significant estimation uncertainty performed substantive analytical procedures developing could material impact reported revenue independent expectation accrual balance three significant payer channels also referred buying key segments based historical claims received adjusted groups within rar accrual managed healthcare reflect market changes period including assessment organisations medicaid medicare part time lag initial point sale claim receipt compared independent expectation two main causes significant estimation uncertainty management evaluate appropriateness managements utilisation rate portion total sales ending accrual position made payer channel estimated management recalculated accrual recognised determine recording accruals utilisation assumption consistent assumptions determined challenging key assumptions used derive accrual managements process given influenced market demand factors outside control group selected sample individual utilisation rates giving particular focus products experienced increased generic time lag point sale point competition current year challenged obtained exact rebate amounts known group upon receipt support utilisation rates selected included claim payer channels longest time lag result comparison historical utilisation rates greater accrued period therefore greater level estimation uncertainty estimating period end accrual challenged appropriateness periodend adjustments liability made part ongoing review estimated level estimation uncertainty also impacted significant accrual impact market events year end shifts channel mix often driven changes competitive accrual considered reflected part overall audit landscape including competitor generic product launches approach us pharmaceuticals business million tested key controls estimation rar accruals rar deductions made gross revenue including controls associated biannual forecasting million resulting net revenue million balance utilisation rates process monthend accrual review sheet accrual december combined us controls pharmaceuticals vaccines businesses amounted million key observations communicated audit risk committee us pharmaceuticals returns rebates disclosed key satisfied managements estimated liability rar accounting estimate note group financial statements accruals year end appropriate reasonable disclosures provided note matter also assessed independent expectations discussed audit risk committee report within assessment accuracy historical estimates actual corporate governance section annual report rebates gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation intangible assets recognised tesaro audit procedures performed pfizer transactions performed following audit procedures amongst others year group recognised million related probability success pipeline products intangible assets including licences patents trademarks product innovations likelihood regulatory approval future sales brand names excluding goodwill acquisitions growth rates profit margin levels discount rates used tesaro inc pfizer consumer healthcare business valuation acquired intangible assets determination fair value acquired intangible met key individuals senior leadership team assets relies certain management assumptions product category leads key personnel involved estimates future trading performance including probability forecasting process discuss evaluate managements success pipeline products product innovations evidence support future sales growth rates profitability likelihood regulatory approval future sales growth rates assumptions profit margin levels discount rates challenged business assumptions applied management identified valuation intangible assets recognised estimating sales forecasts including benchmarking sales acquisitions key audit matter forecasts product compound annual growth rates external inherent judgements involved estimating future cash flows data specific market segment included independent auditing estimates required extensive audit effort market research expected category growth assessment challenge evaluate reasonableness forecasts sources contradictory evidence also engaged fair value specialists assess evaluated probability success factors related regulatory discount rates valuation methodologies applied approval applied pipeline products calculate forecast sales disclosures relating intangible assets included derived future commercialised assets note group financial statements matter assessed historical accuracy managements forecasts also discussed audit risk committee report within including consumption data estimates new sales corporate governance section annual report innovation compared forecast sales plan data asset asset internal forecasts approved senior management board directors assistance fair value specialists assessed reasonableness valuationspecific assumptions used management including discount rate terminal growth rate whether assumptions consistent wellinformed independent third party would value assets tested management review controls key inputs assumptions used valuation intangible assets controls encompass review valuation models contain number assumptions revenue growth rates probability success pipeline products profit margins discount rates key observations communicated audit risk committee whilst noting potential risks forecasts uncertainties regulatory approval pipeline products sales growth product innovations concluded judgements made management reasonable accordance ifrs gsk annual report independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation uncertain tax positions including transfer audit procedures performed pricing support tax specialists assessed group operates numerous jurisdictions appropriateness uncertain tax provisions performing open tax transfer pricing matters exposures uk following audit procedures amongst others us overseas tax authorities give rise uncertain tax assessed challenged provisions uncertain tax positions positions range possible outcomes provisions focused work jurisdictions group contingencies wide management required greatest potential exposure highest level make certain judgements respect estimates tax judgement required exposures contingencies order assess adequacy tax provisions sometimes complex result assessed managements policies recognition considerations required multiple tax laws measurement uncertain tax positions compliance regulations guidance per ifric december group recorded provisions involved transfer pricing specialists review transfer million respect uncertain tax positions pricing methodology group associated approach provisioning valuation uncertain tax positions disclosed key source estimation uncertainty note group financial involved uk us international tax transfer pricing statements disclosures included note specialists challenge conclusions reached matter also discussed audit risk committee report management relation expected outcome within corporate governance section annual report financial impact considered evidence actual results recent tax authority audits enquiries thirdparty tax advice obtained tax specialists knowledge market practice relevant jurisdictions tested key controls preparation review reporting judgmental tax balances transactions include provisions uncertain tax provisions key observations communicated audit risk committee satisfied managements judgements relation uncertain tax positions related disclosures accordance ifrs work concluded management applied consistent approach estimating uncertain tax provisions judgements continue prudent appropriately recorded gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter systems impact financial reporting audit procedures performed systems systems within group form critical component result control deficiencies identified incorporated groups financial reporting activities impact account additional considerations performing risk assessment balances controls context scope audit procedures follows financial audit primarily relate user access security considered impact risk assessment change control evaluating audit risks context deficiencies year group continued implement assistance specialist team remediation plan address user access change tested additional manual business process controls control deficiencies identified prior year primarily addressed related risks involved removal inappropriate access together implementation appropriate privileged access management key observations communicated audit risk committee processes controls planned fully complete managements actions made significant progress reducing number deficiencies year relating user access identified systems impact financial change management group many layers business reporting key audit matter process controls mitigate risk associated control deficiencies reliance systems within group satisfied mitigating business process controls address importance controls systems maintaining risk material misstatement impacting financial reporting effective control environment key interdependency caused control deficiencies exists ability rely controls ability rely system configured automated controls system reports pervasive nature systems fact remediation activities yet complete continue considerable involvement specialists additional effort needed audit team test compensating controls mitigate unaddressed risks systems impact financial reporting discussed audit risk committee report within corporate governance section annual report key systems impact range business processes including general ledger procurement sales financial consolidation gsk annual report independent auditors report continued report audit financial statements continued information directors responsible information information comprises information included annual report financial statements auditors report thereon opinion financial statements cover information except extent otherwise explicitly stated report express form assurance conclusion thereon connection audit financial statements responsibility read information consider whether information materially inconsistent financial statements knowledge obtained audit otherwise appears materially misstated identify material inconsistencies apparent material misstatements required determine whether material misstatement financial statements material misstatement information based work performed conclude material misstatement information required report fact nothing report respect matters summarise work relation areas information including areas upon specifically required report matters specifically required report responsibility reporting fair balanced understandable consider whether statement given directors consider consider directors statement consistent annual report financial statements taken whole fair balanced knowledge obtained audit understandable provides information necessary shareholders assess groups position performance business model strategy materially inconsistent knowledge obtained audit audit risk committee report consider whether deals appropriately matters reported matters reported appropriately covered audit risk committee audit risk committee report directors statement compliance uk corporate governance code code identify matters consider whether parts directors statement required listing rules relating parent companys compliance code containing provisions specified review auditor accordance listing rule r properly discloses departure relevant provision code principal risks viability statement review confirmation description light knowledge set section conclusions relating going gathered audit considering directors concern principal risks viability statement processes support statements made challenging managements key nothing material report add draw attention judgements estimates consideration historical forecasting accuracy respect matters evaluating macroeconomic assumptions consider statements aligned relevant provisions code directors remuneration report report whether part directors remuneration report audited set section opinions matters properly prepared disclosures specified companies act prescribed companies act opinion made part directors remuneration report audited prepared accordance companies act strategic report directors report report whether consistent audited financial statements set section opinions matters prepared accordance applicable legal requirements prescribed companies act opinion based work undertaken course audit report identified material misstatements either report information reports consistent light knowledge understanding group parent audited financial statements prepared company environment obtained course audit accordance applicable legal requirements gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued reporting information responsibility reporting alternative performance measures apms apms measures defined generally accepted accounting opinion practice gaap therefore typically included financial use calculation disclosure apms statement part annual report group use apms adjusted consistent groups published definitions profit free cash flow constant currency growth rates quarterly policies annual reporting financial performance use apms groups reporting results reviewed assessed managements calculation reporting consistent guidelines produced esma metrics assess consistency groups published definitions frc policies items appropriate balance use also considered assessed whether use apms statutory metrics apms together clear groups reporting results consistent guidelines produced definitions reconciliation apms used financial regulators european securities markets authority esma reporting guidelines use apms frc alternative performance measures thematic review published november also considered whether appropriate balance use statutory metrics apms addition whether clear definitions reconciliation apms used financial reporting provided dividends distribution policy consider whether dividends policy transparent dividends opinion dividends policy appropriately paid consistent policy outlined strategic report disclosed dividends paid consistent policy gsk annual report independent auditors report continued report audit financial statements continued responsibilities directors enquiring management internal audit audit risk committee including obtaining reviewing supporting explained fully directors responsibilities documentation concerning groups policies statement directors responsible preparation procedures relating financial statements satisfied give true fair view internal control directors identifying evaluating complying laws determine necessary enable preparation financial regulations whether aware instances statements free material misstatement whether noncompliance due fraud error detecting responding risks fraud whether preparing financial statements directors knowledge actual suspected alleged responsible assessing groups parent fraud companys ability continue going concern disclosing internal controls established mitigate risks related applicable matters related going concern using fraud noncompliance laws regulations going concern basis accounting unless directors either discussing among engagement team including significant intend liquidate group parent company cease component audit teams involving relevant internal operations realistic alternative specialists including tax valuations pensions industry auditors responsibilities audit specialists regarding fraud might occur financial statements financial statements potential indicators fraud objectives obtain reasonable assurance obtaining understanding legal regulatory whether financial statements whole free frameworks group operates focusing material misstatement whether due fraud error laws regulations direct effect financial issue auditors report includes opinion reasonable statements provisions uk companies act assurance high level assurance guarantee pensions legislation tax legislations audit conducted accordance isas uk fundamental effect operations group including always detect material misstatement exists good clinical practice fda regulations general misstatements arise fraud error considered data protection requirements antibribery corruption material individually aggregate could reasonably policy foreign corrupt practices act expected influence economic decisions users taken audit response risks identified basis financial statements procedures respond risks identified included details extent audit considered capable following detecting irregularities including fraud set reviewing financial statement disclosures testing description responsibilities audit supporting documentation assess compliance financial statements located frcs website provisions relevant laws regulations described wwwfrcorgukauditorsresponsibilities description forms direct effect financial statements part auditors report enquiring management audit risk committee extent audit considered inhouse external legal counsel concerning actual capable detecting irregularities including fraud potential litigation claims identify assess risks material misstatement performing analytical procedures identify unusual financial statements whether due fraud error unexpected relationships may indicate risks material design perform audit procedures responsive risks misstatement due fraud including obtaining audit evidence sufficient reading minutes meetings charged appropriate provide basis opinion governance reviewing internal audit reports correspondence regulators identifying assessing potential risks related irregularities also considered risks noted addressing identifying assessing risks material misstatement risk fraud management override controls respect irregularities including fraud noncompliance testing appropriateness journal entries laws regulations considered following adjustments nature industry sector control environment assessing whether judgements made making business performance including design accounting estimates indicative potential bias groups remuneration policies key drivers directors remuneration bonus levels performance targets evaluating business rationale significant transactions unusual outside normal course business gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued also communicated relevant identified laws regulations matters potential fraud risks engagement team members significant component audit teams remained alert auditor tenure indications fraud noncompliance laws following recommendation audit risk committee regulations throughout audit effect january appointed board directors audit financial statements year report legal regulatory requirements ended december subsequent financial periods period total uninterrupted engagement firm opinions matters prescribed two years companies act consistency audit report additional report opinion part directors remuneration report audit risk committee audited properly prepared accordance audit opinion consistent additional report companies act audit risk committee required provide opinion based work undertaken course accordance isas uk audit use report information given strategic report directors report made solely parent companys members report financial year financial statements body accordance chapter part prepared consistent financial statements companies act audit work undertaken strategic report directors report might state parent companys members prepared accordance applicable legal requirements matters required state auditors report purpose fullest extent permitted law light knowledge understanding group accept assume responsibility anyone parent company environment obtained parent company parent companys members course audit identified material body audit work report opinions misstatements strategic report directors report formed matters required report parent company passed resolution accordance exception section companies act senior statutory auditors name stated adequacy explanations received accounting records companies act required report opinion received information explanations require audit adequate accounting records kept deloitte llp parent company returns adequate audit statutory auditor received branches visited us london united kingdom parent company financial statements march agreement accounting records returns nothing report respect matters directors remuneration companies act also required report opinion certain disclosures directors remuneration made part directors remuneration report audited agreement accounting records returns nothing report respect matters gsk annual report consolidated income statement year ended december notes turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit finance income finance expense profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p consolidated statement comprehensive income year ended december profit year comprehensive expenseincome year items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries fair value movements equity investments deferred tax fair value movements equity investments reclassification fair value movements equity investments deferred tax reversed reclassification equity investments fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement deferred tax reversed reclassification cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments deferred tax fair value movements equity investments remeasurement lossesgains defined benefit plans tax remeasurement defined benefit plans comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year gsk annual report strategic report governance remuneration financial statements investor information consolidated balance sheet december notes noncurrent assets property plant equipment right use assets goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings contingent consideration liabilities trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings corporation tax payable deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments contingent consideration liabilities noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings revised see note reserves shareholders equity noncontrolling interests revised see note total equity financial statements pages approved board march signed behalf sir jonathan symonds chairman gsk annual report consolidated statement changes equity year ended december shareholders equity share share retained noncontrolling total capital premium earnings reserves total interests equity january profit year comprehensive income year total comprehensive income year distributions noncontrolling interests contribution noncontrolling interests dividends shareholders changes noncontrolling interests shares issued shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december implementation ifrs implementation ifrs december adjusted profit year comprehensive income year total comprehensive income year distributions noncontrolling interests contribution noncontrolling interests derecognition noncontrolling interests consumer healthcare joint venture dividends shareholders realised profits disposal equity investments share associates joint ventures realised profits disposal equity investments shares issued writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december reported adjustment noncontrolling interest see note december revised implementation ifrs december adjusted profit year comprehensive income year total comprehensive income year distributions noncontrolling interests changes noncontrolling interests dividends shareholders recognition interest consumer healthcare joint venture realised losses disposal equity investments shares issued shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december gsk annual report strategic report governance remuneration financial statements investor information consolidated cash flow statement year ended december notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments contingent consideration paid purchase businesses net cash acquired disposal businesses investments associates joint ventures proceeds disposal interests associates decrease liquid investments interest received dividends associates joint ventures equity investments net cash outflow investing activities cash flow financing activities shares acquired esop trusts issue share capital purchase noncontrolling interests increase longterm loans repayment shortterm notes increase inrepayment shortterm loans repayment lease liabilities interest paid dividends paid shareholders distributions noncontrolling interests contributions noncontrolling interests financing cash flows net cash outflow financing activities increasedecrease cash bank overdrafts cash bank overdrafts beginning year exchange adjustments increasedecrease cash bank overdrafts cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents cash cash equivalents reported assets held sale overdrafts gsk annual report notes financial statements presentation financial statements description business preparation financial statements conformity gsk major global healthcare group engaged generally accepted accounting principles requires management creation discovery development manufacture make estimates assumptions affect reported marketing pharmaceutical products vaccines overthe amounts assets liabilities disclosure contingent counter otc medicines healthrelated consumer assets liabilities date financial statements products gsks principal pharmaceutical products include reported amounts revenues expenses medicines following therapeutic areas respiratory hiv reporting period actual results could differ estimates immunoinflammation oncology antivirals central nervous adjustment retained earnings noncontrolling system cardiovascular urogenital metabolic antibacterials interests balances dermatology group acquired novartis noncontrolling interest compliance applicable law ifrs old consumer healthcare joint venture result financial statements prepared accordance transaction noncontrolling interest ceased exist companies act article ias regulation fully eliminated consolidated international financial reporting standards ifrs reserves adjustment million made related interpretations adopted european union closing balances retained earnings noncontrolling interests reallocate cumulative translation financial statements also compliance ifrs exchange eliminate remaining noncontrolling interest issued international accounting standards board balance impact profit year composition financial statements comprehensive income net assets total equity consolidated financial statements drawn sterling impact items earlier years effect functional currency glaxosmithkline plc adjustment relevant equity balances follows accordance ifrs accounting presentation financial statements comprise december december consolidated income statement reported adjustment revised consolidated statement comprehensive income retained earnings shareholders equity consolidated balance sheet noncontrolling interests consolidated statement changes equity total equity consolidated cash flow statement implementation ifrs leases notes financial statements group applied ifrs leases effect composition group january ifrs introduces new requirements list subsidiaries associates opinion definition lease lessee accounting lessor accounting directors principally affected amount profit net well number new disclosures assets group given note principal group general leases within scope ifrs required companies brought balance sheet lessees recognising rightofuse asset related lease liability financial period commencement lease subsequent accounting financial statements cover financial year similar finance lease model set ias ifrs january december comparative figures establishes control model identification leases financial years january december distinguishing leases service contracts basis appropriate january december whether identified asset controlled customer accounting principles policies gsk adopted ifrs applying modified retrospective financial statements prepared using approach accordingly prior year results historical cost convention modified revaluation certain restated larger leases leases annual payments items stated accounting policies going million right use asset january concern basis calculated based original lease inception date financial statements prepared accordance smaller leases leases annual payments less groups accounting policies approved board million right use asset set equal lease described note accounting principles policies liability january adjusted prepaid accrued information application accounting policies lease payments onerous lease provisions business including areas estimation judgement given note combination fair value adjustments difference key accounting judgements estimates previous carrying amount revised carrying amount january recognised adjustment opening retained earnings january gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued presentation financial statements continued group applied definition lease related million reduction property plant equipment guidance set ifrs lease contracts entered arose transfer asset retirement obligations either date initial application existing finance leases right use assets million significant changes result vast majority adjustment noncurrent liabilities arose business contracts combination fair value adjustments derecognised transition ifrs corresponding adjustment following permitted practical expedients applied right use assets transition application ifrs material impact rightofuse asset date transition adjusted groups income statement earnings per share overall amount existing onerous lease provision cash flows group however presentation december without reassessment lease payments cash flow statement changed leases ending within months transition date resulting increase net cash inflow operating treated shortterm leases leasebylease basis activities hence free cash flow corresponding initial direct costs excluded measurement increase net cash outflow financing items split right use asset transition date leaseby interest paid repayment lease liabilities lease basis reconciliation operating lease commitments hindsight applied determining lease term previously reported year ended december contracts contained options extend terminate discounted groups incremental borrowing rate lease lease liabilities recognised balance sheet initial application ifrs follows weighted average incremental borrowing rate applied lease liabilities recognised january operating lease commitments december impact ifrs balance sheet line item effect discounting groups incremental borrowing rate table shows amount adjustment january financial statement line item affected application reasonably certain extension options ifrs january termination options reasonably certain exercised shortterm leases ifrs reported adjustments adjusted adjustments lease liabilities recognised january noncurrent assets parent company financial statements property plant equipment financial statements parent company right use assets glaxosmithkline plc prepared accordance noncurrent assets uk gaap uk accounting presentation company deferred tax assets balance sheet presented accounting current assets policies given pages trade receivables current liabilities trade payables provisions shortterm borrowings noncurrent liabilities longterm borrowings noncurrent liabilities provisions deferred tax liabilities total effect net assets retained earnings revised total effect equity gsk annual report notes financial statements continued accounting principles policies consolidation part payment relating original estimate consolidated financial statements include fair value contingent consideration acquisition reported within investing activities cash flow statement assets liabilities results cash flows part payment relating increase company subsidiaries including esop trusts liability since acquisition date reported within operating groups share results net assets associates cash flows joint ventures consideration transferred together non groups share assets liabilities revenue expenses controlling interest exceeds fair value net assets joint operations liabilities contingent liabilities acquired excess financial statements entities consolidated made recorded goodwill costs effecting acquisition december year charged income statement period incurred entities group power direct relevant activities affect returns group goodwill capitalised separate item case generally control financial operating subsidiaries part cost investment case policies accounted subsidiaries joint ventures associates goodwill denominated currency operation acquired group ability exercise joint control rights net assets entities entities cost acquisition fair value net accounted joint ventures group ability assets acquired difference recognised directly exercise joint control arrangement rights income statement specified assets obligations specified liabilities equity subsidiary acquired arrangement arrangement accounted joint noncontrolling interest recognised either fair value operation group ability exercise noncontrolling interests share net assets significant influence entities accounted subsidiary casebycase basis changes groups associates results assets liabilities associates ownership percentage subsidiaries accounted within joint ventures incorporated consolidated equity financial statements using equity method accounting groups rights assets liabilities revenue expenses foreign currency translation joint operations included consolidated financial foreign currency transactions booked functional statements accordance rights obligations currency group company exchange rate ruling date transaction foreign currency monetary assets interests acquired entities consolidated date liabilities retranslated functional currency group acquires control interests sold deconsolidated rates exchange ruling balance sheet date exchange date control ceases differences included income statement transactions balances subsidiaries eliminated consolidation assets liabilities including related profit tax taken sales subsidiaries goodwill overseas subsidiaries associates joint products sold customers outside group ventures translated sterling rates exchange relevant proportion profits transactions joint ruling balance sheet date results cash flows ventures joint operations associates also deferred overseas subsidiaries associates joint ventures products sold third parties transactions non translated sterling using average rates exchange controlling interests recorded directly equity deferred tax relief unrealised intragroup profit accounted exchange adjustments arising opening net assets extent considered recoverable profits year retained overseas subsidiaries associates joint ventures translated sterling less business combinations exchange differences arising related foreign currency business combinations accounted using acquisition borrowings hedge groups net investment accounting method identifiable assets liabilities contingent operations taken separate component equity liabilities acquired measured fair value acquisition date translating sterling assets liabilities results consideration transferred measured fair value cash flows overseas subsidiaries associates joint includes fair value contingent consideration ventures reported currencies hyperinflationary fair value contingent consideration liabilities economies adjustments made material reflect reassessed balance sheet date changes current price levels loss net monetary assets charged recognised income statement payments contingent consolidated income statement consideration reduce balance sheet liability result recorded income statement gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued accounting principles policies continued revenue applicable january advertising promotion expenditure charged income group receives revenue supply goods external statement incurred shipment costs intercompany customers orders received majority contracts transfers charged cost sales distribution costs gsk enters relate sales orders containing single sales customers included selling general performance obligations delivery pharmaceutical administrative expenditure vaccine consumer healthcare products average restructuring costs recognised provided duration sales order less months appropriate respect direct expenditure business product revenue recognised control goods reorganisation plans sufficiently detailed well passed customer point control passes advanced appropriate communication determined customer arrangement generally affected undertaken occurs delivery customer research development product revenue represents net invoice value including fixed research development expenditure charged variable consideration variable consideration arises income statement period incurred sale goods result discounts allowances given development expenditure capitalised criteria accruals estimated future returns rebates revenue recognising asset met usually regulatory filing recognised full highly probable significant made major market approval considered reversal amount cumulative revenue recognised highly probable property plant equipment used occur methodology assumptions used estimate research development capitalised depreciated rebates returns monitored adjusted regularly accordance groups policy light contractual legal obligations historical trends past experience projected market conditions environmental expenditure uncertainty associated returns rebates resolved environmental expenditure related existing conditions revenue adjusted accordingly resulting past current operations current future benefit discernible charged income gsk enters development marketing collaborations statement group recognises liability sitebysite outlicences groups compounds products basis reliably estimated liability includes parties contracts give rise fixed variable groups portion total costs also portion consideration upfront payments development milestones potentially responsible parties costs probable salesbased milestones royalties able satisfy respective shares income dependent achievement development cleanup obligation recoveries reimbursements milestone recognised highly probable recorded assets virtually certain significant reversal amount cumulative revenue recognised occur usually related legal disputes event occurs salesbased milestone income recognised provision made anticipated settlement costs legal highly probable sales threshold disputes group outflow resources reached considered probable reliable estimate made likely outcome respect product liability claims related salesbased royalties licence intellectual property certain products provision made sufficient recognised relevant product sale occurs history claims made settlements enable management time recognition revenue payment make reliable estimate provision required cover customer expected one year unasserted claims certain cases incurred impact material amount consideration discounted reported ibnr actuarial technique used determine using appropriate discount rates estimate addition provision made legal expenses arising claims received disputes value added tax sales taxes excluded revenue group may become involved legal proceedings respect possible make reliable estimate expenditure expected financial effect could result expenditure recognised respect goods services ultimate resolution proceedings cases received supplied accordance contractual terms appropriate disclosure cases would included provision made obligation exists future liability provision would made respect past event amount obligation reliably estimated manufacturing startup costs associated claims made group third costs validation achievement normal parties charged income statement production expensed incurred incurred gsk annual report notes financial statements continued accounting principles policies continued pensions postemployment benefits disposal ppe cost related accumulated costs providing pensions defined benefit schemes depreciation impairments removed financial calculated using projected unit credit method statements net amount less proceeds taken spread period benefit expected income statement derived employees services consistent leases applicable january advice qualified actuaries pension obligations measured group recognises right use assets lease present value estimated future cash flows discounted arrangements lessee rights use assets rates reflecting yields highquality corporate bonds owned third parties lease agreements capitalised pension scheme assets measured fair value inception lease recognised consolidated balance sheet date balance sheet corresponding liability lessor costs postemployment liabilities calculated recognised lease obligation within short longterm similar way defined benefit pension schemes spread borrowings carrying amount subsequently increased period benefit expected derived reflect interest lease liability reduced lease employees services accordance advice payments made qualified actuaries calculating discounted lease liability leases actuarial gains losses effect changes actuarial annual payments million implicit rate assumptions recognised statement comprehensive lease used available incremental borrowing income year arise rate lease specific adjustment used neither groups contributions defined contribution plans available leases annual payments less charged income statement incurred million incremental borrowing rate used incremental borrowing rate calculated rate interest employee share plans gsk would able borrow similar term incentives form shares provided employees similar security funds necessary obtain share option share award schemes similar asset similar market fair values options awards calculated finance costs charged income statement grant dates using blackscholes option pricing model produce constant periodic rate charge remaining charged income statement relevant vesting balance obligations accounting period periods variable rents part lease liability right group provides finance esop trusts purchase use asset payments charged income company shares meet obligation provide shares statement incurred shortterm lowvalue leases employees exercise options awards costs running capitalised lease rentals also charged income esop trusts charged income statement shares statement incurred held esop trusts deducted reserves nonlease components accounted separately transfer made reserves retained earnings lease components plant equipment leases vesting periods related share options awards separately accounted land buildings vehicle leases reflect ultimate proceeds receivable employees exercise modifications reassessments occur lease liability right use asset remeasured property plant equipment property plant equipment ppe stated cost right use assets title expected pass gsk purchase construction less provisions depreciation point future depreciated basis consistent impairment financing costs capitalised within cost similar owned assets cases right use assets qualifying assets construction depreciated shorter useful life asset lease term depreciation calculated write cost less residual value ppe excluding freehold land using straightline goodwill basis expected useful life residual values lives goodwill stated cost less impairments goodwill reviewed appropriate adjusted annually deemed indefinite useful life tested normal expected useful lives major categories impairment least annually ppe fair value interest acquired entitys assets liabilities contingent liabilities exceeds freehold buildings years consideration paid excess recognised immediately leasehold land buildings lease term years gain income statement plant machinery years equipment vehicles years gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued accounting principles policies continued intangible assets investments associates joint ventures joint intangible assets stated cost less provisions operations amortisation impairments investments associates joint ventures carried consolidated balance sheet groups share net licences patents knowhow marketing rights separately assets date acquisition postacquisition acquired acquired part business combination retained profits losses together goodwill arising amortised estimated useful lives generally acquisition group recognises rights assets exceeding years using straightline basis liabilities revenue expenses joint operations time available use estimated useful lives determining amortisation charge take account patent inventories lives applicable well value obtained inventories included financial statements lower periods nonexclusivity asset lives reviewed cost including raw materials direct labour direct costs appropriate adjusted annually related production overheads net realisable value contingent milestone payments recognised point cost generally determined first first basis contingent event becomes probable development prelaunch inventory held asset high costs incurred group associated acquired probability regulatory approval product licences patents knowhow marketing rights written point provision made carrying value income statement incurred unless criteria recoverable amount provision reversed point recognition internallygenerated intangible asset met high probability regulatory approval determined usually regulatory filing made major market financial instruments applicable january approval considered highly probable financial assets acquired brands valued independently part fair financial assets measured amortised cost fair value value businesses acquired third parties brand comprehensive income fvtoci fair value value substantial longterm profit loss fvtpl measurement basis brands either contractual legal nature sold determined reference business model separately rest businesses acquired brands managing financial asset contractual cash flow amortised estimated useful lives years characteristics financial asset financial assets except considered useful economic life trade receivables month expected credit loss ecl indefinite allowance recorded initial recognition costs acquiring developing computer software subsequent evidence significant increase credit risk internal use internet sites external use capitalised asset allowance increased reflect full lifetime intangible fixed assets software site supports ecl realistic prospect recovery asset significant business system expenditure leads written creation durable asset erp systems software amortised expected credit losses recognised income statement seven ten years computer software three financial assets measured amortised cost fair value five years comprehensive income apart equity impairment noncurrent assets investments carrying values noncurrent assets reviewed investments impairment either standalone basis part larger investments comprise equity investments cash generating unit indication assets investments limited life funds group elected might impaired additionally goodwill intangible assets designate equity investments measured fvtoci indefinite useful lives intangible assets yet initially recorded fair value plus transaction costs available use tested impairment annually remeasured subsequent reporting dates fair value provision impairment charged income statement unrealised gains losses recognised year concerned comprehensive income impairments goodwill reversed impairment losses disposal equity investment gains losses noncurrent assets reversed deferred comprehensive income transferred change estimates used determine recoverable amounts directly retained earnings investments limited life funds extent revised recoverable amounts measured fvtpl initially recorded fair value exceed carrying values would existed net remeasured subsequent reporting dates fair value depreciation amortisation impairments unrealised gains losses recognised income recognised statement gsk annual report notes financial statements continued accounting principles policies continued dividends equity investments distributions funds derivative financial assets liabilities including derivatives recognised income statement groups right embedded host contracts separated receive payment established host contract classified heldfortrading measured fair value changes fair value derivative purchases sales investments accounted instruments qualify hedge accounting trade date recognised immediately income statement trade receivables hedge accounting trade receivables measured accordance derivatives designated hedging instruments classified business model portfolio trade receivables inception hedge relationship cash flow hedges net held group portfolios three business investment hedges fair value hedges models ifrs due factoring arrangements place collect contractual cash flows measured amortised cost changes fair value derivatives designated cash flow sell contractual cash flows measured fvtpl hedges recognised comprehensive income collect sell contractual cash flows measured extent hedges effective ineffective portions fvtoci trade receivables measured amortised cost recognised profit loss immediately amounts deferred carried original invoice amount less allowances comprehensive income reclassified income expected credit losses statement hedged item affects profit loss expected credit losses calculated accordance net investment hedges accounted similar way simplified approach permitted ifrs using provision matrix cash flow hedges applying lifetime historical credit loss experience trade changes fair value derivatives designated fair value receivables expected credit loss rate varies depending hedges recorded income statement together whether extent settlement trade changes fair value hedged asset liability receivables overdue also adjusted appropriate reflect current economic conditions estimates future taxation conditions purpose determining credit loss rates current tax provided amounts expected paid customers classified groupings similar loss applying tax rates enacted substantively patterns key drivers loss rate nature enacted balance sheet date business unit location type customer deferred tax provided full temporary differences arising trade receivable determined reasonable tax bases assets liabilities carrying expectation recovery written firstly amounts financial statements deferred tax assets expected credit loss allowance available recognised extent probable future taxable income statement profits available temporary differences utilised deferred tax provided temporary subsequent recoveries amounts previously provided differences arising investments subsidiaries associates written credited income statement longterm joint ventures except timing reversal receivables discounted effect material temporary difference controlled probable cash cash equivalents temporary difference reverse foreseeable cash held deposit accounts measured amortised cost future deferred tax provided using rates tax investments money market funds held fair value enacted substantively enacted balance sheet date profit loss funds fail solely payments uncertain tax position identified management principal interest sppi test make judgement probable outcome assuming relevant tax authority full knowledge borrowings situation assessed economic outflow borrowings initially recorded amount proceeds probable arise provision made best estimate received net transaction costs borrowings subsequently liability estimating liability gsk applies riskbased carried amortised cost difference approach takes account appropriate proceeds net transaction costs amount due probability group would able obtain redemption recognised charge income compensatory adjustments international tax treaties statement period relevant borrowing estimates take account specific circumstances derivative financial instruments dispute relevant external advice derivative financial instruments used manage exposure discounting market risks principal derivative instruments used time value money material balances gsk foreign currency swaps interest rate swaps foreign discounted current values using appropriate discount rates exchange forward contracts options group unwinding discounts recorded finance income hold issue derivative financial instruments trading finance expense speculative purposes gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued accounting principles policies continued revenue applicable december trade receivable determined uncollectable revenue recognised income statement goods written firstly provision available services supplied made available external customers income statement orders received title risk loss passed subsequent recoveries amounts previously provided customer reliable estimates made relevant deductions credited income statement longterm receivables relevant obligations fulfilled discounted effect material earnings process regarded complete borrowings turnover represents net invoice value deduction borrowings initially recorded amount proceeds discounts allowances given accruals estimated received net transaction costs borrowings subsequently future rebates returns methodology assumptions carried amortised cost difference used estimate rebates returns monitored proceeds net transaction costs amount due adjusted regularly light contractual legal redemption recognised charge income obligations historical trends past experience projected statement period relevant borrowing market conditions market conditions evaluated using wholesaler thirdparty analyses market research data derivative financial instruments hedging internallygenerated information value added tax derivative financial instruments used manage exposure sales taxes excluded revenue market risks principal derivative instruments used gsk group copromotes product counterparty foreign currency swaps interest rate swaps foreign records sale group records share revenue exchange forward contracts options group copromotion income within turnover nature co hold issue derivative financial instruments trading promotion activities group records costs speculative purposes sales addition initial eventbased milestone income derivative financial instruments classified heldfortrading excluding royalty income arising development marketing carried balance sheet fair value derivatives collaborations groups compounds products designated hedging instruments classified inception parties recognised turnover cash flow hedges net investment hedges fair value royalty income recognised accruals basis hedges accordance terms relevant licensing agreements changes fair value derivatives designated cash flow financial instruments applicable hedges recognised comprehensive income december extent hedges effective ineffective portions recognised profit loss immediately amounts deferred availableforsale investments comprehensive income reclassified income liquid investments investments classified statement hedged item affects profit loss availableforsale investments initially recorded fair value plus transaction costs remeasured subsequent net investment hedges accounted similar way reporting dates fair value unrealised gains losses cash flow hedges availableforsale investments recognised directly changes fair value derivatives designated fair value comprehensive income impairments arising significant hedges recorded income statement together prolonged decline fair value equity investment reduce changes fair value hedged asset liability carrying amount asset directly charged changes fair value derivative instruments income statement qualify hedge accounting recognised immediately disposal impairment investments gains income statement losses deferred comprehensive income reclassified income statement dividends equity leases applicable december investments recognised income statement leasing agreements transfer group substantially groups right receive payment established equity benefits risks ownership asset treated investments recorded noncurrent assets unless finance leases asset purchased outright expected sold within one year assets included ppe computer software capital elements leasing commitments shown purchases sales equity investments accounted obligations finance leases assets held finance trade date purchases sales availablefor leases depreciated basis consistent similar owned sale investments accounted settlement date assets lease term shorter interest element trade receivables lease rental included income statement leases trade receivables carried original invoice amount less operating leases rental costs charged provisions doubtful debts provisions made income statement straightline basis lease term evidence risk nonpayment taking account ageing previous experience general economic conditions gsk annual report notes financial statements continued key accounting judgements estimates preparing financial statements management required taxation make judgements items tax charge year million recognised financial statements estimates million december current tax payable assumptions affect amounts assets liabilities million million noncurrent corporation revenue expenses reported financial statements tax payable million million current actual amounts results could differ estimates tax recoverable million million following considered critical accounting estimates judgements key sources estimation uncertainty group open tax issues number revenue turnover authorities management makes judgement whether reported group turnover million sufficient information able make reliable estimate million outcome dispute insufficient information available provision made estimates gross turnover reduced rebates discounts allowances sufficient information available estimating potential tax product returns given expected given liability gsk applies riskbased approach takes vary product arrangements buying groups account appropriate probability group would arrangements purchasing organisations dependent able obtain compensatory adjustments international upon submission claims time initial tax treaties estimates take account specific recognition sale accruals made time sale circumstances dispute relevant external advice estimated rebates discounts allowances payable inherently judgemental could change substantially returns made based available market information time dispute progresses new facts emerge historical experience december group recognised provisions us pharmaceuticals business largest million respect uncertain tax positions complex arrangements rebates discounts allowances million nature uncertain us pharmaceuticals turnover million positions practicable give meaningful sensitivity million recording deductions estimates million million rebates discounts factors affecting tax charge future years set allowances returns balance sheet accruals rebates note taxation gsk continues believe made discounts allowances returns us pharmaceuticals adequate provision liabilities likely arise open vaccines businesses managed combined basis assessments open issues exist ultimate liability december total accrual amounted matters may vary amounts provided million million nature dependent upon outcome negotiations relevant accruals practicable give meaningful sensitivity tax authorities necessary litigation proceedings estimates legal disputes amounts estimated may fully reflect legal costs year million final outcome amounts subject change million december provisions legal dependent upon amongst things types buying disputes amounted million million group product sales mix estimates level accrual rebates returns reviewed management makes judgement whether sufficient adjusted regularly light contractual legal information able make reliable estimate likely obligations historical trends past experience projected outcome dispute legal expenses arising market conditions market conditions evaluated using claims group insufficient information wholesaler thirdparty analyses market research data available provision made disclosure claim internallygenerated information revenue recognised given full highly probable significant reversal amount cumulative revenue recognised occur estimated provisions take account specific amount turnover recognised year performance circumstances dispute relevant external advice obligations satisfied previous periods set note inherently judgemental could change substantially time turnover segment information dispute progresses new facts emerge details status various uncertainties involved significant future events could cause assumptions unresolved disputes set note legal proceedings accruals based change could materially affect future results group gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued key accounting judgements estimates continued companys directors taken legal advice pensions postemployment benefits established provisions taking account relevant judgement facts circumstances matter accordance surplus defined benefit scheme arises accounting requirements respect product liability claims potential surplus arise committed future related certain products sufficient history claims contributions rights trustees prevent group made settlements enable management make reliable obtaining refund surplus future considered estimate provision required cover unasserted claims determining whether necessary restrict amount group may become involved legal proceedings respect surplus recognised two uk schemes surplus possible make reliable estimate combined surplus million december expected financial effect practicable give million gsk made judgement meaningful range outcomes could result ultimate amounts meet requirements recoverability resolution proceedings cases appropriate disclosure cases would provided provision estimates would made contingent liability quantified costs providing pensions postemployment benefits assessed basis assumptions selected ultimate liability legal claims may vary amounts management assumptions include future earnings provided dependent upon outcome litigation pension increases discount rates expected longterm rates proceedings investigations possible settlement negotiations return assets mortality rates disclosed note position could change time therefore pensions postemployment benefits assurance losses result outcome legal proceedings exceed amount provisions discount rates derived aa rated corporate bond yields reported groups financial statements material amount except countries deep market corporate bonds government bond yields used sensitivity contingent consideration analysis provided note pensions post income statement charge contingent employment benefits reduction discount consideration million million rate would lead increase net pension deficit december liability contingent consideration approximately million increase annual amounted million million pension cost approximately million selection amount million million related different assumptions could affect future results acquisition former shionogiviiv healthcare joint venture group estimates contingent consideration included consideration payable business combination recorded fair value date acquisition fair values generally based riskadjusted future cash flows discounted using appropriate posttax discount rates fair values reviewed regular basis least annually changes reflected income statement see note contingent consideration liabilities new accounting requirements following new amended accounting standards interest rate benchmark reform amendments ifrs issued iasb likely affect future annual ias ifrs issued september reports implemented group january amendments modify specific hedge accounting requirements amendment ifrs business combinations issued allow hedge accounting continue affected hedges october implemented group period uncertainty hedged items hedging amendment clarifies definition business instruments referencing current interest rate benchmarks permits simplified initial assessment whether acquired amended result ongoing interest rate benchmark set activities assets group assets rather reforms business amendments expected material impact amendment apply prospectively acquisitions results financial position group completed implementation date change accounting acquisitions date gsk annual report notes financial statements continued exchange rates group uses average exchange rates prevailing period translate results cash flows overseas subsidiaries joint ventures associates sterling period end rates translate net assets entities currencies influence translations relevant exchange rates average rates period end rates us us euro euro yen yen turnover segment information operating segments reported based financial information provided chief executive officer responsibilities corporate executive team cet gsk reports results four segments pharmaceuticals pharmaceuticals rd vaccines consumer healthcare individual members cet responsible segment groups management reporting process allocates intragroup profit product sale market sale recorded profit analyses presented basis corporate unallocated turnover costs included results certain consumer healthcare products held sale number markets order meet antitrust approval requirements together costs corporate functions revenue recognised year performance obligations satisfied previous periods totalled million million included million million reported turnover arising changes prior year estimates rar accruals million million royalty income turnover segment pharmaceuticals vaccines consumer healthcare segment turnover corporate unallocated turnover gsk reviewed presentation respiratory product sales january reporting ellipta products portfolio nucala respiratory category respiratory products established pharmaceuticals comparative information revised onto consistent basis revised revised pharmaceuticals turnover therapeutic area respiratory hiv immunoinflammation oncology established pharmaceuticals vaccines turnover category meningitis influenza shingles established vaccines gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued turnover segment information continued us operations pharmaceuticals vaccines businesses made sales three wholesalers approximately million million million million million million million million million respectively allocating finalcustomer discounts wholesalers consumer healthcare turnover category wellness oral health nutrition skin health segment profit pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment profit corporate unallocated costs reconciling items segment profit operating profit operating profit finance income finance costs profit disposal interest associates share aftertax profits associates joint ventures profit taxation taxation profit taxation year reconciling items segment profit operating profit comprise items specifically allocated segment profit include impairment amortisation intangible assets major restructuring costs include impairments tangible assets computer software transactionrelated adjustments related significant acquisitions proceeds costs disposals associates products businesses significant legal charges expenses settlement litigation government investigations operating income royalty income items pretax impact enactment us tax cuts jobs act depreciation amortisation segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment depreciation amortisation corporate unallocated depreciation amortisation reconciling items segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report notes financial statements continued turnover segment information continued ppe intangible asset goodwill impairment segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment impairment corporate unallocated impairment reconciling items segment impairment total impairment total impairment ppe intangible asset impairment reversals segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment impairment reversals corporate unallocated impairment reversals reconciling items segment impairment reversals total impairment reversals total impairment reversals net assets segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment net operating assets corporate unallocated net operating assets net operating assets net debt investments associates joint ventures derivative financial instruments current deferred taxation assets held sale excluding cash cash equivalents net assets pharmaceuticals segment includes shionogiviiv healthcare contingent consideration liability million million pfizer put option million million net assets pharmaceuticals consumer healthcare segments increased year following acquisitions tesaro pfizer consumer healthcare business respectively gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued turnover segment information continued geographical information uk regarded groups country domicile turnover location customer uk us rest world external turnover noncurrent assets location subsidiary uk us rest world noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivables operating incomeexpense fair value remeasurements equity investments ifrs disposal businesses assets fair value remeasurements contingent consideration recognised business combinations remeasurement viiv healthcare put option liabilities preferential dividends remeasurement consumer healthcare put option liability fair value adjustments derivative financial instruments incomeexpense impairment availableforsale equity investments ias disposal availableforsale equity investments ias disposal businesses assets included profit disposal rabies tickborne encephalitis vaccines million gain arising increase value shares hindustan unilever limited received disposal horlicks consumer healthcare brands million including fair value movements related derivatives fair value remeasurements contingent consideration recognised business combinations included million related acquisition former shionogiviiv healthcare joint venture million related vaccines acquisition novartis together fair value movements related hedging contracts gsk annual report notes financial statements continued operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals depreciation right use assets impairment right use assets amortisation intangible assets impairment intangible assets net reversals impairment goodwill allocated disposal group net reversals net foreign exchange gainslosses inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories shortterm lease charge lowvalue lease charge variable lease payments operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration net foreign exchange gains include net gain million nil million loss arising reclassification exchange liquidation disposal overseas subsidiaries included within operating profit major restructuring charges million million million see note major restructuring costs fees payable companys auditor associates audit parent company consolidated financial statements including attestation sarbanesoxley act audit companys subsidiaries total audit services taxation compliance taxation advice audit related assurance services services total auditrelated nonaudit services assurance services provided auditor related agreed upon procedures assurance services outside statutory audit requirements services provided auditor primarily related advisory services year ended december addition fees paid auditor respect gsk pension schemes audit services fees million nil nil also paid auditors respect audits certain companys subsidiaries acquired year gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities increase wages salaries included impact movements exchange rates group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance cost sharebased incentive plans analysed follows share value plan performance share plan share option plans cash settled plans average monthly number persons employed group including directors year number number number manufacturing selling general administration research development average monthly number group employees excludes temporary contract staff numbers group employees end financial year given financial record compensation directors senior management members cet aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans information remuneration directors given remuneration report pages gsk annual report notes financial statements continued major restructuring costs within pharmaceuticals sector highly regulated manufacturing operations supply chains long lifecycle business mean restructuring programmes particularly involve rationalisation closure manufacturing rd sites likely take several years complete major restructuring costs related specific boardapproved major restructuring programmes including integration costs following material acquisitions structural significant scale costs individual related projects exceed million existing combined restructuring integration programme incorporates previous major change programme pharmaceuticals restructuring programme restructuring integration programme following novartis transaction programme subsequently complete july boardapproved major restructuring programme designed significantly improve competitiveness efficiency groups cost base savings delivered primarily supply chain optimisation reductions administrative costs february boardapproved new major restructuring programme generate synergies integration pfizer consumer healthcare business gsks consumer healthcare business total restructuring costs million incurred following areas manufacturing site restructuring including worthing united kingdom cork ireland restructuring following integration pfizer consumer healthcare business gsk consumer healthcare restructuring pharmaceutical consumer healthcare supply chains leading simplification operating model improved resource allocation continued transformation central functions including gsk technology platforms interfaces deliver greater digital synergies simplification applications staff reductions analysis costs charged operating profit programmes follows increase provision major restructuring programmes see note amount provision reversed unused see note impairment losses recognised noncash charges cash costs provision reversals million million million reflected provision releases combined restructuring integration programme asset impairments million noncash charges million principally comprised fixed asset writedowns across manufacturing research facilities accelerated depreciation asset lives rd manufacturing shortened result major restructuring programmes charges settled cash include termination leases site closure costs consultancy project management costs analysis major restructuring charges programme follows cash noncash total major restructuring programme including tesaro consumer healthcare joint venture integration programme combined restructuring integration programme analysis major restructuring charges income statement line follows cost sales selling general administration research development operating expense gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued finance income years december december ifrs finance income arising financial assets measured amortised cost financial assets measured fair value profit loss net gains arising forward element forward contracts net investment hedge relationships year december ias interest income arising cash cash equivalents availableforsale investments loans receivables fair value adjustments derivatives fair value profit loss finance income arising financial assets measured amortised cost includes interest income arising assets would classified availableforsale investments loans receivables ias also includes interest income arising certain cash cash equivalents finance income arising financial assets measured fair value profit loss includes interest income arising cash cash equivalents net gains arising hedge ineffectiveness net investment hedges recorded fair value adjustments derivatives fair value profit loss derivatives accounted fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments finance expense finance expense arising financial liabilities amortised cost derivatives fair value profit loss net losses arising financial instruments mandatorily measured fair value profit loss reclassification hedges comprehensive income unwinding discounts provisions finance expense arising lease liabilities finance expense derivatives accounted fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments finance expense arising derivatives fair value profit loss relates swap interest expense prior year figures finance expense arising lease liabilities related interest arising finance leases previous leasing standard ias originally reported finance expense finance expense included million charge interest relating historical income tax settlements gsk annual report notes financial statements continued associates joint ventures groups share aftertax profits losses associates joint ventures set share aftertax profits associates share aftertax lossesprofits joint ventures december group held one significant associate innoviva inc summarised income statement information respect innoviva set groups share aftertax profits associates comprehensive income includes profit million comprehensive income nil respect innoviva results innoviva included summarised income statement information represent estimated earnings innoviva relevant periods based publicly available information balance sheet date innovivas turnover arises royalty income gsk relation relvarbreo ellipta anoro ellipta trelegy ellipta sales turnover profit taxation comprehensive income total comprehensive income estimated results innoviva exclude deferred tax credit million announced innoviva group finalised results accordingly gsks share credit million recognised share aftertax profits associates aggregated financial information respect gsks share associated undertakings joint ventures set share turnover share aftertax lossesprofits share comprehensive income share total comprehensive expenseincome groups sales associates joint ventures million million million gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued taxation groups tax charge sum total current deferred tax expense taxation charge based profits year uk current year charge rest world current year charge credit respect prior periods current taxation deferred taxation gsk made payments million uk corporation tax hmrc amounts uk corporation tax include various business taxes borne uk gsk year deferred tax credit reflected origination current year expenses offset taxable profits future periods probable also included uplift tax carrying value certain consumer healthcare brands result acquisition novartis interest former consumer healthcare joint venture deferred tax credit reflected revaluation existing deferred tax liabilities reflect lower swiss tax rate applicable following swiss tax reform increase deferred tax assets related intragroup profit inventory impact items partly offset revaluation existing deferred tax assets reflect lower us tax rate applicable following enactment us tax reform following table reconciles tax charge calculated uk statutory rate group profit tax actual tax charge year revised revised reconciliation taxation group profits profit tax uk statutory rate taxation differences overseas taxation rates benefit intellectual property incentives rd credits fair value remeasurement nontaxable put options tax losses benefit recognised permanent differences disposals acquisitions permanent differences reassessments prior year estimates changes tax rates tax chargetax rate gsk substantial business presence many countries around world impact differences overseas taxation rates arose profits earned countries tax rates higher uk statutory rate significant us belgium india japan adverse impact partly offset increased benefit intellectual property incentives uk patent box belgian patent income deduction regimes regimes provide reduced rate corporate income tax profits earned qualifying patents claim incentives manner intended relevant statutory regulatory framework changes tax rates included items expense tax relief available future periods lower rates due reduction statutory tax rates uk belgium respectively impact us swiss tax reform incorporated changes tax rates category years respective values million debit million credit groups tax rate influenced reassessment open issues tax authorities various jurisdictions fair value accounting movements groups put option liabilities viiv healthcare hedges shares hindustan unilever limited received disposal horlicks consumer healthcare brands future tax charges therefore effective tax rate may affected factors acquisitions disposals restructurings location research development activity tax regime reforms resolution open matters continue bring tax affairs date around world gsk annual report notes financial statements continued taxation continued tax items charged equity statement comprehensive income current taxation sharebased payments defined benefit plans deferred taxation sharebased payments defined benefit plans fair value movements cash flow hedges fair value movements equity investments total creditcharge equity statement comprehensive income items charged statement comprehensive income except tax sharebased payments issues relating taxation integrated nature groups worldwide operations involves significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets line current oecd guidelines base transfer pricing policy arms length principle however different tax authorities may seek attribute profit activities undertaken jurisdiction potentially resulting double taxation group also open items several jurisdictions concerning matters deductibility particular expenses tax treatment certain business transactions gsk applies risk based approach determine transactions likely subject challenge assuming relevant tax authority review full knowledge relevant information probability group would able obtain compensatory adjustments international tax treaties calculation groups total tax charge therefore necessarily involves degree estimation judgement respect certain items tax treatment finally determined resolution reached relevant tax authority appropriate formal legal process december group recognised provisions million respect uncertain tax positions million decrease recognised provisions driven reassessment estimates utilisation provisions uncertain tax positions following settlement number open issues tax authorities various jurisdictions whilst ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate group continues believe made appropriate provision periods open yet agreed tax authorities provision deferred tax liabilities million december million made respect taxation would payable remittance profits certain overseas subsidiaries whilst aggregate amount unremitted profits balance sheet date approximately billion billion majority unremitted profits would subject tax including withholding tax repatriation uk legislation relating company distributions provides exemption tax overseas profits subject certain exceptions deferred tax provided temporary differences million million arising unremitted profits management ability control future reversal consider reversal probable gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued taxation continued movement deferred tax assets liabilities pensions share accelerated post option net capital intangible contingent intragroup employment tax award temporary allowances assets consideration profit benefits losses schemes differences total january exchange adjustments creditcharge income statement creditcharge statement comprehensive income equity reclassification disposal december implementation ifrs december adjusted exchange adjustments creditcharge income statement creditcharge statement comprehensive income equity acquisitions disposals rd credits utilisation december deferred tax liabilities provided relation intangible assets predominately relate temporary differences arising assets liabilities acquired part historic business combinations acquisitions disposals included deferred tax liabilities million related pfizer consumer healthcare business acquisition million related tesaro acquisition group continues recognise deferred tax assets future obligations respect contingent consideration amounts payable minority shareholders payments tax deductible point time payment made deferred tax asset recognised intragroup profits arising intercompany inventory eliminated within consolidated accounts intragroup profits eliminated individual entities tax returns temporary difference arises reverse point time inventory sold externally deferred tax asset recognised tax losses million million relates trading losses included amount deferred tax assets million relation losses recognised basis sufficient future taxable profits utilise losses forecast entities losses relate net temporary differences included accrued expenses tax deduction available paid basis pensions deferred tax asset liabilities recognised balance sheet follows deferred tax assets deferred tax liabilities deferred tax assets recognised us foreign tax credits probable future taxable profits available net amount foreign tax credits deferred tax provided million million unrecognised unrecognised deferred tax deferred tax tax losses asset tax losses asset unrecognised tax losses trading losses expiring within years years available indefinitely december capital losses expiring available indefinitely december gsk annual report notes financial statements continued earnings per share pence pence pence basic earnings per share diluted earnings per share basic earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares trustees waived rights dividends shares held esop trusts diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options awards diluted dividends dividend total dividend total dividend total per share dividend per share dividend per share dividend paidpayable pence paid pence paid pence first interim july july july second interim october october october third interim january january january fourth interim april april april total ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued property plant equipment plant land equipment assets buildings vehicles construction total cost january exchange adjustments additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december implementation ifrs december adjusted exchange adjustments additions business combinations additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december depreciation january exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december implementation ifrs december adjusted exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december impairment january exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december implementation ifrs december adjusted exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december gsk annual report notes financial statements continued property plant equipment continued weighted average interest rate capitalised borrowing costs year disposals writeoffs year included number assets nil net book value longer use business impairment losses principally arose decisions rationalise facilities calculated based either fair value less costs disposal value use fair value less costs disposal valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate specific segment country currency risk value use calculations posttax cash flows include impact future uncommitted restructuring plans improvements impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately net impairment losses charged cost sales million million rd million million sga million million included million million arising major restructuring programmes reversals impairment arose subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales million million computer software reclassified assets construction intangible assets becoming ready use right use assets land plant buildings equipment vehicles total net book value january exchange adjustments additions business combinations additions depreciation disposals impairments reclassifications net book value december total cash outflow leases amounted million significant lease commitments leases commenced yearend analysis lease liabilities set note net debt gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued goodwill cost january exchange adjustments additions business combinations note transfer fromto assets held sale cost december net book value january net book value december goodwill allocated groups segments follows pharmaceuticals vaccines consumer healthcare net book value december recoverable amounts cash generating units assessed using fair value less costs disposal model fair value less costs disposal calculated using discounted cash flow approach posttax discount rate applied projected riskadjusted posttax cash flows terminal value discount rate used based group wacc cash generating units integrated operations across large parts group discount rate adjusted appropriate specific segment country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy details relating discounted cash flow models used impairment tests pharmaceuticals vaccines consumer healthcare cash generating units follows valuation basis fair value less costs disposal key assumptions sales growth rates profit margins terminal growth rate discount rate taxation rate determination assumptions growth rates internal forecasts based internal external market information margins reflect past experience adjusted expected changes terminal growth rates based managements estimate future longterm average growth rates discount rates based group wacc adjusted appropriate taxation rates based appropriate rates region period specific projected cash flows five years terminal growth rate discount rate terminal growth rate discount rate pharmaceuticals pa vaccines pa consumer healthcare pa terminal growth rates exceed longterm projected growth rates relevant markets reflect impact future generic competition take account new product launches goodwill monitored impairment segmental level case valuations indicated sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill pharmaceuticals cash generating unit comprises collection smaller cash generating units including assets indefinite lives carrying value nil million consumer healthcare cash generating unit also comprises collection smaller cash generating units including brands indefinite lives carrying value billion billion details indefinite life brands given note intangible assets gsk annual report notes financial statements continued intangible assets licences patents computer amortised indefinite life software brands etc brands total cost january exchange adjustments capitalised development costs capitalised borrowing costs additions disposals asset writeoffs transfer assets held sale reclassifications cost december exchange adjustments capitalised development costs capitalised borrowing costs additions business combinations additions disposals asset writeoffs transfer assets held sale reclassifications cost december amortisation january exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december impairment january exchange adjustments impairment losses reversal impairments disposals asset writeoffs transfer assets held sale impairment december exchange adjustments impairment losses reversal impairments disposals asset writeoffs transfer assets held sale impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weighted average interest rate capitalised borrowing costs year net book value computer software included million million internally generated costs carrying value december intangible assets impairments charged reversed year following impairments reversals million million patent expiry dates groups significant assets relevant set pages gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development licences patents amortised brands etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development note acquisitions disposals gives details additions business combinations year book values largest individual items follows zejula meningitis portfolio dolutegravir benlysta bms merck assets fluarixflulaval stiefel trade name others meningitis portfolio includes menveo bexsero men abcwy menjugate stiefel trade name moved licences patents amortised brands etc following decision start amortisation indefinite life brands comprise portfolio consumer healthcare products primarily acquired acquisitions sterling winthrop inc block drug company inc cns inc novartis consumer healthcare business pfizer consumer healthcare business book values major brands follows advil voltaren centrum caltrate otrivin preparation h robitussin nexium fenistil chapstick emergenc theraflu panadol lamisil sensodyne breathe right stiefel trade name others gsk annual report notes financial statements continued intangible assets continued brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factors could limit useful lives accordingly amortised brand tested annually impairment amortised intangible assets tested indicators impairment arise testing applies fair value less costs disposal methodology generally using posttax cash flow forecasts terminal value calculation discount rate equal group posttax wacc adjusted appropriate specific segment country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions exchange rates assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied managements estimates future longterm average growth rates relevant markets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment intangible assets investments associates joint ventures joint joint ventures associates total ventures associates total january exchange adjustments additions disposals distributions received movements profitloss tax recognised consolidated income statement december group held one significant associate december innoviva inc december group owned million shares innoviva biopharmaceutical company listed nasdaq innoviva partnered gsk development long acting beta agonist vilanterol currently receives royalty income sales products contain component namely relvarbreo ellipta anoro ellipta also economic interest royalties paid gsk sales trelegy ellipta remaining economic interest royalties held theravance biopharma inc group holds common stock investment innoviva market value million december million summarised balance sheet information based information published post balance sheet date respect innoviva set december december noncurrent assets current assets current liabilities noncurrent liabilities net assets carrying value groups investment innoviva analysed follows interest net assets associate goodwill fair value adjustments carrying value december gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued investments investments investments designated investments designated investments measured measured measured measured fvtoci fvtpl fvtoci fvtpl january additions net fair value movements comprehensive income net fair value movements profit loss disposals settlements transfers assets held sale december investments comprise noncurrent equity investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments recent financing rounds discounted cash flows underlying net assets net fair value movements include impact exchange losses million comprehensive income million profit loss gains million million respectively investments include listed investments million million gsk elected designate majority equity investments measured fair value comprehensive income fvtoci significant investments held december andme group holds common stock progyny inc group holds theravance biopharma inc group holds lyell immunopharma inc group holds investments fair value december million million million million million million million respectively investment individually material investments include equity stakes companies gsk research collaborations companies provide access biotechnology developments potential interest disposal equity investments measured fvtoci accumulated fair value movements reclassified fair value reserve retained earnings investments fair value million million disposed year cumulative gain investments tax million million certain investments investments funds limited lives measured fair value profit loss fvtpl investments fair value million disposed year cumulative impairments investments designated measured fvtoci ifrs transferred retained earnings fair value reserve january adoption ifrs noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables amounts receivable insurance contacts held fair value profit loss within receivables million million million million classified financial assets million million classified fair value profit loss remaining balance million million expected credit loss allowance immaterial december gsk annual report notes financial statements continued inventories raw materials consumables work progress finished goods trade receivables trade receivables net loss allowance accrued income prepayments interest receivable employee loans advances receivables trade receivables included nil million due associates joint ventures receivables included nil nil due associates joint ventures loss allowance january implementation ifrs january adjusted exchange adjustments charge year subsequent recoveries amounts provided utilised december total trade receivables balance million million considered credit impaired million million expected credit loss allowance applied amount purchased originated credit impaired within receivables million million million million classified financial assets nil million classified fair value profit loss remaining balance million million expected credit loss allowance million million recognised december charge reported profit loss year discussion credit risk practices please refer note gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued cash cash equivalents cash bank hand shortterm deposits addition million million cash cash equivalents reported assets held sale see note assets held sale cash cash equivalents included billion billion available general use due restrictions applying subsidiaries held restrictions include exchange controls taxes repatriation assets held sale property plant equipment right use assets lease liabilities goodwill intangibles inventory cash cash equivalents noncurrent assets disposal groups transferred assets held sale expected carrying amounts recovered principally disposal sale considered highly probable held lower carrying amount fair value less costs sell assets held sale primarily reflect thermacare disposal group acquired pfizer part consumer healthcare business sold group meet antitrust requirements disposal group representing horlicks consumer healthcare nutritional brands sold unilever plc included within assets held sale inventory written fair value less costs sell million million valuation methodology used significant inputs based observable market data therefore valuation classified level fair value hierarchy impairment allocated goodwill million recognised reflect fair value less costs sell disposal group gsk annual report notes financial statements continued trade payables trade payables wages salaries social security viiv healthcare put option payables deferred income customer return rebate accruals accruals trade payables included million million due associates joint ventures group provides limited supplier financing arrangements certain customers amounts involved december material revenue recognised year included deferred income january million million customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers included million million respect us pharmaceuticals vaccines fully described group financial review accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual amounts paid changes arrangements future events could cause assumptions accruals based change could affect future results group pfizers put option shareholding viiv healthcare currently exercisable pfizer may request ipo viiv healthcare time either gsk consent ipo offering completed within nine months pfizer could require gsk acquire shareholding amount liability put option held gross redemption basis derived internal valuation viiv healthcare business utilising discounted forecast future cash flow multiplesbased methodologies table shows indicative basis income statement balance sheet sensitivity pfizer put option reasonably possible changes key assumptions increasedecrease financial liability lossgain income statement increase sales forecasts decrease sales forecasts cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued net debt listing exchange current assets liquid investments cash cash equivalents cash cash equivalents reported assets held sale shortterm borrowings commercial paper bank loans overdrafts drawn bank facility european medium term note london stock exchange euribor european medium term note london stock exchange european medium term note london stock exchange lease liabilities longterm borrowings euribor european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange libor us us medium term note new york stock exchange euribor european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange longterm borrowings lease liabilities net debt gsk annual report notes financial statements continued net debt continued current assets liquid investments classified financial assets amortised cost december included us treasury notes government bonds effective interest rate liquid investments december approximately approximately liquid investment balances december earning interest floating rates amount million million liquid investment balances december earning interest fixed rates amount million nil balances reported within cash cash equivalents original maturity three months less effective interest rate cash cash equivalents december approximately approximately cash cash equivalents december earning interest floating fixed rates amounted million million respectively million million noninterest bearing holdings amounted million million gsks policy regarding credit quality cash cash equivalents set note financial instruments related disclosures shortterm borrowings gsk billion billion us commercial paper programme billion billion issue december billion billion gsk billion threeyear committed facility billion billion day committed facility threeyear committed facility day committed facility agreed september undrawn december additional bank facility agreed support transactions remained active december june billion drawn support acquisition novartis remaining stake consumer healthcare joint venture billion repaid november leaving billion outstanding december weighted average interest rate commercial paper borrowings december weighted average interest rate current bank loans overdrafts december shortterm loan rates argentina disproportionate effect weighted average interest rate average effective preswap interest rate notes classified shortterm december continued decrease rate reflects maturities euribor coupon note may coupon note september longterm borrowings yearend gsk longterm borrowings billion billion billion billion fell due five years average effective preswap interest rate notes issue december approximately approximately longterm borrowings repayable five years carry interest effective rates repayment dates ranging pledged assets group held pledged investments us treasury notes par value million million million million security irrevocable letters credit issued groups behalf respect groups selfinsurance activity provisions respect selfinsurance included within provisions legal disputes discussed note provisions lease liabilities maturity analysis discounted lease liabilities recognised group balance sheet follows revised rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total lease liabilities gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service pension costs defined benefit schemes accounting purposes calculated using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years actuarial movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting saps standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line cmi projections longterm rate improvement per year males females us mortality rates calculated using rp white collar table adjusted reflect recent experience rates projected using mp allow future improvements life expectancy gsk annual report notes financial statements continued pensions postemployment benefits continued average life expectancy assumed individual age projected apply individual age follows uk us male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment physical asset allocation strategy three four uk plans adjusted returnseeking assets liabilitymatching assets returnseeking assets liabilitymatching assets buyin insurance contract purchased cover substantially obligations uk plan december value insurance contract million asset allocation us plans currently set returnseeking assets liabilitymatching assets pension plans exposed risk arises estimated market value plans assets might decline investment returns might reduce estimated value plans liabilities might increase line agreed mix returnseeking assets generate future returns liabilitymatching assets better match future pension obligations group defined overall longterm investment strategy plans investments across broad range assets main market risks within asset hedging portfolio credit risk interest rates longterm inflation equities property currency bank counterparty risk plan liabilities series future cash flows relatively long duration ias basis cash flows sensitive changes expected longterm inflation rate discount rate aa corporate bond yield curve increase longterm inflation corresponds increase liabilities increase discount rate corresponds decrease liabilities interest rate risk credit rate risk us partially hedged targets based accounting measure plan liabilities uk plans interest rate inflation hedging strategy place targets based economic measure plan liabilities furthermore plans also currently hedge portion equity exposure staggered maturity profile uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme addition group operates number postretirement healthcare schemes principal one us group applied following financial assumptions assessing defined benefit liabilities uk us rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate sensitivity analysis detailing effect changes assumptions provided analysis provided reflects assumption changes material impact results group gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest incomecost gains settlements expenses remeasurement losses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest incomecost gains settlements expenses remeasurement gainslosses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest cost expenses remeasurement gainslosses recorded statement comprehensive income amounts included within past service costs uk included million million million augmentation costs million arose major restructuring programmes see note provisions past service costs uk included charge million relation estimated impact gmp equalisation gsk annual report notes financial statements continued pensions postemployment benefits continued summarised balance sheet presentation group defined benefit pension schemes postretirement benefits set table recognised noncurrent assets pension schemes surplus recognised assets held sale postretirement benefits recognised pensions postemployment benefits pension schemes deficit postretirement benefits event plan windup gsk believes uk pension scheme rules provide company right refund surplus assets following full settlement plan liabilities result net surplus uk defined benefit pension schemes recognised full fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets multiasset funds comprise investments pooled investment vehicles invested across range asset classes increasing diversification within growth portfolio assets category comprises cash mark market values derivative positions indexlinked gilts held part uk repo programme included government bonds related loan million december nil million deducted within assets gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets uk us rest world group december equities listed unlisted multiasset funds property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits uk us rest world group group movements fair values assets assets january exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments additions business combinations interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december group made special funding contributions uk pension schemes million nil million nil million million us schemes gsk reached revised agreement trustees uk pension schemes make additional contributions eliminate pension deficits identified within schemes december actuarial funding valuation based funding agreements additional contributions eliminate pension deficit expected million payments agreed years included within note commitments funding commitment supersedes previous agreement made contributions based government bond yield curve approach selecting discount rate rate chosen included allowance expected investment returns reflected asset mix schemes employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits uk us rest world group group movements defined benefit obligations obligations january exchange adjustments service cost past service costcredit interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service costcredit interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments additions business combinations service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december defined benefit pension obligation analysed follows funded unfunded liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter december us postretirement healthcare scheme obligation million million million postretirement benefits unfunded gsk annual report notes financial statements continued pensions postemployment benefits continued movement net defined benefit liability follows january exchange adjustments additions business combinations service cost past service cost interest cost settlements curtailments remeasurements return plan assets excluding amounts included interest gain change demographic assumptions lossgain change financial assumptions experience losses employer contributions expenses december remeasurements included within postretirement benefits detailed gain change demographic assumptions lossgain change financial assumptions experience gains defined benefit pension obligation analysed membership category follows active retired deferred postretirement benefit obligation analysed membership category follows active retired deferred weighted average duration defined benefit obligation follows years years years pension benefits postretirement benefits gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued sensitivity analysis effect changes assumptions used benefit obligations annual defined benefit pension post retirement costs detailed information determined taking account duration liabilities overall profile plan memberships decrease discount rate would following approximate effect increase annual pension cost decrease annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation decrease discount rate would following approximate effect increase annual pension cost decrease annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation oneyear increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation increase rate future healthcare inflation would following approximate effect increase annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation gsk annual report notes financial statements continued provisions legal major employee restructuring related disputes programmes provisions provisions total january implementation ifrs january adjusted exchange adjustments additions business combinations charge year reversed unused unwinding discount utilised reclassifications movements transfer pension obligations december settled within one year settled one year december legal disputes group potential settlement discussions number group involved substantial number legal disputes amounts provided based disputes including notification possible claims set current assessment progress disputes note legal proceedings provisions legal estimates million amount provided disputes include amounts relating product liability antitrust december settled within one year december government investigations contract terminations self expected million million insurance provision made legal disputes reimbursed third parties discussion legal issues net charge year million including reversals see note legal proceedings estimated insurance recoveries primarily related provisions product liability cases commercial disputes major restructuring programmes various government investigations group undertaking three major restructuring programmes combined restructuring discount provisions increased million integration programme substantially complete increased million discount calculated major restructuring programme consumer using riskadjusted projected cash flows riskfree rates healthcare joint venture integration programme return programmes focused primarily simplifying supply chain respect product liability claims related certain products processes rationalising groups manufacturing network provision made sufficient history claims restructuring pharmaceuticals commercial operations made settlements enable management make reliable integrating pfizer consumer healthcare business estimate provision required cover unasserted claims provisions staff severance payments made ultimate liability matters may vary amounts management made formal decision eliminate certain provided dependent upon outcome litigation positions communicated groups proceedings investigations possible settlement employees affected appropriate consultation procedures negotiations completed appropriate provision made staff nature groups business number severance payments made immediately matters may subject negotiation litigation pension augmentations arising staff redundancies many years litigation proceedings including various million million charged appeal procedures often take many years reach resolution year transferred pension obligations provision outofcourt settlement discussions also often shown note pensions postemployment protracted indemnified disputes result provision benefits asset writedowns recognised charge corresponding receivable impairments property plant equipment note property plant equipment majority amounts provided expected utilised next two years gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued provisions continued employee related provisions employee related provisions include obligations certain given nature provisions amounts likely medical benefits disabled employees spouses settled many years us december provision benefits provisions amounted million million employee included provisions insurance provisions benefits reflect variety provisions severance costs million million number jubilee awards longservice benefits provisions including vehicle insurance regulatory matters contingent consideration liabilities consideration certain acquisitions includes amounts contingent future events development milestones sales performance group provided fair value contingent consideration follows shionogi viiv novartis healthcare vaccines total january remeasurement income statement cash payments operating cash flows cash payments investing activities december remeasurement income statement cash payments operating cash flows cash payments investing activities december remeasurement income statement cash payments operating cash flows cash payments investing activities movements december contingent consideration payable december million million expected paid within one year consideration payable acquisition shionogiviiv healthcare joint venture novartis vaccines business expected paid number years result total estimated liabilities discounted present values shown shionogiviiv healthcare contingent consideration liability discounted novartis vaccines contingent consideration liability discounted commercialised products pipeline assets shionogiviiv healthcare novartis vaccines contingent consideration liabilities calculated principally based forecast sales performance specified products lives products table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key inputs valuations contingent consideration liabilities shionogi novartis viiv healthcare vaccines increasedecrease financial liability lossgain income statement increase sales forecasts decrease sales forecasts increase discount rate decrease discount rate increase probability milestone success decrease probability milestone success cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report notes financial statements continued noncurrent liabilities accruals deferred income payables payables includes number employeerelated liabilities including employee savings plans prior year also included acquisition accounting market value lease adjustments reclassified right use asset transition ifrs contingent liabilities december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted million million december million nil financial assets pledged collateral contingent liabilities provision made outcome tax legal disputes probable group suffer outflow funds possible make reliable estimate outflow december disputes provision made possible make reliable estimate potential outflow funds might required settle disputes possibility outflow remote descriptions significant legal disputes group party set note legal proceedings commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments pensions interest loans future finance charges leases commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted increase intangible commitments mainly attributable number new rd collaborations including merck kgaa lyell immunopharma gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation payment million due payments million due table includes commitment excludes normal ongoing annual funding requirement uk approximately million group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued share capital share premium account share ordinary shares p premium number share capital issued fully paid january issued employee share schemes ordinary shares acquired esop trusts december issued employee share schemes december issued employee share schemes ordinary shares acquired esop trusts december december december number shares issuable employee share schemes number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes gsk annual report notes financial statements continued movements equity retained earnings reserves amounted million december million loss revised million loss million million million related associates joint ventures adjustment cumulative translation exchange retained earnings noncontrolling interests million made described note presentation financial statements cumulative translation exchange equity follows net translation exchange included non total retained fair value controlling translation earnings reserve interests exchange january exchange movements overseas net assets reclassification exchange liquidation disposal overseas subsidiaries december exchange movements overseas net assets december reported adjustment exchange movements overseas net assets december revised exchange movements overseas net assets reclassification exchange movements liquidation disposal overseas subsidiaries december analysis comprehensive income equity category follows non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries fair value movements cash flow hedges reclassification cash flow hedges income expense deferred tax fair value movements cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments deferred tax fair value movements equity investments remeasurement losses defined benefit plans tax remeasurement losses defined benefit plans comprehensive expenseincome year non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements cash flow hedges reclassification cash flow hedges income expense deferred tax fair value movements cash flow hedges deferred tax reversed reclassification cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments deferred tax fair value movements equity investments remeasurement gains defined benefit plans tax remeasurement gains defined benefit plans comprehensive incomeexpense year gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued movements equity continued non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments fair value movements cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement gains defined benefit plans tax remeasurement gains defined benefit plans comprehensive incomeexpense year analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total january exchange adjustments transferred income expense year disposals net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december implementation ifrs december adjusted exchange adjustments transferred retained earnings year disposal equity investments net fair value movement year writedown shares held esop trusts december exchange adjustments transferred retained earnings year disposal equity investments net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december reserves include various nondistributable merger premerger reserves amounting million december million million reserves also include capital redemption reserve created result share buyback programme amounting million december million million gsk annual report notes financial statements continued noncontrolling interests total noncontrolling interests includes following individually material noncontrolling interests noncontrolling interests individually material viiv healthcare gsk holds viiv healthcare subgroup giving rise material noncontrolling interest summarised financial information respect viiv healthcare subgroup follows turnover profit taxation comprehensive expenseincome total comprehensive income noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net liabilities net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities increasedecrease cash bank overdrafts year financial information relates viiv healthcare group standalone basis impact grouprelated adjustments primarily related recognition preferential dividends profit taxation million million million stated charging preferential dividends payable gsk shionogi pfizer charge million million million remeasurement contingent consideration payable consideration expected paid number years following amounts attributable viiv healthcare group included gsks financial statements share profit year attributable noncontrolling interest dividends paid noncontrolling interest noncontrolling interest consolidated balance sheet gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued noncontrolling interests continued consumer healthcare joint venture gsk holds consumer healthcare subgroup giving rise material noncontrollling interest summarised financial information respect consumer healthcare subgroup follows turnover profit taxation comprehensive expenses total comprehensive expenses noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities decrease cash bank overdrafts period financial information relates consumer healthcare joint venture standalone basis since formation july impact grouprelated adjustments classification cash pooling accounts group companies outside consumer healthcare joint venture major restructuring charges following amounts attributable consumer healthcare joint venture included gsks financial statements share profit period attributable noncontrolling interest noncontrolling interest consolidated balance sheet gsk annual report notes financial statements continued related party transactions december gsk owned million shares innoviva inc biopharmaceutical company listed nasdaq gsk began recognising innoviva associate september royalties due gsk innoviva year million million december balance payable gsk innoviva million million january gsk held interest japan vaccine co ltd jvc subsidiary glaxosmithkline kk joint venture daiichi sankyo co ltd primarily responsible development marketing certain prophylactic vaccines japan gsk sold million vaccine products joint venture daiichi sankyos shares jvc acquired gsk point jvc ceased related party loans million medicxi ventures lp million index ventures life vi jersey lp remained due gsk december gsk increased investment kurma biofund ii fcpr million apollo therapeutics llp million investments also made medicxi ventures lp million index ventures life vi jersey lp million part joint venture agreement qura therapeutics llc group obligation fund joint venture million per quarter april june agreement extended second fiveyear period april gsk joint venture partner committing additional financial support amount million december outstanding liability due qura million cash distributions received investments medicxi ventures lp million longwood founders fund lp million aggregate compensation directors cet given note employee costs acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given business acquisitions pfizer consumer healthcare business acquisition pfizers consumer healthcare business completed july gsk pfizer contributed respective consumer healthcare businesses new consumer healthcare joint venture noncash transaction whereby gsk acquired pfizers consumer healthcare business return shares joint venture gsk equity interest majority control joint venture pfizer equity interest group control consumer healthcare joint venture consolidated within groups financial statements number territories legal completion acquisition occurred regulatory constraints however consumer healthcare joint venture obtained control majority businesses territories july consolidated net assets businesses date cases entitled benefits trading businesses delayed territories noncontrolling interest consumer healthcare joint venture calculated applying proportionate goodwill method represents pfizers share net assets joint venture excluding goodwill goodwill billion expected deductible tax purposes recognised goodwill represents potential synergies arising combining acquired businesses gsks existing business together value workforce acquired total transaction costs recognised acquisition amounted million since acquisition july sales billion arising pfizer consumer healthcare business included group turnover business acquired beginning year estimated group turnover would approximately billion higher business integrated groups existing activities practicable identify impact group profit period tesaro inc january gsk acquired tesaro inc oncology focused biopharmaceutical company cash consideration billion billion order strengthen groups pharmaceutical pipeline transaction costs amounted million goodwill billion none expected taxdeductible recognised goodwill represents potential synergies arising combining acquired businesses gsks existing business together value workforce acquired since acquisition january sales billion arising tesaro business included group turnover business integrated groups existing activities practicable identify impact group profit period gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued acquisitions disposals continued fair value assets acquired business combinations including goodwill set table amounts related pfizer consumer healthcare business acquisition provisional subject change pfizer consumer healthcare business tesaro net assets acquired intangible assets property plant equipment right use assets inventory trade receivables assets including cash cash equivalents trade payables net deferred tax liabilities liabilities term loan noncontrolling interest goodwill total consideration settled shares gsk consumer healthcare joint venture cash consideration paid fair value investment joint venture converted subsidiary total consideration noncontrolling interest million represents pfizers share fair value pfizer consumer healthcare business excluding goodwill total noncontrolling interest initially recognised consolidated statement changes equity million also includes pfizers share book value gsk consumer healthcare business disposals gsk made number business disposals net cash consideration received year million profit disposal businesses year million calculated follows total cash consideration receivable net subsidy payable net assets sold goodwill intangible assets property plant equipment inventory cash cash equivalents net assets transaction costs reclassification exchange comprehensive income noncontrolling interest divested transaction signed yet completed gain embedded derivative transaction signed yet completed transaction costs total profit disposal transaction signed yet completed december gsk agreed divest horlicks consumer healthcare nutrition brands unilever plc form merger glaxosmithkline consumer healthcare limited hindustan unilever limited total consideration valued approximately billion glaxosmithkline consumer healthcare limited public company listed national stock exchange nse bombay stock exchange bse gsk holds stake following merger glaxosmithkline consumer healthcare limited hindustan unilever limited public company listed nse bse gsk million hindustan unilever limited shares gsk annual report notes financial statements continued acquisitions disposals continued group entered forward foreign exchange contracts relation transaction contracts value billion designated cash flow hedge part foreign exposure arising transaction contracts value billion designated net investment hedges inr eur assets addition exposure share price movements forward purchase shares hindustan unilever limited recognised embedded derivative embedded derivative asset position fair value million december million associates joint ventures year gsk made investments million associates joint ventures million paid cash cash flows associates joint business business venture acquisitions disposals investments cash consideration paidreceived net deferred consideration received transaction costs cash cash equivalents acquireddivested cash outflowinflow business acquisitions business acquisitions business disposals gsk made number small business disposals year net cash consideration million cash flows associates associates joint joint business venture venture disposals investments disposals cash consideration net deferred consideration received cash inflowoutflow business acquisitions business acquisitions business disposals gsk made number small business disposals year net cash consideration million including contingent consideration receivable million profit disposal determined follows total consideration including currency forwards purchase adjustments net assets sold goodwill intangible assets property plant equipment inventory cash cash equivalents net assets transaction costs reclassification exchange comprehensive income profit disposal gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued acquisitions disposals continued associates joint ventures year gsk made cash investments million associates joint ventures addition gsk sold holdings two associates million cash total cash consideration net book value shares reclassification exchange comprehensive income transaction costs profit disposal cash flows associates associates joint joint business venture venture disposals investments disposals cash consideration net deferred consideration received cash cash equivalents divested transaction costs paid cash inflowoutflow adjustments reconciling profit tax operating cash flows profit tax tax profits share aftertax profits associates joint ventures finance expense net finance income depreciation amortisation intangible assets impairment assets written profit sale businesses profit sale intangible assets profit sale investments associates profit sale equity investments gain novartis consumer healthcare joint venture put option hedging business acquisition costs changes working capital decreaseincrease inventories increase trade receivables increase trade payables increasedecrease receivables contingent consideration paid see note noncash increase contingent consideration liabilities increase payables decreaseincrease pension provisions sharebased incentive plans fair value adjustments cash generated operations gsk annual report notes financial statements continued reconciliation net cash flow movement net debt net debt previously reported implementation ifrs net debt beginning year adjusted increasedecrease cash bank overdrafts decrease liquid investments net increase longterm loans repayment shortterm notes increase inrepayment shortterm loans repayment lease liabilities debt subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year ifrs january implement debt profit reclass december ation exchange acquired loss ifications cash flow analysis changes net debt liquid investments cash cash equivalents cash cash equivalents ahfs overdrafts debt due within one year commercial paper europeanus medium term notes bank facilities lease liabilities debt due one year europeanus medium term notes bank facilities lease liabilities net debt analysis changes liabilities financing activities debt due within one year debt due one year hedge borrowings derivative financial instruments financing items interest payable total liabilities financing activities information significant changes net debt see note net debt gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures objective gsks treasury activity minimise additional bank facilities agreed support posttax net cost financial operations reduce volatility transactions one remains active december benefit earnings cash flows gsk uses variety june billion drawn support acquisition financial instruments finance operations derivative novartis remaining stake consumer financial instruments manage market risks healthcare joint venture billion repaid november operations derivatives principally comprise foreign exchange leaving billion outstanding december forward contracts swaps used swap december facility extended june borrowings liquid assets currencies required group gsk billion european medium term note purposes well interest rate swaps used programme december billion manage exposure financial risks changes interest notes issue programme group also rates financial instruments reduce uncertainty billion billion notes issue december foreign currency transactions interest payments us shelf registration gsks borrowings mature derivatives used exclusively hedging purposes dates relation underlying business activities trading put option owned pfizer viiv healthcare speculative instruments exercisable reviewing liquidity requirements gsk considers capital management sufficient financing options available put gsks financial strategy supports groups strategic option exercised priorities regularly reviewed board gsk manages market risk capital structure group appropriate mix interest rate risk management debt equity objective gsks treasury activity minimise capital structure group consists net debt effective net interest cost balance mix debt fixed billion see note net debt total equity floating rates time including items related noncontrolling interests groups main interest rate risk arises borrowings billion see consolidated statement changes investments floating rates refinancing maturing fixed equity total capital including provided rate debt changes interest rates affect future noncontrolling interests billion cash flows fair values financial instruments policy group continues manage financial policies credit interest rate risk management limits net amount profile particularly targets shortterm credit ratings floating rate debt specific cap reviewed agreed p maintaining single longterm ratings consistent less annually board targets groups longterm credit rating majority debt issued fixed interest rates standard poors negative outlook moodys changes floating rates interest significantly investor services moodys negative outlook affect groups net interest charge includes groups shortterm credit ratings p borrowings interest rate swaps place standard poors moodys respectively removes impact associated periodic repricing liquidity risk management shortterm borrowings including bank facilities exposed gsks policy borrow centrally order meet anticipated risk future changes market interest rate funding requirements strategy diversify liquidity majority cash liquid investments sources using range facilities maintain broad access financial markets interest rate benchmark reform interest rate benchmark reform amendments ifrs december gsk billion borrowings ias ifrs issued iasb september repayable within one year held billion cash amendments modify specific hedge accounting cash equivalents liquid investments billion requirements allow hedge accounting continue held centrally gsk access shortterm finance affected hedges period uncertainty billion billion us commercial paper programme hedged items hedging instruments affected current billion billion issue december interest rate benchmarks amended result billion billion gsk billion ongoing interest rate benchmark reforms threeyear committed facility billion billion day committed facility threeyear committed december group directly exposed facility day committed facility agreed interest rate benchmark reform held interest rate september facilities undrawn derivatives referenced libor matured end december gsk considers level committed floating rate bonds due mature facilities adequate given current liquidity requirements end gsk annual report notes financial statements continued financial instruments related disclosures continued group closely monitored market output group considers maximum credit risk december various industry working groups managing million december transition new benchmark interest rates includes million total groups financial assets announcements made libor regulators including exception investments comprising equity financial conduct authority fca us commodity investments bear equity risk rather credit risk futures trading commission regarding transition away see details groups total financial assets libor including gbp libor usd libor december gsks greatest concentration euribor sterling overnight index average rate credit risk billion legal general investment sonia secured overnight financing rate sofr management class gbp liquidity fund aaaaaa euro shortterm rate str respectively fca billion citibank aa made clear end longer change estimation techniques seek persuade compel banks submit libor significant assumptions made current reporting group undertaking interest rate benchmark transition period assessing loss allowance financial assets programme identify potential exposures within business amortised cost since adoption ifrs start deliver smooth transition appropriate alternative reporting period benchmark rates treasuryrelated credit risk foreign exchange risk management gsk sets global counterparty limits gsks banking groups objective minimise exposure overseas investment counterparties based longterm credit operating subsidiaries transaction risk matching local ratings moodys standard poors usage currency income local currency costs possible limits monitored daily foreign currency transaction exposures arising external gsk actively manages exposure credit risk reducing internal trade flows selectively hedged gsks internal surplus cash balances wherever possible part gsks trading transactions matched centrally intercompany strategy regionalise cash management concentrate payment terms managed reduce foreign currency risk cash centrally much possible table sets possible gsk manages cash surpluses credit exposure counterparties rating liquid borrowing requirements subsidiary companies centrally investments cash cash equivalents derivatives using forward contracts hedge future repayments back originating currency gross asset position derivative contract considered purpose table although isda order reduce foreign currency translation exposure agreements amount risk net position group seeks denominate borrowings currencies counterparty table e sets groups principal assets cash flows primarily financial assets liabilities offset basis denominated us dollars euros sterling borrowings swapped currencies required december million cash categorised held unrated subinvestment grade rated counterparties borrowings denominated swapped foreign lower bbbbaa million cash transit currencies match investments overseas group assets remaining exposure concentrated overseas banks used may treated hedge relevant assets forward local cash management investment purposes including contracts major currencies also used reduce exposure million nigeria held united bank africa zenith groups investment overseas assets see net bank stanbic ibtc bank million btv austria investment hedges section note details million bradesco brazil million banco de credit risk la nacion panama million halk bank uk credit risk risk counterparty default million bank balances deposits held contractual obligations resulting financial loss group bbbbaa rated counterparties million held arises cash cash equivalents favourable bbbbaa rated counterparties including balances derivative financial instruments held banks financial deposits million hdfc bank india institutions well credit exposures wholesale retail million state bank india banks used customers including outstanding receivables local investment purposes gsk measures expected credit losses cash cash equivalents function individual counterparty credit ratings associated month default rates expected credit losses cash cash equivalents thirdparty financial derivatives deemed immaterial loss experienced gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued credit ratings assigned standard poors moodys respectively opinions two rating agencies differ gsk assigns lower rating two counterparty local rating agency fitch data source available ratings converted global ratings equivalent standard poors moodys using published conversion tables credit ratings form basis assessment expected credit loss treasury related balances held amortised cost bank balances deposits government securities bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities rd party financial derivatives total bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities rd party financial derivatives total gsks centrally managed cash reserves amounted new customers subject credit vetting process billion december available within three existing customers subject review least annually months includes billion cash managed vetting process subsequent reviews involve obtaining group viiv healthcare owned subsidiary information including customers status government billion cash managed group gsk consumer private sector entity audited financial statements credit bureau healthcare owned subsidiary group invested reports debt rating agency eg moodys standard poors centrally managed liquid assets bank deposits aaaaaa reports payment performance history trade references rated us treasury treasury repo money market funds industry credit groups bank references aaaaaa rated liquidity funds trade receivables consist amounts due large number wholesale retail credit risk customers spread across diverse industries outside us customer accounts geographical areas ongoing credit evaluation performed groups trade receivables balance financial condition accounts receivable appropriate credit insurance purchased factoring us line pharmaceutical companies arrangements put place group sells products small number wholesalers addition hospitals pharmacies physicians amount information obtained proportional level groups sales three largest wholesalers amounted exposure considered information evaluated approximately sales us pharmaceuticals quantitatively ie credit score qualitatively ie judgement vaccines businesses december conjunction customers credit requirements group trade receivables due three wholesalers determine credit limit totalling million million group trade receivables grouped customer segments exposed concentration credit risk respect similar loss patterns assess credit risk wholesalers one encounters receivables financial assets assessed individually financial difficulty could materially adversely affect historical forwardlooking information considered groups financial results determine appropriate expected credit loss allowance groups credit risk monitoring activities relating group believes credit risk provision wholesalers include review quarterly financial required excess allowance expected credit losses information standard poors credit ratings development see note trade receivables gsk internal risk ratings establishment periodic review credit limits gsk annual report notes financial statements continued financial instruments related disclosures continued credit enhancements following methods assumptions used estimate group uses credit enhancements including factoring fair values significant financial instruments credit insurance minimise credit risk trade measured fair value balance sheet receivables group december million receivables payables including put options million gsk trade receivables insured approximates carrying amount protecting gsks trade receivables balance loss due credit risks default insolvency bankruptcy liquid investments approximates carrying amount group entity assesses credit risk private cash cash equivalents approximates carrying customers determine credit insurance required amount factoring arrangements managed locally entities longterm loans based quoted market prices level used mitigate risk arising large credit risk fair value measurement case european us concentrations factoring arrangements nonrecourse medium term notes approximates carrying amount case fixed rate borrowings floating rate bank fair value financial assets liabilities loans table presents carrying amounts fair values groups financial assets liabilities shortterm loans overdrafts commercial paper december december approximates carrying amount short maturity instruments fair values financial assets liabilities included price would received sell asset paid lease liabilities approximates carrying amount transfer liability orderly transaction market participants measurement date following methods assumptions used measure fair values significant financial instruments carried fair value balance sheet investments equity investments traded active market determined reference relevant stock exchange quoted bid price equity investments determined reference current market value similar instruments recent financing rounds discounted cash flows underlying net assets trade receivables based invoiced amount interest rate swaps foreign exchange forward contracts swaps options based present value contractual cash flows option valuation models using market sourced data exchange rates interest rates balance sheet date companyowned life insurance policies based cash surrender value cash cash equivalents based net asset value funds contingent consideration business acquisitions divestments based present values expected future cash flows gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued carrying fair carrying fair value value value value notes financial assets measured amortised cost noncurrent assets b trade receivables b liquid investments cash cash equivalents items assets held sale b financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables ab financial assets mandatorily measured fair value profit loss fvtpl investments noncurrent assets ab trade receivables ab held trading derivatives designated effective hedging relationship ade cash cash equivalents derivatives designated effective hedging instruments fair value movements comprehensive income ade total financial assets financial liabilities measured amortised cost borrowings excluding obligations lease liabilities bonds designated hedging relationship bonds bank loans overdrafts commercial paper borrowings total borrowings excluding lease liabilities f lease liabilities total borrowings trade payables c provisions c noncurrent liabilities c items assets held sale c financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities ac held trading derivatives designated effective hedging relationship ade derivatives designated effective hedging instruments fair value movements comprehensive income ade total financial liabilities net financial assets financial liabilities valuation methodology used measure fair value table described categorised trade receivables noncurrent assets trade payables provisions noncurrent liabilities contingent consideration liabilities items assets held sale reconciled relevant notes pages cash cash equivalents table include million reported assets held sale see note assets held sale gsk annual report notes financial statements continued financial instruments related disclosures continued fair value investments gsk shares december employee share ownership plan esop trusts held gsk shares carrying value million million market value million million based quoted market price shares held esop trusts satisfy future exercises options awards employee incentive schemes carrying value lower cost expected proceeds shares recognised deduction reserves december gsk held treasury shares cost million million deducted retained earnings financial instruments held fair value following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level investments classified level tables comprise equity investments unlisted entities group entered research collaborations also investments emerging life science companies level level level total december financial assets fair value financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables financial assets mandatorily measured fair value profit loss fvtpl investments noncurrent assets trade receivables held trading derivatives designated effective hedging relationship cash cash equivalents derivatives designated effective hedging instruments fair value movements oci financial liabilities fair value financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities held trading derivatives designated effective hedging relationship derivatives designated effective hedging instruments fair value movements oci level level level total december financial assets fair value financial assets fair value comprehensive income fvtoci investments designated fvtoci trade receivables financial assets mandatorily measured fair value profit loss fvtpl investments noncurrent assets trade receivables held trading derivatives designated effective hedging relationship cash cash equivalents derivatives designated effective hedging instruments fair value movements oci financial liabilities fair value financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities held trading derivatives designated effective hedging relationship derivatives designated effective hedging instruments fair value movements oci gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued movements year financial instruments measured using level valuation methods presented january net losses recognised income statement net gains recognised comprehensive income settlement contingent consideration liabilities settlement contingent consideration receivables additions disposals settlements transfers level movements december net losses million million attributable level financial instruments recognised income statement included net losses million million respect financial instruments held end year losses million million reported operating income gains million nil reported finance income charges million million arose remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture million million arose remeasurement contingent consideration payable acquisition novartis vaccines business net gains million million attributable level financial instruments reported comprehensive income fair value movements equity investments included net gains million net gains million respect financial instruments held end year net gains million net gains million arose prior transfer level equity investments transferred level valuation methodology result listing recognised stock exchange year net gains losses include impact exchange movements financial liabilities measured using level valuation methods december included million million respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years vary line future performance specified products movements certain foreign currencies also included million million respect contingent consideration acquisition novartis vaccines business consideration expected paid number years vary line future performance specified products achievement certain milestone targets movements certain foreign currencies sensitivity analysis balances provided note contingent consideration liabilities b trade receivables noncurrent assets items assets held sale scope ifrs following table reconciles financial instruments within trade receivables noncurrent assets items assets held sale fall within scope ifrs relevant balance sheet amounts financial assets predominantly noninterest earning financial instruments within noncurrent assets balance include companyowned life insurance policies nonfinancial instruments include tax receivables pension surplus balances prepayments outside scope ifrs non non amortised financial financial amortised financial financial fvtpl fvtoci cost instruments instruments total fvtpl fvtoci cost instruments instruments total trade receivables note noncurrent assets note items assets held sale note gsk annual report notes financial statements continued financial instruments related disclosures continued c trade payables provisions noncurrent liabilities contingent consideration liabilities items assets held sale scope ifrs following table reconciles financial instruments within trade payables provisions noncurrent liabilities contingent consideration liabilities items assets held sale fall within scope ifrs relevant balance sheet amounts financial liabilities predominantly noninterest bearing accrued wages salaries included within financial liabilities nonfinancial instruments include payments account tax social security payables provisions arise contractual obligations deliver cash another financial asset outside scope ifrs non non amortised financial financial amortised financial financial fvtpl cost instruments instruments total fvtpl cost instruments instruments total trade payables note provisions note noncurrent liabilities note contingent consideration liabilities note items assets held sale note derivative financial instruments hedging programmes derivatives used economic hedging purposes speculative investments classified held trading designated effective hedging instruments presented current assets liabilities expected settled within months end reporting period otherwise classified noncurrent group following derivative financial instruments fair value fair value assets liabilities assets liabilities noncurrent cash flow hedges interest rate swap contracts principal amount million million net investment hedges cross currency swaps principal amount million million current cash flow hedges interest rate swap contracts principal amount million nil cash flow hedges foreign exchange contracts principal amount million million net investment hedges foreign exchange contracts principal amount million million derivatives designated effective hedging instruments noncurrent embedded derivatives current foreign exchange contracts principal amount million million embedded derivatives derivatives classified held trading total derivative instruments fair value hedges december group designated fair value hedges gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued net investment hedges december certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment european euro singaporean sgd indian inr japanese jpy foreign operations shown table carrying value bonds included million million designated hedging instruments net investment hedges cash flow hedges group entered forward foreign exchange contracts designated cash flow hedges entered hedge foreign exchange exposure arising cash flows euro denominated coupon payments relating notes issued groups european medium term note programme buyout novartis noncontrolling interest consumer healthcare joint venture planned divestment horlicks nutrition brands refinancing existing debt maturities group manages cash flow interest rate risk using floatingtofixed interest rate swaps addition group carries balance reserves arose prehedging fluctuations longterm interest rates pricing bonds issued prior years current year balance reclassified finance costs life bonds foreign exchange risk current year group designated certain foreign exchange forward contracts swaps cash flow net investment hedges foreign exchange derivative financial assets liabilities presented line derivative financial instruments either assets liabilities consolidated balance sheet following tables detail foreign exchange forward contracts swaps outstanding end reporting period well information related hedged items notional value foreign exchange forward contracts swaps absolute total outstanding positions balance sheet date hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessments ensure economic relationship exists hedged item hedging instrument group enters hedge relationships critical terms hedging instrument match exactly terms hedged item qualitative assessment effectiveness performed changes circumstances affect terms hedged item critical terms longer match exactly critical terms hedging instrument group uses hypothetical derivative method assess effectiveness main source hedge ineffectiveness hedging relationships effect counterparty groups credit risk fair value foreign exchange forward contracts swaps reflected fair value hedged item attributable changes foreign exchange rates ineffectiveness rolling cash flow hedges divestments mentioned sources ineffectiveness emerged hedging relationships ineffectiveness recorded cash flow hedges amounted million nil ineffectiveness recorded net investment hedges nil included table borrowings bonds notional value us billion swapped fixed interest rate eur debt cross currency interest rate swap notional carrying average foreign value value hedging instruments exchange rate currency cash flow hedges foreign exchange contracts buy foreign currency months eur months eur sell foreign currency less months inrgbp less months inrsgd gsk annual report notes financial statements continued financial instruments related disclosures continued notional carrying average foreign value value hedging instruments exchange rate currency net investment hedges foreign exchange contracts sell foreign currency less months eur less months sgd less months inr less months jpy borrowings including cross currency interest rate swaps months eur months eur cumulative balance cash periodic change value flow hedge reserveforeign calculating hedge currency translation reserve ineffectiveness continuing hedges hedged items cash flow hedges variability cash flows highly probable forecast transaction variability cash flows foreign exchange exposure arising euro denominated coupon payments relating debt issued net investment hedges net investment foreign operations balances cash flow hedge reserve arising hedging relationships hedge accounting longer applied average foreign notional carrying exchange rate currency value value hedging instruments cash flow hedges foreign exchange contracts buy foreign currency months eur sell foreign currency months inr net investment hedges foreign exchange contracts sell foreign currency less months eur months eur borrowings including cross currency interest rate swaps months eur gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued cumulative balance cash periodic change value flow hedge reserveforeign calculating hedge currency translation reserve ineffectiveness continuing hedges hedged items cash flow hedges variability cash flows highly probable forecast transaction variability cash flows foreign exchange exposure arising euro denominated coupon payments relating debt issued net investment hedges net investment european foreign operations balances cash flow hedge reserve arising hedging relationships hedge accounting longer applied following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss line item hedged amount profit future cash line item hedging hedge loss flows gainslosses ineffectiveness hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows highly probable forecast transaction operating operating income income expense expense variability cash flows foreign exchange exposure arising finance finance euro denominated coupon payments relating debt issued income income expense expense net investment hedges net investment foreign operations finance finance income income expense expense following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss line item hedged amount profit future cash line item hedging hedge loss flows gainslosses ineffectiveness hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows highly probable forecast transaction operating operating income income expense expense variability cash flows foreign exchange exposure arising finance finance euro denominated coupon payments relating debt issued income income expense expense net investment hedges net investment european foreign operations finance finance income income expense expense gsk annual report notes financial statements continued financial instruments related disclosures continued interest rate risk group manages cash flow interest rate risk using floatingtofixed interest rate swaps quarterly intervals difference fixed contract rates floating rate interest amounts calculated reference agreed notional principal amounts exchanged interest rate swap contracts exchanging floating rate interest fixed interest designated cash flow hedges hedge variability interest cash flows associated floating rate debt relating notes issued groups european medium term note programme interest rate swaps interest payments loan occur simultaneously amount accumulated equity reclassified profit loss period floating rate interest payments affect profit loss critical terms interest rate swap contracts corresponding hedged items qualitative assessment effectiveness performed expected value interest rate swap contracts value corresponding hedged items systematically change opposite directions response movements underlying interest rates main sources ineffectiveness hedge relationships effects groups credit risk fair value interest rate swap contracts reflected fair value hedged item attributable change interest rates sources ineffectiveness emerged hedging relationships following tables provide information regarding interest rate swap contracts outstanding related hedged items december december interest rate swap contract assets liabilities presented line derivative financial instruments either assets liabilities consolidated balance sheet change fair value average notional recognising fair value contracted fixed principal hedge assets rate value ineffectiveness liabilities hedging instruments less year years change value balance cash used flow hedge calculating reserve hedge continuing ineffectiveness hedges hedged items variable rate borrowings change fair value average notional recognising fair value contracted fixed principal hedge assets rate value ineffectiveness liabilities hedging instruments years years change value balance cash used flow hedge calculating reserve hedge continuing ineffectiveness hedges hedged items variable rate borrowings gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss line item hedged amount profit future cash line item hedging hedge loss flows gainslosses ineffectiveness hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows finance finance income income expense expense prehedging longterm interest rates finance finance income income expense expense amount reclassified profit loss line item hedged amount profit future cash line item hedging hedge loss flows gainslosses ineffectiveness hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows finance finance income income expense expense prehedging longterm interest rates finance finance income income expense expense e offsetting financial assets liabilities financial assets liabilities offset net amount reported balance sheet legally enforceable right offset recognised amounts intention settle net basis realise asset settle liability simultaneously also arrangements meet criteria offsetting still allow related amounts offset certain circumstances bankruptcy termination contract following tables set financial assets liabilities offset subject enforceable master netting arrangements similar agreements offset december december column net amount shows impact groups balance sheet offset rights exercised gross financial financial liabilities net financial related assets assets assets amounts net liabilities offset liabilities offset amount december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments gsk annual report notes financial statements continued financial instruments related disclosures continued gross financial financial liabilities net financial related assets assets assets amounts net liabilities offset liabilities offset balance december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments amounts meet criteria offsetting balance sheet could settled net certain circumstances principally relate derivative transactions isda international swaps derivatives association agreements party option settle amounts net basis event default party presently legally enforceable right offset amounts offset balance sheet presented separately table f debt interest rate repricing table following table sets exposure group interest rates debt including commercial paper maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings lease liabilities total debt total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest total interest bearing noninterest bearing gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued g sensitivity analysis tables illustrate estimated impact income statement equity result hypothetical market movements foreign exchange interest rates relation groups financial instruments range variables chosen sensitivity analysis reflects managements view changes reasonably possible oneyear period foreign exchange sensitivity group operates internationally primarily exposed foreign exchange risk relation sterling movements us dollar euro japanese yen foreign exchange risk arises translation financial assets liabilities functional currency entity holds based groups net financial assets liabilities december weakening strengthening sterling currencies variables held constant illustrated tables tables exclude financial instruments expose group foreign exchange risk risk fully hedged another financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent depreciation us dollar cent depreciation euro yen depreciation yen equity impact shown foreign exchange sensitivity relates derivative nonderivative financial instruments hedging groups net investments european euro foreign operations cash flow hedges foreign exchange exposure arising euro denominated coupon payments relating notes issued groups european medium term note programme increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent appreciation euro increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent depreciation euro gsk annual report notes financial statements continued financial instruments related disclosures continued tables present groups sensitivity weakening strengthening sterling relevant currency based composition net debt shown note adjusted effects foreign exchange derivatives part net debt affect future foreign currency cash flows increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent appreciation us dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent depreciation us dollar cent depreciation euro yen depreciation yen interest rate sensitivity group exposed interest rate risk outstanding borrowings investments changes interest rates affect future cash flows fair values financial instruments majority debt issued fixed interest rates changes floating rates interest significantly affect groups net interest charge although majority cash liquid investments earn floating rates interest table hypothetically shows groups sensitivity changes interest rates relation sterling us dollar euro floating rate financial assets liabilities interest rates applicable floating rate financial assets liabilities increased basis points assuming variables remained constant estimated groups finance income would decreased approximately million million decrease basis points movement interest rates deemed material effect equity increasedecrease increasedecrease income income income statement impact interest rate movements basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase euro interest rates gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued h contractual cash flows nonderivative financial liabilities derivative instruments following tables provide analysis anticipated contractual cash flows including interest payable groups non derivative financial liabilities undiscounted basis purpose table debt defined classes borrowings except lease liabilities interest calculated based debt held december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates december finance trade payables charge interest lease lease liabilities debt debt liabilities liabilities net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows contractual cash flows respect operating lease vacant space provisions december excluded table finance charge trade payables obligations obligations interest finance finance liabilities debt debt leases leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows anticipated contractual cash flows repayment debt debt interest increased billion year primarily due funding acquisition tesaro table provides analysis anticipated contractual cash flows groups derivative instruments excluding equity options give rise cash flows embedded derivatives material using undiscounted cash flows cash flows foreign currencies translated using spot rates december gross cash flows foreign exchange contracts presented purpose table although practice group uses standard settlement arrangements reduce liquidity requirements instruments cash flows interest rate swaps shown table significant gross cash inflows gross cash ouflows gross cash inflows gross cash outflows foreign foreign foreign foreign cross exchange cross exchange cross exchange cross exchange currency forward currency forward currency forward currency forward interest rate contracts interest rate contracts interest rate contracts interest rate contracts swaps swaps swaps swaps swaps swaps swaps swaps due less one year one two years two three years gross contractual cash flows amounts gross cash inflows outflows foreign exchange forward contracts swaps less one year increased compared december predominantly increased levels net investment hedging hedging increased levels external internal commercial paper balances gsk annual report notes financial statements continued employee share schemes gsk operates several employee share schemes including share value plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost three year vesting period performance share plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost subject achievement group specified performance targets granting restricted share awards replaced granting options employees cost schemes readily equates potential gain made employee group also operates savings related share option schemes whereby options granted employees acquire shares glaxosmithkline plc discounted price grants restricted share awards normally exercisable end threeyear vesting performance period awards normally granted employees acquire shares ads glaxosmithkline plc circumstances may settled cash grants savingsrelated share option schemes normally exercisable three years saving accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant options historical share option schemes granted market price ruling date grant total charge sharebased incentive plans million million million amount million million million arose share value plan see note employee costs details glaxosmithkline share award schemes share value plan share value plan share awards granted certain employees cost awards vest two half three years performance criteria attached fair value awards determined based closing share price day grant deducting expected future dividend yield duration award shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december performance share plan performance share plan share awards granted directors senior executives cost percentage award vests based upon performance group defined measurement period dividends reinvested period awards granted performance conditions based three equally weighted measures threeyear performance period adjusted free cash flow tsr rd new product performance fair value awards determined based closing share price day grant tsr performance elements adjusted likelihood condition met assessed time grant awards made million shares weighted fair value million ads weighted fair value december outstanding awards million shares million ads gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued employee share schemes continued share options savingsrelated options purposes valuing savingsrelated options arrive sharebased payment charge blackscholes option pricing model used assumptions used model follows grant grant grant riskfree interest rate dividend yield volatility expected life years years years savingsrelated options grant price including discount share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes weighted weighted weighted number exercise number exercise number exercise price price price december range exercise prices options outstanding year end weighted average market price exercise year weighted average remaining contractual life years years years options million shares granted year savingsrelated share option scheme weighted average fair value december million savingsrelated share options exercisable share options ads options currently exercisable expire exercised july change effective exercise price outstanding options year employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares finance provided group way loans contributions costs running esop trusts charged income statement shares held esop trusts deducted reserves amortised value proceeds receivable employees exercise transfer retained earnings trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report notes financial statements continued principal group companies following represent principal subsidiaries countries incorporation group december equity share capital entities wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated england us glaxo group limited block drug company inc glaxo operations uk limited corixa corporation glaxosmithkline capital plc glaxosmithkline capital inc glaxosmithkline consumer healthcare holdings limited glaxosmithkline consumer healthcare holdings us llc glaxosmithkline consumer healthcare uk trading limited glaxosmithkline consumer healthcare lp glaxosmithkline export limited glaxosmithkline holdings americas inc glaxosmithkline finance plc glaxosmithkline llc glaxosmithkline holdings limited human genome sciences inc glaxosmithkline research development limited gsk consumer health inc glaxosmithkline services unlimited pf consumer healthcare llc glaxosmithkline uk limited sr one limited setfirst limited stiefel laboratories inc smithkline beecham limited tesaro inc viiv healthcare finance limited viiv healthcare company viiv healthcare limited viiv healthcare uk limited europe others glaxosmithkline pharmaceuticals sa belgium glaxosmithkline australia pty ltd australia glaxosmithkline sante grand public sas france glaxosmithkline consumer healthcare australia pty ltd australia laboratoire glaxosmithkline france glaxosmithkline brasil limitada brazil viiv healthcare sas france glaxosmithkline consumer healthcare inc canada glaxosmithkline consumer healthcare gmbh co kg germany glaxosmithkline inc canada glaxosmithkline gmbh co kg germany id biomedical corporation quebec canada gsk vaccines gmbh germany pf consumer healthcare canada ulcpf soins de sante sri canada glaxosmithkline consumer healthcare spa italy glaxosmithkline limited china hong kong glaxosmithkline spa italy sinoamerican tianjin smith kline french laboratories ltd china gsk vaccines srl italy wyeth pharmaceutical co ltd china pfizer consumer manufacturing italy srl italy glaxosmithkline asia pvt limited india gsk services sp z oo poland glaxosmithkline consumer healthcare limited india glaxosmithkline trading services limited republic ireland glaxosmithkline pharmaceuticals limited india glaxosmithkline healthcare ao russia glaxosmithkline consumer healthcare japan kk japan glaxosmithkline sa spain glaxosmithkline kk japan laboratorios viiv healthcare sl spain viiv healthcare kabushiki kaisha japan gsk consumer healthcare sa switzerland glaxosmithkline pakistan limited pakistan glaxo wellcome manufacturing pte ltd singapore glaxosmithkline korea limited republic korea glaxosmithkline llaclari sanayi ticaret turkey e xempt provisions section companies act ireland accordance exemptions noted section act subsidiaries disclosed pages exempt provisions also consolidated group financial statements directly held whollyowned subsidiary glaxosmithkline plc subsidiaries associates listed principally affect figures groups financial statements glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc see pages complete list subsidiary undertakings associates joint ventures form part financial statements gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued legal proceedings group involved significant legal administrative intellectual property proceedings principally product liability intellectual property intellectual property claims include challenges validity tax antitrust consumer fraud governmental investigations enforceability groups patents various products significant matters tax matters processes well assertions noninfringement described group makes provision patents loss cases could result loss patent proceedings regular basis summarised note protection product issue consequences accounting principles policies note loss could significant decrease sales product provisions could materially affect future results operations group group may become involved significant legal proceedings dolutegravirtivicaytriumeqdovatojuluca respect possible make reliable estimate september october viiv healthcare received patent expected financial effect could result challenge letters hatchwaxman act cipla ultimate resolution proceedings cases dr reddys labs apotex triumeq tivicay letters appropriate disclosures cases would included lupin mylan triumeq letter sandoz note provision would made cases tivicay viiv healthcare lists two patents fda orange book tivicay triumeq one patent covers molecule respect legal proceedings described dolutegravir expires october second patent provision made claims crystal form dolutegravir expires december group unable make reliable estimate expected letters challenged laterexpiring crystal financial effect stage group believe form patent several generic companies allege information amount sought plaintiffs crystal form patent invalid others claim crystal known would meaningful respect legal form patent invalid infringed proposed proceedings due number factors including products viiv healthcare filed patent infringement limited stage proceedings entitlement suits six generic companies case mylan parties appeal decision clarity theories liability proceeding northern district west virginia damages governing law set trial september cases legal expenses incurred provisions related legal claims defendants proceeding us district court charged selling general administration costs provisions district delaware court yet set trial date made taking appropriate legal specialist matters advice outflow resources considered probable september viiv healthcare received paragraph iv reliable estimate made likely outcome letter cipla relating dovato challenging dispute certain product liability claims group make crystal form patent november viiv healthcare provision sufficient history claims made filed suit cipla us district court district settlements enable management make reliable estimate delaware provision required cover unasserted claims december groups aggregate provision legal january viiv healthcare received paragraph iv letter disputes including tax matters described note lupin relating juluca challenging crystal form taxation million ultimate liability legal patent well patent relating combination claims may vary amounts provided dependent dolutegravir rilpivirine expires january upon outcome litigation proceedings investigations february viiv healthcare filed suit lupin possible settlement negotiations patents groups position could change time therefore february viiv healthcare filed patent infringement assurance losses result litigation gilead sciences inc gilead bictegravir outcome legal proceedings exceed material us district court district delaware us patent amount amount provisions reported groups canadian federal court canadian financial statements happen could patent viiv healthcare alleged gileads material adverse impact results operations triple combination hiv drug containing hiv integrase group reporting period judgements inhibitor bictegravir infringes viiv healthcares patent covering incurred settlements entered dolutegravir compounds include dolutegravirs unique chemical scaffold us canada viiv healthcare seeking financial redress rather injunctive relief gsk annual report notes financial statements continued legal proceedings continued july gilead filed motion judgement seroxatpaxil paxil cr pleadings us case arguing matter law group received numerous lawsuits claims alleging bictegravir compound infringe viiv healthcares use paxil paroxetine caused variety injuries patent february court denied gileads motion lawsuits contain one following us case gilead set trial september allegations use paxil pregnancy caused canadian matter fourday summary trial congenital malformations persistent pulmonary hypertension issue infringement held january autism ii paxil treatment caused patients commit decision canadian court expected end suicidal violent acts iii group failed warn march november viiv healthcare patients could experience certain symptoms commenced actions uk france germany japan discontinuing paxil treatment korea australia gilead alleging gileads pregnancy biktarvy infringes certain viiv healthcares hiv integrase group reached agreements settle majority inhibitor patents us claims relating use paxil pregnancy kivexa january eleven lawsuits related use june biogaran commenced proceedings france pregnancy still pending various courts us seeking revocation french spc covering kivexa singh action alberta canada seeks certify national trial date set action class action relating birth defects generally court heard q viiv healthcare commenced proceedings argument january plaintiffs class certification sandoz switzerland sandoz countered challenging motion yet ruled validity patent relating kivexa matter settled another canadian class action jensen alleging claims paxil q ssri use autism filed saskatchewan product liability january however activity case group currently defendant number product since filing liability lawsuits related groups pharmaceuticals acts violence vaccines consumer healthcare products group january six pending claims cases able make reliable estimate expected concerning allegations patients took paroxetine financial effect matters discussed category paxil committed attempted commit suicide acts included provision appropriate matters violence five claims cases us one case provision legal disputes matters canada one us cases dolin involving suicide group made provision also noted note man allegedly took generic paroxetine manufactured provisions mylan resulted million verdict plaintiff however avandia august us court appeals seventh january three remaining us avandia circuit reversed jury verdict found favour cases two class actions brought thirdparty payers group us supreme court denied plaintiffs certiorari asserting claims racketeer influenced corrupt request review case thereafter however plaintiff organizations act rico state consumer protection laws filed motion federal district court asking reinstate december third circuit court appeals reversed jury verdict light us supreme courts preemption summary judgements granted favour group decision merck v albrecht district court denied remanded thirdparty payer cases back district court plaintiffs motion july plaintiff appealed third case santa clara county california action decision seventh circuit oral argument heard parties reached agreement settle remaining january ruling court appeals claims pending remaining us cases involving claims violence largely dormant additionally class action settlement canada approved avandia class actions canada one pending canadian action carmichael group either discontinued dismissed filed motion summary judgement based statute limitations denied group appealed ruling oral argument took place december ruling yet issued gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued legal proceedings continued discontinuation manufacturers ppis also named codefendants uk longpending group action alleges seroxat mdl group filed motions dismiss several caused severe discontinuation symptoms legal hundred cases mdl court yet ruled services commission lsc withdrew public funding motions first ppi bellwether trial set november hundreds claimants causing termination claims zantac legal aid agency formerly lsc discharged group contacted several regulatory authorities public funding certificate following recommendation regarding detection genotoxic nitrosamine ndma special cases review panel cases poor zantac ranitidine products based information received prospects success date correspondence regulators group made however recently fortitude law engaged decision september suspend release purpose resurrecting seroxat group action obtained distribution supply dose forms zantac markets thirdparty funding experts remaining pending outcome ongoing tests investigations claimants group asked court require thirdparty also precautionary action group made decision funder provide security litigation costs event early october initiate voluntary pharmacyretail level plaintiffs lose recall zantac products globally ranitidine subject regulatory scrutiny group continuing december high court ruled favour investigations potential source ndma first group application order claimants litigation zantac personal injury claim filed october funder give security costs sum excess total gsk several pharmaceutical companies funding committed case trial action us federal court eastern district california followed commenced april judge dismissed cases additional filings february multidistrict grounds allegations insufficient prove litigation mdl proceeding hear zantac cases plaintiffs claims cases far advanced established southern district florida allow plaintiffs reframe plaintiffs appeal heard late october november court zofran appeal held favour gsk dismissing appeal plaintiffs allege children suffered birth defects unanimously january supreme court issued result mothers ingestion zofran andor generic order denying plaintiffs request appeal court ondansetron pregnancyrelated nausea vomiting case sent back trial court judge plaintiffs assert group sold zofran knowing determination whether judgement cases unsafe pregnant women failed warn risks entered gsk illegally marketed zofran offlabel use pregnant women addition uk matters one individual us january group defendant personal discontinuationtype claim pending central district injury lawsuits two lawsuits part multi california plaintiff matter alleges claims district litigation mdl proceeding us federal court dystoniadyskinesia caused ingestion paxil trial set district massachusetts october wake us supreme courts preemption decision ppi litigation merck v albrecht mdl judge directed gsk refile group defendant ongoing proton pump inhibitor motion summary judgment federal preemption grounds ppi litigation plaintiffs allege use ppis caused serious bodily injuries including acute kidney injury chronic kidney disease endstage renal failure january approximately personal injury lawsuits involving prevacidhr pending group nearly pending multidistrict litigation mdl proceeding district new jersey addition part consumer business transaction pfizer approximately cases involving nexiumhr pending group mdl small subset cases involving products also pending several state courts gsk annual report notes financial statements continued legal proceedings continued court heard oral argument gsks renewed motion average wholesale price november additionally response plaintiffs claims attorney general illinois filed suit group fda would changed zofrans labelling gsk number pharmaceutical companies claiming provided certain additional information fda november damages restitution due average wholesale price awp gsk submitted citizen petition fda providing andor wholesale acquisition cost wac price reporting information identified plaintiffs requesting fda pharmaceutical products covered states medicaid provide guidance whether information merits label programmes case alleged group reported change court deferred first trial date may caused reported false awp wac prices allow fda time respond petition turn allegedly caused state medicaid agency reimburse providers money covered medicines agency gsk also defendant four proposed class actions intended state sought recovery behalf payer canada significant activity matters behalf instate patients consumers gsk settled sales marketing regulation matter state announced october groups marketing promotion pharmaceutical thereby concluding matter vaccine products subject certain governmental cidra thirdparty payer litigation investigations private lawsuits brought litigants july major us healthcare insurers filed lawsuit various theories law group able make group seeking compensation reimbursements reliable estimate expected financial effect matters made medicines manufactured discussed category included provision groups former cidra plant puerto rico matters provision legal disputes except insurers claimed group knowingly marketed sold noted adulterated drugs manufactured conditions noncompliant matters group made provision also cgmp current good manufacturing practices noted note provisions thirdparty insurers unlawfully induced pay sfo secdoj anticorruption enquiries november group resolved lawsuit may uk serious fraud office sfo began reached settlement plaintiffs thereby concluding formal criminal investigation groups commercial matter operations number countries including china sfo inquiry followed investigations initiated chinas ministry public security june china investigations parallel investigations undertaken us securities exchange commission sec us department justice doj underlying commercial operations investigations resolved previously reported course inquiry sfo requested additional information group regarding thirdparty advisers engaged company course china investigations sec doj also investigating matters group cooperating responding requests february sfo announced closed investigation confirmed would taking action group sec doj investigations matters continue group unable make reliable estimate expected financial effect investigations provision made gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued legal proceedings continued antitrustcompetition commercial corporate certain governmental actions private lawsuits group defendant certain cases allege brought group alleging violation competition violations us federal securities erisa laws group antitrust laws group able make reliable able make reliable estimate expected estimate expected financial effect matters financial effect matters discussed category discussed category included provision included provision matters provision matters provision legal disputes legal disputes matters group made except noted provision also noted note provisions matters group made provision also securitieserisa class actions stiefel noted note provisions december us securities exchange commission sec filed formal complaint stiefel uk competition markets authority investigation laboratories inc charles stiefel us district court february uk competition markets district florida alleging stiefel principals authority cma issued decision fining group violated federal securities laws inducing stiefel employees million infringement competition act sell shares employee stock plan back connection agreements settle patent disputes company greatly undervalued price without disclosing group entered potential suppliers employees company sold generic paroxetine formulations group appealed group several years inactivity case competition appeal tribunal cat delivered initial reassigned new judge set trial date july judgement upholding fine march referred february parties reached agreement certain questions law european union court justice principle settle case subject final approval ecj january ecj issued judgement sec endorsing criteria used cma levying fine matter return cat entry final addition sec case one private matter martinolich judgement case remains also pending federal district court florida stayed pending trial sec matter lamictal allegations martinolich case largely track purported classes direct indirect purchasers filed suit sec matter plaintiff former stiefel employee alleges us district court district new jersey alleging stiefel officers directors violated us employee group teva pharmaceuticals unlawfully conspired retirement income security act erisa federal state delay generic competition lamictal resulting overcharges securities laws inducing stiefel employees sell shares purchasers entering allegedly anticompetitive employee stock plan back stiefel greatly reverse payment settlement resolve patent infringement undervalued price without disclosing employees litigation separate count accuses group monopolising stiefel sold group market june court appeals reversed trial courts decision dismiss case remanded action back trial court may trial court denied indirect purchaser class plaintiffs motion reconsideration courts dismissal claims result indirect purchaser class representatives agreed settlement exit case resolve remaining claims december trial judge granted plaintiffs class certification motion certifying class direct purchasers action group pursuing appeal court appeals regarding class certification march third circuit court appeals granted groups motion agreeing review class certification decision briefing appeal concluded oral argument expected occur march gsk annual report company balance sheet uk gaap including frs reduced disclosure framework december notes fixed assets investments e current assets trade receivables f cash bank total current assets bank overdrafts short term borrowings g trade payables h total current liabilities net current assets total assets less current liabilities provisions liabilities noncurrent liabilities j net assets capital reserves share capital k share premium account k reserves retained earnings january loss year changes retained earnings l equity shareholders funds financial statements pages approved board march signed behalf sir jonathan symonds chairman glaxosmithkline plc registered number company statement changes equity year ended december share share premium retained total capital account reserves earnings equity january loss total comprehensive expense attributable shareholders dividends shareholders shares issued employee share schemes december loss year distribution received glaxosmithkline consumer healthcare holdings limited total comprehensive income year dividends shareholders shares issued employee share schemes treasury shares transferred esop trusts december gsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet uk gaap including frs reduced disclosure framework presentation financial statements accounting principles policies description business preparation balance sheet conformity glaxosmithkline plc parent company gsk major generally accepted accounting principles requires management global healthcare group engaged creation make estimates assumptions affect reported discovery development manufacture marketing amounts assets liabilities disclosure contingent pharmaceutical products including vaccines overthecounter assets liabilities date balance sheet actual otc medicines healthrelated consumer products amounts could differ estimates preparation financial statements balance sheet prepared accordance financial statements prepared using companys accounting policies approved board historical cost convention modified include revaluation described note b policies consistently certain financial instruments going concern basis applied unless otherwise stated prepared accordance financial reporting standard key accounting judgements estimates reduced disclosure framework uk accounting key accounting judgements estimates required presentation companies act december current year comparative figures december b accounting policies permitted section companies act foreign currency transactions income statement company presented foreign currency transactions recorded exchange annual report rate ruling date transaction foreign currency assets company included group financial statements liabilities translated rates exchange ruling glaxosmithkline plc publicly available balance sheet date following exemptions requirements ifrs dividends paid received applied preparation financial statements dividends paid received included financial accordance frs statements period related dividends paragraphs b ifrs sharebased actually paid received payment expenditure ifrs financial instruments disclosures expenditure recognised respect goods services received supplied accordance contractual terms paragraphs ifrs fair value measurement provision made obligation exists future liability paragraph ias presentation financial statements respect past event amount comparative information requirements respect obligation reliably estimated paragraph iv ias investments subsidiary companies paragraphs f b investments subsidiary companies held cost less ias presentation financial provision impairment also adjusted movements statements contingent consideration ias statement cash flows impairment investments carrying value investments reviewed impairment paragraph ias accounting policies changes indication investment might accounting estimates errors impaired provision resulting impairment review paragraph ias related party disclosures charged income statement year concerned requirement ias disclose related party sharebased payments transactions entered two members issuance company subsidiaries grant group companys shares represents additional capital accounting convention standards contributions company subsidiaries additional balance sheet prepared using historical investment subsidiaries results corresponding increase cost convention complies applicable uk accounting shareholders equity additional capital contribution standards based fair value grant issued allocated underlying grants vesting period gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework continued taxation financial guarantees current tax provided amounts expected paid liabilities relating guarantees issued company applying tax rates enacted substantively behalf subsidiaries initially recognised fair value enacted balance sheet date amortised life guarantee deferred tax provided full using liability method c perating profit temporary differences arising tax bases assets fee relating audit liabilities carrying amounts financial company charged operating profit statements deferred tax assets recognised dividends extent considered recoverable future directors declared four interim dividends resulting taxable profits dividend year pence line dividend deferred tax measured average tax rates details see note group financial expected apply periods temporary statements dividends differences expected realised settled deferred tax liabilities assets discounted e fixed assets investments shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline consumer healthcare holdings limited shares glaxosmithkline mercury limited capital contribution relating sharebased payments contribution relating contingent consideration shares glaxosmithkline consumer healthcare holdings limited received year dividend specie part group reorganisation prior acquisition pfizer consumer healthcare business f trade receivables amounts due within one year uk corporation tax recoverable amounts owed group undertakings amounts due one year amounts owed group undertakings gsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet uk gaap including frs reduced disclosure framework continued g shortterm borrowings billion borrowing december relates balance facility taken june part financing buyout noncontrolling interest consumer healthcare joint venture held novartis maturity date remaining borrowing june h trade payables amounts due within one year creditors contingent consideration payable amounts owed group undertakings company guaranteed debt issued subsidiary companies two receives fees aggregate company outstanding guarantees billion debt instruments billion amounts due subsidiary company relation guarantee fees recovered life bonds disclosed within trade receivables see note f provisions liabilities january exchange adjustments charge year utilised december provisions relate number legal disputes company currently involved j noncurrent liabilities contingent consideration payable contingent consideration relates amount payable acquisition novartis vaccines portfolio current year liability included within trade payables gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework continued k share capital share premium account share premium ordinary shares p account number share capital issued fully paid january issued employee share schemes december issued employee share schemes ordinary shares acquired esop trusts december december december number shares issuable employee share schemes number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes l retained earnings loss glaxosmithkline plc year million million loss dividends paid million million effect million treasury shares transferred subsidiary company nil million distribution received shares subsidiary company retained earnings december stood million million million unrealised million dividends shareholders paid realised profits company december amounted million million group companies see pages complete list subsidiaries associates joint ventures forms part financial statements gsk annual report ssttrraatteeggicic r erepporotrt ggoovveerrnnaannccee nadn dre rmeumnuernaetiroantion ffiinnaanncciaial ls stattaetmemenetsnts iinnvveessttoor ri ninfoformrmataiotnion investor information section quarterly trend pharmaceuticals turnover vaccines turnover five year record product development pipeline products competition intellectual property principal risks uncertainties share capital share price dividends financial calendar annual general meeting tax information shareholders shareholder services contacts us law regulation group companies glossary terms ggsskk aannnnuuaall rreeppoorrtt financial record quarterly trend unaudited analysis group results provided quarter sterling financial year income statement total months q q q q reported proforma reported reported reported reported cer cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare corporate unallocated turnover total turnover cost sales selling general administration research development royalty income operating incomeexpense operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement adjusted total turnover cost sales selling general administration research development royalty income operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation adjusted results described gsk annual report strategic report governance remuneration financial statements investor information financial record continued quarterly trend quarterly trend continued unaudited analysis group results provided quarter sterling financial year income statement total months q q q q reported proforma reported reported reported reported cer cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare corporate unallocated turnover total turnover cost sales selling general administration research development royalty income operating incomeexpense operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement adjusted total turnover cost sales selling general administration research development royalty income operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation adjusted results described gsk annual report financial record continued pharmaceutical turnover therapeutic area total us europe international growth growth growth growth therapeutic areamajor products cer cer cer cer respiratory ellipta products anoro ellipta arnuity ellipta incruse ellipta relvarbreo ellipta trelegy ellipta nucala hiv dolutegravir products tivicay triumeq juluca dovato epzicomkivexa selzentry immunoinflammation benlysta oncology zejula established pharmaceuticals established respiratory seretideadvair flixotideflovent ventolin avamysveramyst respiratory dermatology augmentin avodart imigranimitrex lamictal seroxatpaxil valtrex pharmaceuticals gsk annual report strategic report governance remuneration financial statements investor information financial record continued pharmaceutical turnover therapeutic area total us europe international growth growth growth growth therapeutic areamajor products cer cer cer cer respiratory ellipta products anoro ellipta arnuity ellipta incruse ellipta relvarbreo ellipta trelegy ellipta nucala hiv dolutegravir products tivicay triumeq juluca dovato epzicomkivexa selzentry immunoinflammation benlysta oncology zejula established pharmaceuticals established respiratory seretideadvair flixotideflovent ventolin avamysveramyst respiratory dermatology augmentin avodart imigranimitrex lamictal seroxatpaxil valtrex pharmaceuticals gsk annual report financial record continued vaccines turnover total us europe international growth growth growth growth major products cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingles shingrix established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccines represents growth actual exchange rates cer represents growth constant exchange rates vaccines turnover total us europe international growth growth growth growth major products cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingles shingrix established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccines represents growth actual exchange rates cer represents growth constant exchange rates gsk annual report strategic report governance remuneration financial statements investor information financial record continued five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board group turnover geographic region us europe international group turnover segment pharmaceuticals vaccines consumer healthcare segment turnover corporate unallocated turnover revised revised revised revised pharmaceuticals turnover respiratory hiv immunoinflammation oncology established pharmaceuticals vaccines turnover meningitis influenza shingles established vaccines consumer healthcare turnover wellness oral health nutrition skin health gsk annual report financial record continued five year record continued financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share diluted earnings per share millions millions millions millions millions weighted average number shares issue basic diluted financial results adjusted turnover operating profit profit taxation profit taxation pence pence pence pence pence adjusted earnings per share return capital employed return capital employed calculated total profit taxation percentage average net assets year gsk annual report strategic report governance remuneration financial statements investor information financial record continued five year record continued balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity revised see note noncontrolling interests revised see note total equity number employees us europe international manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported bank england pm buying rate average rate year calculated average pm buying rates day year average feb jan dec nov oct sep high low pm buying rate february us gsk annual report financial record continued five year record continued divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs profit disposal associates share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions gsk annual report strategic report governance remuneration financial statements investor information financial record continued five year record continued divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal us tax adjusted results amortisation impairment restructuring related items reform results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs profit disposal associates share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions gsk annual report financial record continued five year record continued divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs profit disposal associates share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation lossprofit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition pharmaceuticals vaccines product development pipeline key nlicense alliance relationship third party maa marketing authorisation application europe exception rituxan owned biogen inc nda new drug application us v iiv healthcare global specialist hiv company phase e valuation clinical pharmacology usually conducted gsk pfizer inc shionogi limited shareholders volunteers responsible developing delivering hiv medicines phase ii etermination dose initial evaluation efficacy optionbased alliance immunocore ltd conducted small number patients r receipt complete response letter phase iii l arge comparative study compound versus placebo bla biological licence application andor established treatment patients establish clinical benefit safety maa ndabla regulatory review milestones shown table achieved future filing dates included list achieved regulatory review milestones compound type indication phase maa ndabla oncology zejula poly adpribose polymerase parp inhibitor fourth line treatment ovarian cancer approved oct niraparib quadra first line maintenance ovarian cancer submitted feb dec solid tumours prima iii dostarlimab antiprogrammed cell death protein receptor dmmrmsih endometrial cancer submitted dec pd antibody tumours garnet iii belantamab bcell maturation antigen antibody drug conjugate multiple myeloma submitted dec dec mafodotin dreamm iii induced tcell costimulator icos agonist head neck squamous cell carcinoma iiiii antibody nonsmall cell lung cancer solid tumours bintrafusp alfa transforming growth factor beta tgf trap biliary tract cancer l l iiiii immune checkpoint pd inhibitor bispecific nonsmall cell lung cancer tumours ii nyeso autologous engineered tcrt cells sarcoma solid heme malignancies ii engineered tcr molibresib bet family bromodomain inhibitor er breast cancer solid tumours ii cobolimab antitcell immunoglobulin mucin domain nonsmall cell lung cancer tumours ii tsr tim antibody protein arginine methyltransferase prmt solid tumours heme malignancies iii inhibitor antilymphocyte activation gene lag cancer iii tsr antibody ox agonist monoclonal antibody cancer tolllike receptor tlr agonist cancer type protein arginine methyltransferase cancer type prmt inhibitor nyesotargeting bispecific cancer sting cytosolic dna pathway agonist cancer hiv infectious diseases dectova neuraminidase inhibitor iv influenza approved apr zanamivir iv dolutegravir hiv integrase strand transfer inhibitor nucleoside hiv infection approved jul apr lamivudine reverse transcriptase inhibitor nrti fostemsavir hiv attachment inhibitor hiv infection submitted jan dec cabotegravir hiv integrase strand transfer inhibitor non hiv infection submitted jul apr rilpivirine nucleoside reverse transcriptase inhibitor nnrti r dec longacting regimen cabotegravir hiv integrase strand transfer inhibitor longacting hiv preexposure prophylaxis iii gepotidacin triazaacenaphthylene bacterial type ii topoisomerase uncomplicated urinary tract infection uuti iii inhibitor gonorrhea gc hbv antisense oligonucleotide hepatitis b ii gsk annual report pipeline products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla hiv infectious diseases continued hiv maturation inhibitor hiv infection ii leucyl trna synthetase inhibitor tuberculosis ii hiv broadly neutralizing antibody hiv infection crk inhibitor visceral leishmaniasis combinectin hiv entry inhibitor hiv infection immunoinflammation benlysta rituxan b lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody sc cluster differentiation cd sjogren 's syndrome ii monoclonal antibody iv benlysta b lymphocyte stimulator monoclonal lupus nephritis iii antibody sc otilimab granulocyte macrophage colony rheumatoid arthritis iii stimulating factor monoclonal antibody oncostatin osm monoclonal systemic sclerosis ii antibody lymphocyte activation gene lag ulcerative colitis ii protein monoclonal antibody ccl inhibitor pain osteoarthritis respiratory fluticasone furoate glucocorticoid agonist longacting asthma submitted jan sep vilanterol beta agonist muscarinic umeclidinium acetylcholine antagonist mepolizumab interleukin il monoclonal antibody copd iii hypereosinophilic syndrome nasal polyposis interleukin r ilr monoclonal asthma ii antibody selective androgen receptor modulator copd muscle weakness ii interleukin il longacting monoclonal asthma antibody nemiralisib phosphatidylinositol kinase delta activated pik delta syndrome pik inhibitor pharmaceuticals daprodustat prolyl hydroxylase inhibitor oral anaemia associated chronic renal disease jnda jnda submitted aug iii oxytocin inhaled oxytocin postpartum hemorrhage ii linerixibat ileal bile acid transporter ibat inhibitor cholestatic pruritus pbc ii hematopoietic prostaglandin duchenne muscular dystrophy hpgd synthase inhibitor gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla vaccines shingrix recombinant protein adjuvanted herpes zoster prophylaxis immunocompromised submitted dec zoster vaccine bexsero recombinant protein meningococcal b disease prophylaxis infants us iii rotarix live attenuated pcv porcine circovirus rotavirus prophylaxis submitted nov free mmr live attenuated measles mumps rubella prophylaxis us iii therapeutic recombinant protein adjuvanted reduction frequency moderate severe ii copd acute exacerbations copd patients targeting nontypeable haemophilus influenzae moraxella catarrhalis malaria next recombinant protein adjuvanted malaria prophylaxis plasmodium falciparum ii generation fractional dose men abcwy recombinant protein conjugated meningococcal abcw disease prophylaxis ii adolescents menveo conjugated liquid formulation meningococcal acw disease prophylaxis ii adolescents shigella conjugated tetravalent outer shigella diarrhea prophylaxis ii membrane vesicles monovalent rsv replicationdefective recombinant respiratory syncytial virus prophylaxis paediatric ii viral vector population recombinant protein respiratory syncytial virus prophylaxis pregnant woman ii population prevent respiratory syncytial virus lower respiratory tract illness infants first months life transfer maternal antibodies recombinant protein adjuvanted respiratory syncytial virus prophylaxis older adult iii population therapeutic hbv primeboost viral vector vaccines hepatitis b virus therapeutic functional elimination iii co sequentially administrated immune system mediated chronic infection adjuvanted recombinant proteins c difficile recombinant protein adjuvanted active immunization prevention primary c diff diseases prevention recurrences sam rabies model selfamplifying mrna rabies prophylaxis brand names appearing italics trade marks owned licensed gsk group companies gsk annual report pipeline products competition continued pharmaceutical products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu respiratory anoro ellipta umeclidinium bromide copd stiolto respimat vilanterol trifenatate utibronultibro nce nce breezhaler duaklir genuair device device bevespi aerosphere formulation formulation arnuity ellipta fluticasone furoate asthma qvar pulmicort asmanex alvesco nce nce device device formulation formulation avamysveramyst fluticasone furoate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expired expired diskus device diskus device expired hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva handihaler respimat eklira genuair nce nce seebri breezhaler device device formulation formulation nucala mepolizumab severe eosinophilic asthma egpa xolair cinqair expired fasenra dupixent relvarbreo ellipta fluticasone furoate asthmacopd symbicort foster vilanterol trifenatate flutiform dulera nce nce device device formulation formulation seretideadvair salmeterol xinafoate asthmacopd symbicort foster expired expired fluticasone propionate flutiform dulera diskus device diskus device expired hfadevice hfadevice trelegy ellipta fluticasone furoate copd trimbow vilanterol trifenatate brextri aerosphere nce nce umeclidinium bromide device device formulation formulation ventolin hfa albuterol sulphate asthmacopd generic companies expired hfadevice hfadevice antivirals valtrex valaciclovir genital herpes coldsores shingles famvir expired expired central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expired expired imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired seroxatpaxil paroxetine depression various anxiety effexor cymbalta expired expired disorders lexapro cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia proscar flomax expired expired finasteride antibacterials augmentin amoxicillinclavulanate common bacterial generic products na expired potassium infections oncology zejula niraparib ovarian cancer lynparza rubraca nce nce immunoinflammation benlysta benlysta sc belimumab systemic lupus erythematosus generic competition commenced includes supplementary protection certificates granted multiple countries eu patent term extensions granted us data exclusivity expires eu us gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition continued pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands us eu hiv juluca dolutegravir rilpivirine hivaids descovy genvoya odefsey biktarvy nce nce dovato dolutegravir lamivudine hivaids descovy genvoya odefsey biktarvy nce nce selzentrycelsentri maraviroc hivaids isentress intelence prezista nce nce tivicay dolutegravir hivaids isentress prezista symtuza reyataz nce nce biktarvy triumeq dolutegravir lamivudine hivaids descovy genvoya abacavir odefsey biktarvy nce nce vaccine products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu bexsero meningococcal groupb meningitis group b prevention trumenba vaccine boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel expired expired pertussis pertussis booster vaccination infanrix hexapediarix diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expired expired polio hepatitis b haemophilus tetanus pertussis polio pentaxim pentavac influenzae type b eu hepatitis b haemophilus hexaxim hexyon influenzae type b eu vaxelis cervarix hpv virus like human papilloma virus gardasil silgard particles vlps type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza prophylaxis intenza flumist qiv antigens virus subtypes vaxigrip qiv subtype b fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza prophylaxis vaxigrip mutagrip antigens virus subtypes fluzone influvac subtype b aggripal fluad intenza flumist menveo meningococcal group c w meningitis group c w nimenrix menactra conjugate vaccine prophylaxis prepandrix derived split inactivated pandemic hn influenza aflunov vepacel influenza virus antigen prophylaxis adjuvant priorix priorix tetraab live attenuated measles mumps measles mumps rubella mmr ii mmrvaxpro expired expired varilrixb rubella varicella vaccine chickenpox prophylaxis proquad varivax rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugated pneumococcal prophylaxis invasive prevenar prevnar na polysaccharide disease pneumonia acute otitis media shingrix zoster vaccine herpes zoster zostavax recombinant adjuvanted shingles see note financial statements legal proceedings generic competition commenced many markets includes supplementary protection certificates granted multiple countries eu patent term extensions granted us related compoundsindications measles mumps rubella vaccineprophylaxis b related compound varicella vaccine gsk annual report pipeline products competition continued consumer healthcare products competition brand products application markets competition wellness respiratory otrivin nasal spray nasal decongestant germany netherlands afrin bayer nasivin proctor norway russia sweden gamble tyzine johnson johnson theraflu hot liquids tablets syrups cold flu relief russia poland us tylenol cold flu johnson johnson mucinex reckitt benckiser lemsip reckitt benckiser flixonaseflonase nasal spray tablets allergy relief us china uk ireland claritin bayer allegra sanofi piriton zyrtec johnson johnson nicorette us lozenges gum treatment nicotine withdrawal global nicorette johnson johnson nicoderm transdermal patches aid smoking reduction niquitin perrigo nicotinell cessation ex australia pain relief panadol tablets caplets infant paracetamolbased treatment global except us aspirin bayer panadol cold syrup drops headache joint pain fever tylenol johnson johnson flu cold symptoms voltaren topical gel nonsteroidal diclofenac based global except us aspirin bayer antiinflammatory tylenol johnson johnson advil tablets caplets gel caplets ibuprofen based treatment us canada brazil tylenol tylenol pm tylenol nonrespiratory liquid filled suspension drops headache toothache backache colombia mexico childrens motrin motrin range childrens menstrual cramps muscular childrens johnson johnson pains minor pain arthritis aleve aleve pm bayer advil respiratory tablets allergy relief cold flu tylenol cold flu johnson cold flu relief johnson lemsip mucinex advil respiratory reckit benckiser allergy eno effervescent immediate relief antacid global except us estomazil hypermarca gelusil tums chewable tablets immediate relief antacid us alkaseltzer bayer gaviscon reckitt benckiser rolaids sanofi oral health sensodyne toothpastes toothbrushes relief dentinal hypersensitivity global colgate sensitive prorelief pronamel mouth rinse pronamel additionally protects colgatepalmolive acid erosion elmex colgatepalmolive oral b procter gamble parodontax toothpaste dailymedicated helps stop prevent global colgate total gum health corsodyl mouthwash gel spray bleeding gums treats colgatepalmolive prevents gingivitis oral b gum enamel repair crest gum detoxify procter gamble polident denture adhesive denture improve retention comfort global fixodent kukident poligrip cleanser wipes dentures cleans dentures procter gamble corega steradent reckitt benckiser aquafresh toothpastes toothbrushes aids prevention dental cavities global colgate colgatepalmolive mouthwashes maintains healthy teeth gums crest procter gamble fresh breath oralb procter gamble skin health zovirax topical cream lip care treat prevent global compeed johnson johnson abreva nonmedicated patch onset cold sores carmex carma labs blistex blistex incorporated retail label chapstick lip balm protect moisturise prevent global blistex burts bees carmex soothe chapped lips carma labs eos nivea beiersdorf vaseline unilever nutrition centrum tablets vitamin mineral global nutralite infinitus cheongkwan gummies supplementation jung byhealth nature made herbalife swisse caltrate tablets gummies calcium supplement global citracal bayer oscal nature soft chews made private label gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties principal risks discussed risks affect cost product development also uncertainties relevant business financial condition time required reach market likelihood results operations may affect performance successfully uninterrupted basis ability achieve objectives risks rules regulations change government interpretation believe could cause actual results differ materially evolves business activities change nature expected historical results particular risk may change changes certain regulatory continued embed changes risk regimes may substantial change failure management reporting cycle help us identify manage comply applicable laws regulations could materially report important risks across organisation adversely affect financial results consistent proportionate way completed similarly global business exposes us litigation enterprise risk plans important risks government investigations including limited product ensured businesses adopted adapted liability litigation patent antitrust litigation sales approval deployed confirmation across marketing litigation litigation government investigations organisation reinforcing leader accountability risk including related provisions may make unfavourable management measured well controls set outcomes increases related costs insurance enterprise risk plans implemented gaps premiums could materially adversely affect financial closed evolved risk management process results introducing new reports board focus data key risk indicators leading better informed discussions detail status various uncertainties risk exposure action needed introduced new significant unresolved disputes potential litigation set approach annual risk review support cet decisions note legal proceedings changes required important risks uk regulations require discussion mitigation activities required comply broad range laws company takes address principal risks uncertainties regulations apply research development description principal risks manufacturing testing approval distribution sales summary activities take manage risk marketing pharmaceutical vaccines consumer across businesses principal risks uncertainties healthcare products listed order significance patient safety risk definition questions safety products may raised failure appropriately collect review follow report ongoing safety surveillance postmarketing human safety information hsi including adverse events studies also governmental agencies third parties potential sources act relevant findings may analyse publicly available clinical trial results constant timely manner vigilance flexibility required order respond varied regulatory environment continues evolve diverge risk impact globally externally developments data interrogation present risk impact potential compromise ability potential benefits patient safety volume data conduct robust safety signal detection interpretation analysed presents significant challenge intensifies ensure appropriate decisions taken respect coupled fragmented regulatory requirements privacy risk benefit profile products including completeness concerns economic arena mergers acquisition accuracy product labels pursuit additional activities introduce data integrity risks technology presents studies analyses appropriate additionally risk could significant opportunity patient safety risk management potentially negatively impact ability incorporate verified creating reliable data interrogation tools accurate safety signals local country labelling could lead data collection mechanisms even though pace artificial potential harm patients reputational damage product liability intelligence development great claims litigation governmental investigation regulatory expected cyberattacks evergrowing concern given action fines penalties loss product authorisation volume data digital dependency context group currently defendant number product liability preclinical clinical trials conducted lawsuits including class actions involve significant claims development investigational pharmaceutical vaccine damages related products litigation particularly consumer healthcare products determine safety us inherently unpredictable class actions seek sweep efficacy products use humans notwithstanding together persons take products increase potential efforts make determine safety products liability claims pain suffering punitive damages appropriate preclinical clinical trials unanticipated side frequently asserted product liability actions allowed effects may become evident products widely represent potentially openended exposure thus could introduced marketplace materially adversely affect groups financial results gsk annual report principal risks uncertainties continued patient safety continued mitigating activities group product approved marketing chief medical officer cmo accountable extensive postmarketing surveillance signal detection patient safety enterprise risk authoritative role system information possible side effects products evaluating addressing matters human safety cmo received several sources including unsolicited reports supported enterprisewide safety governance board healthcare professionals hcps patients regulatory provide oversight management control framework authorities medical scientific literature traditional media including risk management process product specific safety social media governance boards place ensure human safety information changes riskbenefit profile one addressed proactively throughout product lifecycle products result certain actions characterise business named medical officer subsidiary business communicate minimise risk proposed actions specific boards provide oversight governance discussed regulatory authorities include modifying policy employees required report immediately prescribing information communications physicians issues relating safety quality products healthcare providers restrictions product prescribing country managers responsible monitoring exception availability help assure safe use sometimes carrying tracking training helps assure collection safety clinical trials certain cases may appropriate information reporting information relevant central stop clinical trials withdraw medicine market safety department accordance policy legal implemented organisational changes create requirements flexible scalable fit purpose organisation meet changing internal external demands also investing system upgrades quality checks reduce risks individual case safety reports product quality risk definition technological developments increasingly used failure gsk contractors suppliers ensure enhance manufacture support inclusion packaging features help secure legitimate supply chain eg appropriate controls governance quality product serialisation threat cyberattacks remains key risk development integrity product quality data audit trail compliance good manufacturing practice good significant changes taking place gsk implement distribution practice regulations commercial clinical new organisational alignments iptc strategy trials manufacture distribution activities changes assessed quality organisations ensure compliance terms gsk product licences quality procedures governance facilitate supporting regulatory activities strategy whilst also ensuring unintended consequences risk impact increase product quality risk failure ensure product quality could far reaching mitigating activities implications terms patient consumer safety delays extensive global network quality compliance launching products drug shortages product recalls well professionals aligned business unit provide regulatory legal financial consequences could oversight assist delivery quality performance materially adversely affect gsks reputation financial operational compliance site level senior management results level management oversight activities accomplished context hierarchy quality councils external environment product quality continues independent chief product quality officer global product challenging single biggest change since quality office provides oversight product quality risk political instability uncertainty surrounding delivery across company brexit implications medicine supply continuity developed implemented single quality mainland europe two new sets requirements management system defines quality standards due implemented ema shortly systems businesses associated pharmaceuticals preparing first quarter vaccines consumer healthcare products clinical trial new reporting requirements potential drug shortages materials system broad scope applicable may new regulations covering throughout product lifecycle rd mature licensing medical devices commercial supply augmented consolidation numerous regulatory requirements defined markets across world assures meets external expectations product quality markets supplied based internationally recognised principles ich q pharmaceutical quality systems framework gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued product quality continued quality management system routinely updated product incident committee processes place ensure keeps pace evolving external regulatory investigate product issues make recommendations environment new scientific understanding remediation activities including necessary recall products processes part drive continually product marketplace order protect patients improve operational deployment quality management consumers complaints process also place ensure system making policies procedures simpler gsk responds product quality issues raised patients understand implement well adopting innovative tools customers give userfriendly experience staff members allegations noncompliance misconduct received regularly trained regulatory expectations learnings formal informal speak channels reviewed inspections current procedures ensure continued triaged independent functions global disciplinary maintenance cgmp standards enforcement procedures apply breaches implemented riskbased approach assessing standards initiated following investigation managing third party suppliers provide materials key risk indicators leveraged support risk management used finished products contract manufacturers making activities provide corporate executive team products expected comply gsk standards risk oversight compliance council integrated regularly audited provide assurance standards met assessment product quality performance financial controls reporting risk definition treasury group deals high value transactions failure comply current tax laws incurring significant mostly foreign exchange cash management transactions losses due treasury activities failure report accurate daily transactions involve market volatility financial information compliance accounting standards counterparty risk applicable legislation groups effective tax rate reflects rates tax risk impact jurisdictions group operates higher noncompliance existing new financial reporting lower uk rate considers regimes disclosure requirements changes recognition income encourage innovation investment science providing expenses could expose us litigation regulatory action tax incentives changed could affect groups tax could materially adversely affect financial results rate addition worldwide nature operations means current period significant political uncertainty especially intellectual property rd manufacturing operations usa uk significant changes short centered several key locations consequence notice failure comply changes substance crossborder supply routes necessary ensure application governing laws covering transfer pricing supplies medicines numerous end markets dividends tax credits intellectual property could materially complex result conflicting claims tax authorities adversely affect financial results profits taxed individual countries tax legislation also complex differs across countries significant losses may arise inconsistent application operate tax risk also arise due differences treasury policies transactional settlement errors interpretation legislation tax charge included counterparty defaults financial statements best estimate tax liability context pending audits tax authorities group required laws various jurisdictions expect continued focus tax reform driven disclose publicly financial results events could initiatives organisation economic cooperation materially affect financial results group regulators development address taxation digital economy routinely review financial statements listed companies european commission initiatives including use fiscal state compliance new revised existing accounting aid investigations together domestic initiatives around regulatory requirements group believes complies world may result significant changes established appropriate regulatory requirements concerning tax principles increase tax authority disputes financial statements disclosure material information regardless merit outcomes costly divert including transactions relating business restructuring management attention may adversely impact reputation acquisitions divestitures however subject relationship key stakeholders investigation potential noncompliance accounting disclosure requirements lead restatements previously reported results significant penalties gsk annual report principal risks uncertainties continued financial controls reporting continued mitigating activities counterparty exposure subject defined limits approved financial results reviewed approved regional board credit rating individual counterparties management reviewed financial controller oversight treasurys role managing counterparty risk line chief financial officer cfo allows financial agreed policy performed corporate compliance controller cfo assess evolution business officer operates independently treasury details time evaluate performance plan significant mitigation treasury risks found pages judgments reviewed confirmed senior management note financial instruments related disclosures technical organisational transformation newly acquired tax risk managed robust internal policies processes activities integrated risk assessments appropriate training compliance programmes ensure controls reviews applied alignment across business meet tax obligations maintain control environment designed identify material seek maintain open positive relationships errors financial reporting disclosure design governments tax authorities worldwide welcome operating effectiveness key financial reporting controls constructive debate taxation policy monitor government regularly reviewed management tested external third debate tax policy key jurisdictions deal proactively parties minimum standard control set place potential future changes tax law engage finance locations irrespective size reviewed advisors legal counsel confirm implications management monitored independently provides us business tax legislation appropriate active assurance controls key financial reporting providing relevant business input tax policy makers disclosure processes operated effectively global significant decisions submitted consideration finance risk management controls centre excellence tax governance board meets quarterly comprises provides extra support significant transformations senior personnel across gsks finance division system deployment managementstructural tax affairs managed global basis reorganisations also add operational resources ensure coordinated team tax professionals led global head processes controls maintained changes tax works closely business tax professionals additional risk mitigation introduced amending suitably qualified roles perform support programme timelines system upgrades optimize delivery training needs order continue able disclosure committee reporting board reviews provide date technical advice submit tax returns groups quarterly results annual report determines according statutory time limits engage tax authorities throughout year consultation legal advisors seek ensure tax affairs current entering whether necessary disclose publicly information arrangements continuous audit programmes group stock exchange announcements keep advance pricing agreements appropriate uptodate latest developments financial reporting agreements provide longterm certainty tax authorities requirements working external auditor legal us tax treatment business exceptional advisors cases matters settled agreement tax authorities may resolve disputes formal treasury management group meets regular basis appeals proceedings seek ensure liquidity interest rate counterparty foreign currency transaction foreign currency translation risks managed line conservative approach detailed associated risk strategies policies adopted board antibribery corruption abac risk definition risk impact abac risk comprises five subrisk areas failure mitigate risk could expose group associated persons governmental investigation regulatory bribery public officials gsk action civil criminal liability may compromise bribery commercial nonpublic entities gsk groups ability supply products certain government bribery third parties acting behalf gsk contracts addition legal financial penalties failure prevent bribery complying abac legislation gsk employees receiving andor requesting bribes andor regulations could substantial implications reputation undue personal benefit company credibility senior leaders erosion corruptionnoncompliance laws regulations investor confidence governance risk management related money laundering facilitation tax evasion third partiesclientspartners gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued antibribery corruption abac continued context abac programme built best class principles macro risk level remains unchanged continue see subject ongoing review development provides us legal frameworks similar uk us develop emerging basis seek manage risk top economies high standards expected individuals bottom example programme comprises corporations aided improved technology increased toplevel commitment board directors enforcement leadership new data analytics programme create embed local key risk indicators enable targeted overall environment abac remained intervention risk management activities challenging divergence legislation making compliance harder countries increasingly holding individuals programme underpinned global abac policy accountable well corporations increasing employer written standards address commercial duty care society holding corporations ever higher practices give rise abac risk addition standards technology providing speedy anonymous programme mandates enhanced controls interactions avenue dissemination previously privileged information government officials business development even damaging false reports enforcement actions penalties transactions controls abac policy establish due increased across globe focus use third diligence requirements engagement third parties party intermediaries supportive aspects new policies abac team continually works together tpo team include latin america moving towards compliance regimes address improve controls monitoring requirements like established us uk india engaging third parties amendment corruption act explicitly provide mandatory periodic abac training staff makes offence pay bribe china introduced relevant third parties accordance roles significant antibribery anticorruptionlegislative responsibilities risks face regulatory reforms dedicated abac team responsible gsk exposure remains unchanged implementation evolution programme response mitigating activities developments internal external environment programme governance provided enterprise risk example introduced global process management overseen abactpo governance board centrally document conflicts interest coi employees includes representation key functional areas complementary workers supported simpler policy business joint board created ensure ensure collate report coi management strategic focus across two principle risk areas organisation considerable codependency complemented independent oversight enterprisewide abac programme designed assurance undertaken audit assurance ensure compliance abac policies mitigate risk independent business monitoring teams issues identified bribery corruption builds business standards oversight assurance exercises well resulting values expectations form comprehensive practical investigations used identify areas specific approach compliance flexible evolving nature intervention markets well continuously improve business programme appropriate controls place training continually benchmark abac programme awareness raising strong monitoring around transactions large multinational companies use external expertise payments third parties plan continue pre internal insights drive improvements programme posttransaction abac due diligence increase capabilities formal informal speak channels available report business monitoring oversight red flag resolution misconduct noncompliance allegations noncompliance third parties review controls accountabilities reviewed triaged central investigations team government officials continue understand assess allocated investigation appropriate moneylaundering risk exposure mitigate existing risk code conduct values expectations commitment zero tolerance integral mitigate risk light complexity geographic breadth risk constantly evolve oversight activities data reinforce workforce clear expectations regarding acceptable behaviours maintain regular communications centre local markets gsk annual report principal risks uncertainties continued commercial practices risk definition promotion approved products seeks ensure hcps failure engage commercial activities consistent globally access information need patients letter spirit law industry groups consumers access information products requirements relating marketing communications need products prescribed recommended used medicines associated therapeutic areas appropriate manner provides maximum healthcare benefit interactions healthcare professionals hcps patients patients consumers committed communicating legitimate transparent transfer value information related approved products responsible legal ethical manner risk impact failure manage risks related commercial practices could mitigating activities materially adversely affect ability deliver strategy strategic objectives designed ensure achieve longterm priorities failure comply applicable laws purpose helping people feel better live longer rules regulations may result governmental investigation continue strive new product launches regulatory action legal proceedings brought competitive resourced effectively also strive group governmental private plaintiffs could result healthy proportion groups sales ratio attributable new government sanctions criminal andor financial penalties product innovation sales failure provide accurate complete information related innovation helps us defray effect example products may result incomplete awareness risk downward price pressure major markets declining emerging benefit profile products possibly suboptimal market growth rapidly evolving digital landscape negative treatment patients consumers practices foreign exchange impact establishing new products found misaligned values could also result priced balance expectations patients consumers reputational harm dilute trust established external hcps payers shareholders community enables us stakeholders maintain strong global business remain relevant context needs patients consumers values behaviours continue evolve business operations including provide guide lead make decisions acquisitions joint ventures operate global basis constantly strive right thing deliver quality industry highly competitive highly regulated products ensure supply sustained meet customer competitors may make significant product innovations needs demand requirements seeking ensure actions technical advances may intensify price competition reflect values behaviours purpose company light competitive environment continued development taken action enhance improve standards commercially viable new products development application data analytics ecommerce channels additional uses existing products reflect insights policies standards governing commercial help ensure products address needs activities undertaken us behalf training patientsconsumers hcps payers critical achieve implemented support evolution activities strategic objectives relevant employees activities conduct worldwide pharmaceutical vaccine consumer companies must conform high ethical regulatory industry standards face downward price pressure major markets declining local standards differ global standards emerging market growth rapidly evolving digital landscape stringent two applies standards acquired negative foreign exchange impact company joint venture partner differ global standards expediently remediate legacy policies implement developing new pharmaceutical vaccine consumer revisions gain alignment harmonised policies healthcare products costly lengthy uncertain procedures guide abovecountry commercial practice process product candidate may fail stage including processes well clarified applicable standards significant economic human resources operations various markets operate invested competitors products pricing strategies business adopted internal control framework support failure part develop commercially successful assessment management risks commercial products develop additional uses existing products practices activities appropriate monitoring programmes could materially adversely affect ability achieve oversight business unit risk management compliance strategic objectives boards manage risks across incountry business activities committed ethical responsible past fallen commercialisation products support purpose regulatory industry standards sought improve improve quality human life enabling people framework culture compliance processes feel better live longer accomplish purpose engage healthcare community various ways provide important information medicines gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued commercial practices continued promotional materials activities must reviewed allow fair market value payments made gsk approved according policies standards expert practitioners speak innovative medicines conducted accordance local laws regulations vaccines limited number countries restricted seek ensure materials activities fairly represent time period products lifecycle controls training ensure products services group necessary appropriate oversight across markets report payments disciplined including termination employees individual hcps part commitment transparency engaged misconduct claw back remuneration responsible disclosure senior management event misconduct consumer healthcare developed digital risk plan made changes incentive programme support implementation robust control framework actions pharmaceutical vaccines sales representatives include development new written standards use tools better recognise reward individual effort specifically increase visibility control social media presence specialty care capped variable pay element sales increase management monitoring representatives compensation evaluated basis gsk committed comply applicable sanctions individual sales targets changes implemented laws regulations deployed sanctions us uk canada july supported programme designed enable management sanctions comprehensive training control monitoring framework risk programme owned finance comprises various ensure implementation new programme fully aligned systems controls including limited policies gsks valuesbased approach hcp engagement procedures training awareness screening monitoring risk reporting privacy risk definition mitigating activities failure collect secure use destroy personal chief compliance officer also chairperson information pi accordance data privacy laws lead privacy governance board pgb oversees gsks harm individuals gsk including fines operational overall data privacy operating model business financial reputational risk function appointed risk owner accountable oversight privacy risks business functional area risk impact supported privacy leaders within business noncompliance lead harm individuals gsk function additionally countries data privacy laws also damage trust gsk individuals require data protection officer dpo appointed communities business partners government authorities gsk appointed single dpo european union general data protection regulation gdpr represented supported specific countries privacy legislation following suit increased enforcement country privacy advisors chief compliance officer powers supervisory authorities including ability impose enterprise risk owner ero ero appointed fines suspend processing pi gdpr privacy delegate risk owner global privacy officer gpo laws also give individuals right bring collective legal accountability daytoday basis designing actions gsk failure comply data privacy laws implementing control framework gpo coleads context crossfunctional privacy centre excellence coe together data privacy legislation diverse limited harmonisation global privacy counsel supported privacy simplification despite europes adoption gdpr officers privacy counsel region multiple challenging multinationals standardise approach country privacy advisors familiar local privacy compliance data privacy laws due highlevel regulations local variation governments enforcing compliance gsk evolved initial control framework implemented data privacy laws rigorously focus ethical use gdpr comprehensive privacy control framework based pi growing compliance data privacy global privacy principles common across many local privacy laws due increase data volume processed laws global framework deployed countries advancements technology individuals aware robust privacy legislation place coming effect rights data privacy laws soon strengthen local risk mitigation measures gsk annual report principal risks uncertainties continued privacy continued privacy centre excellence global ethics monitoring continuously improve processes compliance responsible improving control issue identification reporting handling framework ii implementing control framework implemented legislative scanning process detect outside european economic area iii remediating certain assess new privacy regulations early allowing us prepare existing business activities ensure compliance gdpr mitigate regulatory risk gsk privacy centre iv deploying comprehensive training programme drive excellence involved new business development greater awareness accountability managing pi across opportunities early stage ensure appropriate due entire organisation key roles privacy network diligence performed right steps taken gsk certified accredited international privacy onboarding splitting business unit association research practices risk definition integrity data essential success stages research practices risk failure adequately conduct research data lifecycle design generation recording ethical sound preclinical clinical research addition management analysis reporting storage retrieval failure engage scientific activities research data governed legislation regulatory consistent letter spirit law industry requirements research data supporting documents groups requirements comprises following sub core components various stages pipeline progression risks nonclinical laboratory research human subject decisionmaking form content regulatory research data integrity care welfare treatment animals submissions publications patent filings poor data integrity human biological samples management data disclosure compromise research efforts negatively impact regulatory filings engagement scientific engagement company reputation intellectual property innate complexities interdependencies required risk impact regulatory filings particularly given global research impacts risk include harm human subjects development footprint continually changing increasingly reputational damage failure obtain necessary regulatory stringent submission requirements continue increase approvals products governmental investigation legal complexity worldwide product registration continued proceedings brought group governmental supply gsk medicines patients dependent private plaintiffs product liability suits claims damages ongoing compliance maintenance licenses across loss revenue due inadequate patent protection inability many geographies whose requirements timelines differ supply gsk products regulatory action fines secure management high volume lifecycle changes penalties loss product authorisation licenses renewal critical enable compliant consequences could materially adversely affect financial supply failure maintain licenses directly impact patients results cause loss trust customers patients company revenue context scientific engagement defined interaction exchange research relating animals raise ethical concerns information gsk external communities however many cases research animals method advance scientific medical understanding including used investigate effects potential new appropriate development use products medicine living body humans animal research essential part scientific discourse nonpromotional provides critical information causes mechanisms engagement external stakeholder groups vital gsks diseases therefore remains vital part research purpose necessary scientific medical advance continually seek ways minimise use scientific engagement activities essential present legal animals research whilst complying regulatory regulatory reputational risk sharing data invited requirements reduce impact animals used media coverage payments hcps perceived promotional intent clinical trials healthy volunteers patients used assess demonstrate investigational products efficacy wide variety biological materials used gsk safety evaluate product discovery research development phases approved marketing also work human biological convention biological diversity cbd nagoya samples samples fundamental discovery protocol international community established global development safety monitoring products gsk framework regulating access use genetic resources committed ensuring human biological samples nonhuman origin rd managed accordance relevant laws regulations ethical principles manner respects interests sample donors gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued research practices continued support principles access benefit sharing global human biological samples management genetic resources outlined cbd nagoya hbsm governance framework place oversee ethical protocol recognising importance appropriate effective lawful acquisition management human biological proportionate implementation measures national samples hbsm enterprise risk management team works regional levels minimise risks related acquisition storage use transfer disposal hbs patent rights awarded protect innovation play important role providing gsk competitive advantage remains important priority enhance data integrity market limited period time loss patent controls data integrity committees place provide protection market gsks products developed oversight data integrity quality assurance teams conduct rd including reducing term availability scope assessments provide independent business monitoring patent rights could materially adversely affect financial internal controls rd activities results market absence adequate patent data regulatory governance board serves global exclusivity protection could lead example regulatory risk management compliance board promoting competition manufacturers generic biosimilar compliance regulatory requirements procedures pharmaceutical products could limit opportunity rely oversees groupwide written standards cross business markets future sales growth products regulatory processes significant program progress could also materially adversely impact financial results transform regulatory information management systems following expiration certain intellectual property rights replace modernise information systems crossenterprise generic biosimilar manufacturer may lawfully produce established access benefit sharing centre generic version product introduction generic products excellence oversee applicable requirements enforcement typically leads rapid dramatic loss sales reduces measures acquisition use genetic material revenues margins proprietary products nonhuman origin scope nagoya protocol mitigating activities rd maintains controls prepublication procedures established office animal welfare ethics guard public disclosure advance filing patent strategy oawes led chief veterinary officer applications addition loss patent protection supports humane responsible care animals shares occur due lack data integrity preparing patent knowledge advocates application nonanimal application data information legal experts collaborate alternatives oawes provides framework animal rd support review process new patent applications welfare governance promotes application rs replacement refinement reduction animals research conducts research practices risk overseen enterprise quality assessments manages program external animal framework seeks ensure strengthened governance diligence develops deploys strategies across rd businesses pharmaceuticals vaccines reproducibility translatability consumer healthcare chief medical officer oversees following enterprise leadership research practices enterprise medical governance boards risk owner management risk takes pragmatic approach information sharing streamlining risk identification human subject research board place provide escalation ensuring ownership stays oversight human subject research sponsored business supported us ensure conforms ethical medical scientific standards data disclosure board provides oversight disclosure sponsored supported human subject research make information available clinical studies including summaries results whether positive negative first company publish clinical study reports form basis submissions regulatory agencies publicly posted clinical study reports addition study result summaries specific accountability authorisation scientific engagement overseen scientific engagement promotional practices board board responsible oversight applicable policies seeking ensure highest level integrity continuous development scientific engagement gsk annual report principal risks uncertainties continued third party oversight tpo risk definition enterprisewide tpo programme takes enterprisewide risk third parties fail meet contractual view third party related risks ensure compliance regulatory ethical obligations resulting significant abac policies additional risks labour rights operational reputational legal financial risk gsk health safety human safety information forms cases employees directly comprehensive practical approach third party oversight flexible evolving nature business put simply risk third parties fail deliver type engagement managed programme goods services expect fail deliver legal designed governed global ethics compliant way compliance organisation globally deployed risk impact operational service assisting business completion failure adequately manage third party relationships could assessments transitioned global procurement early result business disruption exposure risks ranging bring closer core procurement processes suboptimal contractual terms conditions severe tpo strengthened risk assessment contractual terms business legal sanctions andor significant reputational due diligence efforts third parties improved overall damage consequences could materially management third party risks lifecycle adversely affect business operations financial results third party engagement context dedicated tpo team responsible third parties critical business delivery implementation evolution programme response integral part solution meeting business objectives developments internal external environment rely third parties including suppliers advisors programme governance provided enterprise risk distributors individual contractors licensees management overseen abac tpo governance pharmaceutical biotechnology collaboration partners board includes representation key functional areas discovery manufacture marketing products business joint board created supporting important business processes ensure strategic focus across two principle risk areas business relationships present material risk considerable codependency example example share critical sensitive information new abac conflict interest tool better protects marketing plans clinical data employee data specific gsk working third parties global ethics third parties conducting relevant outsourced compliance working global procurement legal business activities inadequate protection misuse tech organisations plan simplifications order information third parties could significant business maintain oversight reduce complexity business impact similarly use distributors agents range business leadership team retains ultimate accountability activities promotion tendering inherent managing third party interactions risks working risks inappropriate promotion corruption insufficient third parties employees expected manage internal compliance controls distributors could affect external interactions commitments responsibly reputation risks increased expectation embedded values code conduct complexities working large numbers third parties responsibility activities carried behalf across diverse geographical spread performed safely compliance applicable laws mitigating activities values expectations standards code conduct guide enforce global principles interactions see abac report third parties global policy framework applicable programme complemented independent oversight buying goods services managing external spend assurance undertaken audit assurance paying working third parties policy framework independent business monitoring teams review tpo applies employees complementary workers programme large multinational companies use worldwide external expertise internal insights drive improvements programme gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued environment health safety sustainability ehss risk definition mitigating activities failure management corporate executive team cet responsible ehss governance risk oversight ensures effective execution hazardous activities control framework place use manage risks gsks physical assets infrastructure impacts legal compliance issues relate ehss handling processing hazardous chemicals across businesses includes assigning biological agents responsibility senior managers providing maintaining controls ensuring tiered monitoring control releases substances harmful environment governance processes place within businesses short long term leading incidents individual managers seek ensure ehss control could disrupt rd supply activities harm employees framework effective well implemented respective harm communities operate harm business area fully compliant applicable environment longerterm sustainability laws regulations adequately resourced maintained risk impact communicated monitored additionally employee failure manage ehss risks could lead significant harm personally responsible ensuring applicable local people environment communities operate standard operating procedures followed fines failure meet stakeholder expectations regulatory expected take responsibility ehss matters requirements litigation regulatory action damage riskbased proactive approach articulated global groups reputation could materially adversely affect ehss policy detailed global ehss standards financial results audit operations ensure compliance context ensure hazards appropriately controlled safe gsk subject health safety environmental laws design facilities plant equipment following various jurisdictions laws impose duties protect rigorous procedures help us provide effective barriers people environment communities protect employees health wellbeing operate well potential obligations remediate control antibiotic emissions manufacturing effluents contaminated sites overall control framework managing increasing concern number stakeholders forming ehss risk effective frequency serious events part wider concern around amr antimicrobial similar peers lower high hazard industries resistance address ensuring eg petrochemicals manufacturing facilities suppliers following good operational practice meeting emission limits defined amr alliance manufacturing framework year made assessment business resilience climate change task force climate related financial disclosures tcfd framework guidelines identify fundamental risks overall business gsk annual report principal risks uncertainties continued information security risk definition mitigating activities risk unauthorised disclosure theft unavailability global information security policy accompanying corruption gsks information key information systems information technology standards processes may lead harm patients workforce customers supported dedicated team programme activity disruption business andor loss commercial gsk technology security risk function provides strategic advantage damage reputation regulatory strategy direction oversight including active monitoring sanction cybersecurity enhancing global information security capabilities ongoing programme investment risk impact following mitigation activities represent significant failure adequately protect critical sensitive systems investments made past year continue information may result loss commercial strategic improve coming year advantage could materially affect ongoing business operations scientific research clinical trials engaging external expertise next generation tools fully manufacturing supply chain activities map inventory ot environment enable high confidence real time snapshot connected devices inadequately applying controls would expected within network improve patching timeframe gsk may result regulatory fines present reputational systems months weeksdays risk organisation site technology refresh plan approved context underway gsks substantial sites rely critical sensitive systems data corporate strategic plans intellectual property manufacturing significant upgrade tools funded progressing systems trade secrets potential focused key control areas computer systems information may exposed misuse gsks core information technology organisation information unauthorised disclosure security organisation business units working together gsk operates highly connected information network validate critical apps data stores ensure exposes confidential research development adequate backup restore capabilities manufacturing commercial workforce financial data new unified security standard approved across risk external attacks gsks digital data analytics sites operational technology security office strategy also substantially increases businesses established ciso tooling extended dependency digital assets distributed data deployment ot programme increasing number assets potentially impacted cyberattack threats evolve provide broad deployment new tools prioritised deployment plan assurances significant efforts deliver identity access management fully resourced protection monitoring systems information moving speed addressing financial manufacturing always successful preventing compromise disruption systems priorities continue cybersecurity losses increasingly involve highlyresourced balance systems coming years organised threat actors nationstates online plan enhancement thirdparty practices criminal collectives targeting gsks large complex automate visibility security critical vendors information technology operational technology ot established process footprint well systems supply chain partners team dedicated solely securing systems data including outsourced operations means systems expansion growth markets eg china information continue target formed overseen ciso cyberattacks additionally extensive use third parties store process data increases gsks reliance suppliers operate effectively dependence increases complexity around security controls practices also reduces gsks ability monitor controls effectively investigate respond incidents involving gsk information systems gsk stands ready address cybersecurity incidents risks occur past year gsk experienced material cybersecurity incident would resulted substantial harm gsk eg injury reputation financial performance customer vendor relationships gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued supply continuity risk definition mitigating activities failure deliver continuous supply compliant finished supply chain model adopted pharmaceuticals vaccines product inability respond effectively crisis incident consumer healthcare business units designed ensure timely manner recover sustain critical operations supply quality security products globally far possible risk impact recognise failure supply products adversely supply chain governance committees within business impact consumers patients rely material unit used closely monitor inventory status delivery interruption supply exclusion healthcare programmes products aim ensuring customers could expose us litigation regulatory action financial products need improved links commercial penalties could adversely affect groups financial forecasting manufacturing made possible core results groups international operations commercial cycle time reduce risk associated partners expose workforce facilities operations demand fluctuations impact ability supply information technology potential disruption natural cost writeoffs products exceed expiry events eg storm earthquake manmade events eg trading date node supply chain also periodically barriers imposed short notice civilpolitical unrest terrorism reviewed ensure adequate safety stock balancing global emergencies eg coronavirus outbreak ebola working capital endtoend supply chain particular outbreak flu pandemic important robust attention placed mitigating supply risks associated crisis management recovery plans place manage medically critical highrevenue products events routinely monitor compliance manufacturing external context suppliers service providers identify manage risks supply chain operations subject review approval supply base practical minimise dependence various regulatory agencies effectively provide single sources supply critical items alternative license operate failure manufacturing distribution sourcing arrangements possible certain materials facilities suppliers key services materials could lead inventory strategy aims limit impact ultimately litigation regulatory action product recalls protect supply chain unanticipated disruption seizures interruption supply delays approval new continue implement anticounterfeit systems products suspension manufacturing operations pending product serialisation accordance new emerging resolution manufacturing logistics issues supply chain requirements around world eu rely materials services provided third party falsified medicines regulation suppliers make products including active pharmaceutical corporate policy requires business functional area ingredients antigens intermediates commodities head ensure effective crisis management business components development manufacture packaging continuity plans place include authorised response pharmaceutical vaccine consumer healthcare recovery strategies key areas responsibility clear products thirdparty services procured communication routes business disruption occurs services provided contract manufacturing clinical corporate security supports business coordinating research organisations support development key products crisis management business continuity training facilitating important ensure continuous operation business simulation exercises assessing preparedness recovery although undertake risk mitigation recognise certain capability providing assurance oversight central events could nevertheless still result delays service repository plans supporting critical business processes interruptions use effective crisis management business business unit performs risk oversight continuity planning provide health safety respective risk management compliance board rmcb people minimise impact us maintaining functional assure adequate risk mitigation including identifying new operations following natural manmade disaster public emerging threats example taken coordinated health emergency approach evaluate manage implications business arising brexit activities help ensure appropriate level readiness response capability maintained also develop maintain partnerships external bodies like business continuity institute un international strategy disaster risk reduction helps improve business continuity initiatives disasterprone areas supports development community resilience disasters gsk annual report shareholder information share capital control details issued share capital number shares interests voting rights held treasury december found stated far aware note financial statements share capital share persons significant direct indirect holdings premium account company information provided company pursuant financial conduct authoritys disclosure guidance ordinary shares listed london stock exchange transparency rules dtr published regulatory also quoted new york stock exchange nyse information service companys website form american depositary shares ads ads wwwgskcom represents two ordinary shares details listed debt listed refer note financial statements company received notifications accordance net debt dtr following notifiable interests voting rights companys issued share capital holders ordinary shares ads entitled receive dividends declared companys annual report december february attend speak general meetings company percentage percentage appoint proxies exercise voting rights total voting total voting voting rights rights voting rights rights restrictions transfer limitations blackrock inc holding ordinary shares ads requirements c omprising indirect interest ordinary shares obtain approval prior transfers ordinary shares holding qualifying financial instruments cfd ads carry special rights regard control p ercentage total voting rights date notification company company restrictions voting rights major company acquired disposed interests shareholders voting rights per share shares period review shareholders known arrangements exception transferred treasury satisfy awards financial rights held person holder groups employee share plans shares known agreements restrictions share transfers voting rights share buyback programme board authorised issue allot ordinary shares acquired groups employee share plans shares article companys articles association rank equally shares issue special power article authority company rights trustees employee share ownership plan make purchases shares subject shareholder trusts waived rights dividends shares held authorities sought annual basis annual trusts general meeting agm shares purchased exchange controls limitations affecting security company may cancelled held treasury shares holders used satisfying share options grants group 's certain economic sanctions may employee share plans force time time currently applicable laws programme covers purchases shares cancellation decrees regulations force uk restricting import held treasury shares accordance export capital restricting remittance dividends authority renewed shareholders agm may payments holders companys shares company authorised purchase maximum nonresidents uk similarly certain economic million shares details shares purchased sanctions may force time time cancelled held treasury shares limitations relating nonresidents uk english subsequently transferred treasury satisfy awards law companys articles association right groups employee share plans disclosed holder vote respect companys shares note financial statements share capital share premium account determining specific share repurchase levels company considers development free cash flow year shares purchased since company confirms currently intend make market purchases company review potential future share buybacks line usual annual cycle subject return ratings criteria gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued share capital control continued market capitalisation uk us market capitalisation based shares issue excluding treasury shares gsk december billion date gsk th largest company market capitalisation ftse index share price january december increasedecrease high year low year table sets middle market closing prices companys share price increased uk share price uk us ads price us compares increase ftse index year middle market closing share price february nature trading market following tables set periods indicated high low middle market closing prices pence companys shares london stock exchange high low closing prices us dollars companys ads nyse ordinary shares ads pence per share us dollars per share high low high low february january december november october september quarter ended december quarter ended september quarter ended june quarter ended march quarter ended december quarter ended september quarter ended june quarter ended march year ended december year ended december year ended december year ended december year ended december year ended december february gsk annual report shareholder information continued analysis shareholdings december number total total number accounts accounts shares shares holding shares held nominee companies investment trust companies insurance companies individuals corporate bodies guaranty nominees limited held treasury shares glaxosmithkline effective july jp morgan chase bank na appointed successor depositary companys american depository receipt adr programme companys ads listed nyse ordinary shares representing companys adr programme managed depositary registered name guaranty nominees limited february guaranty nominees limited held ordinary shares representing issued share capital excluding treasury shares date february number holders ordinary shares us holdings ordinary shares number registered holders ads holdings ads certain ordinary shares ads held brokers nominees result number holders record registered holders us representative number beneficial holders residence beneficial holders dividends company pays dividends quarterly continues return board intends maintain dividend cash shareholders dividend policy dividends current level p per share subject material change remain essential component total shareholder return external environment performance expectations gsk recognises importance dividends shareholders time free cash flow strengthens intends build free cash company aims distribute regular dividend payments flow cover annual dividend target range determined primarily reference free cash flow x returning dividend growth details generated business funding investment dividends declared amounts payment dates necessary support groups future growth given note financial statements dividends dividends per share dividend calendar table sets dividend per share per ads exdividend last five years dividend per ads translated quarter date record date payment date q february february april us dollars applicable exchange rates q may may july year dividend pence us q august august october q november november january q february february april special q ordinary dividend receivable ads holders calculated based exchange rate april annual fee per ads per ads per quarter charged depository cumulative dividend receivable ads holders q q q special dividend related return part net cash proceeds novartis transaction completed march paid fourth quarter ordinary dividend gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued financial calendar results announcements event date results announcements issued london stock quarter results announcement april exchange available news service also annual general meeting may sent us securities exchange commission quarter results announcement july nyse issued media made available website quarter results announcement october preliminaryquarter results announcement february financial reports annual report publication februarymarch company publishes annual report made annual report distribution march available website date publication shareholders may elect receive notification email information company including share ads publication annual reports registering price available website wwwgskcom information wwwshareviewcouk may also elect receive made available website constitute part printed copy annual report contacting registrar annual report equiniti limited copies previous annual reports available website printed copies also obtained registrar see contact details annual general meeting annual general meeting agm held pm ads holders wishing attend meeting contact uk time wednesday may sofitel london depositary jp morgan chase bank na request heathrow terminal london heathrow airport tw gd proxy appointment see contact details enable attend vote business agm companys principal forum communication transacted ads holders reminded private shareholders addition formal business instruct depositary way shares presentation ceo performance represented ads voted completing group future development returning voting card provided depositary opportunity questions asked board chairs shares voted boards committees workforce engagement director take questions relating roles documents display investors holding shares nominee service articles association company directors arrange nominee service appointed proxy service contracts applicable letters appointment respect shareholding order attend vote directors company subsidiaries meeting side letters relating severance terms pension arrangements available inspection companys registered office made available inspection agm gsk annual report shareholder information continued tax information shareholders summary certain uk tax us federal income tax corporation taxpayers may entitled indexation consequences holders shares ads citizens allowance applies reduce capital gains extent uk us set complete gains arise due inflation indexation allowance may analysis possible tax consequences purchase reduce chargeable gain create allowable loss ownership sale securities intended assets acquired january legislation general guide holders advised consult advisers finance act freezes level indexation allowance respect tax consequences purchase ownership given calculating companys chargeable gains sale shares ads consequences state value would apply disposal asset december local tax laws us implications current assets acquired january onwards ukus tax conventions legislation finance act removes indexation allowance disposal us holders ads generally treated owners underlying shares purposes current usuk inheritance tax double taxation conventions relating income gains individual ukdomiciled otherwise shareholders may income tax convention estate gift taxes estate gift liable uk inheritance tax transfer shares ads tax convention purposes internal revenue tax may charged amount value code amended shareholders estate reduced result transfer way lifetime gift disposal less full market uk shareholders value case bequest death tax may charged summary applies uk resident shareholder value shares date shareholders death holds shares capital assets gift disposal subject uk taxation dividends inheritance tax us estate gift tax estate gift tax uk years uk resident individuals convention would generally provide tax paid us entitled dividend tax allowance credited tax payable uk first dividends received tax year free stamp duty stamp duty reserve tax tax dividends excess allowance taxed uk stamp duty andor stamp duty reserve tax sdrt basic rate taxpayers higher rate taxpayers subject certain exemptions payable transfer additional rate taxpayers shares rate rounded nearest uk resident shareholders corporation taxpayers case stamp duty consideration transfer note dividends payable ordinary shares generally notwithstanding provided instrument executed entitled exemption corporation tax pursuance agreement gave rise charge sdrt instrument stamped within six years taxation capital gains agreement including stamped exempt sdrt uk resident shareholders may liable uk tax gains charge cancelled sdrt already disposal shares ads paid repaid disposals individuals uk tax year taxable capital gain accruing disposal shares ads us shareholders taxed basic rate taxpayers summary applies shareholder citizen allowable deductions individuals taxable income resident us domestic corporation person year exceeds basic rate income tax limit note otherwise subject us federal income tax net income following use exemptions available individual basis respect shares ads holds shares ads taxpayer annual exempt amount capital assets resident uk uk tax purposes hold shares purposes trade profession vocation carried uk branch agency summary also address tax treatment holders subject special tax rules banks taxexempt entities insurance companies dealers securities currencies persons hold shares ads part integrated investment including straddle comprised share ads one positions persons directly indirectly companys stock vote value address tax treatment may applicable result international income tax treaties gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued tax information shareholders continued taxation dividends taxation capital gains gross amount dividends received treated foreign generally us holders subject uk capital gains source dividend income us tax purposes eligible tax subject us tax capital gains realised dividend received deduction allowed us corporations sale disposal shares ads gains dividends ads payable us dollars dividends longterm capital gains subject reduced rates taxation ordinary shares payable sterling dividends paid individual holders shares ads held sterling included income us dollar amount one year date shares vestedreleased calculated reference exchange rate day shortterm capital gains subject taxation rates dividends received holder subject certain whereas longterm capital gains may subject exceptions shortterm hedged positions individual rates state local tax rates capital gains eligible us holder subject us taxation maximum may also apply federal rate plus applicable state local tax information reporting backup withholding respect qualified dividends qualified dividend defined dividends payments proceeds sale shares us internal revenue service irs dividend ads paid within us certain usrelated financial meets following criteria intermediaries subject information reporting may ust issued us corporation corporation subject backup withholding unless us holder incorporated us possession corporation corporation exempt recipient provides taxpayer eligible benefits comprehensive income tax treaty identification number certifies loss exemption deemed satisfactory published irs occurred nonus holders generally subject dividends listed irs dividends information reporting backup withholding may qualify required provide certification nonus status connection payments received amounts withheld required dividend holding period met allowed refund credit holders us federal shares must owned days income tax liability provided required information furnished holding period defined day irs period begins days exdividend date day stock trades without dividend priced estate gift taxes example stocks exdividend date october estate gift tax convention us shareholder shares must held days period generally subject uk inheritance tax however us august november year order capital shareholder may subject us estate gift tax count qualified dividend stamp duty dividends qualified subject taxation uk stamp duty andor sdrt subject certain exemptions us federal graduated tax rates maximum rate payable transfer shares ads custodian types dividends automatically excluded depository rate amount consideration qualified dividends even meet requirements provided transferred sale value transferred include limited consideration capital gains distributions however stamp duty sdrt payable dividends bank deposits transfer agreement transfer ads ividends held corporation employee stock ownership plan esop dividends paid taxexempt corporations us state local tax rates qualified nonqualified dividends may vary would assessed addition federal tax rates communicated gsk annual report statutory disclosures shareholder services contacts registrar companys registrar equiniti limited aspect house spencer road lancing bn da wwwshareviewcouk tel uk tel outside uk equiniti provides range services shareholders service offers participate dividend reinvestment plan alternative receiving cash dividends may choose drip election form downloaded drip reinvest dividends buy gsk shares wwwshareviewcouk requested contacting equiniti dividend payment direct bank april gsk cease paying dividends via cheque dividend bank mandate form account bank mandate dividends paid directly bank building downloaded wwwshareviewcouk society account receive cash dividends must requested contacting equiniti provide equiniti bank building society account details quicker secure method payment avoids risk cheques going astray dividend payment direct bank april gsk cease paying dividends via cheque details service costs account overseas shareholders instead equiniti convert dividend local involved please contact equiniti currency send direct local bank account service available countries worldwide electronic communications shareholders may elect receive electronic notifications please register wwwshareviewcouk company communications including annual report dividend payments dividend confirmations availability online voting general meetings time gsk mails hard copy shareholder documents receive email containing link document relevant website shareview portfolio service enables create free online portfolio view please register wwwshareviewcouk share balance movements update address dividend payment instructions register votes general meetings deduplication publications mailings receive duplicate copies mailings may please contact equiniti one account please contact equiniti arrange accounts merged one convenience avoid waste unnecessary costs share dealing service shareholders may trade shares either held certificated online transactions please log please note market trading hours form held corporate sponsored nominee online wwwshareviewcoukdealing pm uk time telephone via postal dealing service provided equiniti telephone transactions please call monday friday excluding public financial services limited uk holidays england wales outside uk postal transactions please call request dealing form corporate sponsored nominee account convenient way manage shares without requiring application form requested share certificate service provides facility hold wwwshareviewcouk shares nominee account sponsored company contacting equiniti continue receive dividend payments annual reports attend vote companys general meetings shareholders names appear publicly available share register service free join individual savings accounts isas company arranged equiniti financial services details available wwwshareviewcouk limited provide gsk corporate isa hold gsk shares requested telephoning equiniti lines open pm dealing pm enquiries monday friday excluding public holidays england wales llines open pm monday friday excluding public holidays england wales provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued shareholders services contacts continued ads depositary contacts adr programme administered jp morgan investor relations chase bank na investor relations may contacted follows regular correspondence uk eq shareowner services great west road po box brentford middlesex tw gs st paul mn tel delivery stock certificates overnight mail us eq shareowner services crescent drive centre point curve suite philadelphia pa mendota heights mn tel us toll free wwwshareowneronlinecom tel outside us general gsk response center outside us tel us toll free depository also provides global invest direct direct share scam alert ads purchasesale dividend reinvestment plan ads receive unsolicited telephone call offering sell buy holders details enrol please visit wwwadrcom shares please take extra care caller may part call helpline number obtain enrolment pack highly organised financial scam glaxo wellcome smithkline beecham uk shareholder please contact financial corporate peps conduct authority wwwfcaorgukconsumers share centre limited consumer helpline oxford house oxford road aylesbury bucks hp sz tel tel uk wwwsharecom tel outside uk donating shares save children lines open pm uk time monday friday except uk public holidays pm saturdays gsk embarked ambitious global partnership save children share expertise resources aim helping save lives one million children shareholders small number shares value makes uneconomical sell may wish consider donating save children donated shares aggregated sold save children use funds raised help reach goal obtain share donation form please contact registrar equiniti managing donation sale uk shares save children free charge provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report statutory disclosures continued us law regulation number provisions us law regulation apply section corporate responsibility company shares quoted nyse financial reports form ads sarbanesoxley requires ceo cfo complete formal certifications confirming nyse rules general nyse rules permit company follow uk reviewed annual report form f corporate governance practices instead applied based knowledge annual report form f us provided explain significant variations contains material misstatements omissions explanation contained form f based knowledge financial statements accessed securities exchange commissions financial information fairly present material respects sec edgar database via website nyse rules require financial condition results operations cash flows us file annual interim written affirmations concerning dates periods presented annual report audit risk committee arc statement significant form f differences corporate governance responsible establishing maintaining sarbanesoxley act disclosure controls procedures ensure material following number corporate accounting scandals information made known evaluated us congress passed sarbanesoxley act effectiveness controls procedures year sarbanesoxley wideranging piece legislation end results evaluation contained concerned largely financial reporting corporate annual report form f governance responsible establishing maintaining internal recommended sec company established control financial reporting provides reasonable disclosure committee committee reports ceo assurance regarding reliability financial reporting cfo arc chaired company secretary preparation financial statements external purposes members consist senior managers finance legal accordance generally accepted accounting principles corporate communications investor relations disclosed annual report form f external legal counsel external auditors internal experts changes internal controls financial reporting invited attend disclosure committees meetings period covered annual report form f periodically committee responsibility considering materially affected reasonably likely affect materially materiality information timely basis determining companys internal control financial reporting disclosure information responsibility disclosed based recent evaluation timely filing reports sec formal review internal control financial reporting external auditor annual report form f committee met arc significant deficiencies material times weaknesses design operation internal controls sarbanesoxley requires annual report form f financial reporting reasonably likely affect contains statement whether member arc adversely companys ability record process audit committee financial expert defined rules summarise report financial information fraud sarbanesoxley statement relevant member regardless materiality involving persons arc judy lewent included arc report significant role companys internal control financial biography additional disclosure reporting requirements arise section section group carried evaluation supervision sarbanesoxley respect disclosure controls participation management including ceo procedures internal control financial reporting cfo effectiveness design operation groups disclosure controls procedures december inherent limitations effectiveness system disclosure controls procedures including possibility human error circumvention overriding controls procedures accordingly even effective disclosure controls procedures provide reasonable assurance achieving control objectives gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued us law regulation continued ceo cfo expect complete certifications group exports certain pharmaceutical vaccine report conclusions effectiveness disclosure consumer products iran via sales nonus entities controls procedures march following subsidiaries us entity two privately held iranian certifications filed sec part groups distributors form f group regularly receive information regarding section managements annual report internal identity distributors ' downstream customers control financial reporting intermediaries iran possible parties accordance requirements section include entities governmentowned hospitals sarbanesoxley following report provided pharmacies owned directly indirectly iranian management respect companys internal control government persons entities sanctioned connection financial reporting defined rules af df terrorism proliferation activities group understands us securities exchange act amended subdistributor group 's privately held exchange act distributor iran previously sold group medicines may entity whose property blocked pursuant executive order management responsible establishing maintaining consequence indirect ownership structure adequate internal control financial reporting upon learning subdistributor 's potential ownership group internal control financial reporting designed structure group required distributor iran terminate provide reasonable assurance regarding reliability relevant subdistributor financial reporting preparation financial statements external purposes accordance ifrs group regularly receive information regarding identity distributors ' downstream customers management conducted evaluation effectiveness establish proportion gross revenue sales internal control financial reporting based potentially attributable entities affiliated iranian framework internal control integrated framework government parties sanctioned disclosable activities issued committee sponsoring organisations result group reporting entire gross revenues treadway commission coso million net loss million group 's changes groups internal control sales iran financial reporting materially group also aware hospitals medical affected reasonably likely affect materially facilities lebanon may affiliated controlled groups internal control financial reporting hezbollah groups designated united management assessed effectiveness internal states pursuant executive order group control financial reporting december deal directly hospitals facilities sells conclusion filed part groups form distributors group unable establish f proportion gross revenue sales potentially attributable reportable activities result group reporting deloitte llp audited consolidated financial entire gross revenues million net profits statements group year ended december million group 's sales lebanon also assessed effectiveness groups internal control financial reporting auditing unless noted group intends continue activities standard public company accounting oversight described board united states audit report filed addition section r exchange act us law groups form f generally restricts dealings us persons dealings section r exchange act otherwise subject us jurisdiction certain countries territories subject comprehensive sanctions currently section r exchange act requires issuers make crimea cuba iran north korea syria well specific disclosure annual reports certain types government venezuela though country dealings iran including transactions dealings venezuela whole group business via nonus governmentowned entities well dealings entities entities owned controlled us entities sanctioned activities related terrorism proliferation certain jurisdictions believe group complies weapons mass destruction even activities applicable us sanctions material respects prohibited us law involve us persons laws complex continue evolve rapidly gsk annual report statutory disclosures continued donations political organisations political expenditure ensure consistent approach political contributions result definitions may cover legitimate business across group global policy introduced activities ordinary sense considered political voluntarily stop corporate political contributions donations political expenditure designed support political party independent election candidate period january december group make political donations eu therefore notwithstanding policy noneu organisations intend make donations eu political parties organisations incur eu political expenditure notwithstanding introduction policy accordance annually seek shareholder authorisation inadvertent federal election campaign act us continue expenditure support employeeoperated political action committee pac facilitates voluntary political donations eligible authority precautionary measure ensure gsk employees company subsidiaries inadvertently breach legislation pac controlled gsk decisions amounts recipients contributions made authorisation process expenditure participating employees exercising legal right pool year dates back agm held may following resources make political contributions introduction political parties elections subject strict limitations total us referendums act authority since us donated political organisations renewed annually gsk employee pac english law requires prior shareholder approval political contributions eu political parties independent election candidates well eu political expenditure definitions political donations political expenditure political organisations used legislation however quite broad particular definition eu political organisations may extend bodies concerned policy review law reform representation business community special interest groups concerned environment company subsidiaries might wish support gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies accordance section companies act full list subsidiaries associates joint ventures joint arrangements address registered office effective percentage equity owned december disclosed unless otherwise stated share capital disclosed comprises ordinary shares indirectly held glaxosmithkline plc percentage held class share stated less unless otherwise stated subsidiary companies registered office tax resident country incorporation name security registered address wholly owned subsidiaries alberta ulc common nd street sw calgary ab tp j canada action potential venture capital limited ordinary great west road brentford middlesex tw gs england adechsa gmbh ii ordinary co prv provides treuhandgesellschaft ag dorfstrasse baar switzerland affymax research institute common corporation service company gateway oaks drive suite n sacramento california united states alenfarma especialidades farmaceuticas limitada ii ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal allen hanburys limited ii ordinary great west road brentford middlesex tw gs england allen hanburys pharmaceutical nigeria limited ordinary abimbola way ilasamaja isolo lagos nigeria allen farmaceutica sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain allen pharmazeutika gesellschaft mbh ordinary wagenseilgasse euro plaza gebude stock vienna austria barrier therapeutics inc common corporation service company little falls drive wilmington delaware united states beecham group plc p shares p shares b great west road brentford middlesex tw gs england beecham pharmaceuticals pte limited ordinary quality road jurong industrial estate jurong singapore beecham portuguesaprodutos farmaceuticos e quimicos lda ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal beecham sa ii ordinary parc de la noire epine rue fleming wavre belgium biovesta ilalari ltd sti ii nominative bykdere caddesi levent plaza b blok levent istanbul turkey burroughs wellcome co bangladesh limited ordinary sweden tower harinnachala konabari gazipur bangladesh cascan gmbh co kg partnership capital industriestrasse bad oldesloe germany castleton investment ltd iv ordinary co dtos cybercity th floor standard chartered tower ebene mauritius cellzome gmbh ordinary meyerhofstrasse heidelberg germany cellzome therapeutics inc ii common corporation service company little falls drive wilmington delaware united states cellzome inc common corporation service company little falls drive wilmington series preferred delaware united states series b preferred series c convertible preferred series c convertible preferred charles midgley limited ii ordinary cumulative preference great west road brentford middlesex tw gs england clarges pharmaceuticals trustees limited ii iv ordinary great west road brentford middlesex tw gs england colleen corporation common corporation service company little falls drive wilmington delaware united states corixa corporation common corporation service company little falls drive wilmington delaware united states coulter pharmaceutical inc ii common corporation service company little falls drive wilmington delaware united states dealcyber limited ordinary great west road brentford middlesex tw gs england desarrollo energia solar alternativa sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain duncan flockhart australia pty limited ii iv ordinary mountain highway boronia vic australia etex farmaceutica ltda social capital avenue andres bello piso las condes santiago cp chile fipar thailand ltd liquidation ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand genelabs technologies inc common corporation service company gateway oaks drive suite n sacramento california ca united states glaxo group limited ordinary great west road brentford middlesex tw gs england glaxo kabushiki kaisha ii ordinary akasaka minatoku tokyo japan glaxo laboratories nigeria limited ii ordinary marine road apapa lagos nigeria glaxo laboratories limited ii ordinary great west road brentford middlesex tw gs england gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxo new zealand pension plan trustee limited ordinary level zurich house queen street auckland new zealand glaxo operations uk limited ordinary great west road brentford middlesex tw gs england glaxo properties bv ordinary huis ter heideweg lz zeist netherlands glaxo trustees limited ii iv ordinary great west road brentford middlesex tw gs england glaxo verwaltungs gmbh ordinary industriestrasse bad oldesloe germany glaxo wellcome australia pty ltd ii iv ordinary mountain highway boronia vic australia glaxo wellcome farmaceutica limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxo wellcome international bv ii iii ordinary huis ter heideweg lz zeist netherlands glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production sas ordinary rue franois jacob rueilmalmaison france glaxo wellcome vidhyasom limited ii ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxo wellcome sa ordinary poligono industrial allendeduero avenida de extremadura aranda de duero burgos spain glaxo sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxoallenburys nigeria limited ii ordinary creek road apapa lagos pmb nigeria glaxochem pte ltd iii ordinary rochester park singapore glaxosmithkline produtos farmaceuticos limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxosmithkline cambodia co ltd liquidation ordinary th floor dksh building preah monivong boulevard corner street sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment co ltd ordinary room building ocean international center mid th east ring road bejing chaoyang district china glaxosmithkline china rd company limited equity f building huanke road pilot free trade zone shanghai china glaxosmithkline cyprus limited ordinary arch makariou iii capital center th floor nicosia pc cyprus glaxosmithkline gsk srl ordinary costache negri street opera center one th th floors zone district bucharest romania glaxosmithkline ireland limited vii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline malta limited ordinary first floor de la cruz avenue qormi qrm malta glaxosmithkline private limited ii ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline aebe ordinary kifissias avenue halandri athens greece glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada iv quotas luanda bairro petrangol estrada de cacuaco n angola glaxosmithkline argentina sa ordinary tucumn piso buenos aires caaa argentina glaxosmithkline ordinary drammensveien oslo norway glaxosmithkline asia pvt limited equity patiala road nabha dist patiala punjab india glaxosmithkline australia pty ltd ordinary mountain highway boronia vic australia glaxosmithkline bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline beteiligungs gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biologicals shanghai ltd ordinary niudun road china shanghai pilot free trade zone glaxosmithkline biologicals kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biologicals sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biologicals sa ordinary preference rue de l'institut b rixensart belgium glaxosmithkline brasil limitada quotas estrada dos bandeirantes rio de janeiro brazil glaxosmithkline capital inc common wilmington trust sp services inc north market street suite wilmington delaware united states glaxosmithkline capital plc ordinary great west road brentford middlesex tw gs england glaxosmithkline caribbean limited ordinary great west road brentford middlesex tw gs england glaxosmithkline chile farmaceutica limitada social capital avenue andres bello piso las condes santiago cp chile glaxosmithkline colombia sa ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer healthcare holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare investments ireland ordinary knockbrack dungarvan co waterford x ry ireland limited iii iv gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline consumer healthcare ireland ip limited iii iv ordinary knockbrack dungarvan co waterford x ry ireland glaxosmithkline consumer holding bv ii ordinary huis ter heideweg lz zeist netherlands glaxosmithkline doo quotas zmja od bosne broj sarajevo bosnia herzegovina glaxosmithkline doo equity capital ulica damira tomljanovica gavrana zagreb croatia glaxosmithkline doo beograd ordinary omladinskih brigada new belgrade city belgrade serbia glaxosmithkline ecuador sa ordinary av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline eesti ou ordinary ltsa tallinn estonia glaxosmithkline el salvador sa de cv ordinary avenida el boqueron calle izalco parque industrial el boqueron santa elen antiguo custatlan la libertad el salvador glaxosmithkline eood ordinary g tsarigradsko shose blvd floor mladost region sofia bulgaria glaxosmithkline export limited ordinary great west road brentford middlesex tw gs england glaxosmithkline export panama sa ordinary panama city republic panama panama glaxosmithkline far east bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex tw gs england glaxosmithkline gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline guatemala sa ordinary novena avenida zona guatemala city guatemala glaxosmithkline holding ordinary drammensveien oslo norway glaxosmithkline holdings americas inc common wilmington trust sp services inc north market street suite wilmington delaware united states glaxosmithkline holdings ireland limited ordinary deferred great west road brentford middlesex tw gs england glaxosmithkline holdings one limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings pty ltd ordinary mountain highway boronia vic australia glaxosmithkline honduras sa ordinary tegucigalpa mdc honduras glaxosmithkline ihc limited ordinary great west road brentford middlesex tw gs england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithkline inc class common class c preference mississauga road north mississauga ln l canada glaxosmithkline insurance ltd ordinary parlaville road hamilton hm bermuda glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property holdings limited ordinary b ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary deferred great west road brentford middlesex tw gs england glaxosmithkline intellectual property management limited ordinary great west road brentford middlesex tw gs england glaxosmithkline international limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investigacin desarrollo sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain glaxosmithkline investments ireland limited iii iv ordinary riverwalk citywest business campus dublin ireland glaxosmithkline investments pty ltd ordinary mountain highway boronia vic australia glaxosmithkline kk ordinary akasaka minatoku tokyo japan glaxosmithkline korea limited ordinary f ls yongsan tower hangangdaero yongsangu seoul republic korea glaxosmithkline latin america sa ordinary panama city republic panama panama glaxosmithkline latvia sia ordinary duntes iela riga latvia glaxosmithkline lietuva uab ordinary ukmerges st vilnius lt lithuania glaxosmithkline limited ordinary f tower gateway canton road tsimshatsui kowloon hong kong glaxosmithkline llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline manufacturing spa ordinary via alessandro fleming verona italy glaxosmithkline maroc sa ordinary angle bd rachidi et abou hamed el glaza casablanca morocco glaxosmithkline medical healthcare products limited ordinary h csorsz utca budapest hungary glaxosmithkline mercury limited ordinary great west road brentford middlesex tw gs england glaxosmithkline mexico sa de cv ordinary ordinary b calzada mexicoxochimilco colonia san lorenzo huipulco delegacion tlalpan mexico gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline nz limited ordinary level zurich house queen street auckland new zealand glaxosmithkline oy ordinary piispansilta po box espoo fin finland glaxosmithkline peru sa ordinary av javier prado oeste san isidro lima peru glaxosmithkline pharma ordinary nykaer brondby dk denmark glaxosmithkline pharma gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline pharmaceutical kenya limited ordinary likoni road po box nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pharmaceutical sdn bhd ordinary level quill jalan prof khoo kay kim petaling jaya selangor malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals costa rica sa ordinary metros al este de la rotonda de la betania mercedes de montes de oca sabanilla montes de oca san jose costa rica glaxosmithkline pharmaceuticals sa ordinary ordinary b ul grunwaldzka poznan poland ordinary c ordinary glaxosmithkline pharmaceuticals sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline pharmaceuticals ukraine llc chartered capital pavla tychyny avenue v kiev ukraine glaxosmithkline pte ltd ordinary rochester park singapore glaxosmithkline puerto rico inc common prenticehall corporation system puerto rico inc co fast solutions llc ponce de leon avenue floor san juan puerto rico glaxosmithkline republica dominicana sa ordinary ave lope de vega torre novocentro local santo domingo dominican republic glaxosmithkline research development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline spa ordinary via alessandro fleming verona italy glaxosmithkline sro ordinary hvezdova c prague czech republic glaxosmithkline services gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline services inc ii common corporation service company little falls drive wilmington delaware united states glaxosmithkline services unlimited ordinary great west road brentford middlesex tw gs england glaxosmithkline sl holdings llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline sl llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline sl lp ii ix partnership great west road brentford middlesex tw gs england glaxosmithkline slovakia sro ordinary galvaniho bratislava slovakia glaxosmithkline south africa pty limited ordinary flushing meadows building campus sloane street bryanston south africa glaxosmithkline trading ordinary leningradskiy prospect building floor premises xv room moscow russian federation glaxosmithkline trading services limited iii vii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline tunisia sarl ordinary immeuble les quatres r rue du lac lochness berges du lac tunis tunisia glaxosmithkline uk limited ordinary great west road brentford middlesex tw gs england glaxosmithkline uruguay sa registered shares provisory stock salto cp montevideo uruguay glaxosmithkline us trading limited ordinary great west road brentford middlesex tw gs england glaxosmithkline venezuela ca ordinary urbanizacion la trinidad calle luis de camoems edif apatado posta caracas venezuela glaxosmithkline vietnam limited liability company ii iv equity capital metropolitan dong khoi street district th floor unit ho chi minh city viet nam glycovaxyn ag iv common preferred preferred b grabenstrasse schlieren switzerland preferred c groupe glaxosmithkline sas ordinary rue franois jacob rueilmalmaison france gsk australia nvd pty ltd ii iv ordinary mountain highway boronia vic australia gsk business service centre sdn bhd ordinary level quill jalan prof khoo kay kim petaling jaya selangor malaysia gsk capital kk ordinary akasaka minatoku tokyo japan gsk ch argentina sa nominative non endorseable ordinary tucumn piso buenos aires caaa argentina shares gsk commercial sp z oo ordinary ul rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued gsk finance limited ordinary great west road brentford middlesex tw gs england gsk kazakhstan llp participationparticipating interest nursultan nazarbayev ave almaty medeu district kazakhstan gsk limited ii ordinary great west road brentford middlesex tw gs england gsk pharmaceutical trading sa ii iv ordinary poienelor street brasov romania gsk services sp z oo ordinary ul grunwaldzka poznan poland gsk vaccines bv ordinary hullenbergweg amsterdam cl netherlands gsk vaccines gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quotas via fiorentina siena italy gsk vaccines srl quotas via fiorentina siena italy gsk vaccines vertriebs gmbh ii ordinary rudolfdieselring holzkirchen germany hgs france sarl ii iv ordinary rue de la belle feuille boulognebillancourt france horlicks limited ordinary preference great west road brentford middlesex tw gs england human genome sciences inc common corporation service company little falls drive wilmington delaware united states id biomedical corporation quebec common boul du parc technologique qubec gp r canada instituto luso farmaco limitada ii ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal interpharma dienstleistungen gmbh quotas wagenseilgasse euro plaza gebude stock vienna austria jj technologies lc ii llc interests corporation service company shockoe slip nd floor richmond va united states laboratoire glaxosmithkline ordinary rue franois jacob rueilmalmaison france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoires paucourt ii ordinary rue franois jacob rueilmalmaison france laboratoires saintgermain ii ordinary rue franois jacob rueilmalmaison france laboratorios dermatologicos darier sa de cv ordinary ordinary b calzada mexico xochimilco san lorenzo huipulco district federal mexico mexico laboratorios farmaceuticos stiefel portugal ltda ii ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal laboratorios stiefel de venezuela sa ordinary calle luis de camoens edificio glaxosmithkline urb la trinidad caracas venezuela laboratorios stiefel ltda ordinary rua professor joao cavalheiro salem bairro de bonsucesso municipality guarulhos sao paulo cep brazil laboratorios wellcome de portugal limitada ii ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal montrose pharma company limited ii iv ordinary quota h csorsz utca budapest hungary okairos ag liquidation common preferred preferred b co obc suisse ag aeschenvorstadt basel switzerland penn labs inc ii common corporation service company little falls drive wilmington delaware united states sr one international bv ordinary huis ter heideweg lz zeist netherlands sr one limited units common corporation service company interstate drive suite harrisburg pennsylvania united states setfirst limited ordinary preference great west road brentford middlesex tw gs england sitari pharma inc common stock corporation service company little falls drive wilmington delaware de united states smith kline french portuguesaprodutos farmaceuticos ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges lda ii portugal smithkline beecham bangladesh private limited ii ordinary house road gaishari dhaka bangladesh smithkline beecham cork limited vii ordinary riverwalk citywest business campus dublin ireland smithkline beecham manufacturing limited vii ordinary riverwalk citywest business campus dublin ireland smithkline beecham biologicals us partnership partnership interest corporation service company little falls drive wilmington delaware united states smithkline beecham egypt llc quotas amoun street el salam city cairo egypt smithkline beecham farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain smithkline beecham interamerican corporation ii common corporation service company little falls drive wilmington delaware united states smithkline beecham limited ordinary great west road brentford middlesex tw gs england gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued smithkline beecham overseas limited ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limited ii ordinary great west road brentford middlesex tw gs england smithkline beecham pension trustees limited ii ordinary great west road brentford middlesex tw gs england smithkline beecham pharma gmbh co kg partnership capital prinzregentenplatz munchen germany smithkline beecham pharma verwaltungs gmbh ordinary prinzregentenplatz munchen germany smithkline beecham pharmaceuticals pty limited ii iv ordinary flushing meadows building campus sloane street bryanston south africa smithkline beecham pharmaceuticals co common corporation service company little falls drive wilmington delaware united states smithkline beecham port louis limited iv ordinary co cim corporate services ltd les cascades building edith cavell street port louis mauritius smithkline beecham senior executive pension plan ordinary great west road brentford middlesex tw gs england trustee limited ii stiefel distributors ireland limited ii iv vii ordinary finisklin business park sligo ireland stiefel dominicana srl ii iv ordinary ave lope de vega torre novocentro local santo domingo dominican republic stiefel farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain stiefel gmbh co kg partnership capital industriestrasse bad oldesloe germany stiefel india private limited equity wing th floorfloral deck plaza opp rolta bhavan central midc road mumbai andheri e india stiefel laboratories legacy ireland limited vii ordinary finisklin business park sligo ireland stiefel laboratories limited ii ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratories pte limited ii ordinary gul circle singapore stiefel laboratories inc common corporation service company little falls drive wilmington delaware united states stiefel maroc sarl ii iv ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd ordinary mountain highway boronia vic australia stiefel research australia pty ltd ordinary mountain highway boronia vic australia stiefel west coast llc llc interests corporation service company little falls drive wilmington delaware united states strebor inc common corporation service company little falls drive wilmington delaware united states tempero pharmaceuticals inc series preference corporation service company little falls drive wilmington series b preference common delaware united states tesaro bio austria gmbh common fleischmarkt vienna austria tesaro bio france sas shares avenue le jour se lve boulogne france tesaro bio germany gmbh shares leopoldstr munich germany tesaro bio gmbh ordinary poststrasse zug switzerland tesaro bio italy srl shares via vincenzo bellini roma italy tesaro bio netherlands bv x shares joop geesinkweg ab amsterdamduivendrecht netherlands tesaro bio spain slu sharesparticipation quota severo ochoa parque tecnolgico de madrid tres cantos madrid spain tesaro bio sweden ab common co bdo mlarden ab skatt box stockholm sweden tesaro development limited shares clarendon house church street hamilton hm bermuda tesaro securities corporation iv common ct corporation federal st ste boston united states tesaro inc common corporation service company little falls drive wilmington delaware de united states sydney ross co ii common corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states wellcome foundation investment company limited ii iv limited guarantee great west road brentford middlesex tw gs england ucb pharma asia pacific sdn bhd ii ordinary th floor menara symphony jalan prof khoo kay kim seksyen petaling jaya malaysia wellcome consumer healthcare limited ii ordinary great west road brentford middlesex tw gs england wellcome consumer products limited ii ordinary great west road brentford middlesex tw gs england wellcome developments pty ltd ii iv ordinary mountain highway boronia vic australia wellcome limited ordinary great west road brentford middlesex tw gs england wellcome operations pty ltd ii iv ordinary mountain highway boronia vic australia gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less alacer corp common c corporation system west th street los angeles california united states amoun pharmaceutical industries co sae new monetary shares el salam city po box cairo egypt beecham enterprises inc ii common corporation service company little falls drive wilmington delaware united states biddle sawyer limited equity dr annie besant road mumbai india block drug company inc common corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states block drug corporation ii common corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states british pharma group limited captial great west road brentford middlesex tw gs england consumer healthcare holdings limited ordinary ramsgate road sandwich kent ct nj england consumer healthcare intermediate holdings limited ordinary ramsgate road sandwich kent ct nj england duncan consumer healthcare philippines inc common chino roces avenue makati city philippines duncan pharmaceuticals philippines inc common chino roces avenue city makati philippines exlax inc common prentice hall corporation system puerto rico inc co fast solutions llc citi tower ponce de leon avenue floor san juan puerto rico ferrosan aps shares b shares lautrupvang ballerup denmark ferrosan international aps ordinary lautrupvang ballerup denmark ferrosan srl registered capital c calea turzii clujnapoca cluj county romania galvani bioelectronics inc common corporation service company little falls drive wilmington delaware united states galvani bioelectronics limited ordinary b ordinary great west road brentford middlesex tw gs england glaxo saudi arabia limited ordinary po box area warehouse city first stage al khomrah jeddah saudi arabia glaxo wellcome ceylon limited ordinary ordinary b galle road kaldemulla moratuwa sri lanka glaxosmithkline tianjin co ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya de boumerdes algeria glaxosmithkline bangladesh limited iv ordinary fouzderhat industrial area dhaka trunk road north kattali chittagong bangladesh glaxosmithkline brasil produtos para consumo quotas bl vitor civita street barra tijuca rio de janeiro e saude ltda brazil glaxosmithkline consumer healthcare china co ltd ordinary floor xizangzhong road huangpu district shanghai china glaxosmithkline consumer healthcare hong kong ordinary f tower gateway canton road tsimshatsui kowloon limited hong kong glaxosmithkline consumer healthcare ireland limited vii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline consumer healthcare overseas limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare thailand limited ordinary th floor unit wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline consumer healthcare uk ip limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare uk trading ordinary great west road brentford middlesex tw gs england limited glaxosmithkline consumer healthcare us ip llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline consumer healthcare ordinary nykaer brondby dk denmark glaxosmithkline consumer healthcare ab v ordinary nykaer brondby dk denmark glaxosmithkline consumer healthcare australia pty ltd ordinary hughes avenue ermington nsw australia glaxosmithkline consumer healthcare bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline consumer healthcare colombia sas ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer healthcare czech ordinary hvezdova c prague czech republic republic sro glaxosmithkline consumer healthcare finance limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finance ordinary great west road brentford middlesex tw gs england limited glaxosmithkline consumer healthcare finland oy ordinary piispansilta fin espoo finland glaxosmithkline consumer healthcare gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline consumer healthcare gmbh co kg partnership capital barthstr mnchen germany gsk annual report statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued glaxosmithkline consumer healthcare greece societe ordinary kifissias avenue halandri athens greece anonyme glaxosmithkline consumer healthcare holdings b preference great west road brentford middlesex tw gs england limited glaxosmithkline consumer healthcare holdings us llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline consumer healthcare inc common mississauga road north mississagua ln l canada glaxosmithkline consumer healthcare investments ordinary knockbrack dungarvan co waterford x ry ireland ireland limited iii vii glaxosmithkline consumer healthcare investments ordinary knockbrack dungarvan co waterford x ry ireland ireland unlimited company iii vii glaxosmithkline consumer healthcare japan kk ordinary akasaka minatoku tokyo japan glaxosmithkline consumer healthcare korea co ltd ordinary f ls yongsan tower hangangdaero yongsangu seoul korea republic glaxosmithkline consumer healthcare llc llc interests corporation service company interstate drive suite harrisburg pennsylvania united states glaxosmithkline consumer healthcare limited iv ordinary patiala road nabha dist patiala punjab india glaxosmithkline consumer healthcare mexico ordinary calzada mexicoxochimilco colonia san lorenzo huipulco de rl de cv delegacion tlalpan mexico df mexico glaxosmithkline consumer healthcare new zealand ulc ordinary level zurich house queen street auckland new zealand glaxosmithkline consumer healthcare norway ordinary drammensveien lysaker norway glaxosmithkline consumer healthcare pakistan limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline consumer healthcare philippines inc common chino roces avenue makati city philippines glaxosmithkline consumer healthcare pte ltd ordinary rochester park singapore glaxosmithkline consumer healthcare sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline consumer healthcare sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline consumer healthcare spa ordinary via zambeletti sncbaranzate milan italy glaxosmithkline consumer healthcare saudi limited ordinary salamah tower th floor madinah road alsalamah district jeddah saudi arabia glaxosmithkline consumer healthcare sdn bhd ordinary lot jalan enggang ampangulu kelang industrial estate ampang selangor darul ehsan malaysia glaxosmithkline consumer healthcare slovakia r ownership interest galvaniho bratislava slovakia glaxosmithkline consumer healthcare south africa ordinary flushing meadows building campus sloane street bryanston pty ltd south africa glaxosmithkline consumer healthcare spzoo ordinary ul grunwaldzka poznan poland glaxosmithkline consumer healthcare srl ordinary costache negri street opera center one th floor zone district bucharest romania glaxosmithkline consumer healthcare vietnam charter capital floor metropolitan dong khoi ben nghe ward district company limited ii ho chi minh city viet nam glaxosmithkline consumer healthcare lp partnership capital corporation service company little falls drive wilmington delaware united states glaxosmithkline consumer healthcare produtos para ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges saude e higiene lda portugal glaxosmithkline consumer nigeria plc vi ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline consumer private limited equity patiala road nabha dist patiala punjab india glaxosmithkline consumer trading services limited ordinary great west road brentford middlesex tw gs england glaxosmithkline costa rica sa ordinary metros al este de la rotonda de la betania mercedes de montes de oca sabanilla montes de oca san jose costa rica glaxosmithkline dungarvan limited vii ordinary knockbrack dungarvan co waterford x ry ireland glaxosmithkline healthcare ao ordinary premises iii room floor presnenskaya nab moscow russian federation glaxosmithkline healthcare gmbh ordinary barthstr mnchen germany glaxosmithkline healthcare ukraine ooo ownership interest pavla tychyny avenue v kiev ukraine glaxosmithkline limited ordinary likoni road po box nairobi kenya glaxosmithkline pakistan limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline panama sa ordinary urbanizacion industrial juan calles b republic panama panama glaxosmithkline paraguay sa ordinary oficial gilberto aranda planta alta casi salvador del mundo asuncion paraguay gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued glaxosmithkline pharmaceuticals limited equity dr annie besant road mumbai india glaxosmithkline philippines inc common chino roces avenue city makati philippines glaxosmithkline sae ordinary boomerang office building land zone j st district town center th tagammoe new cairo city egypt glaxosmithkline sante grand public sas ordinary rue franois jacob rueilmalmaison france glaxosmithkline tuketici sagligi anonim sirketi nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithklineconsumer hungary limited liability membership h csorsz utca budapest hungary company gsk canada holding company limited ordinary great west road brentford middlesex tw gs england gsk ch kazakhstan llp charter capital manasa str bostandyk district almaty kazakhstan gsk consumer health inc common corporation service company little falls drive wilmington delaware de united states gsk consumer healthcare holdings us inc common corporation service company little falls drive wilmington delaware de united states gsk consumer healthcare holdings llc iii unit corporation service company little falls drive wilmington delaware de united states gsk consumer healthcare israel ltd iv ordinary basel street petech tikva israel gsk consumer healthcare levice sro ordinary priemyselny park gena ul e sachsa levice slovakia gsk consumer healthcare sa ordinary route de i'etraz prangins switzerland gsk consumer healthcare schweiz ag ordinary suurstoffi rotkreuz switzerland gsk consumer healthcare services inc common corporation service company little falls drive wilmington delaware united states gsk consumer healthcare singapore pte ltd ordinary rochester park singapore gsk new zealand holding company limited ordinary great west road brentford middlesex tw gs england gskgebro consumer healthcare gmbh ordinary bahnhofbichl fieberbrunn kitzbhel austria iodosan spa ordinary via zambeletti sncbaranzate milan italy kuhs gmbh ordinary barthstr mnchen germany laboratorios viiv healthcare sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain modern pharma trading company llc quotas amoun street po box el salam city cairo egypt nch nutrition consumer health ltd ii ordinary hamephalsim st petach tikva israel new pch llc membership interest corporation trust company corporation trust center orange street wilmington delaware united states pt smithkline beecham pharmaceuticals shares b shares jl pulobuaran raya kav iii dd kawasan industri pulogadung jakarta indonesia pt sterling products indonesia shares b shares graha paramita building th f jalan denpasar raya blok jakarta indonesia panadol gmbh ordinary barthstr mnchen germany pf consumer fzllc ordinary atlas business center dubai united arab emirates pf consumer healthcare llc membership interest corporation trust company corporation trust center orange street wilmington delaware united states pf consumer healthcare bv class class b rivium westlaan ld capelle aan den ijssel netherlands pf consumer healthcare brazil importadora e distribuidora quota barueri state sao paolo avenida ceci block iii de medicamentos ltda park tambore district brazil pf consumer healthcare canada ulc pf soins de common burrad street three bentall centre po box suite sante sri vancouver british columbia canada vx l pf consumer healthcare holding bv ordinary rivium westlaan ld capelle aan den ijssel netherlands pf consumer healthcare mexico de rl de cv quota paleo de los tamarindos piso bosques de las lomas cuajimalpa de morelos mexico mexico pf consumer healthcare new zealand ulc ordinary level queen street auckland central auckland new zealand pf consumer healthcare singapore pte ltd ordinary pasir panjang road mapletree business centre singapore pf consumer healthcare uk limited ordinary ramsgate road sandwich kent ct nj england pf consumer ireland company limited ordinary riverwalk national digital park citywest business park dublin ireland pf healthcare australia pty ltd ordinary hughes avenue emington nsw australia pfizer consumer healthcare ab ordinary vetenskapsvagen se sollentuna sweden pfizer consumer healthcare gmbh ordinary linkstrasse berlin germany pfizer consumer healthcare italy srl quota stock latina via isonzo italy pfizer consumer manufacturing italy srl quota stock via nettunese aprilia prov di latin italy gsk annual report statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued pfizer laboratories pfe pty ltd common flushing meadows building campus sloane bryanston south africa pfizer pfe colombia sas common avenida suba bogota colombia pfizer sante familiale sas ordinary avenue du docteur lannelongue paris france phivco jersey ii limited ii iii iv vii ordinary ifc st helier je st jersey united kingdom phivco jersey limited ii iii iv vii ordinary ifc st helier je st jersey united kingdom phivco uk ii limited ordinary great west road brentford middlesex tw gs england phivco uk limited ordinary great west road brentford middlesex tw gs england phivco llc llc interests corporation service company little falls drive wilmington delaware united states phivco llc llc interests corporation service company little falls drive wilmington delaware united states prism pch limited voting shares non voting ramsgate road sandwich kent ct nj england shares pt glaxo wellcome indonesia shares b shares jl pulobuaran raya kav iii dd kawasan industri pulogadung timur jakarta indonesia pt gsk consumer healthcare indonesia ordinary graha paramita building th f jalan denpasar raya blok kuningan jakarta selatan indonesia pt bina dentalindo liquidation ordinary gedung graha ganesha lantai jl raya bekasi km jakarta timur indonesia shionogiviiv healthcare llc ii common interests corporation service company little falls drive wilmington delaware united states sinoamerican tianjin smith kline french laboratories ordinary cheng lin zhuang industrial zone dong li district tianjin ltd china smithkline beecham private limited ordinary world trade center level west tower echelon square colombo sri lanka smithkline beecham research limited ordinary great west road brentford middlesex tw gs england smithkline beecham sa ordinary ctra de ajalvir km alcala de henares madrid spain smithkline beechambiomed ooo participation interest leningradskiy prospect building floor premises xiv room moscow russian federation staffordmiller ireland limited vii ordinary clocherane youghal road dungarvan co waterford ireland sterling drug malaya sdn berhad ordinary lot jalan enggang ampanghung kelang industrial estate ampang selangor darul ehsan malaysia sterling products international incorporated ii common corporation service company little falls drive wilmington delaware united states stiefel consumer healthcare uk limited ordinary great west road brentford middlesex tw gs england stiefel egypt llc ii quota amoun street po box el salam city cairo egypt stiefel laboratories ireland limited vii ordinary finisklin business park county sligo ireland treerly health co ltd capital contribution unit room east zhujiang road tianhe district guangzhou city prc china vesteralens naturprodukter ab ordinary uddevallavgen se strmstad sweden vesteralens naturprodukter aps ordinary lautrupvang ballerup denmark vesteralens naturprodukter common drammensveien oslo lysaker norge po box norway vesteralens naturprodukter oy common tietokuja fi helsinki finland viiv healthcare south africa proprietary limited ii iv ordinary flushing meadows building campus sloane street bryanston south africa viiv healthcare bv ordinary huis ter heideweg lz zeist netherlands viiv healthcare company common corporation service company little falls drive wilmington delaware united states viiv healthcare finance limited iv ordinary great west road brentford middlesex tw gs england viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england viiv healthcare finance limited ordinary redeemable great west road brentford middlesex tw gs england preference viiv healthcare gmbh ordinary prinzregentenplatz munchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland viiv healthcare hong kong limited ii ordinary f tower gateway canton road harbour city tsimshatsui kowloon hong kong viiv healthcare kabushiki kaisha ordinary akasaka minatoku tokyo japan gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued viiv healthcare limited class shares deferred great west road brentford middlesex tw gs england class b shares class c shares class class class e cumulative preference viiv healthcare pty ltd ordinary mountain highway boronia vic australia viiv healthcare puerto rico llc llc interests centro international de mercadeo carr torre suite guaynabo puerto rico viiv healthcare srl quota via alessandro fleming verona italy viiv healthcare sas ordinary rue franois jacob rueilmalmaison france viiv healthcare sprl ordinary site apollo avenue pascal wavre belgium viiv healthcare trading llc ii participation interest leningradskiy prospect building floor premises xiv room moscow russian federation viiv healthcare trading services uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ii iv ordinary ifc st helier je st jersey united kingdom viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare ulc common nd street sw calgary ab tp j canada viiv healthcare venture llc llc interests corporation service company little falls drive wilmington delaware united states viivhiv healthcare unipessoal lda quota rua dr antonio loureiro borges arquiparque miraflores alges portugal vog au pty ltd ii ordinary redeemable hughes avenue ermington nsw australia preference winster pharmaceuticals limited ii ordinary association avenue ilupeju industrial estate lagos po box nigeria wyeth consumer healthcare llc membership interest ct corporation system n nd st suite harrisburg pennsylvania united states wyeth pharmaceutical co ltd registered capital baodai west road suzhou jiangsu province china wyeth pharmaceuticals company viii capital contribution state road kilometer guayama puerto rico associates apollo therapeutics llp partnership interest gunnels wood road stevenage sg fx england glaxosmithkline landholding company inc common chino roces avenue city makati philippines index ventures life vi jersey lp partnership interest esplanade st helier je wg jersey innoviva inc common sierra point parkway suite brisbane ca united states kurma biofund ii fcpr partnership interest rue royale e tage paris france longwood founders fund lp partnership interest prudential tower boylston street suite boston united states medicxi ventures lp partnership interest great pulteney street soho london wf nd england joint ventures chiron panacea vaccines private limited ii equity shares th floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india qualivax pte limited ordinary robinson road singapore quell intellectual property corp llc membership interest corporation service company little falls drive wilmington delaware united states qura therapeutics llc units corporation service company little falls drive wilmington delaware united states gsk annual report statutory disclosures continued group companies continued following uk subsidiaries take advantage audit exemption set within section companies act period ended december unless otherwise stated undertakings listed owned either directly indirectly glaxosmithkline plc company name security registered address number uk registered subsidiaries exempted audit burroughs wellcome international limited ordinary great west road brentford middlesex tw gs england cellzome limited ordinary great west road brentford middlesex tw gs england clarges pharmaceuticals limited ordinary preference great west road brentford middlesex tw gs england domantis limited ordinary great west road brentford middlesex tw gs england edinburgh pharmaceutical industries limited ordinary preference shewalton road irvine ayrshire ka ap scotland sc eskaylab limited p ordinary great west road brentford middlesex tw gs england glaxochem uk unlimited ordinary ordinary b great west road brentford middlesex tw gs england ordinary c glaxosmithkline consumer healthcare sri lanka ordinary great west road brentford middlesex tw gs england holdings limited glaxosmithkline consumer healthcare uk limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investment holdings limited iv ordinary great west road brentford middlesex tw gs england glaxosmithkline investment services limited iv ordinary great west road brentford middlesex tw gs england glaxo wellcome uk limited ordinary great west road brentford middlesex tw gs england mixis genetics limited iv ordinary ordinary euro great west road brentford middlesex tw gs england montrose fine chemical company ltd ordinary shewalton road irvine ayrshire ka ap scotland sc smithkline beecham export limited ordinary great west road brentford middlesex tw gs england smithkline beecham h limited noncumulative great west road brentford middlesex tw gs england nonredeemables ordinary smithkline beecham investments limited ordinary great west road brentford middlesex tw gs england smithkline beecham marketing technical ordinary great west road brentford middlesex tw gs england services limited smithkline beecham nominees limited ordinary great west road brentford middlesex tw gs england smithkline beecham swg limited ordinary great west road brentford middlesex tw gs england smith kline french laboratories limited ordinary great west road brentford middlesex tw gs england staffordmiller ltd ordinary noncumulative great west road brentford middlesex tw gs england non redeemable preference stiefel laboratories maidenhead ltd iv ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratories uk ltd ordinary eurasia headquarters concorde road maidenhead berkshire sl england tesaro uk limited ordinary baker street london wu eu england wellcome foundation limited ordinary great west road brentford middlesex tw gs england viiv healthcare overseas limited ordinary great west road brentford middlesex tw gs england company effective ownership viiv healthcare overseas limited accordance section c companies act company guarantee debts liabilities uk subsidiary undertakings december total sum debts liabilities million key directly owned glaxosmithkline plc ii ormant entity iii ax resident uk iv entity expected disposed removed v incorporated sweden vi consolidated subsidiary accordance section companies act grounds dominant influence vii exempt provisions section companies act ireland accordance exemptions noted section act viii principal business address puerto rico ix exempt provisions regulations partnership accounts regulation accordance exemptions noted regulation regulation x company provided undertaking accordance article paragraph subparagraph f dutch civil code asume joint several liability acts tesaro bio netherlands bv gsk annual report strategic report governance remuneration financial statements investor information glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax equivalent tax depreciation american depositary receipt adr r eceipt evidencing title ads gsk adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share called share capital ordinary shares issued fully paid cer growth growth constant exchange rates company glaxosmithkline plc currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans equity shareholders funds shareholders equity finance lease capital lease freehold ownership absolute rights perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties novartis transaction threepart interconditional transaction novartis ag involving consumer healthcare vaccines oncology businesses completed march ordinary share fully paid ordinary share capital company profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity gsk exercises control treasury share treasury stock turnover revenue uk corporate governance code required uk listing authority company disclosed annual report applied best practice corporate governance provisions financial reporting councils uk corporate governance code gsk annual report index remuneration policy report investments associates joint ventures remuneration policy summary investor relations accounting principles policies key accounting judgements estimates acquisitions disposals key performance indicators adjustments reconciling profit tax operating legal proceedings cash flows major restructuring costs affordability availability modern employer annual general meeting movements equity approach tax net debt assets held sale new accounting requirements associates joint ventures nominations committee report audit risk committee report noncontrolling interests business model noncontrolling interests viiv healthcare cash cash equivalents nonexecutive directors fees cash generation conversion nonfinancial information statement ceos statement notes financial statements chairmans statement operating profit chairmans governance statement intangible assets chairmans remuneration annual statement investments climaterelated financial disclosure noncurrent assets commitments noncurrent liabilities composition succession evaluation operating incomeexpense consolidated balance sheet provisions consolidated cash flow statement board consolidated income statement culture consolidated statement changes equity longterm priorities consolidated statement comprehensive income preparation brexit consumer healthcare pensions postemployment benefits consumer healthcare products competition pharmaceuticals contingent consideration liabilities pharmaceutical products competition contingent liabilities intellectual property corporate executive team pipeline corporate governance presentation financial statements corporate responsibility committee report principal group companies critical accounting policies principal risks uncertainties data engagement property plant equipment directors senior management quarterly trend directors interests shares reconciliation net cash flow movement net debt directors statement responsibilities registrar dividends related party transactions donations political organisations reliable supply political expenditure remuneration governance earnings per share remuneration report employee costs reporting framework employee share schemes responsible leadership environment right use assets ethics values risk management exchange rates science technology executive director remuneration science committee report finance expense section statement finance income share capital control financial calendar share capital share premium account financial instruments related disclosures shareholder information financial performance shareholder services contacts financial position resources stakeholder engagement financial statements glaxosmithkline plc prepared taxation uk gaap tax information shareholders five year record trade payables glossary terms trade receivables goodwill treasury policies group companies trust group financial review turnover segment information independent auditors report us law regulation industry trends vaccines inventories vaccine products competition intellectual property viability statement gsk annual report gsk glaxosmithkline plc incorporated english brand names brand names appearing italics throughout report public limited company december trade marks either owned andor licensed gsk associated companies exception gardasil formed merger glaxo wellcome plc owned merck sharp dohme corp rituxan owned biogen inc zofran owned novartis ag smithkline beecham plc gsk acquired two acknowledgements english companies december part printing printed sustainably uk pureprint carbonneutral merger arrangements company fsc chain custody iso certified environmental management system recycling dry waste shares listed london stock exchange paper new york stock exchange printed innovation premium fsc certified paper pulps used totally chlorine free manufacturing mill iso environmental management certification mills energy produced read wwwgskcom biomass fuels sourced local forestry fossil fuels used carbon emissions measured offset using world land trusts carbon balanced scheme download pdfs nnual report f orm f cautionary statement regarding number nonifrs measures used report groups expectations assume successful delivery forwardlooking statements performance business measures defined groups integration restructuring plans groups reports filed furnished us pages reconciliation adjusted results period including extension securities exchange commission sec including total results set enhancement combined programme announced b c tnh ht ue va ai es rh et yr ee se dm ml tno f toc e e r e nu n nf c x om tt aps sh tn e e e r fn ec ig dat lt aa eda rr ttwo nen eiou td snp ft r tow r itm r co hlhi ot tra eet l ye f p kn e tc ri ou n eoi n b g hcn tf l iato ssc tsr e tt im otai n mn st r ef iet cot h ni f aro e tw fe ln u na u tr b rt ure sd cu rl ee g ur tl hea rev res ob v ee e ek fy natd ni thno c fegr tgr c h ar nr u l ps p u pfh l nvcfe oe e n nr ui n r tt ao mf lo n rs e r e n ein l g pla v ao u ot iti c iro ra ttan ei v sn htn tn oi e uv fh uri li ta p un bd rdio e eo su n c p cc u pt e oeom e r nm frb soe fe tu r rn r ut ed ato dho n n ce e acr es n se e gn ncao pon agt r n tec g ohn fin noln gt ax f obt n ii n rt es yu e tm rot chee aii lh st ia sh e en tdk r line p p nn ir r tvo oe e ej g dg gsu r ur rtl aa cj ttu ie ol nn nt ote p u nr f dt nhhh g ie l ie e n ya r v vn h lm e eie ce l r sm sw k tc co e lm oo ea sn sa n nn essj tdo suu p r mm rhr nt oe hee e q gs e r nt rrhh r eu ca w c mtt l nhu eh ser e suc n p p mag fa r n eep la dp lr l otj oi h wo hsi en ian ea n tt dpn g l tv n r hh teeo hecpnu e u rr ec r ae e ti n use words anticipate estimate expect assumptions related outlook tesaro acquisition consumer healthcare joint win ot dn sd nw tll e r mp sro oje f c st im ip lala r n e ab ne il nie gv e ct oa nrg neet c ion nd w th r pn e riu ot dli n g th e e x pe tc ht ea gio rn os u f po r h dn ed c eh ta fi inv eyear v sue cn ctu er se w fui lt lh pfizer period delivered discussion future operating financial assumptions healthcare sector different material costs investment new product launches performance particular include statements markets group operates delivery rd factored expectations given given relating future actions prospective products product revenues financial benefits current portfolio potential development options groups pipeline approvals future performance results current pipeline restructuring programmes outlook may affected additional datadriven rd anticipated products sales efforts expenses investment decisions expectations given outcome contingencies legal proceedings group specifically period gsk constant currency basis outlook cer dividend payments financial results expects declines sales seretideadvair accordance legal regulatory obligations introduction generic alternative advair us notice regarding limitations including market abuse regulations factored groups assessment director liability english law uk listing rules disclosure transparency future performance group assumes premature uk companies act safe harbour limits rules financial conduct authority group loss exclusivity key products period liability directors respect statements u e c lot n nvn aio l osa le yy ud c ct kr n tee u e pa il omr ad ast gs nd ra e eo u eek sn intr r c de r ti et au ss nn tt l e h wn owa w r meo tl h h h er c td eio ew oe c xci nb rs pt hi pe th cl e si rv lie eg l adt c e r cp ti rs nt aat euui l g ths oo b ir ul en ce ya l n n sr dr ne h e uoa h esu eid lsu lp e rl b sd er ehn hoa ls iu od aet f mhe r n un ao g e cla e ndu r ern w c l fi ad e alu n e f n nkp c dho ef iw hw n nnwr em voia ey thr fa v ee od mt e ri goho wl ao ife n rvk c aso e e h ro k f n eu n eii rnn tt ec hug eu ar l n e c f w l tioo htech iiv r ogtsqse mi hn sd aau u es tpe rp ios us tp fiiis hot nd zlu ty ano e h e e n r rx sp f h fp ip r ntt eo le h eri l vo orc e ae n pt l ne lsga rs oi h nw etst isf cr g apoo e ca u daonr u r n ys ost ep h c da n r pe es e nl ss v c dr upg ces mr e ou nr gx tm u e md nc tu c iu e sep et h c p fn en c os eto dt ts e r afr mom ote l hn f turv r h ba h eo e n fct eh e cim rle ru er r r oa l weve c cl e hj k rie q p ci aa u ia n n r ail n n nr dnm pyr ii v dn u rtie e oog h sp mor n vn e gt ii vh ue oa e ien rr en f es rs frd n rl u c r k soe nom tn ia p r ro et ai os w e c te pt rs erh tr ia ni gs eo e n g l r n c cy sns f ao g rt b cn rr ef l ia ir tu ps eo th oe pbm n n g roul ta e rtc ewh adt tw ne r e pte ehd ar ap u r ne n pgi oo lnr aede rr gt sc r r ea h eo hn ssi c rr ed tsd h w p rh r e ie n se r w e e op ur iny loo ne ct ur oim lnf ct ul fd co ou sbf r ln nno ib ue ive ne cer sce e c er lw ik va caa ui lr eah e ob l si mmboi c mlc ie vsn l oeoh e e pn n r r p rt eee cto ie pa ss p oo oe g est ro mfh f e r op tate phet sh ra e g hs e eee forwardlooking statements subject assumptions made share repurchases company remuneration report drawn inherent risks uncertainties many relate change groups shareholdings viiv presented accordance reliance upon factors beyond groups control precise healthcare assumptions also assume material english company law liabilities directors estimate group cautions investors number changes macroeconomic healthcare connection reports shall subject important factors including document could environment guidance outlook limitations restrictions provided law cause actual results differ materially factored divestments product exits since website expressed implied forwardlooking statement including divestment exit noncore tail brands billion annual sales gsks website wwwgskcom gives additional information factors include limited discussed announced july product divestments group notwithstanding references make principal risks uncertainties pages planned connection formation consumer annual report gsks website none annual report forwardlooking statements healthcare joint venture pfizer information made available website constitutes made behalf group speak date part annual report shall deemed made based upon knowledge incorporated reference herein information available directors date annual reporthead office registered office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel search us registered number wwwgskcom